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Background&and&Importance:"Comparative"evidence"generated"using"systematic"reviews"and"metaBanalyses" can" form" the"basis"of"high"quality"prescribing"decisions" in" clinical"practice."Such" evidence" is" imperative" when" choosing" a" firstBline" treatment" among" multiple"alternatives," particularly" in" the" United" States" where" there" is" no" single" national" authority"responsible"for"providing"practice"guidelines"for"prescribers."
Objective:"Using"cholesterolBlowering"statins"as"a"case"study," this"thesis"set"out"to"evaluate"the"comparative"clinical"benefits"and"harms"of"statins"for"the"prevention"of"coronary"heart"disease.""
Novelty&and&Empirical&Contribution:"The"empirical"work"presented"in"this"thesis"was"based"on"a"systematic"review"and"network"metaBanalysis,"for"the"first"time"combining"the"placeboBcontrolled" and" activeBcomparator" trials" of" statins." Using" 184" randomized" trials" including"260,630" individuals"with" or"without" cardiovascular" disease," this" thesis"makes" four"major"contributions" to" the" literature" on" the" comparative" effectiveness" and" safety" of" statins,"showing"the"following:"(1)"cholesterolBlowering"effects"of"statins"are"less"pronounced"than"suggested" by" the" previous" reviews;" (2)" statins" potentially" differ" in" terms" of" their"comparative"effects"on"clinically"meaningful"benefit"outcomes,"which"are"not"fully"explained"by"their"cholesterolBlowering"effects;"(3)"harms"associated"with"statins"are"rare;"still,"some"statins"are"safer" than"others;"and"(4)"unlike"previous" findings" in"the" literature," there" is"no"evidence"of"industry"sponsorship"bias"affecting"the"trials"of"statins.""
Implications& for& Clinical& Practice:" Although" there" are" statistically" detectable" and" clinically"relevant" differences" among" individual" statins," the" empirical"work" presented" in" this" thesis"does"not"conclusively"identify"a"clear"winner"among"statins"that"should"be"favored"in"clinical"practice.""
Future&Research&Directions:&The"potential"mechanisms"underlying"the"observed"differences"between"individual"statins"should"be"investigated"in"future"studies.&&






















































































































Figure! 4.4! –" DoseBcomparative" absolute" effects" of" statins" on" serum" LDL" cholesterol"concentrations."
Figure!4.5!–"DoseBcomparative"relative"effects"of"statins"on"serum"Total"cholesterol"levels.""
Figure!4.6!–"DoseBcomparative"relative"effects"of"statins"on"serum"HDL"cholesterol"levels.""
Figure! 4.7" –" SubBgroup" analysis" results:" DoseBcomparative" relative" effects" of" statins" on"serum"LDL"cholesterol"levels." ""
Figure! 4.8! –" Comparative" LDL" and" Total" cholesterol" lowering" effects" of" statinBdose"combinations."
Figure!4.9!–"DoseBcomparative"ranking"and"equivalence"of"statins"in"terms"of"both"LDL"and"Total"cholesterol"reduction."
Figure!4.10! –" Sensitivity" of" baseBcase" network"metaBanalysis" findings" to"metaBregression"analyses."
Figure!5.1!–!Flow"diagram"of"trial"identification"and"selection.!
Figure!5.2!–!Network"of"available"comparisons"for"determining"the"comparative"effects"of"individual"statins"on"clinical"benefit"outcomes."!
Figure! 5.3! –" Effect" of" statins" compared" to" control" on" allBcause" mortality" across" all"populations."
Figure!5.4!–"Effect"of" statins" compared" to" control"on"allBcause"mortality" in" the" secondary"prevention"population)."




Figure! 5.7! –" DoseBspecific" analysis" findings:" comparative" effects" of" individual" statins"compared"to"control"for"allBcause"mortality"across"all"populations.!
Figure! 5.8! –" Sensitivity" of" baseBcase" findings" to" metaBregression" analyses" for" allBcause"mortality."!
Figure!5.9!–"Relationship"between"the"observed"event"rate"in"control"group"and"observed"odds"ratio"across"the"placeboBcontrolled"trials"of"statins."
Figure! 5.10! –" Sensitivity" of" baseBcase" findings" to"metaBregression" analysis" exploring" the"effect"of"baseline"risk"on"allBcause"mortality."
Figure! 5.11! –" Effect" of" statins" compared" to" control" on"major" coronary" events" across" all"populations."
Figure! 5.12! –" Effect" of" statins" compared" to" control" on" major" coronary" events" in" the"secondary"prevention"population.!
Figure!5.13!–"Effect"of"statins"compared"to"control"on"major"coronary"events"in"the"primary"prevention"population.!
Figure!5.14!–"Network"of"available"comparisons"for"determining"the"comparative"effects"of"individual"statins"on"major"coronary"events.!
Figure! 5.15! –" DoseBspecific" analysis" findings:" comparative" effects" of" individual" statins"compared"to"control"for"major"coronary"events"across"all"populations."!







Figure! 5.21! –" DoseBspecific" analysis" findings:" comparative" effects" of" individual" statins"compared"to"control"for"major"coronary"events"across"all"populations.!
Figure! 5.22! –!Sensitivity" of" the" baseBcase" findings" to"metaBregression" analyses" for"major"coronary"events."!






Figure! 6.6! –" Effect" of" statins" compared" to" control" on" allBcause" mortality" in" the" primary"prevention"population.!
Figure!6.7!–"Network"of"available"comparisons"for"determining"the"comparative"effects"of"individual"statins"on"discontinuations"due"to"adverse"events.!
Figure! 6.8! –" DoseBspecific" analysis" findings:" Comparative" effects" of" individual" statins"compared"to"control"for"discontinuations"due"to"adverse"events"across"all"populations.""
Figure! 6.9! –" Sensitivity" of" the" baseBcase" findings" to" metaBregression" analyses" for"discontinuations"due"to"adverse"events."
Figure! 6.10! –" Effect" of" statins" compared" to" control" on" incident" myalgia" across" all"populations."
Figure!6.11!–"Effect"of"statins"compared"to"control"on"myalgia"occurrence"in"the"secondary"prevention"population."




Figure! 6.14! –" DoseBspecific" analysis" findings:" comparative" effects" of" individual" statins"compared"to"control"for"myalgia"occurrence"across"all"populations."
Figure!6.15!–"Sensitivity"of"the"baseBcase"findings"to"metaBregression"analyses"for"myalgia."
Figure!6.16!–"Effect"of" statins" compared" to" control" treatment"on" transaminase"elevations"across"all"populations."
Figure! 6.17! –" Effect" of" statins" compared" to" control" on" transaminase" elevations" in" the"secondary"prevention"population."
Figure!6.18!–"Effect"of"statins"compared"to"control"treatment"on"transaminase"elevations"in"the"primary"prevention"population."
Figure!6.19!–"Network"of"available"comparisons"for"determining"the"comparative"effects"of"individual"statins"on"transaminase"elevations."
Figure! 6.20! –" DoseBspecific" analysis" findings:" comparative" effects" of" individual" statins"compared"to"control"for"transaminase"elevations"across"all"populations."
Figure! 6.21! –" Sensitivity" of" the" baseBcase" findings" to" metaBregression" analyses" for"transaminase"elevations."
Figure!6.22!–"Effect"of"statins"compared"to"control"on"creatine"kinase"elevations"across"all"populations."
Figure! 6.23! –" Effect" of" statins" compared" to" control" on" creatine" kinase" elevations" in" the"secondary"prevention"population."
Figure! 6.24! –" Effect" of" statins" compared" to" control" on" creatine" kinase" elevations" in" the"primary"prevention"population."
Figure!6.25!–"Network"of"available"comparisons"for"determining"the"comparative"effects"of"individual"statins"on"creatine"kinase"elevations."












Figure! 7.2! –" Network" of" available" comparisons" for" determining" the" doseBcomparative"effects"of"individual"statins"on"LDL"cholesterol"levels."!
Figure!7.3!–"Distribution"of"methodological"quality" in" the"network"of" available" statin"and"control"comparisons.""
Figure! 7.4! –" Sensitivity" of" network" metaBanalysis" findings" to" methodological" quality"attributes"of"randomized"controlled"trials"of"statins."
Figure! 7.5! –" Dose" comparative" effects" of" statins" on" serum" LDL" cholesterol" levels" in"industryB"vs."nonindustryBsponsored"trials.""
Figure! 7.6! –"MetaBregression" analysis" results:" Evaluation" of" industry" sponsorship" bias" in"the"randomized"controlled"trials"of"statins.!




Figure! 8.3! –" Overall" ranking" of" individual" statins" by" their" probability" to" be" the" best"treatment"in"terms"of"benefit"and"harm"outcomes."!
Figure!8.4!–"Comparative"benefitBharm"profiles"of"individual"statins"on"the"basis"of"placeboBcontrolled"and"activeBcomparator"trials."











Table! 4.4! –! SubBgroup" analysis" results:! DoseBcomparative" relative" effects" of" statins" on"serum"LDL"cholesterol"levels.!
Table! 4.5! –! Sensitivity" of" baseBcase" network" metaBanalysis" findings" to" metaBregression"analyses.!
Table!4.6!–"Statin"Prescribing"Reference"Table."
Table! 5.1! –" Comparative" benefits" of" individual" statins" on" allBcause" mortality" across" all"populations."
Table! 5.2! –" Comparative" benefits" of" individual" statins" on" allBcause" mortality" in" the"secondary"prevention"population.""
Table!5.3!–"Comparative"benefits"of"individual"statins"on"allBcause"mortality"in"the"primary"prevention"population.!
Table! 5.4! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on" allBcause"mortality"across"all"populations."
Table! 5.5! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on" allBcause"mortality"in"the"secondary"prevention"population."!





Table! 5.9! –" Comparative" benefits" of" individual" statins" on" major" coronary" events" in" the"secondary"prevention"population."
Table! 5.10! –" Comparative" benefits" of" individual" statins" on"major" coronary" events" in" the"primary"prevention"population."
Table! 5.11! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on"major"coronary"events"across"all"populations."!
Table! 5.12! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on"major"coronary"events"in"the"secondary"prevention"population.""
Table! 5.13! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on"major"coronary"events"in"the"primary"prevention"population."
Table!5.14!–!Findings"of"the"metaBregression"analyses"for"major"coronary"events.""
Table! 5.15! –" Comparative" benefits" of" individual" statins" on"major" cerebrovascular" events"across"all"popuations."
Table!5.16!–"Comparative"benefits"of"individual"statins"on"major"cerebrovascular"events"in"the"secondary"prevention"population."
Table!5.17!–"Comparative"benefits"of"individual"statins"on"major"cerebrovascular"events"in"the"primary"prevention"population."
Table! 5.18! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on"major"cerebrovascular"events"across"all"populations.!
Table! 5.19! –" Sensitivity" analysis" results:" Comparative" benefits" of" individual" statins" on"major"cerebrovascular"events"in"the"secondary"prevention"population."







Table!6.4! –" Findings"of" the"metaBregression"analyses" for"discontinuations"due" to" adverse"events.""
Table! 6.5! –" Comparative" tolerability" of" individual" statins" on" myalgia" events" across" all"populations."
Table! 6.6! –!Comparative" effects" of" individual" statins" on"myalgia" events" in" the" secondary"prevention"population."!
Table! 7! –" Comparative" effects" of" individual" statins" on" myalgia" events" in" the" primary"prevention"population.""
Table!6.8!–"Findings"of"the"metaBregression"analyses"for"myalgia.""
Table!6.9!–"Comparative"effects"of"individual"statins"on"transaminase"elevations"across"all"populations.""
Table! 6.10! –" Comparative" effects" of" individual" statins" on" transaminase" elevations" in" the"secondary"prevention"population."








Table! 7.2! –" Availability" of" statinBdose" comparisons" in" industry" and" nonindustryBfunded"trials."
Table! 8.1! –! Comparative" benefits" and" harms" of" individual" statins" according" to" network"metaBanalyses"across"all"populations."

































































































Chapter!1!"Introduction:"The"Concept"of"Quality"in"Prescription"Drug"Therapy"""Quality"in"healthcare"can"be"defined"as"“the"extent"to"which"health"services"for"individuals"and"populations"increase"the"likelihood"of"desired"health"outcomes"and"are"consistent"with"current"professional"knowledge”.1"An"important"aspect"of"healthcare"quality"is"prescription"drug" therapy." In" the" United" States" alone," about" $230" billion," or" 10" percent" of" the" total"national" healthcare" expenditure," was" spent" on" prescription" drugs" in" 2008.2" Across" the"European"Union"countries,"spending"on"prescription"drugs"accounted"for"about"19%"of"total"health"expenditures" in"2010.3"Prescription"drug"therapy" is"not"only"costly,"but"also"widely"common."According"to"a"survey"conducted"by"the"United"States"Centers"for"Disease"Control"and"Prevention,"for"example,"an"estimated"half"of"the"adult"population"in"the"United"States"uses" at" least" one" prescription" drug" every"month,"with" one" fifth" of" adult" Americans" using"three"or"more.4!The"appropriateness"of"prescribing"decisions"has"major"public"health"and"economic"implications."Thus,"quality"of"prescription"drug"therapy"is"of"significant"academic"and"policy"interest"and"forms"the"focus"of"this"thesis."""
1.1!Prescribing!Quality!The"concept"of" “prescribing"quality”"can"be"viewed" from"a"number"of"perspectives"and" its"definition"varies"depending"on"the"perspective"of" the"stakeholder"and"the"target"audience."Quality" of" prescribing" can"be" defined"within" three" different" (but" not" necessarily"mutually"exclusive)"domains."These"are"patients,"governments/payers,"and"prescribers.""
1.1.1& Patient&Perspective&From"a"patient’s"perspective,"quality"of"prescribing"has"to"do"with"respecting"patient"choices"and" preferences.5" This" domain" asks" whether" a" patient’s" ‘specifications’" of" the" goals" and"parameters" of" prescribing" are" considered" in" prescribing" decisions.6" One" aspect" of" this"domain" is" focused" on" the" prescriberBpatient" interaction," spanning" the" range" of"recommendations"by"the"prescriber"that"go"beyond"the"specific"drug"therapy"(e.g." lifestyle"changes).7"
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Patients"increasingly"perceive"themselves"as"active"consumers"of"drugs"rather"than"passive"recipients."It"has"been"a"natural"evolution,"then,"that"concomitant"with"the"rise"of"patients"as"consumers," patient" satisfaction" with" drug" therapy" has" been" promoted" as" an" essential"component" of" quality" evaluations." Satisfaction" with" drug" therapy" is" expected" to" have" an"impact"on"patient"adherence"to"drug"therapy.8B10"Defining" patient" perspectives" on" drug" therapy," however," is" challenging:" choices" and"preferences" are" intrinsically" different" at" the" individual" level," and" continue" to" shift" due" to"external" factors." For" instance," they" may" change" according" to" the" financial" contribution"patients" have" to" make" to" their" own" healthcare.11" Similarly," easier" access" to" information"influences" patient" expectations" from" prescribing.12B14" Making" generalizable" inferences" on"(subjective)"patient"preferences"and"their"interrelationship"with"the"quality"of"prescribing"is"difficult.""
1.1.2&& Government/Payer&Perspective&From" a" government/payer’s" perspective," quality" of" prescribing" is" defined" in" terms" of"achieving" the"best"attainable"health"outcomes" in"relation"to" the"economic"costs"associated"with" prescribing." National" Health" Services" Prescription" Services" in" the" United" Kingdom15"and" Agency" for" Healthcare" Research" and" Quality" in" the" United" States16" have" conducted"assessments"of"prescribing"quality"from"this"perspective.""The" relevance" of" defining" the" quality" of" prescribing" from" the" government/payer’s"perspective" becomes" evident" when" considering" the" future" cost" containment" challenges"facing"healthcare"systems"across"the"world." In"the"United"States," for"example,"prescription"drugs"constitute"one"of"the"fastest"growing"components"of"national"healthcare"spending,"as"the"spending"for"prescription"drugs"amounted"to"$216.7"billion"in"2006"(more"than"5"times"the"$40.3"billion"spent"in"1990).17"It"is"expected"that"the"government/payer"perspective"will"only"become"more"prominent"in"the"future"as"the"adoption"of"new"(costly)"drugs"continue"to"create"challenges"for"health"systems."As"costs"continue"to"increase,"and"the"healthcare"sector"continues" to" come" under" increased" pressure" to" contain" costs," policymakers"will" question"whether"the"rising"level"of"investment"in"drugs"is"an"appropriate"use"of"scarce"resources.""
1.2.3& Prescriber&Perspective&Within"the"complex"framework"of"the"prescribing"practice,"the"critical"step"of"the"process"is"the"prescriber"filling"out"a"prescription"form.18"Quality"of"prescribing"within"this"domain"is"defined" from" two" separate"but" interrelated"perspectives:" sociological" and"biomedical."The"sociological"perspective"attempts"to"shed"light"on"the"prescribing"behavior"of"prescribers"by"gaining" a" deeper" understanding" of" the" interaction" between" the" prescriber’s" knowledge,"attitudes," and" beliefs" and" the" subsequent" translation" of" this" interaction" into" prescribing"decisions.19,20"
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The" biomedical" perspective" focuses" on" the" biomedical" model" of" disease," which" uses" an"objective"(numerical)"measurement"to"define"disease,"and"hence"the" impact"of"prescribing"on" disease.5" From" a" biomedical" perspective" of" prescribing," quality" can" be" defined" using"either" process" or" outcome" measures" (Figure" 1.1)." As" put" forth" by" Donabedian," “process"denotes"what"is"actually"done"in"giving"and"receiving"care.”21"When"applied"to"prescribing,"process" measures" assess" whether" the" prescription" parallels" the" accepted" standards" of"clinical" care"within" each" therapeutic" field.22,23" Outcome"denotes" the" effects" of" care" on" the"health"status"of"patients"and"populations.21""The" context" within" which" patient," government/payer," and" prescriber" domains" interact" is"unique"in"the"United"States,"which"is"the"primary"country"of"interest"in"this"thesis"(Box"1.1).""
Figure!1.1!–"Prescribing"Quality"Framework.3"!
"
Box!1.1!Prescription!Drug!Therapy!in!the!United!States!Several"attributes"of"the"fragmented"American"health"care"system"provide"a"unique"context"for"the"interaction"of"patient,"prescriber,"and"government/payer"perspectives,"influencing"the"nature"of"prescription"drug" therapy," and"providing" an" interesting" case" study" for" this"thesis." For" example" with" the" exception" of" New" Zealand," the" United" States" is" the" only"western" nation" that" permits" the"marketing" of" pharmaceutical" products" to" consumers" in"what" is" commonly" termed" directBtoBconsumer" advertising." Responsible" for" creating" and"shaping" patient" demand" for" prescription" drug" therapy," such" promotional" activity" is"commonly"referred"to"by"prescribers"as"one"of"the"most"important"factors"that"affect"their"decisionBmaking"processes"and"their"interactions"with"patients.24"Against" a" backdrop" of" escalating" costs" and" few" restrictions" on" the" pricing" and" use" of"
                                                3"This"framework"was"developed"on"the"basis"of"a"literature"review"to"define"the"quality"domains"associated"with"prescribing"decisions."Discussions"with"Professor"Nick"Barber"of" the"School"of"Pharmacy" (University" of" London)" and" Professor" Tom" Walley" of" Liverpool" University" were"greatly"helpful"in"conceptualizing"the"interactions"between"various"domains.""
29 
 
pharmaceuticals," the"United"States"–"unlike"Australia,"Canada,"and"a"number"of"European"countries"–"does"not"have"a"single"national"entity"responsible" for"evaluating"prescription"drugs" for" clinical" and" economic" value" and" making" coverage" and" reimbursement"recommendations" or" decisions." Rather," a" number" of" public" and" private" agencies" at" the"federal," state," and" local" levels" undertake" such" activities," albeit" in" an" uncoordinated"fashion.25" These" include" national" and" local" assessments" for" Medicare," stateBlevel"evaluations"for"Medicaid,"and"reviews"conducted"by"the"Agency"for"Health"Care"Research"&"Quality,"Drug"Effectiveness"Review"Project,"and"clinical"specialty"organizations."In"a"similar"fashion," there" is" no" national" entity" tasked"with" developing" authoritative" clinical" practice"guidelines."Of"note," such"activities"were"under" the"purview"of"The"United"States"Office"of"Technology"Assessment"until" the"104th" Congress"withdrew" funding" for" it" in"1995"due" to"political"and"social"controversies"that"still"resonate"today"with"the"Republican"majority"in"the"United"States"House"of"Representatives.25B27"Taken"together,"this"unique"context"leaves"prescribers" in" the"dark"about" the"relative"benefits,"harms,"and"costs"of"seemingly"similar"drugs,"and"their"appropriate"place"in"therapy.""Recognizing" the" current" lack" of" authoritative" information" to" guide" decisions" in" clinical"practice" as" a" limitation," the" United" States" has" recently" embarked" upon" ‘comparative"effectiveness" research’." The"premise" of" comparative" effectiveness" research" is" to" improve"population"health" through"patientBcentered"evidence"on" the"comparative"effectiveness"of"interventions," services," and" procedures" that" are" used" to" prevent," diagnose," or" treat"diseases," disorders," and" other" health" conditions.28,29" If" generated," disseminated," and"enforced" effectively," this" type"of" evidence"has" the"potential" to" help"patients," prescribers,"insurers,"pharmacy"benefit"managers,"and"policymakers"make"more"informed"clinical"and"health"policy"decisions.30""Given" the" importance"of" comparative"evidence" in"effective"decisionBmaking," a"number"of"countries" explicitly" require" and" use" such" evidence" in" making" coverage," reimbursement,"and"prescribing"decisions.31"For"example,"health" technology"assessment"agencies" such"as"the" National" Institute" for" Health" and" Care" Excellence" in" England" and" Wales," which" is"entrusted"to"make"decisions"on"‘value"for"money’"on"behalf"of"the"National"Health"Service,"require" comparative" evidence" as" inputs" to" costBeffectiveness" analyses,"which" are" in" turn"used" to" inform" decisions" on" coverage" and" reimbursement.32" However," the" use" of" costBeffectiveness" to" make" coverage" recommendations" is" highly" controversial" in" the" United"States." In" fact," the" use" of" costBeffectiveness" is" expressively" prohibited" by" the" recently"enacted" health" care" reform" legislation:" the" founding" legislation" for" the" PatientBCentered"Outcomes" Research" Institute" states" that" cost" per" qualityBadjusted" lifeByear" thresholds"cannot" be" used" as" the" basis" for" any" coverage" and" reimbursement" determination" in"
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Medicare,"the"largest"public"insurance"program"in"the"United"States.33,34""In"the"United"States,"comparative"effectiveness"research"is"considered"worthy"of"pursuing"as" long" as" the" focus" is" purely" clinical" –" “what" works”" –" and" not" costBeffectiveness."Comparative"effectiveness"research"encompasses"efforts"that"aim"to"encourage"healthcare"decisionBmaking" (including" prescribing" decisionBmaking)" to" be" increasingly" based" on"comparative" evidence" on" clinical" and" humanistic" patientBcentred" outcomes" at" both" the"individual"and"population"levels."Therefore,"cost"considerations"do"not"explicitly"enter"into"the" decisionBmaking" process" for" covering," reimbursing," or" recommending" prescription"drugs" at" least" at" the" national" stage." Unlike" health" technology" assessment" activities" in"Australia," Canada," and"many" European" countries," which" by" definition" evaluate" both" the"clinical" and" economic" consequences" of" prescription" drugs" (among" other" health"technologies)," the" focus" of" comparative" effectiveness" research" in" the" United" States" is" on"clinical"evidence.35""
1.2!Prescribing!Practice!There" are" multiple" levels" of" decisionBmaking" involved" in" prescribing" practice," which" are"influenced" by" the" domains" of" patients," government/payers," and" prescribers." Regulatory"mechanisms" play" a" pivotal" role" in" prescribing" practice," as" the"multiple" levels" of" decisionBmaking"start"at"the"regulatory"level."Once"a"drug"receives"marketing"approval"from"the"Food"and" Drug" Administration" in" the" United" States," it" is" the" government/payer" domain" that"operates" between"manufacturers" and" consumers" and" dictates" the" decision" regarding" the"supply"and"distribution"of"drugs."This"includes"decisions"about"adding"the"drug"to"a"specific"formulary"and"the"level"of"reimbursement"that"may"be"assigned"to"it."This"level"of"decisionBmaking"is"crucial"and"already"influences"the"number"of"available"drug"options"the"prescriber"can"choose"from"for"a"given"condition.""The"prescriber"is"then"faced"with"two"decisions:"first,"whether"to"prescribe"at"all,"and"second,"
what" to"prescribe."Both"decisions"involve"gaining"an"understanding"of"the"clinical"needs"of"the" patient" and" then" applying" knowledge" and" evidence" to" make" a" decision.11" The" first"decision"involves"an"intricate"interplay"between"the"patient"and"prescriber"domains."Within"the"sociological"perspective"of"prescribing,"the"decision"of"whether"to"prescribe"focuses"on"the"patient’s"expectations"and"the"prescriber’s"perceptions"of"patient’s"expectations.36,37"The"prescriber" domain" tends" to" dominate" this" decision," however," as" filling" out" a" prescription"form" reinforces" the" authority" role" of" the" prescriber," and" provides" the" perception" of" an"unambiguous"diagnosis.11""
31 
 
If" the" decision" is" to" prescribe," then" the" prescriber" needs" to" choose" a" specific" drug" to"prescribe."This" is" a"difficult" task"as"many"drugs"are"not" (at" least" at" first" sight)"necessarily"therapeutically" different" from" each" other" but" are"merely" extensions" of" similar" drugs." The"outcome" of" this" decision" has" significant" implications" because" the" choice" of" drug" has" an"impact"on"whether"the"patient"decides"to"adhere"to"drug"therapy"(with"health"implications)."This" decision" is" mainly" influenced" by" the" biomedical" perspective" of" prescribing," which"emphasizes"the"tradeoff"between"the"clinical"benefit"and"harm"associated"with"various"drug"choices." It" is," however," ultimately" up" to" the" patient" to" decide" whether" to" have" the"prescription"dispensed,"whether"to"take"the"drug,"and"how"to"take"it.5"
1.2.1& Prescribing&Quality&on&the&Basis&of&Indicators&As"highlighted"in"Figure"1.1,"prescribing"quality"can"be"defined"using"process"and"outcome"indicators."Although"the"ultimate"goal"of"the"appropriate"use"of"drugs"is"to"improve"clinical"outcomes," it" is" recognized" that" inferring" on" the" quality" of" prescribing" based" on" clinical"outcome" measures" has" major" methodological" limitations.38" This" is" mainly" because" many"drugs"require"years"of"continued"adherence"before"health"benefits"become"measurable."This"may" be" why" only" a" few" studies" use" outcome"measures" to" assess" prescribing" quality.39B41"Although"a"small"number"of"outcome"indicators"were"assessed"using"administrative"claims"data"in"the"literature,"their"validity"was"not"found"to"be"optimal.42"As"evident"by" the"small"number"of" studies"employing"outcome"measures" in" the" literature,"there"appears"to"be"a"clear"preference"for"using"process"as"opposed"to"outcome"measures."Process" measures" used" in" the" literature" could" be" classified" into" two" categories:" those"detecting" underprescribing," and" those" detecting" medication" errors." Criteria" to" detect"underprescribing" usually" state" that" the" prescriber" failed" to" prescribe" a" drug"when" it"was"clinically"needed.23"Medication"errors"include"overprescribing"(prescribing"more"drugs"than"are" clinically"needed)"and"misprescribing" (incorrectly"prescribing"drugs" that"are" clinically"needed)."Criteria"to"detect"overprescribing"consist"of"a"list"of"invalid"indications"to"prescribe"a" specific" drug.23" Misprescribing" criteria" include" drugs" that" should" be" avoided" in" any"circumstances" (‘drugsBtoBavoid’" criteria)," doses" that" should"not"be" exceeded," and"drugs" to"avoid"in"patients"with"specific"disorders.""The"most"widely"used"drugsBtoBavoid"criteria"are" those" that"were"developed"by"Beers.43B45"The"criteria"include"(1)"drugs"that"should"be"avoided"because"they"are"either"ineffective"or"they" pose" unnecessarily" high" risk" and" a" safer" alternative" is" available" and" (2)" drugs" that"should"not"be"used"in"people"with"certain"comorbidities."In"addition"to"the"Beers"criteria,"the"drugsBtoBavoid" approach" also" forms" the" basis" of" quality" indicators" of" prescribing" for" the"STOPP" criteria" (Screening" Tool" of" Older" Persons’" Potentially" Inappropriate"Prescriptions),46,47"as"well"as"the"Canadian"criteria.48"
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1.2.2& Prescribing&Quality&on&the&Basis&of&Clinical&Practice&Guidelines"Adherence" to" clinical" practice" guidelines" are" used" as" an" alternative" approach" to" guiding"prescribing"quality.49"This"approach"has"clear"merits,"as"guidelines"constitute"an"“interface”"between" evidence" and" practice" and" are" instrumental" in" translating" research" findings" into"actual" practice" and" reducing" variation"while" improving" health" outcomes.50" Guidelines" are"commonly" defined" as" “systematically" developed" statements" to" assist" practitioner" and"patient"decisions"about"appropriate"healthcare"for"clinical"circumstances.”51"During"the"past"two" decades," the" wide" appeal" of" implementing" guidelines" as" quality" assessment" tools"paralleled"the"surge"of"interest"in"the"development"and"use"of"these"documents."They"have"been"viewed"as"a"“magic"bullet”"solution"to"improving"clinical"practice,"which"followed"the"highly" publicized" efforts" to" standardize" care" delivery" in" the" United" States.52" Considerable"effort"and"resources"have"been"spent"on"the"development"and"dissemination"of"guidelines53"and"several"major"medical"organizations"have"put"in"place"processes"for"developing"them.54B57"A"growing"body"of" literature"evaluates" the"quality"of"prescribing" in" terms"of"deviations"from"guidelines.""Such"evaluations"show"variable"results"in"terms"of"quality"of"prescribing.58B69"In"a"number"of"studies,"recommendations"from"guidelines"had"little"effect"on"prescribing"patterns."Lack"of"adherence" to" guidelines"may" be" due" to" extensive" criticisms" over" their" recommendations."Unlike" their" counterparts" in" many" European" settings," such" as" those" developed" by" the"National"Institute"for"Health"and"Care"Excellence"in"England"and"Wales,"recent"evaluations"in" the" US" demonstrated" that" guidelines" fall" considerably" short" of" meeting" established"methodological" standards.70" It" has" been" shown" that" recommendations" made" in" United"StatesBbased" guidelines" are" largely" developed" from" lower" levels" of" evidence" or" expert"opinion.71"Additionally,"the"proportion"of"recommendations"for"which"there"is"no"conclusive"evidence" is"also"growing."Too"many"of" the"current"guidelines"have"become"marketing"and"opinionBbased"pieces,"delivering"directive" rather" than"assistive" statements.72"Worse," some"guidelines"offer"conflicting"recommendations.73,74""
1.2.3& Insights&from&the&Literature&The" literature" on" prescribing" quality" highlights" the" complexity" of" drug" therapy" and" the"challenges"facing"those"evaluating"its"quality."There"are"a"number"of"conclusions"that"can"be"drawn:"1. Indicators& do& not& measure& prescribing& quality:& rather,& they& measure& the& lack& of& it." The"literature" relying" on" indicators" does" not" actually" assess" the" quality" of" prescribing;"rather," it" assesses" the" lack" of" it." Instead" of" quality" of" prescribing," an" alternative" (and"more" relevant)" term" to" frame" the" focus" of" the" literature," therefore," would" be"
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‘inappropriateness"of"prescribing’."This"encompasses"a"range"of"values"and"behaviors"to"express" in"a" simple" term" the" lack"of"quality"of"prescribing.23" Inappropriateness"would"then" refer" to" medication" errors" and" underprescribing." Within" this" construct" of"inappropriateness,"most"indicators"in"the"literature"would"be"categorized"as"providing"a"measurable" lower" limit" of" pharmacological" inappropriateness" (and" a" floor" of" quality"below"which" no" patient" and" prescriber" should" go)," rather" than" a" continuous" scale" of"prescribing"quality.23"2. Clinical& practice& guidelines& do& not& provide& an& ideal& platform& for& guiding& prescribing&
quality." Even" the" quality" standards" based" on" clinical" practice" guidelines" –" those"attempting"to"measure"a"continuous"scale"of"quality"–"do"not"provide"an"ideal"platform"for" assessing" prescribing" quality.75" As" guidelines" are" intended" to" improve" practice" by"describing"a"set"of"actions"that"should"be"considered"when"caring"for"patients,"they"are"rarely" written" with" retrospective" audit" of" quality" in" mind."When" it" comes" to" guiding"prescribing" decisions," in" particular," most" guidelines" in" the" United" States" leave"considerable"discretion"to"prescribers,"who"are"faced"with"a"decision"to"choose"between"a"large"number"of"(seemingly)"equally"useful"drugs"for"a"given"condition."For"example,"the" guidelines" developed" by" the" American" Academy" of" Neurology" and" the" Multiple"Sclerosis"Council"failed"to"distinguish"amongst"six"drugs"that"are"currently"used"for"the"treatment"of"multiple"sclerosis,"leaving"it"up"to"the"prescriber"to"decide"how"to"initiate"therapy" in" multiple" sclerosis" patients76" Similar" examples" spanned" across" various"specialties" including" mental" health" (schizophrenia,77" depression78)," " rheumatology"(rheumatoid"arthritis79),"and"respiratory"illness"(asthma80)."This"means"that"prescribers"do" not" have" adequate" information" about" a" drug’s" appropriate" place" in" practice."Prescribers"are"expected"to"sort"out"the"drugs"that"offer"greater"benefit"with"the"help"of"postBmarketing" observational" studies" and" promotional" materials" received" from" the"pharmaceutical"industry."This"‘flexibility’"of"the"guidelines"in"the"United"States,"whether"obtained"by"vagueness"or"complexity,"makes"it"difficult"to"choose"among"multiple"drugs"to"initiate"prescription"therapy."3. Quality& standards& do& not& relate& to& the& aspects& of& prescribing& practice& that& can& be& fully&
controlled& by& prescribers." Widely" used" quality" standards" aimed" at" assessing" the"performance"of"prescribers"focus"on"the"aspects"of"prescribing"practice"that"are"not"only"influenced"by"prescribers"but"also"by"patients."In"most"assessments,"evaluation"metrics"(based"on"both"indicators"and"guidelines)"focus"on"the"decision"of"whether"to"prescribe"for" a" given" condition." By" quantifying" the" prescriber’s" failure" to" (correctly)" prescribe"when" drugs" are" clinically" needed," studies" mainly" target" the" grey" area" of" prescribing"practice" where" the" demands" of" quality" assessments" sit" uncomfortably" with" the"uncertainties"of"deciding"whether"to"prescribe."As"outlined"earlier,"deciding"whether"to"
34 
 
prescribe" (as" opposed" to"what" to" prescribe)" is" complex" and" is" informed" not" only" by"scientific" evidence" but" also" by" the" patient’s" expectations" and" the" prescriber’s"perceptions" and" knowledge.81B83" Therefore," making" decisions" about" whether" to"prescribe" requires" an" optimal" tradeoff" between" clinical" benefit" and" harm" within" the"context"of"patients’"choices"and"preferences."Since"these"factors"are"not"fully"under"the"prescriber’s"control,"assessing"the"prescriber’s"performance"(and"judging"the"quality"of"prescribing)"based"on"decisions"regarding"whether"to"prescribe"is"not"ideal.""
1.3!Research!Opportunity:!The!Role!of!Comparative!Clinical!Evidence!in!Prescription!
Drug!Therapy!Quality"metrics"need"to"relate" to" the"aspects"of"prescribing"practice" that"are"controlled"by"prescribers"–"and"measured"against"an"objective"benchmark,"which"is"optimally"dictated"by"scientific" evidence." One" such" aspect" is" choosing" a" specific" drug" to" prescribe." As" there" are"several"possible"drugs"that"are"available"to"treat"patients"with"the"same"condition,"selecting"the" best" drug" with" which" to" initiate" therapy" is" a" challenging" task." One" aspect" of" this" is"deciding"on"a"specific"drug"class."Also"important"is"selecting"a"particular"drug"within"a"given"class."Albeit"the"standard"thinking"that"similar"drugs"do"not"differ"in"terms"of"their"clinical"efficacy," empirical"evidence"suggests"otherwise.84" In" fact," evidence"suggests" that"assuming"that"all"drugs"within"a"soBcalled"drug"class"are"equivalent"and"can"be"used"interchangeably"may"be"clinically"unwarranted.85B90 "Given" the" clinical" reality" that" comparative" efficacy" of" drugs" varies," assessing" whether"prescribers"make"an"effective"choice"out"of"the"many"available"similar"drugs"is"important."In"order" to" ensure" that" the" ‘right’" decision" is" made" in" prescribing" a" specific" drug," quality"standards" need" to" take" into" account" evidence" regarding" the" comparative" effectiveness" of"similar" drugs." As" defined" by" the" United" States" Institute" of" Medicine," comparative"effectiveness"evidence"“compares"the"benefits"and"harms"of"alternative"methods"to"prevent,"diagnose,"treat,"and"monitor"a"clinical"condition"or"to"improve"the"delivery"of"care”.28""Defining"prescribing"quality"on"the"basis"of"comparative"effectiveness"requires"prescribers"to" appraise" all" the" available" evidence" prior" to" reaching" conclusions" about" which" drug" to"prescribe."This"is"unrealistic,"as"prescribers"already"cannot"keep"up"with"evidence."Previous"research" has" shown" that,"with" the" recent" explosion" in" the" number" of" clinical" trials" and" a"proliferation"of"similar"drug"options,"prescribers"feel"overwhelmed"by"new"evidence;"do"not"know" where" to" look" for" information;" and" do" not" have" sufficient" time" to" learn" new"information.91,92" Moreover," information" on" comparative" effectiveness" is" not" always"available." A" randomized" controlled" trial" comparing" all" similar" drugs" would" provide" such"information." However," randomized" controlled" trials" are" often" designed" for" regulatory"purposes"and"therefore"do"not"include"all"available"comparator"drugs."The"comparator"arms"
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of" randomized" controlled" trials" are" often" limited" to" a" placebo" intervention." In" order" to"obtain"insight"into"the"relative"efficacy"(or"safety)"of"similar"drugs,"prescribers"need"to"turn"to" summaries" of" evidence" to" discern" the" most" promising" drugs" from" their" less" effective"comparators."
1.3.1& The&Role&of&Evidence&Review&and&Synthesis&Evidence" review"and" synthesis" approaches" such" as" systematic" reviews" and"metaBanalyses"have"a"clear"role"in"ensuring"that"healthcare"interventions"are"based"on"complete"and"up"to"date"evidence.93"In"terms"of"prescribing"practice,"they"are"essential"in"assembling"evidence"on" the" comparative" effectiveness" of" similar" drugs." There" is" an" opportunity" to" use" this"evidence"to"guide"the"quality"of"prescribing"practice."In"theory,"this"seems"straightforward:"first" a" systematic" review" is" conducted" to" identify" all" relevant" evidence" on" similar" drugs."Then,"this"evidence"is"synthesized"in"a"metaBanalysis"to"determine"the"most"efficacious"drug"and" guide" prescribing" decisionBmaking." This" evidence" can" in" turn" be" used" to" evaluate"whether"prescribers"are"choosing"the"‘right’"drug"option"when"initiating"therapy.""In"practice,"however,"there"are"technical"issues"to"consider"that"influence"the"utility"of"this"approach." The" first" relates" to" the" reliability" of" the" clinical" literature." Emerging" evidence"suggests"that"the"vast"majority"of"published"research"have"weak"designs,"resulting"in"biased"findings.94" Equally" challenging," the" majority" of" existing" tools" to" synthesize" the" clinical"literature" are" largely" capable" of" pairBwise," direct" comparisons" of" drugs" (often" with" the"comparator" being" a" placebo" or" control" group)." This" means" that" comparisons" are" often"limited"to"two"drugs,"with"simultaneous"comparisons"of"all"similar"drugs"not"being"feasible."This"focus"on"two"drugs"makes"it"difficult"for"prescribers"to"determine"the"best"drug"among"all"available"comparators."In"the"absence"of"metaBanalyses"that"compare"all"similar"drugs"of"interest,"it"is"not"possible"to"guide"and"inform"prescribing"decisions"on"the"basis"of"pairBwise"direct"comparisons.95"The"only"option"is"to"rely"on"indirect"comparisons.""Methodological" advances" in" statistical" synthesis"approaches" called"network"metaBanalyses"(also" known" as" mixed" treatment" comparisons," multipleBtreatments" metaBanalyses," or"multiple" treatments" comparisons)" allow" the" indirect" comparison" of" multiple" treatment"options." What" distinguishes" these" methods" from" pairBwise" metaBanalyses" is" that" they"facilitate" the" synthesis" of" a" larger" pool" of" evidence" by" incorporating" both" direct" (when"treatments" are" compared" to" each" other" within" a" trial)" and" indirect" evidence" (when"treatments" are" compared" between" trials"with" a" common" comparator" treatment," which" is"often"placebo).96,97"By"implication"of"including"both"direct"and"indirect"evidence,"attempts"at"statistically"synthesizing"the"existing"body"of"evidence"are"no"longer"limited"to"a"comparison"of"two"drugs."Rather,"they"are"capable"of"comparing"all"relevant"drugs"even"when"they"are"not"trialed"against"each"other.98"Quantitative"comparative"effectiveness"estimates"obtained"
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from" such" analyses" have" the" potential" to" provide" prescribers" with" valuable" evidence" to"make" an" effective" choice" out" of" the" many" available" apparently" similar" drugs." This" thesis"focuses" on" the" role" of" evidence" review" and" synthesis" methods" to" generate" comparative"evidence," which" can" subsequently" be" used" to" guide" highBquality" prescribing" decisions" in"clinical" practice." As" a" result," it" demonstrates" the" potential" value" of" evidence" review" and"synthesis"approaches"in"generating"comparative"effectiveness"evidence"on"individual"drugs,"and" in"doing" so" illustrates"how"such"evidence" can" fill" the"existing"gaps" in" clinical"practice"guidelines."This"work"is"timely"and"relevant"within"the"evidenceBbased"medicine"framework"of"the"past"two"decades." EvidenceBbased"medicine" is" “the" conscientious," explicit," and" judicious"use" of"current" best" evidence" in" making" decisions" about" the" care" of" individual" patients.”99,100"According" to" Archie" Cochrane," current" best" evidence" is" “upBtoBdate" information" from"relevant,"valid"research"about"the"effects"of"different"forms"of"health"care,"the"potential"for"harm"from"exposure" to"particular"agents”.101"By"synthesizing"existing"highBquality"data"on"clinical" benefits" and" harms" of" individual" drugs" within" a" therapeutic" class," the" empirical"findings" presented" in" this" thesis" aim" to" provide" the" current" best" evidence" to" prescribers"who"are"tasked"with"choosing"among"individual"drugs.""
1.4!Disease!Area!of!Focus:!Hypercholesterolemia!The" focus"of" the"empirical"work"presented" in" this" thesis" is" on" cholesterolBlowering"drugs,"also" known" as" statins," which" are" widely" prescribed" to" lower" the" risk" of" coronary" heart"disease" and" stroke." Currently" there" are" six" statins" (atorvastatin," fluvastatin," lovastatin,"pravastatin," rosuvastatin," simvastatin)" marketed" for" the" same" indication" of" “reducing"elevated"totalBcholesterol,"lowBdensity"lipoprotein"(LDL)"cholesterol,"apolipoproteinBB,"nonBhighBdensity"lipoprotein"(nonBHDL)"cholesterol,"and"triglyceride"levels"and"increasing"highBdensity"lipoprotein"(HDL)"cholesterol"in"patients"with"primary"hypercholesterolemia.”102"Assessing" the" comparative" effectiveness" evidence" on" statins" is" crucial" for" a" number" of"reasons." Statin" therapy," initially" focused" on" individuals" at" highBrisk" of" developing"cardiovascular" disease," has" become" widely" common" as" the" limits" of" treatment" expanded"over" time" to" include" persons" at" progressively" lower" risk" of" developing" coronary" heart"disease."While"6.5%"of"Americans"of"all"ages"took"cholesterolBlowering"medications"between"1999"and"2002," the" corresponding" share"of" the"population"was"12.5%"between"2007"and"2010," with" over" 45%" of" people" aged" 65" years" or" older" taking" cholesterolBlowering"medications" during" this" latter" period.103" As" the" number" of" individuals" in" need" for" statin"therapy"continues"to"increase,"information"regarding"the"relative"clinical"value"of"statins"is"needed" to" better" inform" patients," prescribers," and" other" healthcare" decision" makers" in"clinical"practice.""
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With"the"basic"mechanism"of"cholesterol"lowering"remaining"the"same,"the"six"statins"differ"to"a"various"extent"in"pharmacological"properties"and"it"would"be"expected"that"they"differ"in" terms" of" their" clinical" efficacy.87,104" However," their" comparative" effectiveness" has" only"been"partially"documented.105"Almost"all"of"the"metaBanalyses"conducted"on"statins"assumed"that"they"are"equivalent,"and"hence"interchangeable."There"has"not"been"any"attempt"to"rank"statins" on" the" basis" of" clinical" efficacy" (in" terms" of" surrogate" outcomes" [cholesterol"reduction]"as"well"as"clinical"outcomes"[both"primary"and"secondary"prevention"of"coronary"heart"disease"outcomes]),"which"would"greatly"assist"in"evaluating"the"quality"of"prescribing"decisions.""
1.5!Thesis!Objectives!and!Overview"The"proponents"of"the"evidenceBbased"medicine"movement"have"called"for"an"increased"use"of" evidence" reviews" and" syntheses" to" inform" prescribing" decisions." Existing" data" from"randomized"controlled"trials"is"a"suitable"starting"point"for"guiding"drug"selection"decisions"in" clinical" practice." The" overarching" objective" of" this" thesis" is" to" synthesize" the" existing"randomized" controlled" data" available" in" the" literature" to" distinguish" among" individual"statins"in"terms"of"clinically"meaningful"benefit"and"harm"outcomes."As"such,"it"investigates"whether"synthesizing"a"disparate"body"of"randomized"trial"literature"would"identify"a"clear"winner"among"multiple"treatment"options"in"a"given"drug"class,"and"provide"adequate,"valid,"and" yet" simple" guidance" for" decision"makers" in" clinical" practice." As" discussed" in" the" next"chapter" (Chapter" 2:" Evolution& of& Clinical& Evidence:& The& Case& of& Statins)" existing" clinical"practice" guidelines" in" the"United" States" provide" no" specific" guidance" around"which" statin"should" be" the" preferred" option" to" initiate" cholesterolBlowering" therapy." To" address" this"significant" gap," this" thesis" sets" out" to" examine" the" comparative" clinical" benefit" and" harm"profiles"of"individual"statins"using"existing"randomized"trial"evidence"available"in"the"peerBreviewed"literature."Specifically,"this"thesis"addressed"the"following"empirical"questions:"1. What"are"the"doseBcomparative"effects"of"individual"statins"on"cholesterol"levels?"2. Are" individual" statins" interchangeable" in" terms" of" their" effects" on" clinical" benefit"outcomes?"3. How"do"individual"statins"compare"in"terms"of"their"side"effect"profiles?"4. Are"the"findings"of"comparative"assessments"on"statins"free"of"industry"sponsorship"bias?"The" methods" underpinning" the" empirical" work" presented" in" this" thesis" are" outlined" in"Chapter" 3." Chapters" 4B7" address" the" research" questions" listed" above," and" form" the"main"empirical"body"of"the"thesis."Chapter"8"brings"together"key"findings"with"an"emphasis"on"the"opportunities" and" challenges" of" basing" future" prescribing" decisions" on" existing" clinical"evidence." Chapter" 9" examines" the" future" research" directions" and" practical" policy"
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Chapter!2!"Evolution"of"Clinical"Evidence:"The"Case"of"Statins"""The" first" HMGBcoA" reductase" inhibitor," lovastatin" (originally" marketed" as" Mevacor®),"received"the"Food"and"Drug"Administration’s"regulatory"approval"in"the"United"States"in"July"1987,"marking" the"beginning"of" the"quarterBcentury"history"of" ‘statins’" in" clinical"practice."Dramatically" reducing" patients’" LDL" cholesterol" levels" in" clinical" trials" with" an" excellent"safety"and"tolerability"profile,"lovastatin"received"considerable"enthusiasm"upon"its"market"entry.""In"many"aspects,"however,"this"was"a"newly"found"enthusiasm"–"primarily"attributed"to"the"emerging" consensus" to" classify" total" cholesterol," and" specifically" LDL" cholesterol," as" an"important" risk" factor" for" coronary" heart" disease." Only" a" little"more" than" a" decade" before"lovastatin"received"its"marketing"approval,"blood"cholesterol"levels"were"not"believed"to"be"causally" related" to" coronary"heart"disease.106"Termed" the" “cholesterol" controversy”,"many"were"skeptical"about" the"role"of"cholesterol" in" the"development"of"coronary"heart"disease."Clinicians"remained"opposed"to"suggestions"of"any"significant"relationship"between"elevated"cholesterol" levels"and"coronary"heart"disease"until"prospective"observational" studies" such"as" the" Framingham" cohort" provided" an" increasingly" firm" correlation"between"high" serum"cholesterol" levels" and" coronary" heart" disease" mortality" and" morbidity" in" the" early"1980s.106,107""So"the"first"statin"entered"clinical"practice"during"a"time"when"there"was"emerging"interest"in"cholesterol"reduction."Within"a"decade,"this"interest"turned"into"widespread"–"and"almost"unequivocal"–"acceptance"of" lipidBlowering"statins"as"the"wonder"drugs"for"coronary"heart"disease"prevention,"with"statins"quickly"becoming"the"most"widely"prescribed"drugs"in"the"United"States." In"2005"alone,"173.7"million"prescription"statin"purchases"were"responsible"for"$19.7"billion"in"expenditures"for"29.7"million"people.108"According"to"latest"populationBlevel" surveys," roughly" one" in" four" Americans" aged" 45" years" or" older" take" a" cholesterolBlowering"statin"drug.103"
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This"chapter"provides"a"brief"overview"of"the"historical"context"within"which"the"evidence"on" statins" emerged;" how" this" evidence" subsequently" shaped" the" recommendations" in"influential" clinical" practice" guidelines" in" the" United" States;" and" the" role" played" by" metaBanalyses" in" addressing" important" questions" not" investigated" in" individual" trials." The" case"study" on" statins" highlights" important" questions" about" the" existing" approaches" to"incorporating" evidence" into" clinical" practice" guidelines;" determining" the" comparative"benefits" and" harms" of" similar" agents;" and" making" clear" recommendations" as" to" how"decisionBmakers"should"make"the"best"use"of"the"existing"evidence"on"different"drugs."It"also"questions" the" assumption" that" all" drugs" in" a" class" are" the" same" for" a" widely" prescribed"group"of"medicines.""
2.1!Twists!and!Turns!in!the!Cholesterol!Controversy!Evidence"linking"elevated"cholesterol"concentrations"(or"more"accurately,"LDL"cholesterol)"to"coronary"heart"disease"emerged"first"in"the"form"of"prospective"observational"studies,109"and"then"in"randomized"controlled"trials.110"The"most"influential"of"the"latter"was"the"United"States" National" Institutes" of" Health" Coronary" Primary" Prevention" Trial." This" trial"demonstrated" that" lowering" LDL" cholesterol" levels" reduced" the" risk" of" coronary" heart"disease"morbidity"and"mortality" in"men"at"high"risk" for"coronary"heart"disease"because"of"raised"LDL"cholesterol"levels.110"The"United"States"National"Institutes"of"Health"decisively"accepted"the"findings"of"this"trial"and,"in"response,"convened"a"panel"of"experts"to"evaluate"the"new"randomized"trial"evidence"within" the" wider" context" of" the" scientific" literature." This" Consensus" Development"Conference" of" the" United" States" National" Institutes" of" Health" recommended" in" 1985" that"individuals" with" highB" and" moderateBrisk" blood" cholesterol" levels" should" be" treated"intensively" by" dietary"means," which" could" be" coupled"with" drug" treatment" as" necessary."Partly" reflecting" the"perceived" therapeutic"value"of"existing"drug"regimens"at" the" time"(or"the"lack"thereof),"dietary"therapy"was"prioritized"over"treatment"with"lipidBlowering"drugs."The" lipidBlowering" armamentarium"was" limited" to" bileBacid" sequestrants" (cholestryamine"and"colestipol),"nicotinic"acid"(niacin),"the"fibrates,"and"probucol."Unfortunately,"all"of"these"treatments"had"limited"efficacy"or"tolerability,"or"both."Therefore,"when"lovastatin"entered"clinical" practice," it"was" hailed" as" a"major" advancement" over" existing" lipidBlowering" drugs"and"was"widely" accepted" by" patients" and" clinicians.111,112" According" to" its"manufacturer’s"trial" reports," lovastatin" at" its" maximum" recommended" dose" of" 80" mg/day" resulted" in"estimated"mean"reductions"in"LDL"cholesterol"concentrations"of"40%,"far"greater"than"any"of" the" treatments" available" at" the" time" –" and" with" a" far" more" favorable" side" effect"profile.113,114""
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Following" the" Consensus" Development" Conference" in" 1985," the" United" States" National"Institutes" of"Health"undertook" a"massive" education" and" training"program"and" formed" the"National"Cholesterol"Education"Program"(NCEP)"Expert"Panel"on"Detection,"Evaluation"and"Treatment"of"High"Blood"Cholesterol"in"Adults"(which"was"also"termed"the"Adult"Treatment"Panel" or" in" short," ATP)." Although" no" specific" legislation" established" this" program," it" was"created"under"a"broad"legislative"mandate"for"the"National"Heart,"Lung,"and"Blood"Institute"and" its" predecessor," the" National" Heart" and" Lung" Institute," to" disseminate" health"information"in"the"form"of"clinical"practice"guidelines.115""The" first" report" of" the" NCEP" (ATPBI)," released" in" 1988," identified" LDL" cholesterol" as" the"primary" target" of" clinical" management" and" started" to" establish" the" boundaries" for"therapeutic" intervention" in" high" blood" cholesterol" (also" referred" to" as"hypercholesterolemia).116"It"outlined"a"strategy"for"the"prevention"of"coronary"heart"disease"in"persons"with"high" levels"of"LDL"cholesterol" (160"mg/dL)"or" those"with"borderlineBhigh"LDL"cholesterol" (130B159"mg/dL)"and"multiple"risk" factors"such"as"cigarette"smoking"and"high"blood"pressure.117B119" LipidBlowering"drug" treatment"was" recommended"after"dietary"therapy." Although" this" report" recognized" the" potential" added" benefit" of" lovastatin" in" the"treatment" of" hypercholesterolemia," clinicians" were" cautioned" against" its" widespread" use."This"was"mainly"because"the"longBterm"safety"of"lovastatin"was"not"demonstrated"and"also"it"had"not" been"proven" to" reduce" the" risk" for" coronary" heart" disease"when"used" alone." The"report"recommended"that:"Lovastatin"is"very"effective"in"lowering"LDL"cholesterol"levels,"produces"modest"reductions" in" triglyceride" levels," and" is" easy" to"administer."The" clinical"use"of"lovastatin"has"been"under"study" for"only"a" few"years,"and" its" longBterm"safety"and" effects" on" [coronary" heart" disease]" end" points" have" not" yet" been"established." It" is," therefore,"not"classed"as"a"drug"of" first"choice" in" this"report,"and"some"caution"is"appropriate"in"its"use."
The" second" report" of" the" NCEP" Adult" Treatment" Panel" in" 1993" (ATPBII)" continued" to"emphasize" LDL" cholesterol" as" the" primary" target" of" cholesterol" lowering" therapy;"distinguished"between"different"coronary"heart"disease"risk"categories;"and"emphasized"the"importance"of"intensive"drug"therapy"for"those"individuals"with"established"coronary"heart"disease"(secondary"prevention).120"For"individuals"without"clinically"evident"coronary"heart"disease" (primary"prevention),"drug" treatment"was" recommended" if" LDL" cholesterol" levels"were"(1)"190"mg/dL"or"greater"without"two"other"risk"factors,"or"(2)"160"mg/dL"or"greater"with" two" other" risk" factors," despite" dietary" therapy." The" goals" of" drug" therapy"were" the"same"as"those"of"dietary"therapy:"to"lower"LDL"cholesterol"to"below"160"mg/dL"or"to"below"130"mg/dL" if" two" other" risk" factors"were" present." For" secondary" prevention," the" goal" of"therapy"was"more"intensive"with"LDL"cholesterol"level"of"100"mg/dL"or"lower."Drug"therapy"was" generally" indicated" in" patients" with" established" coronary" heart" disease" or" other"
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atherosclerotic" disease" if" LDL" cholesterol" levels"were" 130"mg/dL" or" greater" after" dietary"therapy.""Since" the" first" report" of" the" NCEP," simvastatin" (originally" marketed" as" Zocor®)" and"pravastatin" (originally" marketed" as" Pravachol®)" had" received" the" Food" and" Drug"Administration’s"marketing" approval" in" 1988" and" 1991," respectively." Both" of" these" drugs"demonstrated" comparable" cholesterolBlowering" effects" to" lovastatin" and" achieved" highly"effective" reductions" in" LDL" cholesterol" levels.121B126" Albeit" these" promising" effects," the"second"report"of"the"NCEP"(ATPBII)"continued"to"caution"against"the"widespread"use"of"these"statins" given" that" there"was" no" longBterm" data" available" to" ascertain" their" safety.127" Also,"individual" randomized" trials" of" statin" therapies" had"not" confirmed" any" survival" benefit" in"terms"of"total"mortality"or"coronary"heart"disease"mortality."The"second"report"of"the"NCEP"(ATPBII)"stated"the"following:"Statins" (lovastatin," pravastatin," and" simvastatin)" are" highly" effective" in"lowering" LDL" cholesterol." They" appear" to" be" relatively" safe," but" longBterm"safety" remains" to" be" demonstrated." Therefore," they" should" be" used" with"particular"caution"in"young"adult"men"and"premenopausal"women."The"statins"have" not" been" proven" to" reduce" risk" for" [coronary" heart" disease]"when" used"alone," but" in" view" of" their" efficacy" for" lowering" LDL" cholesterol," they" are"attractive" for" treatment" of" severe" forms" of" hypercholesterolemia" and" for"maximal"lowering"of"LDL"levels"in"secondary"prevention.""
2.2!The!Lipid!Hypothesis:!Controversy!No!More!By"the"early"1990s," the" first"component"of" the" lipid"hypothesis"–" that"elevated"cholesterol"levels"are"causally"linked"with"a"high"risk"of"atherosclerosis"and"subsequent"coronary"heart"disease"–"was"well"accepted."However," its" second"component,"which"asserts" that" lowering"cholesterol" levels" can" lower" the" risk" of" coronary" heart" disease," and" as" a" result" total"mortality," remained" controversial." Earlier" reviews" on" this" topic" cautioned" against" drug"treatment" in" patients" with" low" to" moderate" risk" of" death" from" coronary" heart" disease"because"of" possible" increases" in" allBcause"mortality"with" treatment.128"As" evidence"on" the"benefits"of" lipid" lowering" therapy" (including"drug" classes"other" than" statins)" continued" to"emerge,"there"remained"important"unanswered"questions."Importantly,"no"previous"trial"of"lipidBlowering"therapy"had"demonstrated"a"reduction"of"risk"for"total"mortality."Also,"there"were" concerns" about" possible" increases" in" some" nonBcardiovascular" causes" of" mortality"associated" with" cholesterol" lowering.129,130" A" review" published" in" 1990" showed" a"significantly" increased" risk" of" death" from" accidents" and" violence" when" the" results" of" six"randomized"trials"of"lipid"lowering"drugs"(including"nonBstatin"drug"classes)"were"pooled.129"This" finding" spurred" considerable" debate" and" led" a" number" of" influential" cardiologists" to"ask:"“Should"there"be"a"moratorium"on"the"use"of"cholesterol"lowering"drugs?”130""
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The"publication" in"1994"of" the"results"of" the"Scandinavian"Simvastatin"Survival"Study"(4S)"marked"a"turning"point"in"the"cholesterol"controversy.131"In"this"study"of"4,444"individuals"with" established" coronary" heart" disease" (secondary" prevention)," simvastatin" produced"highly"significant"reductions"in"the"risk"of"death"and"morbidity"after"five"years"of"followBup."There" was" a" 30%" reduction" in" allBcause" mortality" (due" to" a" 42%" reduction" in" coronary"deaths),"34%"reduction"in"major"coronary"events"and"a"37%"reduction"in"revascularization"procedures." Importantly," there" was" no" indication" of" any" increase" in" nonBcardiovascular"mortality." These" results" reassured" those" who" had" remained" skeptical" to" cholesterolBlowering"therapy"and"led"Michael"Oliver,"a"prominent"Professor"of"Cardiology"in"the"United"Kingdom," to" recommend" in" the" British" Medical" Journal:" “Lower" patients’" cholesterol"now.”132"Later"large"randomized"controlled"trials"of"atorvastatin133"(which"gained"market"approval"in"1997" as" Lipitor®)," fluvastatin134" (which" gained" market" approval" in" 1994" as" Lescol®),"lovastatin,135"pravastatin,136B138"and"simvastatin139" further"distinguished"statins" from"other"lipid" lowering"drugs"and"established"that"statins"not"only"substantially"reduced"the"risk"of"cardiovascular" events," but" did" so" without" any" increase" in" nonBcardiovascular" mortality."According" to" these" large" trials," statins" reduced" the" risk" of" coronary" heart" disease" events"both"in"patients"with"established"coronary"heart"disease"(secondary"prevention)131,133,134,139"and"in"those"without"(primary"prevention).135,136,139""Taken" together," large" statin" trials" contributed" to" the" understanding" that" the" cholesterol"controversy" was" conclusively" over.140" Today," it" is" widely" accepted" that" elevated" serum"cholesterol"levels"are"an"established"risk"factor"for"cardiovascular"disease:"LDL"cholesterol"lowering" decreases" the" risk" of" coronary" heart" disease" mortality" and" morbidity.141B147" A"strong"body"of"clinical"trial,"epidemiological,"and"genetic"literature"has"shown"that"lifetime"risk"of"coronary"heart"disease"increases"sharply"with"higher"LDL"cholesterol"levels"for"men"and"women"at" all" ages.144,148B151"The" relation"between"LDL"cholesterol" and"coronary"heart"disease" risk" appears" to" be" continuous.152" In" addition," net" decreases" in" LDL" cholesterol"translate"logBlinearly"to"net"decreases"in"coronary"heart"disease"and"total"mortality"risk.153""In" light" of" this" accumulating" evidence," the" clinical" practice" guidelines" today"unequivocally"recommend" the" use" of" statins" in" clinical" practice" for" some" patients" with" coronary" heart"disease"or"equivalent."According"to"the"third"NCEP"Adult"Treatment"Panel"guidelines"(ATPBIII),154" persons" with" coronary" heart" disease" or" coronary" heart" disease" risk" equivalent4"(collectively" referred" to" as"highGrisk)"have"an"LDL"cholesterol" goal"of"<100"mg/dL." In" this"
                                                4"The"notion"of"risk"equivalence"suggests"that"individuals"with"certain"characteristics"share"the"same"risk"for"coronary"heart"disease."For"instance,"persons"with"diabetes"without"coronary"heart"disease" (most" of" whom" display"multiple" risk" factors)" are" considered" to" have" the" risk" level" of"coronary"heart"disease"risk"equivalent."
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group" of" individuals" with" LDL" cholesterol" ≥100"mg/dL" dietary" therapy" is" recommended."When"baseline"LDL" cholesterol" is" ≥130"mg/dL," an"LDLBlowering"drug" is" recommended" in"addition" to"dietary" therapy."Those"with"multiple" risk" factors" (considered"moderately"highG
risk)"have"an"LDL"cholesterol"goal"of"<130"mg/dL."Finally,"those"with"0–1"risk"factor"have"a"goal"LDL"cholesterol"of"<160"mg/dL,"for"which"clinical"management"and"dietary"therapy"are"recommended"if"LDL"cholesterol"levels"are"≥160"mg/dL.""As" it"applies" to" lipid" lowering"drug" therapy," the" third"report"of" the"NCEP"was"particularly"important" in" two" ways." First," it" emphasized" the" importance" of" (more)" intensive" LDL"cholesterol" lowering" targets." Second," it" highlighted" the" role" of" lipidBlowering" drugs," and"particularly"statins,"in"achieving"these"intensive"targets."Although"the"report"acknowledged"the"potential"relevance"of"nonBstatin"drugs"such"as"bile"acid"sequestrants"and"nicotinic"acid,"statins" at"moderate"doses" are" considered" as" firstBline"drug" therapy."The" report" stated" the"following:"HMGBcoA" reductase" inhibitors" (statins)" are" powerful" LDLBlowering" drugs."Statin" therapy" reduces" risk" for" [coronary" heart" disease]" outcomes" in" both"primary"and"secondary"prevention..." Statins" should"be"considered"as" firstBline"drugs"when"LDLBlowering"drugs"are"indicated"to"achieve"LDL"treatment"goals."
LipidBlowering" recommendations" of" the" ATPBIII" national" guidelines" had" an" impact" on"clinical"practice"and"prescription"rates" for"statins" in" the"United"States"surged" immediately"after" the" publication" of" the" ATPBIII" report" in" 2001." An" estimated" 12.5"million" Americans"(19.6%" of" the" adult" population"with" high" LDL" cholesterol" levels)"were" prescribed" statins"during" the"period"right"before" the"publication"of" the"clinical"practice"guidelines."However,"the"number"of"individuals"receiving"statins"increased"to"24"million"between"2003"and"2004,"which"was"an"estimated"35.9%"of"United"States"adults"with"high"LDL"choltesterol"levels.155"Partly" as" a" result" of" the" NCEP" ATP" guidelines," statins" are" currently" the" mainstay" of"therapeutic" management" of" high" blood" cholesterol" levels" for" the" prevention" of" coronary"heart"disease."In"November"2013"(following" the"completion"of" the" full"draft"of" this" thesis)," the"American"College" of" Cardiology" and" American" Heart" Association" (ACC/AHA)" issued" a" new" clinical"practice" guideline" on" the" treatment" of" blood" cholesterol" to" reduce" cardiovascular" disease"risk.156B158"These"guidelines"abandoned"specific"LDL"levels"as"treatment"goals;159,160"lowered"the" threshold" of" statin" treatment" and" recommended" drug" therapy" for" the" primary"prevention"of"coronary"heart"disease;161,162"and"recommended"the"use"of"a"newly"developed"pooled"cohort"equations"for"estimating"10Byear"coronary"heart"disease"risk.163,164"By"doing"so,"the"latest"clinical"practice"guidelines"generated"substantial"controversy,"leaving"patients"and" prescribers" perplexed" –" particularly" when" the" new" risk" estimator" was" subsequently"found" to" be" erroneous,165,166" further" fuelling" fierce" debate" and" intense" criticism.167B170"
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According" to" the"ACC/AHA"report,"33"million"Americans"are"expected" to"be"newly"eligible"for" highBintensity" statin" therapy" while" statins" will" be" considered" for" another" 13" million"Americans" under" the" new" guidelines.157,162" Such" considerable" broadening" of"pharmacological" therapy" underscores" the" importance" of" evaluating" the" comparative"benefits"and"harms"associated"with"individual"statins.""
2.3!Piecing!Together!the!Evidence!on!Statins:!Meta@Analyses!of!Randomized!Trials"Although"the"quickly"expanding"literature"on"statins"overwhelmingly"confirmed"the"overall"benefits"of"statins"in"the"general"population,"evidence"on"their"effect"in"certain"patient"subBpopulations"was"less"certain"in"some"trials."For"instance,"until"recently,"the"effect"of"statins"on"the"elderly"was"a"matter"of"continuing"debate."In"addition,"there"was"continuing"interest"in" investigating" the" impact" of" statins" on" major" cerebrovascular" events" such" as" strokes,"which"had"not"been"evaluated" in" individual" trials."A"matter"of" considerable"debate," it"was"not" clear"whether" statins" resulted" in" a" survival" benefit" in" individuals"without" established"coronary" heart" disease" (for" primary" prevention)." To" address" these" questions," a" large"number" of" metaBanalyses" pieced" together" the" findings" of" numerous" trials" and" provided"further" insights" into" the" effectiveness" of" statins" on" various" outcomes" across" a" range" of"patient" populations." Although" the" findings" of" different" metaBanalyses" are" not" directly"comparable"(due"to"variability"in"trial" inclusion"criteria"and"clinical"outcomes"considered),"the" remaining" part" of" this" chapter" provides" a" review" of" these" metaBanalyses" and"demonstrates"how" these" analyses"played"a" key" role" in"not" only" synthesizing" the" evidence"base"but"also"in"answering"important"questions"not"fully"addressed"in"individual"trials.""
2.3.1& Quantifying&the&Overall&Benefits&of&Statins&&Without" differentiating" between" primary" and" secondary" prevention" populations," earlier"metaBanalyses" of" statin" trials" showed" that" individuals" receiving" statins" experienced"significant"reductions"in"the"risk"of"total"mortality"and"major"coronary"events"(Table"2.1)."As"early"as"1997,"the"analysis"by"Hebert"and"colleagues"examined"whether"cholesterol"lowering"with"statins"reduced"the"risk"for"total"mortality,"as"was"the"case"in"large"trials."On"the"basis"of" 16" trials" including" approximately" 20,000" individuals" with" predominantly" established"coronary" heart" disease" treated" and" followed" up" for" an" average" of" 3.3" years," there" were"significant"reductions"in"risks"of"total"mortality"of"22%"(95%"CI:"12%"to"31%).171"In"1999,"the"metaBanalysis"by"LaRosa"and"colleagues"estimated"the"risk"reduction"of"major"coronary"events"and" total"mortality"associated"with" statin"drug" treatment" in" five" trials"with"30,817"individuals." Findings" of" this" metaBanalysis" confirmed" that" reductions" in" LDL" cholesterol"associated"with"statin"drug" treatment" resulted" in" roughly"30%"decline" in" coronary"events"and"16%"decline"in"total"mortality.172"Similarly,"in"another"metaBanalysis"published"in"1999,"Ross"and"colleagues"reviewed"17"trials"with"21,303" individuals"and"reported"that"patients"
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4S:" Scandinavian" Simvastatin" Survival" Study131;" ACAPS:" Asymptomatic" Carotid" Artery" Progression"Study185;" AFCAPS/TexCAPS:" Air" Force/Texas" Coronary" Atherosclerosis" Prevention" Study135;" ALLHAT@
LLA:" Antihypertensive" and" LipidBLowering" Treatment" to" Prevent" Heart" Attack" Trial" –" Lipid" Lowering"Arm186;"ASCOT@LLA:"AngloBScandinavian"Cardiac"Outcomes"Trial"–"Lipid"Lowering"Arm133;"CAIUS:"Carotid"Atherosclerosis" Italian" Ultrasound" Study187;" CARE:" Cholesterol" and" Recurrent" Events" Trial137;" CCAIT:"Canadian"Coronary"Atherosclerosis"Intervention"Trial188;"CIS:"Multicenter"coronary"Intervention"Study189;"
CLAPT:" Cholesterol" Lowering" Atherosclerosis" PTCA" Trial190;" CRISP:" Cholesterol" Reduction" in" Seniors"Program191;" EXCEL:" Expanded" Clinical" Evaluation" of" Lovastatin192;" FLARE:" Fluvastatin" Angiographic"Restenosis" Trial193;" GREACE:" Greek" Atorvastatin" and" CoronaryBheartBdisease" Evaluation194;" HPS:" Heart"Protection"Study139;"KAPS:"Kuopio"Atherosclerosis"Prevention"Study195;"LCAS:" Lipoprotein" and"Coronary"Atherosclerosis" Study196;"LIPID:" LongBTerm" Intervention"with"Pravastatin" in" Ischaemic"Disease" Study138;"
LIPS:" Lescol" Intervention" Prevention" Study134;" LRTS:" Lovastatin" Restenosis" Trial" Study197;" MAAS:"Multicentre" AntiBAtheroma" Study198;" MARS:" Monitored" Atherosclerosis" Regression" Study199;" PLAC@I:"Pravastatin" Limitation" of" Atherosclerosis" in" the" Coronary" Arteries200;" PLAC@II:" Pravastatin," Lipids," and"Atherosclerosis" in" the" Carotid" Arteries201;"PMSG:" Pravastatin" Multinational" Study" Group125;"Post@CABG:"Post"Coronary"Artery"Bypass"Graft"Trial202;"PREDICT:"Prevention"of"Restenosis"by"Elisor"after"Transluminal"Coronary"Angioplasty203;"PROSPER:"Pravastatin"in"Elderly"Individuals"at"Risk"of"Vascular"Disease"Trial204;"




As"the"overall"benefits"of"statins"in"the"prevention"of"coronary"heart"disease"mortality"and"morbidity" became" increasingly" clear" for" middleBaged" individuals," an" important" question"remained" about" the" therapeutic" value" of" statin" therapy" in" the" elderly." According" to"observational" studies," there" appeared" to" be" a" lack" of" association"between" cholesterol" and"coronary" heart" disease" mortality" and" morbidity" in" persons" older" than" 70" years.207" Also,"PROSPER"(Pravastatin" in"Elderly" Individuals"at"Risk"of"Vascular"Disease"Trial),"which"was"the" first" large" trial" of" statins" that" specifically" enrolled" older" participants," did" not"demonstrate" a" reduction" in" allBcause"mortality" risk,204" potentially" resulting" in" suboptimal"utilization"of"statins"among"the"elderly.208,209"Roberts"and"colleagues"performed"one"of"the"first" reviews" of" statin" trials" in" the" elderly" and" showed" that" statin" therapy" is" effective" in"reducing"allBcause"mortality"and"cardiovascular"outcomes,"including"myocardial"infarctions,"coronary" heart" disease" death," and" stroke" in" this" population." The" findings" of" this" metaBanalysis" were" confirmed" in" a" later" review" by" Afialo" and" colleagues," which" showed" that"statins"reduce"allBcause"mortality"by"22%"and"coronary"heart"disease"mortality"by"30%"in"elderly" patients" with" documented" coronary" heart" disease." More" recent" reviews" also"supported"the"use"of"statins"in"the"elderly.210"""
2.3.3& Statins&for&the&Primary&Prevention&of&Coronary&Heart&Disease"
In" contrast" to" the" clear" and" consistent" findings" of" the" metaBanalyses" that" did" not"differentiate" between" primary" and" secondary" prevention" populations," metaBanalyses" that"specifically" focused" on" primary" prevention" trials" yielded" less" certain" results" and" led" to"considerable"debate"that"continues"to"date.161,211"According"to"these"metaBanalyses,"statins"reduced"the"risk"of"major"coronary"events"and"major"cerebrovascular"events"but"their"effect"on" allBcause" mortality" appeared" nonBsignificant" in" some" metaBanalyses" and" marginally"significant"in"others"(Table"2.2).""




benefits" of" proactively" reducing" the" risk" for" coronary" heart" disease" would" outweigh" the"risks" –" particularly" because" the" prevention" of" coronary" events" would" also" prevent"individuals"from"graduating"into"a"considerably"higher"risk"category."The"third"report"of"the"NCEP"ATP"stated"that:"
LDL" lowering"therapy"should"play"an" important"role" in"primary"prevention"of"[coronary" heart" disease]" in" persons" at" increased" risk…" [D]rugs" should" be"considered"when" LDL" levels" are" high" (≥160"mg/dL)." For" higher" risk" persons"with" multiple" risk" factors…," consideration" should" be" given" to" drug" therapy"when" the" LDL" goal" (<130" mg/dL)" cannot" be" achieved" by" lifestyle" therapies."Finally,"multipleBriskBfactor"persons"at"highest"risk"(10Byear"risk">20"percent)"need" to"attain"even" lower"LDL"cholesterol" levels" (LDL"goal"<100"mg/dL),"and"consideration" should" be" given" to" starting" drug" therapy" simultaneously" with"therapeutic"lifestyle."
Following" the" publication" of" the" NCEP" clinical" practice" guidelines," the" results" of" large"primary"prevention" trials" became" available." The"publication" of" the" findings" of" these" trials"added" to" the" confusion"around" the"benefits"of" statins"because" there"emerged"an"apparent"inconsistency" around" the" benefit" of" statins" among" individuals" with" no" symptomatic"coronary" heart" disease." Although" statins" significantly" reduced" the" risk" of"major" coronary"events" in" the" earlier" trials" such" as" AFCAPS/TexCAPS" (Air" Force" B" Texas" Coronary"Atherosclerosis"Prevention"Study)135"and"WOSCOPS"(West"of"Scotland"Coronary"Prevention"Study),136" they" had" no" impact" on" this" outcome" in" later" trials:" PROSPER204" and" ALLHAT"(Antihypertensive" and" LipidBLowering" Treatment" to" Prevent" Heart" Attack" Trial).186"Similarly,"their"effect"on"total"mortality"was"still"not"certain"in"large"trials.""
To"clarify"the"role"of"statins"for"the"primary"prevention"of"coronary"heart"disease,"additional"metaBanalyses"were"performed."The" review"by"Thavendiranathan"and"colleagues" included"42,848"individuals"from"seven"trials"and"showed"that"statin"therapy"decreased"the"incidence"of"major"coronary"events"but"not"coronary"heart"disease"or"overall"mortality"(RR:"0.93,"95%"CI:" 0.86" to" 1.01).213" In" their" metaBanalysis," Mills" and" colleagues" found" a" significant" 7%"reduction"in"the"relative"risk"of"allBcause"mortality"(95%"CI:"1%"to"13%)"based"on"20"trials"with" predominantly" primary" prevention"populations.214" This"metaBanalysis" also" showed" a"significant" 11%" reduction" in" cardiovascular" deaths" (95%" CI:" 2%" to" 19%)." Ward" and"colleagues"obtained"a"similarly"significant"survival"benefit"in"their"metaBanalysis"conducted"for" the" United" Kingdom" National" Health" Service" Research" &" Development" Health"Technology"Assessment"Program.215"
The"publication"in"2008"of"the"findings"of"the"largeBscale"JUPITER"(Justification"for"the"Use"of" Statins" in" Primary" Prevention:" An" Intervention" Trial" Evaluating" Rosuvastatin)" trial"provided"evidence"in"support"of"statins" in"primary"prevention." In"JUPITER,"17,802"healthy"men" and" women" with" normal" LDL" cholesterol" levels" were" randomized" to" receive"
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rosuvastatin"(which"gained"marketing"approval"in"2003"as"Crestor®)"and"placebo.216"There"was" a" 20%" reduction" in" the" risk" for" allBcause" mortality" in" individuals" randomized" to"rosuvastatin"as" compared" to"placebo" (95%"CI:"3%" to"33%)"with" substantial" reductions" in"the" composite" endpoint" of" myocardial" infarction," stroke," arterial" revascularization,"hospitalization"for"unstable"angina,"or"death"from"cardiovascular"causes."However,"this"trial"was" stopped" early" once" the" survival" benefits" of" rosuvastatin" emerged," which" may" have"exaggerated" its" findings.217,218" Indeed," the" trial" investigators" acknowledged" that" the" effect"size" observed" in" this" trial" was" more" pronounced" than" what" was" expected" according" to"previous"metaBanalyses."Prominent"researchers"subsequently"questioned"the"validity"of"the"findings"of"this"trial.219""
Taking" into" account" the" findings" of" the" JUPITER" trial," Brugts" and" colleagues" performed" a"metaBanalysis" of" the" primary" prevention" trials" and" estimated" that" the" survival" benefit" of"statin" therapy"was"a"significant"12%"reduction" in" the"odds"of"allBcause"mortality"(95%"CI:"4%"to"19%)"on"the"basis"of"70,388"individuals"enrolled"in"10"trials"after"a"followBup"period"of"4.1"years.220"The"analysis"conducted"by"Ray"and"colleagues"(2010)"conflicted"the"findings"of"the"Brugts"analysis"and"suggested"that"there"did"not"appear"to"be"a"statistically"significant"survival" benefit" of" receiving" statins" in" primary"prevention.221" In" this" analysis," the" relative"risk"of"allBcause"mortality"when"comparing"statins"versus"placebo"was"0.91"(95%"CI:"0.81"to"1.01)"based"on"10"trials"with"65,229"highBrisk"individuals"with"no"established"disease"after"3.7" years" of" followBup." Unfortunately," an" analysis" of" cardiovascular" morbidity" was" not"undertaken." Further" complicating" the" issue," the" review" conducted" by" the" Cochrane"Collaboration" (2011)" showed" that" statins" reduced" the" risk" of" allBcause"mortality" (relative"risk:"0.83,"95%"CI:"0.73"to"0.95)"as"well"as"the"combined"fatal"and"nonBfatal"cardiovascular"endpoints"(relative"risk:"0.70,"95%"CI:"0.61,"0.79).222""










































ACAPS:"Asymptomatic"Carotid"Artery"Progression"Study185;"AFCAPS/TexCAPS:"Air"Force/Texas"Coronary"Atherosclerosis" Prevention" Study135;" ALERT:" Assessment" of" Lescol" in" Renal" Transplantation" Study226;"
ALLHAT:"Antihypertensive"and"LipidBLowering"Treatment"to"Prevent"Heart"Attack"Trial"–"Lipid"Lowering"Arm186;"ASCOT:"AngloBScandinavian"Cardiac"Outcomes"Trial"–"Lipid"Lowering"Arm133;"ASPEN:"Atorvastatin"Study" for"Prevention"of"Coronary"Heart"Disease"Endpoints" in"nonBinsulinBdependent"diabetes"mellitus227;"
CAIUS:" Carotid" Atherosclerosis" Italian" Ultrasound" Study187;" CARDS:" Collaborative" Atorvastatin" Diabetes"Study228;" CELL:" Cost" Effectiveness" of" Lipid" Lowering" Study229;" DALI:" Diabetes" Atorvastatin" Lipid"Intervention" Study224;" FAST:" Fukuoka" Atherosclerosis" Trial230;"HPS:" Heart" Protection" Study139;"HYRIM:"Hypertension"High"Risk"Management"trial231;"JUPITER:"Justification"for"the"Use"of"Statins"in"Prevention:"an"Intervention" Trial" Evaluating" Rosuvastatin232;"KAPS:" Kuopio" Atherosclerosis" Prevention" Study195;"KLIS:"Kyushu" Lipid" Intervention" Study233;"MEGA:" Management" of" Elevated" Cholesterol" in" Primary" Prevention"Study234;"PHYLLIS:"Plaque"Hypertension"LipidBLowering"Italian"Study235;"PMSG:"Pravastatin"Multinational"Study" Group125;"PREVEND@IT:" Prevention" of" Renal" and" Vascular" Endstage" Disease" Intervention" Trial236;"
PROSPER:" Pravastatin" in" Elderly" Individuals" at" Risk" of" Vascular" Disease" Trial204;"WOSCOPS:" West" of"Scotland"Coronary"Prevention"Study136"
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Given" this" inconsistency" in" the" evidence," the" benefit" of" prescribing" statin" therapy" in"individuals"without"established"coronary"heart"disease"has"continued"to"spur"considerable"debate."At" the" center"of" this"debate"was" the"question"of"whether" the" risk" cutBoff" between"primary"and"secondary"prevention"populations"was"justified."This"question"is"still"relevant"today"as"most"candidates"for"primary"prevention"have"a"certain"level"of"cardiovascular"risk,"although" by" definition" they" have" not" had" a" cardiovascular" event" yet." It" is" increasingly"understood"that"those"who"are"considered"for"treatment"as"primary"prevention"may"already"be"at"an"advanced"stage"of"atherosclerosis"(i.e."hardening"of"the"arteries)."This"suggests"that"patients" may" need" to" be" considered" to" be" on" a" continuum" of" atherosclerosis," instead" of"clearBcut"categories"of"primary"and"secondary"prevention."In"the"words"of"Minder"et"al.:"“we"question" why" the" addition" of" a" statin" the" day" after" a" myocardial" infarction" [which" is"considered" secondary" prevention]" is" considered" more" effective" than" its" addition" in" the"preceding"week,"month,"or"year"[which"is"considered"as"primary"prevention].”237"
The" individual" patientBlevel" metaBanalysis," performed" by" the" Cholesterol" Treatment"Trialists’" Collaboration" and" published" in" 2012," arguably" ended" this" controversy" by"demonstrating" the" benefit" of" statins" in" individuals" with" no" established" coronary" heart"disease."Based"on"data"on"174,149"individuals"from"27"trials,"their"rigorous"analysis"showed"that"statins"resulted"in"reductions"in"the"risk"for"major"coronary"events"(relative"risk:"0.76,"95%"CI:"0.73" to"0.79)"and"allBcause"mortality" (relative"risk:"0.91,"95%"CI:"0.85" to"0.97).238"This"analysis"provided"strong"evidence"that"statin"therapy"was"effective"even"in"individuals"at" very" low" risk" categories." This"metaBanalysis" contributed" to" the" recommendation" in" the"latest" ACC/AHA" guidelines" that" individuals" without" established" coronary" heart" disease"should"be"considered"for"statin"therapy.164"
2.3.4& LDL&Cholesterol&Levels:&Is&Lower&Better?&
Although" statins" differ" in" terms" of" their" multiple" effects" on" the" cardiovascular" system"(termed"pleiotropic"effects),"there"is"widespread"acceptance"that"they"exert"their"beneficial"effects"primarily"by"reducing"the"level"of"LDL"cholesterol.239"Also,"the"reductions"in"the"risk"of" cardiovascular" events" achieved" by" statin" therapy" appear" to" be" similar" regardless" of"baseline"cholesterol"levels."There"does"not"appear"to"be"a"LDL"cholesterol"threshold"below"which"no"further"reduction"in"risk"occurs.""
A" number" of" randomized" controlled" trials" reported" greater" risk" reductions" with" more"intensive"statin"regimens"resulting"in"greater"reductions"in"LDL"cholesterol,"as"compared"to"more" moderate" regimens." In" light" of" these" findings," a" 2004" update" of" the" NCEP" ATPBIII"guidelines" recommended" more" intensive" lipid" lowering" for" highBrisk" individuals:" LDL"cholesterol" goal" of" <70" mg/dL" became" a" therapeutic" option," i.e.," a" reasonable" clinical"
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strategy," for" individuals" at" high" risk" of" developing" coronary" heart" disease" –" even" for"individuals"who"have"a"baseline"LDL"cholesterol"<100"mg/dL."The"treatment"threshold"for"moderately"highBrisk"persons"(2+"risk"factors"and"10Byear"risk"10%"to"20%)"was"similarly"lowered" and" an" LDL" cholesterol" goal" <100" mg/dL" was" recommended" as" a" therapeutic"option.""
Later"metaBanalyses"corroborated"the"notion"that"lower"LDL"cholesterol"levels"would"result"in"greater"risk"reductions."For"example,"Cannon"and"colleagues"compared"the"reduction"of"cardiovascular"outcomes"with"highBdose"statin"therapy"vs."standard"dosing"and"found"that"there" was" a" significant" 16%" odds" reduction" in" major" coronary" events" among" 27,548"individuals" in" four" large" trials.240" Similarly," Josan" and" colleagues" performed" a" systematic"review" and" metaBanalysis" to" examine" the" evidence" for" the" benefits" of" intensive" statin"therapy" in" patients"with" coronary" heart" disease.241" On" the" basis" of" seven" trials" including"29,395" individuals," more" intensive" regimens" reduced" the" odds" of" myocardial" infarctions"(OR:"0.83,"95%"CI:"0.77" to"0.91)"and"stroke"(OR:"0.82,"95%"CI:"0.71" to"0.95),"but"not" total"mortality"(OR:"0.96,"95%"CI:"0.80"to"1.14).""
2.4!Clinical!Evidence!and!Practice!Guidelines!
Over" the"quarterBcentury"history"of"statins," findings"of" randomized"controlled" trials,"alone"or"in"combination,"provided"overwhelmingly"strong"evidence"that"statins"work"equally"well"across"primary"and"secondary"prevention"populations,175"and"that" their"benefits"extend"to"populations" that" had" been" historically" underBresearched" such" as" women,242""hypertensives,243" diabetics,244,245" and" individuals" with" chronic" kidney" disease.246" Clinical"practice"guidelines,"and"particularly" those"developed"by" the"NCEP"ATP,"and"most" recently"ACC/AHA," played" an" important" role" in" interpreting" this" evidence" and" making"recommendations"for"decision"makers"in"clinical"practice."The"limits"of"statin"therapy"have"progressively" expanded" to" include" individuals" at" lower" risk" categories." For" instance,"although" earlier" versions" of" the" ATP" clinical" practice" guidelines" outlined" a" moderate"strategy"for"the"prevention"of"coronary"heart"disease"in"persons"with"elevated"levels"of"LDL"cholesterol," subsequent" versions" lowered" the" threshold" for" drug" treatment," and"considerably"expanded"both"the"scope"and"intensity"of"statin"therapy"(Table"2.3)."(Although"the"recent"ACC/AHA"guidelines"abandoned"LDL"cholesterol"goals,"they"continued"this"trend"by" recommending" statin" therapy" for" individuals" at" very" low" risk" of" developing" coronary"heart"disease.)""




Some"components"of" the"clinical"practice"guidelines"recommendations"were"controversial."For" instance," the" ATP" guidance" to" use" lipidBlowering" drugs" in" individuals" without"established"coronary"heart"disease"(primary"prevention)"was"ahead"of"its"time"–"and"ahead"of"the"existing"evidence."While"the"evidence"on"statins"for"reducing"the"risk"of"total"mortality"remained" inconsistent" in" the"peerBreviewed" literature," the"ATP"clinical"practice"guidelines"recommended"the"use"of"lipidBlowering"drug"therapy,"and"specifically"statins,"in"individuals"without" established" coronary" heart" disease." In" contrast," the" latest" ACC/AHA" guidelines"referred"to"a"stronger"foundation"of"randomized"controlled"trial"evidence"on"this"front.157""










mg/dL!ATPBI" With"coronary"heart"disease"or"two"other"risk"factors"*" <130" ≥160"Without"coronary"heart"disease"or"two"other"risk"factors"*" <160" ≥190"ATPBII" With"coronary"heart"disease" ≤100" ≥130"
Without"coronary"heart"disease"and"with"two"or"more"risk"factors"**" <130" ≥160"Without"coronary"heart"disease"and"with"fewer"than"two"risk"factors"**" <160" ≥190"ATPBIII" With"coronary"heart"disease"or"coronary"heart"disease"equivalents"(10Byear"risk">20%)"†"" <100""In"the"2004"update,"the"optional"goal"for"this"risk"category"was"<70"mg/dL."
≥100""In"the"2004"update,"it"was"recommended"to"consider"drug"therapy"when"patients"had"a"baseline"LDL"cholesterol"level"<100"mg/dL."Without"coronary"heart"disease"and"with"two"or"more"risk"factors"(10Byear"risk"10%"to"20%)"‡" <130""In"the"2004"update,"the"optional"goal"for"this"risk"category"was"<100"mg/dL.""
≥130""In"the"2004"update,"it"was"recommended"to"consider"drug"therapy"when"patients"had"a"baseline"LDL"cholesterol"level"between"100"and"129"mg/dL."Without"coronary"heart"disease"and"wit"two"or"more"risk"factors"(10Byear"risk"<10%)"‡" <130" ≥160"





Today," an" important" question" that" remains" unresolved" is" the" extent" to" which" individual"statins"are"different"from"each"other"in"terms"of"their"effects"on"clinically"meaningful"benefit"and"harm"outcomes."Although"the"latest"report"of"the"ACC/AHA"recommended"that"statins"should"be"considered"as"firstBline"drugs"when"LDL"cholesterolBlowering"drugs"are"indicated"to"achieve"treatment"goals," it"provided"no"specific"guidance"around"which"statin"should"be"the"preferred"option"to"initiate"therapy."Instead,"the"guidelines"suggested"that"the"selection"of" initial" drug" therapy" would" be" influenced" by" the" lipoprotein" profile" and" magnitude" of"change"needed"to" lower"the"risk"of"coronary"heart"disease" in" individual"patients."By"doing"so," guideline"developers" assumed" that" the"benefits" of" statins"were" entirely" attributable" to"their" LDL" cholesterol" lowering" effects" –" implying" that" the" benefits" of" individual" statins"would" be" equivalent" at" comparable" doses" (achieving" equivalent" relative" LDL" cholesterol"reductions)."However,"no"particular"study"has"adequately5"evaluated"this"question.""
Six" statins" (atorvastatin," fluvastatin," lovastatin," pravastatin," rosuvastatin," and" simvastatin)"currently"marketed"in"the"United"States"differ"in"the"degree"of"LDL"cholesterol"lowering"that"can"be"achieved"per"mg"dose."With"the"basic"mechanism"of"cholesterol"lowering"remaining"the" same," the" six" statins" differ" to" a" various" extent" in" pharmacological" properties" and" it"would"be"expected"that"they"differ"in"terms"of"their"clinical"efficacy."Whether"–"and"to"what"extent" –" individual" statins" at" comparable" doses" (with" similar" LDL" cholesterol" lowering"effects)"would" be" different" from" each" other" in" terms" of" their" effect" on" clinical" endpoints,"total" mortality," and" harmful" side" effects" forms" the" basis" of" the" empirical" work" that" is"reported" in" the" next" chapters" of" this" thesis." This" question" has" not" been" addressed" in" a"comprehensive"manner" in"previous"metaBanalyses."Although"a" seventh" statin," pitavastatin"(marketed"as"Livalo®),"has"recently"been"launched"in"the"United"States,"this"product" is"not"included"in"the"empirical"work"presented"in"this"thesis"because"of"its"recent"launch"date"of"2009."""




Chapter!3!"Evidence"Review"and"Synthesis"Methods"""Evidence" review"and" synthesis" approaches" such" as" systematic" reviews" and"metaBanalyses"have"a"clear"role"in"ensuring"that"healthcare"interventions"are"based"on"complete"and"up"to"date" evidence." As" individual" studies" rarely" provide" definitive" answers" to" clinical"effectiveness" and" safety" questions," systematic" reviews" are" pivotal" in" piecing" together" the"available"evidence"from"a"multitude"of"sources"and"making"obvious"the"gap"between"what"is"known"about"a"given"question"and"what"decision"makers"need"to"know"to"make" informed"decisions.28" Clinical" practice" guidelines" increasingly" use" systematic" reviews" of" existing"evidence"to"develop"their"recommendations.""MetaBanalyses"are"statistical" tools" for"combining" the"results"of"several"comparable"studies"identified"in"a"systematic"review"to"summarize"available"evidence"into"a"pooled"estimate"for"the" outcome" of" interest.249" They" increase" the" overall" sample" size" (thus" power)" of" the"analysis," relative" to"any"single" trial,"providing"a"more"precise"estimate"of" treatment"effect."They" are" useful" in" explaining" differences" between" results" of" individual" studies" and" can"provide" for" preBplanned," transparent," proven" methods" to" minimize" bias." Relatively" new"metaBanalytic" approaches" such" as" network"metaBanalyses" also" allow" for" the" simultaneous"comparison"of"multiple"treatments"in"an"internally"coherent"analysis.250""Weighing"the"relative"value"of"waiting"for"comparative"evidence"from"future"prospectively"designed" studies" or" making" decisions" based" on" the" existing" evidence" base," an" efficient"strategy"is"to"initially"prioritize"the"review"and"synthesis"of"the"existing"body"of"evidence"on"statins."As"reviewed"in"the"previous"chapter"(Chapter"2:"Evolution&of&Clinical&Evidence:&The&
Case&of&Statins)," a" large"number"of" randomized"controlled" trials"of"varying"sizes"evaluated"the" benefits" and" harms" of" statins" over" the" past" 25" years." Hundreds" of" thousands" of"individuals"with"or"without"coronary"heart"disease"participated"in"hundreds"of"statin"trials"conducted" in" several" countries" around" the"world."Although"a" large"number"of" these" trials"were"placeboBcontrolled,"a"considerable"number"of"activeBcomparator"(headBtoBhead)"trials"explored" the" comparative"benefits" and"harms"of" individual" statins" at"different"doses."This"
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large" body" of" placeboBcontrolled" and" activeBcomparator" trial" evidence" provides" an"opportunity"to"perform"a"comparative"assessment"of"individual"statins.""The"empirical"work"presented"in"this"thesis"is"grounded"on"a"systematic"review"and"metaBanalysis"of"the"randomized"trial"literature"on"statins."The"objective"of"the"systematic"review"was"to"comprehensively"identify"the"randomized"controlled"trial"evidence"on"statins"based"on"preBdetermined"identification"and"selection"criteria."The"comparative"benefits"and"harms"of" statins" were" explored" using" relatively" novel" evidence" synthesis" approaches" called"network"metaBanalyses." This" chapter" provides" an" overview" of" these" evidence" review" and"synthesis"methods."
3.1!Rationale!for!a!systematic!approach!Systematic" reviews" are"methods" to" systematically" assemble" and" synthesize" evidence" from"multiple" sources" on" the" effectiveness" –" and" increasingly," comparative" effectiveness" –" of"interventions."As"defined"by"the"Cochrane"Collaboration:"A" systematic" review" is" a" review" of" a" clearly" formulated" question" that" uses"systematic"and"explicit"methods"to"identify,"select,"and"critically"appraise"relevant"research,"and"to"collect"and"analyze"data"from"the"studies"that"are"included"in"the"review.251"
In" the" era" of" evidenceBbased" medicine," systematic" reviews" offer" a" powerful" solution" to"finding," evaluating," and" incorporating" new" research" knowledge" into" everyday" clinical"decisionBmaking."Systematic"reviews"allow"researchers"and"health"care"decision"makers"to"interpret"the"evidence,"to"summarize"what"is"known,"and"to"describe"the"extent"to"which"the"evidence" is" applicable" to" individual" patients" seen" in" clinical" practice.28" Only" after" a"systematic" review" and" synthesis" of" the" existing" evidence" is" one" in" a" position" to" plan" and"identify"what"form"of"further"evidence"is"required."Systematic"reviews"adopt"a"methodological"approach"to"ensure"that"evidence" is" identified,"selected,"and"reviewed"in"accordance"with"a"protocol.251"WellBconducted"systematic"reviews"are"reproducible"as"they"follow"a"comprehensive"review"protocol"that"outlines"the"detailed"approach" to" conducting" all" parts" of" the" literature" review."Conducted" in" a" transparent" and"methodological"way,"systematic"reviews"offer"a"less"biased"alternative"to"narrative"reviews,"which" lack"an"explicit"description"of" systematic"methods"of" searching" for," identifying," and"including"studies.93"As"a"result,"narrative"reviews"are"criticized"on"the"grounds"that"they"are"largely" based" on" a" biased" citation" of" studies.252" Given" the" clear" advantages" of" systematic"reviews"over"any"other" type"of"evidence"review"strategy," the"empirical"work"presented" in"this"thesis"is"based"on"a"systematic"review"of"the"existing"statin"evidence"base.""
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3.2!Systematic!Review!Methods!At"the"outset"of"the"systematic"review"undertaken"for"this"thesis,"a"protocol"describing"the"objectives"and"methods"of"the"systematic"review"and"statistical"analysis"was"developed"and"subsequently"made"publicly"available"on"the"London"School"of"Economics"&"Political"Science"website.253" This" protocol"was" developed" to" ensure" that" evidence"was" identified," selected,"and" reviewed" properly" and" based" on" preBspecified" criteria.6" The" protocol" focused" on" the"specific"purpose"of" the" review," the" comparison"groups"of" interest," the" sources" and" search"methods"used"to"find"evidence,"explicit"study"selection"(i.e."inclusion"and"exclusion"strategy)"and" categorization" criteria" (i.e." primary" and" secondary" prevention" of" coronary" heart"disease)," the" variables" to" be" captured" during" data" extraction," and" statistical" methods" for"performing" network" metaBanalyses," including" preBspecified" sensitivity" analyses." The"protocol"was"registered"with"PROSPERO"(International"Prospective"Register"of"Systematic"Reviews,"University"of"York)."The"PROSPERO"registration"number"for"this"systematic"review"was"2011BCRD42011001470."Deviations" from" the"original" protocol" are" outlined" in" a" later"section"of"this"chapter,"subBtitled:"‘Deviations&from&Protocol.’""
3.2.1& Identification&and&Selection&of&Studies&A"systematic"review"was"performed"based"on"the"most"upBtoBdate"Centre" for"Reviews"and"Dissemination" (CRD)" guidelines.254" Instead" of" performing" an" ‘umbrella’" review" of" the"existing" systematic" reviews" of" statins," a" new" search" strategy" was" developed" to"comprehensively" identify" the" activeBcomparator" trials" that"were" not" included" in" previous"metaBanalyses" of" placeboBcontrolled" trials." Search" terms" were" preBdefined," and" searches"were" conducted" in" MEDLINE," Cochrane" Database" of" Systematic" Reviews," and" Cochrane"Central" Register" of" Controlled" Trials." These" electronic" databases" were" searched" starting"from"January"1,"1985"(approximately"five"years"before"the"first"statin"was"available"on"the"market)"until"January"1,"2011."The"actual"search"date"was"January"3,"2011.""The"electronic"search"strategy"was"devised"with"the"assistance"of"an"information"specialist"at" the" London" School" of" Economics"&" Political" Science" Library" in" order" to" ensure" that" an"efficient"search"string"was"developed."The"search"strategy"employed"terms"for"both"the"drug"and" therapeutic" indication." The" following" terms" were" used:" atorvastatin,& simvastatin,&
lovastatin,& pravastatin,& rosuvastatin,& cholesterol,& cardiovascular& disease,& and&
HydroxymethylglutarylGCoA& Reductase& Inhibitors/therapeutic& use." The" search" strategy" also"included" limits" to" ensure" that" the" identified" articles"were" randomized" trials" performed" in"humans" and" published" after" 1985." In" addition" to" the" searches" in" electronic" databases," a"manual" search" was" performed" using" personal" reference" files" and" reference" lists" from"
                                                6"A"copy"of"the"protocol"is"included"in"the"Appendix.""
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original" communications" and" review" articles." The" list" of" identified" qualitative" and"quantitative" systematic" reviews" (metaBanalyses)" was" manually" reviewed" to" cross" check"references"and"confirm"the"comprehensiveness"of"study"identification"and"selection.""The"review"was" limited"to"randomized"controlled"clinical" trials."Randomization" is" the"only"way" to" prevent" systematic" differences" between" baseline" characteristics" of" participants" in"different" intervention" groups" in" terms" of" both" known" and" unknown" (or" unmeasured)"confounders.255" In" the" absence" of" randomization," a" large" number" of" selection" biases" can"render" the" results" of" clinical" trials" invalid." Empirical" evidence" suggests" that," on" average,"nonBrandomized" studies" produce" effect" estimates" that" indicate" more" or" less" extreme"benefits"of"the"effects"of"health"care"than"randomized"trials.256,257"However," the"magnitude"and" even" the" direction" of" these" biases" are" difficult" to" predict." Although" there" are"methodologies"that"would"partly"take"into"account"potential"biases"in"evidence"review"and"synthesis,258" the" research" community" has" not" reached" a" consensus" around" the" relative"validity" of" randomized" and" nonBrandomized" studies;256,259B261" and" hence" the"appropriateness"of"making"decisions"on"the"basis"of"nonBrandomized"studies."Accordingly,"identifying" nonBrandomized" studies" of" statins" was" beyond" the" scope" of" the" current"systematic"literature"review.""The" focus" of" the" review"was" on" coronary" heart" disease." According" to" the" existing" clinical"practice" guidelines,154" statins" are" indicated" for" the" primary" and" secondary" prevention" of"coronary" heart" disease." Given" the" common" coBmorbidity" profile" of" individuals"with," or" at"risk" of" developing," coronary" heart" disease," patient" populations" with" diverse" risk" profiles"(and" coBmorbidities)" were" eligible" for" inclusion." For" instance," patients" with" diabetes" and"hypertension" can" greatly" benefit" from" statin" therapy." In" fact," diabetes" is" considered" as" a"coronary"heart"disease" risk"equivalent," and"a" large"number"of"diabetic" individuals" receive"statin" therapy." However," a" decision" was" made" a& priori" that" trials" including" patient"populations"with" chronic"kidney"disease"were"not" eligible" for" inclusion."This"was"because"individuals"with"chronic"kidney"disease"have"nonBtraditional"risk"factors"such"as"anemia"and"factors" favoring" vascular" calcification," which" may" complicate" the" interpretation" of" the"findings"in"regards"to"the"comparative"benefits"and"harms"of"statins"in"these"populations.262"Studies" with" particularly" short" followBup" durations" (<4" weeks)" were" excluded" with" the"rationale" that" clinical" benefits" of" statins"would" not" be" apparent" during" such" a" short" time"period." To" be" eligible" for" inclusion," trials" had" to" have" at" least" 50" individuals" included" in"every"arm"of" the" trial."This"decision"was"made"on"two"grounds."First," the"objective"was" to"ensure"that"there"would"be"a"sufficient"sample"size"to"observe"rare"clinical"events."Second,"trials" with" fewer" than" 50" individuals" per" treatment" arm" may" not" be" methodologically"rigorous."Randomization"rests"on"the"principle"that"treatment"arms"at"baseline"are"balanced"
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on"potentially"confounding"factors."This"is"often"not"possible"in"small"trials"with"fewer"than"50"individuals"per"trial"arm.263,264&"The" identified" set" of" titles" and" abstracts" were" reviewed" in" two" levels." The" firstBlevel"screening"was" a" review"of" the" titles" and"abstracts" according" to" the" exclusion" criteria."The"fullBtext"copies"of"the"studies"that"were"still"deemed"to"be"relevant"following"the"firstBlevel"screening"were"then"obtained,"and"these"fullBtext"articles"were"reviewed"in"detail"according"to" the" inclusion" criteria." According" to" the" CRD" Systematic" Review" Guidelines," two"researchers7" independently" performed" abstract," title," and" fullBtext" screening," and" one"researcher"was"responsible"for"the"final"selection"for"each"study."Given"that"this"systematic"review" of" the" literature"was" undertaken" specifically" for" this" dissertation," as" the" principle"researcher," I" was" responsible" for" all" aspects" of" the" systematic" review" including" study"identification"and"selection."
3.2.1.1& & Exclusion&Criteria&The"following"exclusion"criteria"were"applied"to"the"titles"and"abstracts"identified"in"each"of"the"searches"(firstBlevel"screening):"









                                                7"Another"researcher"provided"assistance"(worked"in"parallel)"for"this"task.""8"Review"articles"were"excluded"but"filed"for"subsequent"manual"crossBchecking"of"reference"lists."Of"particular"interest"were"metaBanalyses.""
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3.2.1.2& & Inclusion&Criteria&The" following" inclusion" criteria" were" applied" to" the" fullBtext" articles" (secondBlevel"screening):"
• Randomized," controlled" trials" (randomized," prospective," controlled" design);" both"openBlabel"and"doubleBblind"designs"were"included"
• Patients"in"at"least"one"arm"of"the"trial"received"atorvastatin,"fluvastatin,"lovastatin,"pravastatin," rosuvastatin," or" simvastatin" (either" generic" or" brandBname"formulations)"
• The"patients"of"interest"were"patients"who"were"at"least"18"years"of"age"with,"or"at"risk" of" developing," coronary" heart" disease" (secondary" or" primary" prevention"populations,"respectively)"
• Studies" had" to" report" detailed" dosing" regimens" received" by" patients" on" all"comparator"arms"
o To" be" included," studies" had" to" report" whether" they" employed" fixed" or"variable"dosing" regimens." Similarly," average" studyBlevel" dose"of" treatment"received"over"the"course"of"the"trial"had"to"be"reported"
• To"be"included"in"the"statistical"analysis,"each"selected"study"had"to"report"surrogate"endpoints" (e.g." reductions" in" cholesterol" concentrations)," clinical" events" (e.g."reductions" in" the" risk" of" total" mortality," or" the" risk" of" developing" coronary" or"cerebrovascular"events)," tolerability" (e.g.,"discontinuations"due" to"adverse"events),"or" primary" and" secondary" harm" endpoints" of" interest" (e.g.," myalgia," liver"transaminase"elevations," creatine"kinase"elevations," incident"cancers"and"diabetes,"and"rhabdolymyosis)."The"specific"outcomes"of"interest"are"also"listed"below.""Trials"with"crossover"designs"(where"patients"changed"arms)"were"included"only"if"results"were"available"from"the"first"randomized"controlled"period."Studies"that"compared"multiple"doses" of" the" same" statin" were" included." Finally," both" fixedBdose" and" titration" trials" were"eligible"for"inclusion.""The"inclusion"and"exclusion"processes"were"carefully"documented,"including"completion"of"the" PRISMA" (Preferred" Reporting" Items" for" Systematic" Reviews" and"MetaBAnalyses)" flow"chart265"as"reported"in"Chapters"4B7."
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3.2.1.3& & Trial&Categorization&&Whenever"possible," the" included"trials"were"categorized"as"primary"prevention,"secondary"prevention,"or"mixed"patient"population."Primary"prevention"trials"were"those"that"assessed"the" efficacy" and" safety" of" statins" in" patients" free" of" coronary" heart" disease" at" baseline."Secondary"prevention" trials"were" those" that"evaluated"statins" in"patients"with"established"coronary"disease"(i.e."often"following"a"myocardial"infarction)."Given"that"a"number"of"trials"included"a"combination"of"both"primary"and"secondary"prevention"populations,"these"trials"were" categorized" as" having" a" mixed" patient" population." In" cases" where" study" authors"reported" data" separately" on" a" sole" primary" prevention" or" secondary" prevention" group"within" a" mixed" trial," this" information" was" recorded" separately" for" use" in" respective"statistical"analyses.""Although"the"risk"cutBoff"between"primary"and"secondary"prevention"populations"may"not"be" fully" justified" on" the" basis" of" slippery" definitions" between" primary" and" secondary"prevention,237" literature" commonly" refers" to" individuals" as" either" primary" or" secondary"prevention."Therefore,"such"a"categorization"was"adopted"in"this"review."Trials"that"included"at" least" 80%" of" participants" with" established" coronary" heart" disease" or" reported" data"separately"on"a"sole"secondary"prevention"group"were"categorized"as"secondary"prevention"trials." Similarly," trials" that" included" at" least" 80%" of" participants" without" established"cardiovascular"disease"or"reported"data"separately"on"a"sole"primary"prevention"group"were"categorized"as"primary"prevention."All"remaining"trials"were"categorized"as"having"a"mixed"patient"population.""
3.2.3& Data&Extraction&A" structured" dataBextraction" form" implemented" in" Microsoft" Excel" was" used" to" ensure"consistency"of"data"extraction"for"each"study."Data"on"the"following"items"were"extracted:"
3.2.3.1& & StudyGlevel&Characteristics&
• Trial""(trial"reference)"
• Population" severity" (narrative" description" of" cardiovascular" risk" factors" of" the"patient"population)"














• Mean"reduction"in"Total"cholesterol"concentration"from"baseline"The" following" data" elements" were" extracted" for" LDL," HDL," and" Total" cholesterol"endpoints:"
o Mean"concentration"(and"its"standard"deviation"or"variance)"at"baseline"for"all"treatment"arms""
o Mean" concentration" (and" its" standard" deviation" or" variance)" at" followBup"for"all"treatment"arms"
o Alternatively," if" available," mean" difference" between" treatment" arms" (and"standard"deviation"or"variance"of" the"difference)"of" the"mean"reduction" in"concentration"from"baseline""
3.2.3.3& & Clinical&Benefit&Endpoints&
• Number" of" allBcause" deaths" (allBcause"mortality" or" total"mortality)," for" which" the"following"data"elements"were"extracted:"
o Number"of"deaths"due"to"any"reason"in"all"treatment"arms"
o Number"of"individuals"randomized"to"all"treatment"arms"
• Number" of" major" coronary" events" (composite" of" major" coronary" events" were"defined" as" deaths" from" coronary" heart" disease" and" nonBfatal" myocardial"infarctions),"for"which"the"following"data"elements"were"extracted:"
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o Number"of" individuals"with"coronary"heart"disease"deaths" in"all" treatment"arms"
o Number"of"individuals"with"nonBfatal"myocardial"infarctions"in"all"treatment"arms"
o Alternatively," if" this" information"was" available," the" number" of" individuals"with"major"coronary"events"in"all"treatment"arms""
o Number"of"individuals"randomized"to"all"treatment"arms"










• Number" of" individuals" experiencing" clinically"meaningful" transaminase" elevations"from" baseline" levels" (three" times" or" higher" than" baseline" values," as" commonly"defined"by" trial" investigators)" (composite"of" two"hepatic" transaminases:" aspartate"transaminase"[AST]"and"alanine"transaminase"[ALT])," for"which"the"following"data"elements"were"extracted:"
o Number" of" individuals" with" clinically" meaningful" elevations" in" baseline"aspartate"transaminase"concentrations"in"all"treatment"arms"
o Number" of" individuals" with" clinically" meaningful" elevations" in" baseline"alanine"transaminase"concentrations"all"treatment"arms"
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o Alternatively," if" this" information"was" available," the" number" of" individuals"with"clinically"meaningful"hepatic" transaminase"elevations" in"all" treatment"arms"
o Number"of"individuals"randomized"to"all"treatment"arms"
• Number" of" individuals" experiencing" clinically" meaningful" elevations" in" baseline"creatine"kinase"concentrations"(as"defined"by"trial"investigators,"ranging"from"three"to"10"times"higher"than"baseline"levels),"for"which"the"following"data"elements"were"extracted:"























o Question"asked"was:"“did"the"investigators"report"completeness"of"outcome"data" for" LDL" cholesterol" lowering," including" attrition" and" exclusions" from"the"analysis?”"
• Indications"of"selective"reporting&
o Primary"question"asked"was:"“did"the"investigators"fail"to"report"tolerability"and"harm"outcomes"commonly"reported"in"randomized"trials"of"statins"[e.g.,"withdrawals" due" to" adverse" events," creatine" kinase" elevations," hepatic"transaminase"elevations,"or"myalgia]?”&
o Secondary" question" asked" was:" “were" there" deviations" in" trial" outcomes"from"published"protocols"(in"cases"where"trial"protocols"were"available)?”&
3.2.3.6& & Funding&Source&




o In" cases"where" trial" funding" source"was" not" clearly" reported," trial" author"affiliations"were"checked"and"studies"with" industryBaffiliated"authors"were"categorized" as" industryBsponsored." Also," trials"with" industry," government,"and/or" academic" institution" coBsponsorship"were" categorized" as" industryB
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sponsored" (unless" the" trial" investigators" included" a" statement" suggesting"that"the"funding"body"had"no"involvement"in"trial"design,"conduct,"analysis"or"reporting).""Once" the" included" list" of" studies" was" finalized," data" extraction" was" performed" by" one"researcher" for" all" identified" studies." Per" the" CRD" Systematic" Review" Guidelines," another"researcher"checked"the"quality"of"the"completed"data"extraction"sheets"for"consistency"and"accuracy."Discrepancies"were"settled"through"consensus"discussion."To"ensure"the"quality"of"extraction," the" consistency"of" extracted"data" (in" its" entirety)"was" crossBchecked"with"data"used" in" previously" published" metaBanalyses." In" addition" to" primary" data" extraction,"whenever"possible,"data"from"published"reviews"were"used"when"study"authors"of"previous"metaBanalyses" contacted" trial" investigators" and" requested" unpublished" information" on"outcomes"of"interest."

















o Incident"diabetes"Statistical" analyses" included" traditional" pairBwise" metaBanalyses" and" network" metaBanalyses." All" statistical" analyses" were" based" on" the" total" number" of" randomly" assigned"participants,"irrespective"of"how"study"authors"reported"the"results."The"approach"taken"to"perform"the"statistical"analyses"is"outlined"in"detail"below.""
3.3.1& Traditional&PairGwise&MetaGanalysis&First," traditional" pairBwise" metaBanalyses" were" performed" to" synthesize" studies" that"compared"the"same"two"interventions"(e.g."trial"of"atorvastatin"vs."placebo"was"pooled"with"other" trials"of" atorvastatin"vs."placebo)."Traditional"pairBwise"metaBanalysis" is" a" statistical"tool"for"pooling"the"results"of"multiple"comparable"trials"that"directly"compare"the"same"two"interventions.266" By" increasing" the" overall" sample" size" of" the" analysis" (therefore" power),"traditional"pairBwise"metaBanalysis"provides"a"more"precise"estimate"of"a" treatment"effect,"which"is"of"considerable"importance"to"make"inferences"on"a"large"body"of"evidence"such"as"the"one"for"the"statin"literature.93,267,268"As"reviewed"in"the"previous"chapter,"a"large"number"of"metaBanalyses" have" already" been" conducted" to" synthesize" the" evidence" on" statins" and"address"important"questions"that"had"remained"unanswered"in"individual"trials.""The" main" consideration" when" performing" and" interpreting" traditional" pairBwise" metaBanalyses"is"similarity"(also"termed"homogeneity)"across"the"pooled"set"of"studies"in"terms"of"trial" and" patient" population" characteristics." If" the" set" of" trials" are" not" adequately"homogenous"(i.e.,"there"is"considerable"betweenBstudy"heterogeneity),"the"relevance"of"the"pooled" findings" from" traditional" pairBwise"metaBanalysis" to" the" specific" target" population"becomes"less"certain.269"However,"when"heterogeneity"exists,"metaBanalyses"could"be"useful"in" exploring" how" treatment" effects" vary" across" subgroups" (e.g.," age" and" sex)" and" study"settings"on"the"basis"of"subBgroup"analyses"and"metaBregressions.249"
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The" objective" of" performing" traditional" pairBwise" metaBanalyses" was" threeBfold." The" first"objective"was"to"pool"all"statin"trials"together"and"quantify"the"benefits"of"statins"as"a"drug"class"in"comparison"to"control"treatment,"which"has"previously"been"done,"as"referenced"in"Chapter" 2" of" this" thesis," entitled:" “Evolution& of& Clinical& Evidence:& The& Case& of& Statins.”"However," an"attempt"was"made" to"update" the"previous"pairBwise"metaBanalyses" to" reflect"the" changing" nature" of" randomized" controlled" trial" evidence" base" of" statins." The" second"objective" was" to" statistically" summarize" all" direct" headBtoBhead" comparisons" of" statins,"which" has" not" been" performed" in" previous"metaBanalyses." PairBwise"metaBanalyses" of" all"available" direct" comparisons" (first" between" statins" and" control," and" second" among"individual" statins)" constituted" the" building" blocks" of" subsequent" network" metaBanalyses."The" direction" and" magnitude" of" relative" treatment" effects" observed" in" pairBwise" metaBanalyses"of"direct"comparisons"are"often"used"to"gauge"important"assumptions"of"network"metaBanalyses."Indeed,"the"third"objective"was"to"compare"and"contrast"(and"quality"check)"the"findings"of"the"network"metaBanalyses"to"those"obtained"from"pairBwise"metaBanalyses."This"cross"checking"is"particularly"important"to"ensure"the"consistency"of"the"findings"from"different" analyses." (Assumptions" of" network" metaBanalyses" are" discussed" later" in" this"chapter.)"The" approach" to" perform" traditional" pairBwise"metaBanalyses" is" described" in"Box" 3.1." For"each"pairBwise"comparison"between"statins,"the"relative"effect"(in"terms"of"odds"ratios)"was"calculated"with"a"95%"confidence"interval"using"two"separate"approaches."First,"fixedBeffect"analyses" were" performed" using" the" MantelBHaenszel" method.270" Second," randomBeffects"analyses" were" performed" using" the" DerSimonian" Laird" method.271" FixedB" and" randomBeffects"approaches"relate"to"the"concept"of"heterogeneity"and"are"critical"in"traditional"pairBwise" metaBanalyses." Heterogeneity" –" or" more" accurately," betweenBstudy" heterogeneity" –"results" from" systematic" differences" in" (average)" patient" or" study" characteristics" across"trials,"which"influence"the"true"relative"treatment"effect"and"result"in"systematic"differences"in" the" effect" sizes" across" trials." The" fixedBeffect" method" assumes" that" every" trial" has" an"identical"treatment"effect,"suggesting"that"there"is"no"heterogeneity"across"the"identified"set"of"trials.272"This"is"equivalent"to"making"the"strong"assumption"that"the"trials"are"identical"in"every" aspect" of" design" and" implementation," including" the" patient" population"characteristics.273"The"randomBeffects"model"makes"a"more"conservative"assumption"in"that"it" takes" into" account" potential" heterogeneity" by" assuming" that" each" treatment" effect" is"drawn" from" a" common" distribution," whose" mean" and" variance" are" estimated" from" the"data.274"
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Box!3.1:!Analytical!Approach!for!Traditional!Meta@analysis!In"the"traditional"pairBwise"metaBanalysis"with"a"number"of"trials"comparing"the"same"set"of"two" interventions" 1" and" 2," the" relative" treatment" effect" between" these" interventions" is"denoted" as" d12." In" the" fixedBeffect" model," each" study" i" provides" an" estimate" of" the" same"parameter"d12,"with"sampling"error."In"the"randomBeffects"model,"the"study"level"treatment"effect"from"each"study"i"is"obtained"from"a"common"distribution"with"mean"d12"and"variance"σ212."This"common"distribution"is"denoted"as:"
δi,12"~"N(d12,"σ212)" " " " "The"fixedBeffect"model"can"be"obtained"by"setting"the"variance"to"zero.""For"binary"outcomes,"a"binomial"likelihood"is"used:"
rik"~"Binomial(pik,"nik)" " " " "where"rik"is"the"number"of"events"in"arm"k"of"trial"i,"nik"is"the"total"number"of"individuals"in"arm"k"of"trial"i,"and"pik"is"the"probability"of"an"event"in"arm"k"of"trial"i"The"model"is"then"specified"as:" logit(pik)"="µi"+"δi,12I(k≠1)"Where"I(u)"="1"if"u"is"true,"and"0"otherwise."The"model"can"be"written"for"a"randomBeffects"specification:"logit(pi1)"="µi"logit(pi2)"="µi"+"δi,12" "The"model"can"also"be"written"for"a"fixedBeffect"specification:"logit(pik)"="µi"+"d12I(k≠1)" " "where"µi"are"trialBspecific"baselines"(logBodds"of"the"outcome"in"the"control"treatment)"and"
δi,12&are"the"trialBspecific"logBodds"ratios"of"events"on"the"active"comparator"group"compared"to" control," where" the" randomBeffects" for" the" trialBspecific" logBodds" ratios" come" from" a"common"distribution:"δi,12"~"N(d12,"σ212)."For"continuous"outcomes,"a"normal"likelihood"is"used:"" " " " yik"~"N(θik,"se2ik)"where"yik"is"the"mean"change"from"baseline"in"arm"k"of"trial"i,"and"standard"error"se2ik"in"arm"
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k"of"trial"i.&The"parameter"of"interest"is"the"mean"θik,"which"can"be"specified"on"the"natural"scale"as:&" " " " θik"="µi"+"δi,bkI(k≠1)"FixedB"and"randomBeffect"specifications"for"the"normal"likelihood"model"are"as"described"for"the"binomial"likelihood"model."
In"terms"of"fixedB"versus"randomBeffects"models,"guidance"around"which"method"to"adopt"in"traditional" pairBwise" metaBanalyses" varies" in" the" literature." For" instance," Borenstein" and"colleagues"favor"an"approach"whereby"the"decision"to"use"fixedB"vs."randomBeffects"models"are"determined"a&priori.273"Others"suggest"that"both"models"should"be"adopted"subsequently"and" the" sensitivity" of" the" findings" to" different" models" should" be" reported.251" From" a"statistical"standpoint," it"should"be"noted"that"both"models"yield" identical"results" if" there" is"no"heterogeneity"(this"is"to"say"that"the"randomBeffects"model"is"reduced"to"the"fixedBeffect"equivalent" when" there" is" no" betweenBstudy" heterogeneity)." Therefore," the" more"conservative"approach"is"to"adopt"a"randomBeffects"model"with"the"reasonable"expectation"that" some" heterogeneity" may" be" present" across" the" identified" set" of" trials," and" that" this"heterogeneity" should"be" taken" into"account"when" interpreting" the"uncertainty"around" the"pooled" treatment"effect"estimate.251"With" this" rationale," all"baseBcase"analyses" reported" in"this" thesis" are"based"on" randomBeffects"models" (one" exception" is" presented" in"Chapter"7:&
Methodological&Quality&and&Risk&of&Bias&in&Randomized&Controlled&Trials&of&Statins).""In"addition"to"considerations"in"regards"to"the"fixedB"versus"randomBeffects"assumption,"the"potential" heterogeneity" was" investigated" both" qualitatively" and" quantitatively." First," the"forest"plots"of" the"relative"treatment"effects" from"the" individual" trials"and"pairBwise"metaBanalyses" were" visually" inspected" to" search" for" groups" and" outliers." This" was" statistically"supplemented" by" using" the" I2"measure,"which" estimates" the" percentage" of" total" variation"among" studies" that" can" be" considered" to" be" due" to" heterogeneity.275" In" line" with" the"Cochrane"Collaboration" recommendations," rough" thresholds" of" 25%," 50%," and"75%"were"used"to"define" low,"moderate,"and"high"heterogeneity.251"Moderate"and"high"heterogeneity"were" investigated" by" inspecting" trialBlevel" variables" that" could" potentially" explain" the"observed" differences." These" included" baseline" mean" age," baseline" LDL" cholesterol"concentration," and" trial" publication" year,"which" are" discussed" in"more" detail" later" in" this"chapter." Finally," smallBstudy" effects" were" investigated" using" contourBenhanced" funnel"plots.276 All" traditional" metaBanalysis" models" were" implemented" in" Stata" version" 11.0"(StataCorp"LP,"College"Station,"Texas,"United"States)."""
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3.3.2& Network&MetaGanalysis&PairBwise"metaBanalyses"have" important" limitations." First," in" conditions"with" several" drug"options,"pairBwise"metaBanalysis" is" limited"by" the" relatively" small"number"of" trials" (or" the"lack"of"trials)"that"directly"compare"a"particular"pair"of"drugs."By"definition,"pairBwise"metaBanalysis" is" incapable" of" comparing" multiple" active" comparators" simultaneously." Second,"when" there" are" multiple" drugs," performing" separate" pairBwise" metaBanalyses" for" each"comparison" becomes" impractical" (or" impossible" if" there" are" no" trials" that" include" the"comparison"of"interest)."Third,"focusing"on"two"drugs"at"a"time,"such"an"approach"also"does"not" adequately" take" into" account" the" betweenBtrial" variance" structure" in" multiBarm"trials.277,278"To" address" these" limitations" of" pairBwise" metaBanalyses," network" metaBanalyses" were"conducted"to"determine"the"comparative"effects"of"individual"statins."Network"metaBanalysis"is" a" relatively" new" method" to" allow" for" the" simultaneous" comparison" of" multiple"interventions." Although" these" approaches" can" be" considered" as" a" generalization" of"traditional" pairBwise" metaBanalyses," they" are" different" in" several" important" aspects." For"instance,"in"addition"to"analyzing"the"direct"withinBtrial"comparisons"between"two"drugs"(B"vs." A)," the" network" metaBanalysis" framework" enables" the" incorporation" of" indirect"comparisons"constructed"from"trials"that"have"one"drug"in"common"–"also"called"a"common"comparator" (B"vs."A" and"C"vs."A,"where"A" is" a" common"comparator).95" In" this" framework,"direct"evidence"refers" to"evidence" from"trials" that" include"a"specific"pairBwise"comparison"whereas"indirect"evidence"refers"to"evidence"obtained"from"a"network"of"trials"that"do"not"include"that"particular"comparison."In"the"absence"of"trials"involving"a"direct"comparison"of"interventions," an" indirect" comparison" provides" useful" evidence" for" the" relative" treatment"effects"between"competing"interventions.98,279""
3.3.2.1& & Combining&Direct&and&Indirect&Evidence&in&Network&MetaGanalyses&The"Cochrane"Collaboration"recommends"that,"in"situations"where"both"direct"and"indirect"evidence" are" available," the" two" types" of" evidence" should" be" considered" separately.251" To"quote" Caldwell" and" colleagues:" “difficulties" arise," however," if" the" direct" evidence" is"inconclusive" but" the" indirect" evidence," either" alone" or" in" combination" with" the" direct"evidence,"is"not”.95"Furthermore,"considering"direct"and"indirect"evidence"in"isolation"from"each"other"becomes"increasingly"impractical"as"the"number"of"treatments"increases."From"a"decisionBmaking"standpoint,"it"is"particularly"difficult"to"assess"the"relative"effect"of"multiple"drugs"in"the"form"of"disparate"pairBwise"metaBanalyses"on"direct"and"indirect"comparisons"so"combining"direct"and"indirect"evidence"has"clear"appeal.""
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By" integrating" both" direct" and" indirect" evidence," network" metaBanalyses" of" existing"evidence" are" capable" of" comparing" all" relevant" treatments" in" an" evidence" network." This"approach"has"potential"advantages"even"when"direct"comparisons"between"interventions"of"interest"exist."For"instance,"an"indirect"comparison"may"be"less"biased"than"the"findings"of"an" individual"trial" that"directly"compares"the" interventions.280,281"Even"when"the"results"of"the"direct"evidence"are"unbiased"and"conclusive,"combining"direct"estimates"with"the"results"of"indirect"comparisons"in"a"network"metaBanalysis"may"result"in"more"refined"estimates"by"considering"a"broader"evidence"base.257"In"general,"if"the"available"evidence"base"consists"of"a"network"of"connected"multiple"randomized"trials"involving"treatments"compared"directly,"indirectly,"or"both," the"entire"evidence"base"of" randomized" trials" can"be"synthesized" in"an"internally"coherent"analysis.282""Box"3.2"below"provides"a"brief"overview"of"different"evidence"network"structures.""




*& This& figure& was& adapted& from& the& International& Society& for& PharmacoEconomics& and& Outcomes& Research&
(ISPOR)&Task&Force&on&Indirect&Treatment&Comparisons&Report&Part&II&developed&by&Jansen&and&colleagues.283&In" the" third" network" diagram," there" is" direct" evidence" on" the" comparison" between"treatments"B"and"C,"in"addition"to"indirect"evidence"through"treatment"A,"creating"a"‘closed"loop’"(each"comparison"has"both"direct"and"indirect"evidence)."This"evidence"structure"with"a" closed" loop" is" often" referred" to" as" a" mixed" treatment" comparison." The" fourth" network"diagram" is" more" complex" as" it" has" two" closed" loops." Whatever" the" complexity" of" the"network" structure," relative" effects" can" be" obtained" on" all" comparisons" of" interest" in" the"treatment" network." Collectively," evidence" structures" that" contain" a" closed" network" of"comparisons" (of" open" or" closed" loops)" are" referred" to" as" network"metaBanalyses." For" the"sake"of"simplicity,"all"indirect"comparisons"(with"or"without"closed"loops)"are"referred"to"as"network"metaBanalyses"in"this"thesis.""
"As"described"in"Box"3.2,"network"metaBanalysis"can"either"have"a"single"indirect"comparison"between" two" drugs" or" can" include" two" or"more" drugs" being" compared" indirectly"with" at"least"one"pair"of"drugs"compared"both"directly"and"indirectly."The"latest"statistical"methods"facilitate" the" incorporation" of" direct" and" indirect" evidence" in" any" network" structure" and"complexity,"as"long"as"treatments"are"connected"in"a"network.283B285"An" important" consideration" when" using" indirect" evidence" is" that" the" uncertainty" in" an"indirect"comparison"is"always"greater"than"the"uncertainty"in"the"direct"comparisons"from"which" it" is" composed."This" is"particularly" important"when"more" than"a" few" links"separate"two" drugs" of" interest" in" an" evidence" network" (as" an" example," consider" the" comparison"between"treatments"D"and"E" in"the"second"network"diagram"in"Box"3.2)." In"such"cases,"an"indirect"comparison"may"not"provide"a"precise"estimate"of"relative"effect"because"each"link"tends"to"increase"the"uncertainty"of"the"indirect"comparison.286"However,"if"both"direct"and"
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indirect" evidence" is" available," indirect" evidence" carries" less" weight" in" the" analysis" (but"continues" to" contribute" information" to" the" analysis)." Also," the" more" distant" the" indirect"evidence"from"the"comparison"of"interest,"the"lower"the"weight"attached"to"it"in"the"analysis"as"a"function"of"its"greater"variance.286"Notably,"by"combining"relative"treatment"effects"from"randomized"controlled"trials,"network"metaBanalysis" preserves" the" withinBtrial" randomized" treatment" comparison" of" each" trial"while"combining"all"available"comparisons"between"treatments.283"This"is"important"since"a"naïve"comparison"that"does"not"maintain"randomization"(by"comparing"effects"observed"in"single" trialBarms)" would" create" an" observational" study" with" groups" that" may" not" be"comparable"on"potential"confounding"factors.287""While"randomization" is"preserved"within"trials" in"network"metaBanalyses," it"does"not"hold"across"trials."Therefore,"differences"across"trials"that"are"relative"treatment"effect"modifiers"may"result"in"biased"estimates"of"comparative"treatment"effect.288"Examples"of"key"relative"treatment" effect"modifiers" include"differences" in"patient"populations" across" trials," such"as"patient"age"and"disease" severity."Although"some"case" studies"have" suggested" that" indirect"comparisons" have" resulted" in" invalid" estimates" of" comparative" efficacy" and" safety,289,290"biased" findings" were" primarily" due" to" flaws" in" the" systematic" review" methodology,"particularly" the" “lumping" together”" of" different" treatment" doses" or" combinations" (Box"3.3).291,292"The"validity"of"the"statistical"methods"underlying"network"metaBanalysis"is"widely"accepted283,284"and"these"types"of"analyses"are"increasingly"appearing"in"highBimpact"general"medical" journals" but" there" is" still" criticism" of" this" method.88,89,293B299" Criticisms" of" the"network"metaBanalysis"approach"are"discussed"in"Box"3.3.""
Box!3.3:!Criticism!and!Enthusiasm!for!Network!Meta@analysis!Over" the" past" decade," researchers" raised" concerns" about" combining" direct" and" indirect"evidence" in" network" metaBanalysis." These" concerns" primarily" focused" on" the" potential"(in)validity" of" indirect" comparisons.300" According" to" Georgia" Salanti:" “The" criticism" and"enthusiasm"for"network"metaBanalysis"echo"those"that"greeted"the"advent"of"simple"metaBanalysis.”250""In"a"landmark"study"published"in"2003,"Song"and"colleagues"reviewed"the"literature"on"the"use"of" indirect" comparisons.289"According" to" this" review," there"was"moderate" agreement"between"direct"and"indirect"evidence"on"the"basis"of"44"comparisons"available"from"a"wide"range" of" medical" topics," with" three" comparisons" showing" statistically" significant"discrepancy" between" the" direct" and" indirect" estimates." A" closer" examination" suggested"that" the" observed" discrepancies" were" primarily" explained" by" inappropriate" “lumping"together”" of" various" treatments" at" different" doses." Although" there" was" no" significant"
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disagreement"between"different"sources"of"evidence"for"the"majority"of"comparisons"in"the"literature," the" authors" concluded" that" indirect" comparison" may" provide" useful" or"supplementary" information" on" the" comparative" effectiveness" of" treatments" only" when"there"is"no"or"insufficient"direct"evidence"from"randomized"trials.289"In"a"recent"update"of"their" review" in" 2011," Song" and" colleagues" found" that" 16" out" of" 112" trial" networks" had"statistically" detectable" discrepancy" between" direct" and" indirect" evidence," concluding:"“inconsistency" between" direct" and" indirect" comparisons" may" be" more" prevalent" than"previously"observed.”290"As" in" their"previous" review,"however," the"observed"discrepancy"likely"reflected"the"reliability"of"the"identified"systematic"reviews"rather"than"the"indirect"comparisons301" (as" has" been" argued" in" numerous" methodological" guidance" articles," the"validity"of"indirect"comparisons"depends"on"their"proper"use:"metaBanalytic"approaches"–"with" or" without" indirect" comparisons" –" can" only" be" as" good" as" the" existing" pool" of"randomized"trials).95,282,302,303""In"a"separate"study,"Song"and"colleagues"also"surveyed"the"published"literature"to"identify"and" document" the" methodological" limitations" in" the" use" of" indirect" comparisons" in"systematic"reviews.292"They"found"that"six"studies"published"between"2000"and"2007"used"naïve" indirect" comparisons" without" a" common" control" group." As" mentioned" previously,"these" simplistic" approaches" that" informally" compare" armBlevel" estimates" have" clear"methodological" flaws," and" are" duly" criticized.304,305" This" review" also" showed" that"approximately"one" fifth"of"88" identified"reviews"used"advanced"methods"similar" to" those"used"in"this"doctoral"thesis.""Song" and" colleagues" concluded" that" the" main" methodological" problems" in" the" use" of"indirect"comparisons"stemmed"from"an"unclear"understanding"of"underling"assumptions,"which" resulted" in" the" use" of" inappropriate" methods," and" inadequate" assessment" of"consistency"between"direct"and"indirect"evidence.292"A"recent"metaBepidemiological"review"confirmed" that" key" methodological" recommendations" for" conducting" and" reporting"systematic" reviews" were" not" followed" in" the" vast" majority" of" network" metaBanalyses"published"in"highBimpact"medical"journals.306""The"Ad&Hoc"Network"MetaBanalysis"Methods"Meeting"Working"Group,"convened"in"2011"at"the"Johns"Hopkins"Bloomberg"School"of"Public"Health,"highlighted"additional"areas"in"need"of" further" methodological" research.307" Of" particular" importance," the" Working" Group"Members" questioned" the" validity" of" network" metaBanalysis" findings" in" cases" where" the"strength"of"evidence"and"risk"of"bias"for"different"comparisons"in"the"network"varied.""Taken" in" aggregate," previous" criticisms" of" indirect" comparisons" highlighted" the" need" to"demystify" the" basic" assumptions" underlying" network" metaBanalysis" methods." As" Jansen"
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and" Naci" stated:" “[assumptions]" concerning" network" metaBanalysis" for" both" direct" and"indirect" comparisons" might" be" perceived" to" be" more" complex," and" might" be" prone" to"misinterpretation.”308"To"address"this"important"gap"in"the"literature,"a"number"of"‘primer’"articles" have" recently" appeared" in" highBimpact" medical" journals" (including" the" British"Medical" Journal" [BMJ],309" Journal" of" the" American" Medical" Association" [JAMA],310" and"Annals"of"Internal"Medicine311),"clarifying"the"assumptions"of"network"metaBanalysis,"and"providing" guidance" for" their" conduct" and" reporting." By" focusing" on" the" role" of" relative"treatment"effect"modifiers"(discussed"in"more"detail"below),"Jansen"and"Naci"also"provided"a"basic" explanation" for" instances"where"network"metaBanalysis" can"be" expected" to"be" as"valid"as"pairBwise"metaBanalysis.308""In" light" of" these" developments," network" metaBanalyses" are" increasingly" used" in" the"comparative" assessment" of" new" and" existing" health" technologies.312,313" In" fact," over" the"past"decade," there"has"been"an"exponential" increase" in"the"number"of"published"network"metaBanalyses.250" In"a"widelyBcited"example,"Cipriani" and"colleagues"used" this"method" to"compare"existing"options"for"the"treatment"of"acute"mania.88"After"identifying"all"published"and" unpublished" trials" that" compared" antimanic" drugs" either" against" placebo" or" against"one"another,"results"from"68"studies"with"more"than"16,000"participants"were"synthesized,"allowing" for" comparative"estimates"on"13" treatments."This"analysis" indicated" that,"based"on" evidence" available" to" date," antipsychotic" drugs" (risperidone," olanzapine," and"haloperidol" in" particular)" appear" to" be" more" effective" than" mood" stabilizers" for" the"treatment" of" acute" mania," emphasizing" the" need" for" future" treatments" to" show" either"greater"efficacy"or"safety"than"the"existing"best"treatments."""Network" metaBanalytic" approaches" are" also" gaining" traction" in" the" United" States," with"governmental"agencies"showing"interest" in"the"use,"reporting,"and"interpretation"of"these"methods.314" In" a" recent" example," the" United" States" Agency" for" Healthcare" Research" and"Quality" (AHRQ)" commissioned" a" study" to" compare" the" benefits" and" harms" of" secondBgeneration"antidepressants"for"treating"major"depressive"disorder"in"adults."Investigators"of" the" study" concluded" that," on" the" basis" of" a" network"metaBanalysis" of" 234" studies," no"clinically"relevant"differences" in"efficacy"or"effectiveness"were"detected" for" the"treatment"of"acute,"continuation,"and"maintenance"phases"of"major"depressive"disorder.315"
&
3.3.2.2& & Approach&to&Network&MetaGanalysis&In"the"network"metaBanalyses"conducted"to"determine"the"comparative"benefits"and"harms"of"individual"statins,"studyBlevel"relative"treatment"effects"were"combined"using"both"fixedB"and" randomBeffects"models"within"a"Bayesian" framework"employing"Markov"Chain"Monte"
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Carlo"methods.284" This"was"based"on"modeling" the" outcomes" in" every" treatment" group"of"every" study," and"specifying" the" relations"among" the" relative"effects"across" studies"making"different" comparisons.97,316" For" all" network" metaBanalyses," a" Bayesian" framework" was"adopted" for" two" reasons." First," network" metaBanalytic" methods" are" considerably" more"advanced" within" the" Bayesian" framework" as" compared" to" frequentist" approaches.279"Second," the" results" obtained" from" Bayesian" analyses" can" be" interpreted" in" terms" of"probabilities,"which"allow"for"a"more"intuitive"interpretation"of"the"findings"(e.g.,"“There"is"an"x%"probability"that"drug"A"is"better"than"drug"B”)"as"opposed"to"findings"obtained"from"frequentist"analyses"(which"estimate"uncertainty"in"terms"of"confidence"intervals,"which"are"not" probability" statements).317" From" a" Bayesian" perspective," every" analysis" has" three"elements:" the" data,"which" forms" the" likelihood;" the" unknown"basic" parameters"which" are"given"a"prior"distribution"and"are"updated"by"the"information"in"the"likelihood;"and"a"model"that" expresses" the" relationship" between" the" basic" parameters" and" the" data.318,319" For" the"empirical"work"presented" in" this" thesis,"nonBinformative" (vague)"priors"were"used" for" the"unknown"basic"parameters."Previous"research"has"shown"that"Bayesian"metaBanalyses"using"nonBinformative" priors" obtain" identical" posterior" estimates" as" those" obtained" from"metaBanalyses"conducted"within"a"frequentist"framework.95""The" network" metaBanalysis" model" developed" by" Dias" and" colleagues" for" the" National"Institute"of"Health" and"Care"Excellence"Decision"Support"Unit" in" the"United"Kingdom"was"used"for"all"analyses.320,321"This"WinBugs"model"was"generic"in"the"sense"that"it"allowed"for"any" evidence" structure" (indirect" treatment" comparison" or" mixed" treatment" comparison)"and"it"accounted"for"the"correlation"induced"on"the"random"treatment"effects"in"multiBarm"trials.""The"model"specifications"are"described"in"Box"3.4."Examples"of"WinBugs"code"for"the"network"metaBanalysis"models"are"included"in"Appendix"2.""
Box!3.4:!Analytical!Approach!to!Network!Meta@analysis321,322!!In"the"absence"of"direct"headBtoBhead"trial"evidence"on"difference"between"treatments"2"and"3,"d23,"mean"d23"and"variance"σ223"can"be"estimated"from"studies"of"treatments"1"and"3"with"the"common"comparator"2:"" " " " d23"="d13"–"d12"Where"d13"="difference"between"treatments"1"and"3;"and"""""""""""""""d12"="difference"between"treatments"1"and"2"which"can"be"termed"the"transivity"assumption"of"indirect"comparisons,97 and"" " " " σ223"="σ212"+"σ213"B"2ρ(1)23σ12σ13"
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where" ρ(1)23" is" the" correlation" between" the" relative" effects" of" treatment" 3" vs." 1," and" the"relative"effect"of"treatment"2"vs."1,"within"a"trial."The"transivity"assumption"can"be"extended"to"multiple"treatments"as"below:"" " " " d23"="d13"–"d12"" " " " d24"="d14"–"d12"" " " " ."" " " " d(sB1),s"="d1s"–"d(1,(sB1)"In" this" scenario," there" are" (sG1)" basic" parameters" to" be" estimated" from" the" data" (d12,"d13,"
d14…" d1s)." The" remaining" are" functional" parameters" which" are" functions" of" the" basic"parameters.""In"this"framework"of"multiple"treatment"comparisons,"the"model"is"specified"as"below321,323:"δi,1k"~"N(dti1,tik","σ2)" "logit( )"=" "
"Note:" "where"dti1,tik"is"the"mean"treatment"effect"in"arm"k"in"trial"i,"tik,"compared"to"the"treatment"in"arm" 1" of" trial" i," ti1," and" σ2" is" the" betweenBtrial" variability" in" treatment" effects." Model"specification" is" identical" to" traditional"pairBwise"metaBanalysis"as" shown"above," except" for"the"revised"notation"to"account"for"multiple"treatments.""Winbugs," developed" by" the" Medical" Research" Council" Biostatistics" Unit" at" Cambridge"University,"is"the"software"package"that"solves"these"models"via"Markov"Chain"Monte"Carlo"simulation."They"output"a"stream"of"samples"from"the"posterior"distributions,"P(θ"|"data),"as"they"are"updated"with"new"information"from"the"computed"likelihoods,"P(data"|"θ)." "When"the"distributions"stabilize,"sample"means"of"the"distributions"provide"estimates"of"the"basic"parameters,"e.g."d12,"d13,"d14…"d1s."
"The" results" of" the" network" metaBanalyses" were" presented" as" odds" ratios" (for" binary"outcomes)"or"mean"differences"(for"continuous"outcomes)"and"95%"credible"intervals"(95%"
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CrI),"which"may" be" interpreted" as" Bayesian" equivalents" of" 95%" confidence" intervals." The"95%"CrI"can"be"interpreted"as"indicating"a"95%"probability"that"the"true"mean"change"falls"within"the"given"range."The"mean"of"the"posterior"distribution"and"the"95%"CrI"were"plotted"in" forestBplot" graphs" to" assist" in" interpretation." The" difference" between" treatments" was"assessed"on" the"basis"of"95%"CrIs."Given" the"Bayesian"nature"of" the" statistical" analyses," p"values" were" not" provided" for" the" network" metaBanalysis" results." Instead," statistical"significance" (although" this" concept" does" not" apply" within" a" Bayesian" framework)" was"inferred"on"the"basis"of"95%"CrIs.""In"each"of"the"Markov"Chain"Monte"Carlo"iterations,"each"treatment"j"was"ranked"according"to"its"estimated"effect"size."Then,"the"proportion"of"the"iterations"in"which"a"given"treatment"ranked"first"out"of"the"total"gave"the"probability"P(j=1)"that"treatment"j"ranked"first."Similar"probabilities"were" calculated" for" being" the" second" best," the" third" best," and" so" on:" P(j=b),"b=1,…,a." These" probabilities" added" up" to" one" for" each" treatment" and" for" each" rank." To"visually"demonstrate"the"statin"rankings,"rank"probabilities"P(j=b)"were"plotted"against"the"possible" ranks" b" =1,…,a" for" all" competing" treatments," resulting" in" ‘rankograms’.324"Rankograms"were" first"developed"by"Salanti"and"colleagues" in"a"network"metaBanalysis"of"12" selective" serotonin" reuptake" inhibitors" used" for" the" treatment" of" major" depressive"disorder.89"In"addition,"cumulative"probability"plots"were"developed"whereby"ranks"b=1,…,a"were"placed"on"the"horizontal"axis"starting"from"1,"and"the"cumulative"probability"that"each"treatment"was"among"the"top"b"treatments"(anywhere"between"the"first"and"bth"rank)"was"plotted,"following"the"approach"adopted"by"Salanti"and"colleagues."The"graphical"display"of"cumulative"ranking"was"supplemented"with"a"numerical"summary,"which" was" estimated" based" on" the" surface" under" the" cumulative" ranking" line" for" each"treatment:324" the" surface" under" the" cumulative" ranking" line"was" 1"when" a" treatment"was"certain"to"be"the"best"and"0"when"a"treatment"was"certain"to"be"the"worst."The"surface"under"the"cumulative"ranking"line"takes"into"account"not"only"the"magnitude"of"the"effect"(OR)"but"also"the"uncertainty"around"it.&For"each"treatment"j"out"of"the"a"competing"treatments,"the"a"vector"of"cumulative"probabilities"cumj,b" to"be"among"the"b"best" treatments,"b"="1,…,a"was"calculated."The"surface"below"the"cumulative"step"function"for"treatment"j"was"calculated,"as"shown"by"Salanti"and"colleagues"(and"implemented"in"R"2.11.1)."For"all"binary"outcomes"of"interest,"it"was"assumed"that"the"number"of"events"per"trial"arm"had"a"binomial"distribution."The"logit"function"was"used"to"link"the"probability"of"an"event"in"each"arm"of"each"trial,"the"trialBspecific"baseline"effect"(treatment"effect"of"the"control"arm),"and"the"relative"treatment"effect"of"the"treatment"compared"with"control." "Noninformative"(i.e.," vague" or" flat)" priors" [N(0," 1002)]" were" set" for" trial" specific" baselines" and" relative"
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3.3.2.3 Checking&the&Assumptions&of&Network&MetaGanalysis&The"assumption"employed" in"network"metaBanalysis"was"similar" to" the"one" that"underlies"traditional" pairBwise" metaBanalysis." Often" termed" similarity," network" metaBanalyses"assumed" that" the" distribution" of" relative" treatment" effect" modifiers" (e.g.," baseline" age" of"patients"and"baseline"LDL"cholesterol" level)"was"balanced"across"different"comparisons" in"the" network" of" statins." In" other"words," it"was" assumed" that" betweenBstudy"heterogeneity"was" independent" of" the" comparison" being" made." The" similarity" assumption" was" first"visually" investigated" by" plotting" the" relationship" between" baseline" studyBlevel" covariates"such" as" trial" publication" year" and" average" patient" characteristics" such" as" mean" age" with"relative"treatment"effects."Second,"subBgroup"analyses"were"performed"for"binary"variables"such" as" study" population" (e.g." primary" and" secondary" prevention)" and" dose." Third," the"impact" of" continuous" studyBlevel" covariates" and" average" patient" characteristics" on" the"relative"treatment"effect"was"statistically"evaluated"using"metaBregression"analyses."MetaBregression" is" a" statistical" technique" that" attempts" to" account" for" the" difference"between"treatmentBeffects"in"a"collection"of"trials"by"explaining"the"difference"in"effect"sizes"between" trials" by" regressing" the" effect" size" from" each" trial" onto" trialBlevel" covariates" or"average" participant" characteristics." The" application" of" metaBregression" techniques" to"network"metaBanalysis"provides"a"powerful"way"of"accounting"for"heterogeneity"in"complex"evidence" networks." MetaBregressions" conducted" in" the" context" of" network"metaBanalyses"require"a"careful"examination"of"potential"covariates,"and"the"selection"of"covariates"should"be"based"on"a&priori" exploratory"analyses."Although" there"are"a"number"of" covariates" that"can"be"used"to"explain"the"heterogeneity"between"included"studies,"multiple"analyses"using"a" large" number" of" covariates" would" have" a" high" probability" of" finding" falseBpositive"explanatory" variables.325" In" addition," as" shown" by" Jansen" and" colleagues," adjusting" for"covariates"that"are"not"relative"treatment"effect"modifiers"would"actually"introduce"bias"into"the"findings"of"network"metaBanalysis.288"The"metaBregression" approach" has" two" potential" limitations." First," it" is" important" to" note"that,"while"the"studies"used"in"the"metaBregression"are"all"randomized"controlled"trials,"the"relationship"identified"by"the"metaBregression"is"an"observational"relationship"between"the"treatment"effect"and"studyBlevel"covariates"or"average"patient"characteristics"(covariates"are"not" randomized" across" different" studies).326" The" second" is" autocorrelation" where" the"sampled"estimates"of"parameters"in"the"model"may"be"highly"correlated.""
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Recognizing" these" limitations," metaBregression" analyses" were" used" judiciously" and" the"qualitative" approach" of" visually" inspecting" clinically" meaningful" heterogeneity" was"prioritized" over" the" statistical" alternative." The" studyBlevel" covariates" of" interest" were"selected" following" a" review" of" the" literature." Given" the"wealth" of" previous"metaBanalyses"conducted"on"statin"trials,"there"was"ample"information"on"which"factors"would"potentially"modify"the"relative"treatment"effects"of"statins."These"included"factors"evaluated"in"previous"metaBanalyses" such" as" baseline" mean" age" and" baseline" mean" LDL" cholesterol" level." In"addition,"trial"publication"year"was"included"to"examine"whether"the"comparative"effects"of"individual"statins"would"be"different"over"time"(essentially"using"trial"publication"year"as"a"proxy" for" a" host" of" factors" such" as" advances" in" trial" design" over" time," changes" in" clinical"practice," etc.)." For" clinical" outcomes," the" potential" association" between" baseline" risk" and"treatment" effect" was" also" investigated" as" a" possible" explanation" of" betweenBstudy"heterogeneity." Although" gender" was" originally" specified" as" a" potential" relative" treatment"effect" modifier," recent" metaBanalyses" have" demonstrated" that" the" comparative" effects" of"statins"are"not" influenced"by"gender.242"Accordingly,"gender"was"not"evaluated" further."As"described" in"Chapter"7"entitled" ‘Methodological&Quality&and&Risk&of&Bias& in& the&Randomized&






in"the"same"metaBregression"model"given"the"insufficient"power"to"estimate"more"complex"models.328"Findings"of"different"metaBregression"models"were"first"compared"qualitatively"to"examine"any"clinically"meaningful"differences"across"point"estimates"and"95%"CrI"in"different"sets"of"analyses."In"addition,"the"estimate"of"the"betweenBstudy"heterogeneity"was"compared"to"see"if" adding" covariates" in" metaBregression" analyses" could" explain" the" betweenBstudy"heterogeneity.""





variance( )"="variance( )"+"variance( ) "
The"statistical"significance"of"inconsistency"is"then"tested"by:"
"
The"assessment"of"consistency"was"repeated"for"each"closed"loop"in"the"treatment"network,"using"the"automated"functions"developed"by"Salanti"and"colleagues."The"inconsistency" " for"each" closed" loop" was" visualized" in" forest" plots" (termed" inconsistency" plots)" to" inspect"potential" discrepancies" between" direct" and" indirect" evidence" in" the" treatment" network."Graphical"presentation"of"inconsistency"plots"was"developed"in"R"2.11.1."""Given"the"extremely" large"numbers"of"pairBwise"metaBanalyses"required"to"use"the"Bucher"method," an" alternative"method"was" employed" to" check" for" the" consistency" assumption" in"the"analyses"that"evaluated"the"doseBcomparative"effects"of"individual"statins"(all"six"statins"at"low,"medium,"and"high"doses)."The"consistency"of"relative"treatment"effects"obtained"from"an"analysis"of"headBtoBhead"trials"(i.e."direct"evidence)"with"those"obtained"from"an"analysis"combining"both"placeboBcontrolled"and"activeBcomparator"trials"(i.e."mixed"evidence)"were"plotted" and" qualitatively" compared" for" instances" where" the" 95%" CrIs" did" not" overlap."Potential" disrepancy" was" assessed" in" terms" of" the" direction" of" effect," as" well" as" its"magnitude."
3.4!Deviations!from!the!Protocol!There"were"a"number"of"deviations"from"the"original"protocol."These"can"be"categorized"as"changes"in"the"approach"to"(1)"study"identification"and"data"extraction;"(2)"dose"evaluation;"(3)"consistency"exploration;"(4)"sensitivity"analysis;"and"(5)"outcomes"of"interest.""
Study& identification& and& data& extraction:" In" terms" of" the" electronic" database" searches,"Database" of" Abstracts" of" Reviews" of" Effects,"National"Health" Service" Economic" Evaluation"Database,"and"Health"Technology"Assessment"Database"were"not"searched."In"addition,"the"trial" databases" of" regulatory" agencies" (the" Food" and" Drug" Administration" in" the" United"States," the"Medicines" and"Healthcare" products" Regulatory" Agency" in" the" United" Kingdom"and" the" European" Medicines" Agency" in" the" European" Union)" and" ongoing" trial" registers"(clinicaltrials.gov" in" the" United" States" and" National" Research" Register" in" the" United"Kingdom)" were" not" handBsearched" for" unpublished" and" ongoing" randomized" controlled"
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trials." This" change" was" justified" for" two" reasons." First," many" of" the" statin" trials" were"conducted" before" mandatory" trial" registers" such" as" clinicaltrials.gov" were" established330"(the"International"Committee"of"Medical"Journal"Editors"policy"requiring"the"registration"of"clinical" trials" as" a" prerequisite" for" consideration" for" publication"was" only" implemented" in"2005).331"Second,"searching"MEDLINE,"Cochrane"Database"of"Systematic"Reviews,"Cochrane"Central" Register" of" Controlled" Trials" was" considered" to" be" adequate" to" identify" the"published" randomized" controlled" trials" of" statins." As" outlined" in" the" previous" Chapter"(Chapter&2:&Evolution&of&Clinical&Evidence:&The&Case&of&Statins),"a"large"number"of"systematic"reviews"and"metaBanalyses"have"evaluated"the"benefits"and"harms"of"statins."To"ensure"that"the"search"strategy"was"robust"and"that"all"relevant"trials"were"identified,"the"reference"lists"of" all" previous" metaBanalyses" were" documented" and" manually" reviewed." Although" the"protocol"suggested"that"two"researchers"would"extract"data"independently,"one"researcher"was" responsible" for" all" aspects" of" data" extraction." However," two" additional" researchers"assisted"in"checking"the"accuracy"of"data"extraction.9""
Dose& evaluation:" The" impact" of" dose" on" the" comparative" benefits" and" harms" of" individual"statins"was"evaluated"using"a"different"approach"than"what"was"originally"proposed"in"the"protocol."The"protocol"specified"that"a"metaBregression"technique"would"be"used"to"take"into"account" the" doseBresponse" relationship" for" each" individual" statin." Upon" further"consideration,"this"was"deemed"to"be"potentially"inappropriate"for"a"metaBanalysis"aimed"at"determining"relative"treatment"effects"of"multiple"treatments."The"primary"concern"was"that"randomization" would" not" be" maintained" when" armBlevel" factors" (i.e.," dose" differences"between"different"arms"within"a" trial)"were"taken" into"account."Accordingly," the" impact"of"dose" was" evaluated" in" subBgroup" analyses" whereby" all" statinBdose" combinations" were"treated" as" independent" treatments" in" the" network." Although" novel" statistical" approaches"can" take" into" account" doseBeffects" as" subBnodes" in" a" network" of" randomized" controlled"trials,332"a"qualitative"approach"was"preferred"over"its"statistical"alternative."Whether"or"not"to" group" individual" statins" at" different"doses" as" a" single"node" in" the"network"was" further"informed" by" discussions" with" clinician" collaborators." In" the" end," each" statinBdose"combination"was"treated"as"a"different"treatment"and"no"trends"or"statistical"relationships"were"fitted"or"assumed.""
Consistency& evaluation:&As" described" in" the" previous" section," the" consistency" assumption"was" evaluated" using" the" “Bucher"method.”329" Unlike"what"was" originally" proposed" in" the"protocol," a" nodeBsplitting" approach" was" not" used." The" primary" difference" between" these"approaches" is" that" the"Bucher"method" compares"direct" and" indirect" evidence"within" each"
                                                9" Given" that" this" systematic" review" of" the" literature" was" undertaken" specifically" for" this"dissertation," as" the" principle" researcher," I" was" responsible" for" all" aspects" of" the" systematic"review"including"data"extraction.""
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closed" loop" whereas" the" nodeBsplitting" approach" compares" direct" evidence" with" indirect"evidence" obtained" from" the" entire" network." In" the" absence" of" statistically" detectable"inconsistency"within"each"loop"for"the"clinical"benefit"and"harm"outcomes"(as"discussed"in"more" detail" in" Chapter" 5:" Comparative& Benefits& of& Individual& Statins& and" Chapter" 6:&
Comparative&Harms&of&Individual&Statins),"the"nodeBsplitting"approach"was"not"used."Instead,"metaBregression" analyses" were" conducted" to" evaluate" the" potential" impact" of" known"relative"treatment"modifiers"in"the"network"metaBanalysis.""
Sensitivity&analysis:"The"effect"of"trial"duration"on"the"comparative"effects"of"individual"trials"was"evaluated"but"not"reported."This"decision"was"made"following"an"exploratory"analysis"demonstrating" that" trial" duration" did" not" have" an" effect" on" the" reported" cholesterolBlowering"effects"of" individual" statins."For"clinical"and"harm"outcomes," followBup"durations"(and"times"at"which"trial"results"were"reported)"were"surprisingly"consistent"across"groups"of" trials" reporting" different" types" of" outcomes." For" instance," clinical" endpoints" (such" as"mortality"and"major"coronary"events)"were"almost"always"reported"in"trials"with"followBup"durations" longer" than" 52"weeks." Similarly," trials" reporting" cancer" or" diabetes" occurrence"had"longer"followBup"durations."""




Chapter!4!"DoseBComparative"Effects"of"Individual"Statins"on""Cholesterol"Concentrations*"""Clinical" practice" guidelines" identify" LDL" cholesterol" as" the" primary" target" of" cholesterol"lowering" therapy" for" the" primary" and" secondary" prevention" of" cardiovascular" disease.154"The"National" Cholesterol"Education"Program’s"Third"Adult"Treatment"Panel" (ATPBIII)" and"ACC/AHA"clinical"practice"guidelines"recommend"that"statins"should"be"considered"as"firstBline" treatment" when" cholesterolBlowering" drugs" are" indicated" to" lower" the" risk" of"cardiovascular" events." In" addition" to" their" effect" on" LDL" and" Total" cholesterol"concentrations," statins" result" in"modest" increases" in"HDL" cholesterol,"which" is" a" negative"risk" factor" for" cardiovascular" disease" (i.e.," presence" of" high"HDL" cholesterol" removes" one"risk" factor" from" the" total" count" of" risk" factors)." Because" of" their" efficacy" in" reducing" LDL"cholesterol" and" increasing" HDL" cholesterol" and" their" favorable" tolerability" and" safety"profile," statins" are" the"most" commonly" prescribed" agents" for" the" primary" and" secondary"prevention"of"cardiovascular"disease.""At"the"time"of"developing"the"protocol"for"this"research,"there"were"six"statins"available"on"the"market"(atorvastatin," fluvastatin," lovastatin,"pitavastatin,"pravastatin,"rosuvastatin,"and"simvastatin),"which"were"originally"indicated"as"monotherapy"for"the"reduction"of"elevated"LDL" cholesterol" concentrations" (Table" 4.1)." Pitavastatin" (Livalo®)" was" approved" and"marketed" in" the"United"States" in" June"2010" following" its"evaluation"by" the"Food"and"Drug"Administration" in" August" 2009." Pitavastatin" is" not" included" in" the" doseBcomparative"analyses" presented" in" this" chapter." There" are" important" differences" among" the" currently"marketed" statins" in" terms" of" their" chemical," pharmacodynamic," and" pharmacokinetic"properties.333"Lovastatin,"pravastatin,"and"simvastatin"are"derived"from"fungal"fermentation"whereas"fluvastatin,"atorvastatin,"and"rosuvastatin"are"entirely"synthetic."Individual"statins"
                                                
* Part"of"the"work"presented"in"this"chapter"was"published"with"the"following"reference:"Naci"H,"Brugts" JJ," Fleurence" R," Ades" AE." DoseBcomparative" effects" of" individual" statins" on" serum" lipid"levels:"a"network"metaBanalysis"of"256,827"individuals"in"181"randomized"controlled"trials."Eur"J"Prev"Cardiol."2013"Aug;20(4):"658B70. 
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preparations!!Atorvastatin"*"(Lipitor®)" 10"mg" 80"mg" 10,"20,"40,"80"mg"tablets"Fluvastatin"*"(Lescol®)" 20"mg" 80"mg" 20,"40"mg"capsules,"80"mg"extended"release"tablets"Lovastatin"*"(Mevacor®)" 20"mg" 80"mg" 10,"20,"40"mg"tablets"Pravastatin"*"(Pravachol®)" 20"mg" 80"mg" 10,"20,"40"mg"tablets"Rosuvastatin""(Crestor®)" 10"mg" 40"mg" 5,"10,"20,"40"mg"tablets"Simvastatin"*"(Zocor®)" 20"mg" 80"mg" 5,"10,"20,"40,"80"mg"tablets"
*&Also&available&as&a&generic."DoseBcomparative" effects" of" individual" statins" on" cholesterol" concentrations" have" been"previously"studied."In"1997,"Kong"and"colleagues"performed"a"metaBanalysis"to"quantify"the"comparative" effects" of" individual" statins" on" LDL," HDL," and" Total" cholesterol"concentrations.334" Based" on" 52" doubleBblind," fixedBdose," placeboBcontrolled" trials" of"fluvastatin," lovastatin,"pravastatin,"and"simvastatin," reductions" in"baseline"LDL"cholesterol"concentrations"ranged"from"19%"with"pravastatin"10"mg/day"to"41%"with"simvastatin"40"mg/day." The" comparative" effects" of" individual" statins" were" also" explored" by" Law" and"colleagues" in" a"metaBanalysis" that" aimed" to" determine" the" extent" to"which" statins" reduce"serum" concentrations" of" LDL" cholesterol" according" to" dose.148" Their"metaBanalysis" of" 164"shortBterm" (which" typically" lasted" a" few" weeks)," doubleBblind," fixedBdose," placeboBcontrolled"trials"of"six"statins"included"approximately"24,000"individuals."According"to"this"analysis,"there"was"a"clear"doseBresponse"relationship"with"higher"doses"resulting"in"greater"reductions" in"LDL"cholesterol"concentrations."The"estimated"reductions" in"LDL"cholesterol"were" 55%"with" atorvastatin" 80"mg/day," 40%"with" atorvastatin" 10"mg/day," lovastatin" 40"mg/day," simvastatin" 40" mg/day," or" rosuvastatin" 5mg/day," whereas" pravastatin" and"fluvastatin"achieved"smaller"reductions.""Edwards"and"colleagues"performed"a"metaBanalysis"of" randomized,"doubleBblind,"placeboBcontrolled" trials" assessing" the" effect" of" seven" statins" (including" cerivastatin," which" was"
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subsequently"withdrawn" from" the"market)" on" cholesterol" concentrations" in" patients"with"high" blood" cholesterol.335" Trials" were" eligible" for" inclusion" in" this" metaBanalysis" if" they"lasted"longer"than"12"weeks"and"included"at"least"20"patients"per"treatment"group."Based"on"a" total"number"of"68,000" individuals," reductions" in"Total" cholesterol" of"25%"or"more"and"LDL"cholesterol"of"more"than"30%"were"recorded"for"fixed"doses"of"simvastatin"40"mg/day,"atorvastatin"10"mg/day,"and"rosuvastatin"5"mg/day"and"rosuvastatin"10"mg/day."This"metaBanalysis"concluded"that"the"duration"of"the"trial"and"baseline"cholesterol"concentrations"did"not"have"an"impact"on"the"results.""An"important"limitation"of"these"earlier"metaBanalyses"is"that"they"relied"solely"on"placeboBcontrolled"trials,"without"taking"into"account"direct"headBtoBhead"trials."In"addition,"placeboBcontrolled" trials" for"each"statinBdose"combination"were"pooled"separately." In"other"words,"separate"metaBanalyses"were" performed" for" atorvastatin" at" low,"medium," and" high" doses,"simvastatin"at"low,"medium,"and"high"doses,"and"so"on."This"resulted"in"an"enormous"loss"of"valuable" data" given" that" a" large" number" of" direct" headBtoBhead" trials" evaluated" the" doseBcomparative" effects" of" statins." For" example," CURVES" (comparative" dose" efficacy" study" of"atorvastatin" versus" statins)" was" a"multicenter," randomized," openBlabel," parallelBgroup," 8Bweek" study" including" 534" patients," which" evaluated" the" comparative" dose" efficacy" of"atorvastatin," fluvastatin," lovastatin," pravastatin," and" simvastatin" at" various" dosing"regimens.336" Similarly," STELLAR" (Statin" Therapies" for" Elevated" Lipid" Levels" compared"Across" doses" to" Rosuvastatin)" was" a" 6Bweek," parallelBgroup," openBlabel," randomized,"multicenter" trial" including" 2,431" individuals," which" compared" atorvastatin," pravastatin,"rosuvastatin"and"simvastatin"across"dose"ranges"for"reduction"of"LDL"cholesterol.337"These"trials," and" many" others" that" directly" compared" individual" statins" headBtoBhead," provide"valuable" information" about" the" doseBcomparative" effects" of" statins" and" should" be"incorporated"into"metaBanalyses.""Given" the" large"body"of" literature"evaluating" the" cholesterol" reducing"effects"of" individual"statins" at" different" doses," later" reviews" and" metaBanalyses" investigated" the" doseBcomparative"effects"of"statins"on"cholesterol"concentrations."However,"these"studies"focused"on" two"statins"at"a" time"–"without"a"clear" indication"of" the"doseBcomparative"effects"of"all"statins"simultaneously."One"example"was"the"metaBanalysis"by"Rogers"and"colleagues,"which"compared"the"effects"of"atorvastatin"and"simvastatin"in"18"direct"headBtoBhead"randomized"trials" at" doses" ranging" from" 10" to" 80" mg/day.338" Another" example" was" the" analysis"performed" by"Wlodarczyk" and" colleagues," which" compared" atorvastatin" and" rosuvastatin"across"various"dosing"strategies.339"This"metaBanalysis" included"25"openBlabel"and"doubleBblind"randomized"trials"including"approximately"20,000"individuals.""
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In"an"attempt"to"simultaneously"compare"the"doseBcomparative"effects"of"multiple"statins"on"the" basis" of" direct" headBtoBhead" trials," the" systematic" review" conducted" by" the" Drug"Effectiveness"Review"Project"(and"previously"the"Veterans"Health"Administration"Pharmacy"Benefits"Managements"Strategic"Healthcare"Group)"included"102"headBtoBhead"comparisons"of"different" statins" to" address" the"question:" “How"do" statins"…" compare" in" their" ability" to"reduce" [LDL" and" HDL]" cholesterol?”340" Although" this" review" did" not" perform" a" formal"statistical" analysis" to" estimate" the" pooled" effects" of" each" statinBdose" combination" and" the"statistical" uncertainty" around" these" estimates," it" qualitatively" estimated" the" approximate"equivalent" daily" doses" for" statins"with" respect" to" their" LDL" cholesterol" lowering" abilities,"presented"in"a"‘doseBequivalence"chart’"(Table"4.2)."A"similar"qualitative"approach"was"later"adopted"by"Weng"and"colleagues" in"a"systematic"review"on"the" therapeutic"equivalence"of"statins.341" This" doseBequivalence" chart" of" statins" has" since" been" widely" cited" in" publicly"available"reference"materials.""
Table!4.2!–"Equivalent"daily"doses"of"statins"as"reported"by"the"Drug"Effectiveness"Review"Project.!
Atorvastatin! Fluvastatin! Lovastatin! Pravastatin! Rosuvastatin! Simvastatin!BB" 40"mg" 20"mg" 20"mg" BB" 10"mg"10"mg" 80"mg" 40"or"80"mg" 40"mg" BB" 20"mg"20"mg" BB" 80"mg" 80"mg" 5"or"10"mg" 40"mg"40"mg" BB" BB" BB" BB" 80"mg"80"mg" BB" BB" BB" 20"mg" BB"BB" BB" BB" BB" 40"mg" BB"
The" analytic" approach" for" obtaining" this" oftBcited" doseBequivalence" chart" of" statins" has"significant" drawbacks." First," it" does" not" take" into" account" the" correlations" in" relative"treatment"effect"estimates"that"arise"from"trials"with"more"than"two"treatment"arms"(multiBarm" trials)." Second," comparisons" are" implicitly" indirect," neither" taking" into" account"potential" differences" between" baseline" characteristics" nor" maintaining" randomization"within" trials." Qualitatively" –" and" informally" –" comparing" findings" from" separate" pooled"analyses" does" not" take" into" account" the" uncertainty" around" their" point" estimates." It" is"essential" to" provide" an" effect" estimate" for" the"difference"between" treatments" as"well" as" a"measure" of" the" level" of" uncertainty" around" that" estimate." As" a" result" of" these" limitations,"statinBdose"combinations"that"appear"different"on"the"basis"of"point"estimates"may"in"fact"be"statistically"equivalent"when"taking"into"account"the"uncertainty"around"the"point"estimate."A" network" metaBanalysis" approach" that" simultaneously" combines" direct" and" indirect"
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sources" of" evidence" in" a" single" analysis" that" maintains" studyBlevel" randomization" and"accommodates"the"correlation"structure"in"multiBarm"trials"would"address"these"limitations.""
To"date,"there"has"been"no"comprehensive"analysis"of"the"doseBcomparative"effects"of"statins"on" cholesterol" levels" that"builds"on" the" totality"of" the" randomized" trial" evidence."This"has"important"implications"for"clinical"practice"as"prescribers"do"not"have"adequate"evidence"on"the"comparative"effects"of"different"statins"on"serum"cholesterol"levels"based"on"direct"and"indirect"metaBanalyses."The"objective"of"the"empirical"analysis"presented"in"this"chapter"was"to"perform"an"allBencompassing"review"of"the"statin"randomized"trial"literature"and"quantify"the"doseBcomparative"effects"of"individual"statins"on"serum"cholesterol"levels"by"combining"both"placeboBcontrolled" and" activeBcomparator" trials." This" chapter" reports" the" findings" of"the"network"metaBanalysis"on"the"effect"of"different"statins"on"serum"LDL"cholesterol,"total"cholesterol,"and"HDL"cholesterol.""
4.1!Empirical!Considerations!As"outlined"in"Chapter"3"(Evidence&Review&and&Synthesis&Methods),"separate"network"metaBanalyses"were"performed"for"the"mean"change"from"baseline"in"serum"LDL"cholesterol,"HDL"cholesterol," and" Total" cholesterol" between" two" comparator" treatments" for" a" given" dose"(change"from"baseline"in"the"treatment"group"minus"that"in"the"control"group)."The"primary"outcome" of" interest"was" LDL" cholesterol" reduction" from"pretreatment" levels." To" obtain" a"comprehensive" estimate" of" the" comparative" effect" of" statins" at" different" doses" on" serum"lipid" levels," the" baseBcase" network" metaBanalysis" pooled" all" primary" and" secondary"prevention"trials"in"addition"to"trials"with"mixed"patient"populations,"including"all"placeboBcontrolled" and" activeBcomparator" trials" eligible" for" inclusion" in" the" systematic" review." In"addition," for" the"primary" outcome"of" LDL" cholesterol" reduction" from"pretreatment" levels,"separate"analyses"for"the"primary"and"secondary"prevention"populations"were"conducted"to"evaluate"whether"the"doseBcomparative"effects"of"statins"differed"between"individuals"with"and"without"coronary"heart"disease"at"baseline."""




Ranking& of& statins& in& the& network& metaGanalysis:" The" probability" that" each" statinBdose"combination"is"the"best"regimen"was"estimated"by"calculating"its"treatment"effect"compared"with" common" comparator" treatment," and" counting" the" proportion" of" iterations" of" the"Markov" chain" in"which"each" statinBdose" combination"has" the"highest" treatment"effect," the"second"highest,"and"so"on."Rank"probabilities"were"separately"estimated"for"LDL"cholesterol"and"Total" cholesterol."Rankograms"were"developed" to"graphically"present" the"distribution"of"ranking"probabilities." In"addition,"cumulative"probability"plots"were"developed" for"each"outcome" and" the" surface" area" under" the" cumulative" ranking" line" for" each" statinBdose"combination" was" estimated" as" described" in" Chapter" 3" (Evidence& Review& and& Synthesis&
Methods)." The" surface" area" under" the" cumulative" ranking" line" provided" a" numerical"summary"of"the"overall"score"for"each"statinBdose"combination"for"each"outcome."Each"statin"was" scored"with"points" up" to" a"maximum"of" 1.00,"which"was" the"weighted" sum"of" scores"separately"estimated"for"LDL"cholesterol"and"Total"cholesterol.""
Assessment& of& heterogeneity& and& inconsistency& in& the& network& metaGanalysis:" Whether" the"potential" heterogeneity" and" inconsistency" across" the" evidence" base" in" the" network"metaBanalysis" for" the" primary" outcome" of" LDL" cholesterol" lowering" could" be" explained" by"baseline"mean" age," baseline"mean" LDL" cholesterol" concentration," or" publication" year"was"investigated"using"metaBregression"analyses."All"metaBregression"analyses"were"performed"by" allowing" for" a" common" treatmentBcovariate" interaction" for" each" statin" compared" to"control," as" described" in" Chapter" 3" (Evidence& Review& and& Synthesis& Methods)." A" separate"metaBregression"analysis"was" conducted" for"each"of" the" three"potential" relative" treatment"effect" modifiers" to" evaluate" whether" each" studyBlevel" covariate" had" an" effect" on" the"observed"relative"treatment"effects."Multiple"studyBlevel"covariates"were"not"considered"in"the" same" metaBregression" model" given" the" insufficient" power" to" estimate" more" complex"models.328"To" further" explore" any" potential" inconsistency" between" direct" and" indirect" evidence," the"consistency" of" relative" treatment" effects" obtained" from" an" analysis" of" headBtoBhead" trials"(i.e." direct" evidence)" with" those" obtained" from" an" analysis" combining" both" placeboBcontrolled"and"activeBcomparator" trials" (i.e."mixed"evidence)"were"qualitatively"evaluated."
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The"consistency"of"the"relative"treatment"effects"for"potential"differences"between"estimates"obtained" from" two" sets" of" analyses" (i.e." direct" and" mixed" estimates)" were" plotted" and"visually" inspected." This" approach"was" preferred" over" the" Bucher"method" given" the" large"number" of" pairBwise" metaBanalyses" that" needed" to" be" conducted" and" compared" for" 23"statinBdose"combinations,"which"would"result"in"276"pairBwise"metaBanalyses.""
Presentation& of& results:" First," the" findings" of" the" network" metaBanalysis," which" combined"evidence" from" placeboBcontrolled" and" activeBcomparator" trials,"were" presented." This"was"followed" by" the" presentation" of" metaBregression" results," which" provided" a" statistical"assessment"of"heterogeneity"and"inconsistency"in"the"network"metaBanalysis"on"the"basis"of"studyBlevel" covariates" (i.e." baseline" mean" age," baseline" mean" LDL" cholesterol" levels," and"publication"year).""
Interpretation&of&results:"Given"the"Bayesian"nature"of"network"metaBanalyses," the" findings"of"these"analyses"were"presented"as"mean"changes"from"baseline"and"95%"CrIs."If"a"95%"CrI"did"not"include"the"null"value"0.00,"this"was"interpreted"as"indicating"<5%"probability"that"there" was" no" difference" between" the" two" comparators." The" findings" were" considered"‘statistically&significant’&when&the"95%"CrI"did"not"include"the"null"value"0.00.""
4.2!Systematic!Review!Findings!There" were" 181" randomized" controlled" trials" included" in" the" systematic" review" and"network"metaBanalysis"of"serum"lipid"outcomes"(Figure"4.1)."These"trials"included"a"total"of"256,827" individuals."112"trials"were"doubleBblind"while"55"were"openBlabel"and"two"were"singleBblind." Blinding"was" not" clear" for" the" remaining" 12" trials." Overall," the" average" trial"duration"was"66"weeks,"with"53"trials"reporting"serum"lipid"levels"after"at"least"one"year"of"follow" up." There" were" 52" trials" conducted" among" individuals" with" established" coronary"heart"disease;"41"trials"were"in"primary"prevention"(eight"of"which"were"among"individuals"with"diabetes);"10"included"patients"with"acute"coronary"syndromes;"four"included"patients"with"heart"failure;"and"three"were"among"patients"with"metabolic"syndrome."The"remaining"71" trials" included" individuals" with" hypercholesterolemia" with" or" without" established"coronary"heart"disease.""Figure" 4.2" shows" the" network" of" eligible" pairBwise" comparisons" for" LDL," Total," and" HDL"cholesterol" reductions" from"baseline" in"placeboBcontrolled"and"activeBcomparator" trials"of"individuals"across"all"populations."Of"the"15"possible"pairBwise"comparisons"between"the"six"statins,"11"were"available" in" the" identified" literature."No" trial"directly"compared"all" statinBdose" combinations" to" each"other."There"were"83" twoBarmed"placeboBcontrolled" trials" and"the" remaining" 98"were" twoB" or"multiBarmed" activeBcomparator" trials." Of" these" 98" activeBcomparator" trials," 60" were" twoBarm" activeBcomparator" trials," 21" were" multiBarm" activeB
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4.3$Dose)comparative$Effects$of$Statins$on$Serum$Lipid$Levels$Differential,dose0comparative,effects,of, individual, statins,on,serum,LDL,cholesterol, levels,are,shown,in,Figure,4.3,and,Table,4.3.,Higher,statin,doses,were,generally,associated,with,greater,relative, reductions, in, pretreatment, LDL, cholesterol, levels, as, compared, to, control, treatment.,According, to, the, network, meta0analysis, results,, atorvastatin,, pravastatin,, rosuvastatin,, and,simvastatin,were,significantly,better,than,control, treatment,at,all,dosing,regimens, in,terms,of,reducing, baseline, concentrations, of, LDL, cholesterol., However,, fluvastatin, at, ≤20, mg/day, (015.46,mg/dL,,95%,CrI:,045.66,to,4.62,mg/dL),,fluvastatin,between,>20,and,≤40,mg/day,(034.51,mg/dL,,95%,CrI:,060.29,to,0.62,mg/dL),and,lovastatin,at,≤10,mg/day,(020.33,mg/dL,,95%,CrI:,057.98, to, 18.02,mg/dL), did, not, result, in, significant, reductions, from, baseline, LDL, cholesterol,levels,as,compared,to,control,treatment,(Table,4.3).,Atorvastatin,at,>40,mg/day,(060.82,mg/dL,,95%,CrI:, 080.06,to, 050.86,mg/dL),, rosuvastatin,between,>10,and,≤20,mg/day,(069.24,mg/dL,,95%,CrI:, 085.59,to, 038.81,mg/dL),, rosuvastatin,between,>20,and,≤40,mg/day,(067.54,mg/dL,,95%,CrI:, 096.74, to, 032.46,mg/dL),, and, simvastatin, at, >40,mg/day, (066.87,mg/dL,, 95%,CrI:, 087.66, to, 033.99, mg/dL), resulted, in, the, greatest, reductions, in, pretreatment, LDL, cholesterol,concentrations,as,compared,to,control,treatment.,,
Figure$4.3$–,Dose0comparative,relative,effects,of,statins,on,serum,LDL,cholesterol,levels.*,,
,,*, Estimates, shown, are, mean, changes, (mean,, 95%, CrI), from, baseline, in, serum, LDL, cholesterol,concentrations,as,compared,to,control,treatment.,LDL0C:,low0density,lipoprotein,cholesterol,,atorva:,atorvastatin,, fluva:, fluvastatin,, lova:, lovastatin,, prava:, pravastatin,, rosuva:, rosuvastatin,, simva:,simvastatin.,
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Figure,4.4,shows,the,estimated,percentage,reductions,from,an,average,baseline,concentration,of, 150, mg/dL, (approximate, mean, of, pretreatment, LDL, cholesterol, concentrations, in, the,included,trials).,Atorvastatin,(32%,at,≤,10,mg/day,to,45%,at,>40,mg/day),,pravastatin,(15%,at,≤10,mg/day,to,33%,at,>40,mg/day),,rosuvastatin,(33%,at,≤5,mg/day,to,47%,at,>20,mg/day),,and,simvastatin,(26%,at,≤10,mg/day,to,46%,at,>40,mg/day),at,all,dosing,regimens,significantly,reduced, LDL, cholesterol, levels, from, average, baseline, levels, of, approximately, 150, mg/dL,whereas, low, dosing, regimens, of, fluvastatin, (11%, reduction,, 95%, CrI:, 32%, reduction, to, 2%,increase, at, 20, mg/day), and, lovastatin, (16%, reduction,, 95%, CrI:, 40%, reduction, to, 10%,increase),did,not,significantly,reduce,LDL,cholesterol,levels.,
100 
 
Figure'4.4'–#Dose(comparative#absolute#effects#of#statins#on#serum#LDL#cholesterol#concentrations.*###################*# Estimates# shown# are# absolute# reductions# (mean,# 95%# CrI)# at# all# dose# combinations# standardized# to# the# average# pretreatment# LDL# cholesterol#concentration#in#the#included#set#of#trials.#LDL(C:#low(density#lipoprotein#cholesterol.#







' ≤5'mg/day' >5'and'≤10'mg/day' >10'and'≤20'mg/day' >20'and'≤40'mg/day' >40'mg/day'
Atorvastatin' (((# (43.16#((58.77,#(34.08)# (48.33#((67.89,#(36.77)# (54.79#((70.88,#(38.63)# (60.82#((80.06,#(50.86)#
Fluvastatin' (((# (((# (15.46#((45.66,#4.62)# (34.51#((60.29,#0.62)# (52.8#((87.54,#(15.10)#
Lovastatin' (((# (20.33#((57.98,#18.02)# (34.37#((56.22,#(17.54)# (47.15#((68.26,#(20.21)# (53.41#((81.61,#(25.38)#
Pravastatin' (((# (20.41#((40.62,#(4.98)# (31.12#((45.85,#(12.91)# (40.77#((51.68,#(27.00)# (47.14#((79.49,#(7.10)#
Rosuvastatin' (47.37#((68.37,#(31.64)# (56.85#((71.45,#(37.59)# (69.24#((85.59,#(38.81)# (67.54#((96.74,#(32.46)# (((#
Simvastatin' (((# (36.98#((54.78,#(19.25)# (41.69#((60.71,#(27.42)# (54.92#((74.13,#(39.91)# (66.87#((87.66,#(33.99)##
(B)'
'
' ≤5'mg/day' >5'and'≤10'mg/day' >10'and'≤20'mg/day' >20'and'≤40'mg/day' >40'mg/day'
Atorvastatin' (((# (49.49#((63.63,#(37.82)# (66.75#((88.38,#(47.49)# (71.55#((94.70,#(41.28)# (79.22#((101.2,#(57.75)#
Fluvastatin' (((# (((# (19.82#((61.95,#10.99)# (26.27#((72.20,#20.00)# (28.41#((80.73,#5.70)#
Lovastatin' (((# (34.66#((75.46,#22.64)# (40.21#((60.72,#(16.24)# (24.94#((60.82,#(0.54)# (67.26#((105.60,#(30.90)#
Pravastatin' (((# (30.07#((44.94,#(9.58)# (38.61#((50.52,#(17.02)# (41.16#((54.05,#(27.39)# (27.28#((77.76,#6.41)#
Rosuvastatin' (29.03#((52.01,#(8.91)# (61.49#((77.06,#(47.58)# (72.14#((100.20,#(54.28)# (87.75#((113.9,#(55.32)# (((#
Simvastatin' (((# (49.48#((67.77,#(30.16)# (56.93#((72.62,#(40.93)# (60.26#((83.73,#(44.15)# (81.94#((103.90,#(53.73)##
(C)'
'
' ≤5'mg/day' >5'and'≤10'mg/day' >10'and'≤20'mg/day' >20'and'≤40'mg/day' >40'mg/day'
Atorvastatin' (((# 2.01#((2.89,#6.41)# 2.38#((4.47,#7.76)# 1.88#((6.57,#10.35)# 2.58#((4.51,#8.78)#
Fluvastatin' (((# (((# 1.03#((10.77,#12.58)# 1.33#((14.28,#16.65)# 0.27#((14.22,#16.23)#
Lovastatin' (((# 1.48#((17.17,#19.72)# 1.76#((8.8,#10.52)# 0.36#((10.15,#10.89)# 3.00#((10.16,#16.47)#
Pravastatin' (((# 1.23#((9.43,#11.65)# 1.1#((6.93,#8.81)# 2.81#((3.77,#7.30)# (1.63#((21.24,#16.61)#
Rosuvastatin' 2.15#((8.81,#10.40)# 3.16#((2.81,#9.79)# 2.16#((5.94,#12.03)# 4.91#((8.24,#19.86)# (((#
Simvastatin' (((# 2.39#((7.37,#8.89)# 1.79#((4.25,#7.66)# 2.77#((5.3,#11.43)# 1.69#((5.32,#10.56)#*# Estimates# shown# are#mean# changes# from# baseline# (mean,# 95%# CrI)# in# serum# lipid# concentrations# as# compared# to# control# treatment# for# (A)# LDL#cholesterol;#(B)#Total#cholesterol;#and#(C)#HDL#Cholesterol.### #
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Considering- Total- cholesterol- reduction,- except- for- lovastatin- and- pravastatin,- there- was- a-general- linear- dose;response- relationship- for- reducing- Total- cholesterol- from- baseline- as-compared- to- control- (Figure-4.5).- Fluvastatin- at-≤20-mg/day- (;19.82-mg/dL,-95%-CrI:- ;61.95,-10.99-mg/dL),-fluvastatin-between->20-and-≤40-mg/day-(;26.27,-95%-CrI:-;72.20,-20.00-mg/dL),-fluvastatin- at- >40- mg/day- (;28.41- mg/dL,- 95%- CrI:- ;80.73,- 5.70- mg/dL),- lovastatin- at- ≤10-mg/day-(;34.66-mg/dL,-95%-CrI:-;75.46,-22.64-mg/dL),-and-pravastatin-at->40-mg/day-(;27.28-mg/dL,- 95%- CrI:- ;77.76,- 6.41- mg/dL)- did- not- have- adequate- evidence- to- demonstrate-superiority- over- control- treatment- in- terms- of- lowering- pretreatment- Total- cholesterol- levels-(Table-4.3).-Highest-reductions-occurred-with-atorvastatin-at->40-mg/day-(;79.22-mg/dL,-95%-CrI:-;101.2,-;57.75),-rosuvastatin-between->-10-and-≤20-mg/day-(;72.14-mg/dL,-95%-CrI:-;100.2,-;54.28-mg/dL),- rosuvastatin-between->20- and-≤40-mg/day- (;87.75-mg/dL,- 95%-CrI:- ;113.9,- ;55.32-mg/dL),-and-simvastatin-at->40-mg/day-(;81.94-mg/dL,-95%-CrI:-;103.90,-;53.73-mg/dL).--
Figure'4.5'–-Dose;comparative-relative-effects-of-statins-on-serum-Total-cholesterol-levels.*--
-*- Estimates- shown- are- mean- changes- from- baseline- (mean,- 95%- CrI)- in- serum- Total- cholesterol-concentrations- as- compared- to- control- treatment.- Total;C:- total- cholesterol,- atorva:- atorvastatin,-fluva:-fluvastatin,-lova:-lovastatin,-prava:-pravastatin,-rosuva:-rosuvastatin,-simva:-simvastatin.-





-*- Estimates- shown- are- mean- changes- from- baseline- (mean,- 95%- CrI)- in- serum- HDL- cholesterol-concentrations- as- compared- to- control- treatment.- HDL;C:- high;density- lipoprotein- cholesterol,-atorva:- atorvastatin,- fluva:- fluvastatin,- lova:- lovastatin,- prava:- pravastatin,- rosuva:- rosuvastatin,-simva:-simvastatin.-











& ≤5&mg/day& >5&and&≤10&mg/day& >10&and&≤20&mg/day& >20&and&≤40&mg/day& >40&mg/day&




Lovastatin& ''', ,''',!6.41'(!72.46,'67.64)', '37.36,('75.61,,'4.38),!31.07'(!80.46,'23.62)' '37.09,('67.64,,'7.56),!26.03'(!96.05,'37.84)' ''',!47.45'(!91.44,'!3.12)'
Pravastatin& ''', ,'21.98,('47.39,,3.25),!16.35'(!55.80,'25.71)', '33.75,('53.73,,'12.83),!24.11'(!74.84,'13.17)' '42.67,('66.78,,'22.31),!35.22'(!56.73,'!6.13)' '15.03,('78.11,,55.22),!26.22'(!80.22,'25.15)'
Rosuvastatin& '51.40,('113.10,,41.55),''', ,'62.29,('95.24,,'31.68),!41.71'(!78.07,'7.31)', '61.58,('92.33,,'33.96),''', '88.20,('130.00,,'47.17),!45.50'(!109.90,'12.62)'
''',,''',
Simvastatin& ''', ,'39.71,('62.65,,'15.93),!27.90'(!87.12,'28.20)', '43.84,('78.83,,'11.27),!40.90'(!103.80,'18.72)' '50.72,('85.43,,'23.07),!40.35'(!73.20,'!1.33)' '63.89,('105.90,,'25.42),!55.61'(!107.80,'!2.67)'*, Estimates, shown, are,mean, changes, from, baseline, (mean,, 95%, CrI), in, serum, LDL, cholesterol, concentrations, as, compared, to, control, treatment.,Italicized,estimates,are,for,the,secondary,prevention,population.,
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(*(Estimates(shown(are(based(on(the(surface(under( the(cumulative(ranking(plots(by(combining(LDL(cholesterol( (bottom,half(of( the(stacked(bars( in(color)(and(Total(cholesterol( (top,half(of( the(stacked(bars( in(white)( reducing( effects( of( individual( statins.( Statin,dose( combinations( are( ranked( out( of( a(total( of( 1.0( (0.5( for( LDL( cholesterol( and( 0.5( for( Total( cholesterol).( LDL,C:( low,density( lipoprotein(cholesterol,(Total,C:( total(cholesterol,(atorva:(atorvastatin,( fluva:( fluvastatin,( lova:( lovastatin,(prava:(pravastatin,(rosuva:(rosuvastatin,(simva:(simvastatin.(






































































































There&was&no&detectable& inconsistency&between&direct& and& indirect& estimates&when& results& of&direct& and& mixed& comparisons& were& visually& inspected& for& potential& discprepancies.& Relative&reductions& from& baseline& LDL& cholesterol& concentrations& were& similar& for& all& statin=dose&combinations& and& the&95%&CrIs&of&direct=only& and&mixed& (combination&of&direct& and& indirect)&estimates&greatly&overlapped&for&all&comparisons.&Between=study&heterogeneity&in&the&network&meta=analysis&for&the&primary&outcome&of&LDL&cholesterol&reduction&from&baseline&was&low&(sd:&1.71,&95%&CrI:&0.25,&4.64).&& &
4.6$Summary$of$Findings$This& network& meta=analysis& of& 256,827& individuals& provided& comprehensive& evidence& on& the&dose=comparative&effects&of&individual&statins&on&serum&lipid&concentrations.&Overall,&high=dose&statins& were& associated& with& greater& reductions& in& pretreatment& LDL& cholesterol& and& Total&cholesterol& concentrations& as& compared& to& low=dose& regimens.& In& terms& of& increasing& HDL&cholesterol,&all&statin=dose&combinations&failed&to&result&in&clinically&and&statistically&meaningful&increases& in& pretreatment& HDL& cholesterol& levels& and& higher& doses& were& not& associated& with&better&HDL&cholesterol&improvements.&&When& individual& statins&were&compared&head=to=head,& several& statins&appeared& to&outperform&other&statins&in&reducing&serum&LDL&and&Total&cholesterol&concentrations.&In&this&network&meta=analysis,&atorvastatin,&rosuvastatin&and&simvastatin&ranked&first&in&terms&of&reducing&serum&LDL&and& Total& cholesterol& as& compared& to& other& statins.& High=dose& formulations& of& atorvastatin,&rosuvastatin,&and&simvastatin&were&broadly&equivalent.&Fluvastatin,& lovastatin,&and&pravastatin,&however,&were&associated&with&significantly&less&reductions&in&pretreatment&LDL&cholesterol&and&Total&cholesterol&concentrations&relative&to&other&statins.&Low=dose&regimens&of&fluvastatin&and&lovastatin&did&not&lower&pretreatment&cholesterol&levels&over&and&above&the&reduction&observed&in&control&treatment.&Dose=comparative&effects&of& indivudual&statins&on& lowering&LDL&cholesterol&were&not&different&between& those& with& and& without& coronary& heart& disease& at& baseline.& According& to& meta=regression&analyses,&LDL&cholesterol&lowering&effects&of&individual&statins&were&not&impacted&by&differences&across&trials&in&terms&of&baseline&mean&age&and&publication&year.&Pretreatment&LDL&cholesterol& concentrations& had& a& marginally& statistically& significant& effect& on& LDL& cholesterol&changes&from&baseline.&&This& analysis&was& the& first& to& quantitatively& evaluate& the&dose=comparative& effects& of& different&statins& on& serum& lipids& across& all& populations,& and& for& primary& and& secondary& prevention&
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High& Prescribers& can& expect& an& approximately& 45%& reduction& from&pretreatment&LDL&cholesterol&levels&with&95%&of&reductions&ranging&from&23%&to&66%.&Evidence& is& most& consistent& for& atorvastatin.& This& agent& should& be&preferred&to&initate&therapy.&&Atorva&≤40&mg/day&Fluva&>40&mg/day&Lova&>20&mg/day&Prava&>20&mg/day&Rosuva&≤10&mg/day&Simva&>10&and&≤40&mg/day&
Medium& Prescribers& can& expect& an& approximately& 38%& reduction& from&pretreatment&LDL&cholesterol&levels&with&95%&of&reductions&ranging&between&6%&and&61%.&The&uncertainty&is&due&in&large&part&to&the&variability&in&the&evidence&base&for&fluvastatin&and&pravastatin&(at&their&highest&doses).&&Evidence& is& most& consistent& for& atorvastatin,& rosuvastatin,& and&simvastatin.&These&agents&should&be&preferred&to&initiate&therapy.&
Fluva&≤40&mg/day&Lova&≤20&mg/day&Prava&≤20&mg/day&Simva&≤20&mg/day&




and& atorvastatin& which& has& recently& been& released& as& a& generic& –& were& not& found& to& be&statistically&superior&to&simvastatin&in&their&maximum&LDL&cholesterol&lowering&doses&(this&has&been& an& assumption& in& the& literature& and& clinical& practice).!Second,& the& extent& to&which& some&statins&lower&pretreatment&LDL&cholesterol&levels&appeared&to&be&less&pronounced&in&this&review&compared&to&earlier&estimates.&This&was&particularly&the&case&for&atorvastatin&and&rosuvastatin&at& high& doses.& For& instance,& according& to& previous& analyses,& high=dose& atorvastatin& (at& 80&mg/day)& lowers& pretreatment& LDL& cholesterol& levels& by& 55%148,340,342& (and& 60%& according& to&manufacturer’s& prescribing& information).& This& network& meta=analysis& found& that& high=dose&atorvastatin& lowers& baseline& LDL& cholesterol& concentrations& by& an& estimated& 45%& (95%& CrI:&35%,& 54%).& Similarly,& according& to& manufacturer’s& prescribing& information,& high=dose&rosuvastatin&lowers&pretreatment&LDL&cholesterol&levels&by&63%.&However,&the&findings&of&this&network&meta=analysis&suggested&that&high=dose&rosuvastatin&resulted&in&a&46%&mean&reduction&from&baseline,&which&was&associated&with&considerable&uncertainty&(95%&CrI:&23%,&66%).&This&difference&was& also& observed& for& other& statin=dose& combinations:& 20&mg/day& of& fluvastatin& (=22%&per&prescribing&information&vs.&=11%&in&this&analysis),&20&mg/day&of&pravastatin&(=32%&per&prescribing& information& vs.& =22%& in& this& analysis).& LDL& cholesterol=lowering& effects& of&simvastatin& according& to& this& network& meta=analysis& appeared& consistent& with& previous&findings.&&This& difference& can& be& attributed& to& three& main& factors.& First,& previous& assessments& of& dose=comparative& effects& of& statins& were& based& on& small& studies,& which& tend& to& evaluate& highly=selected& patients& in& strictly& controlled& environments,&which&may& not& be& representative& of& the&conditions&in&actual&clinical&practice.&The&systematic&review&that&formed&the&basis&of&the&network&meta=analysis& reported& in& this& chapter&excluded& trials& that& included& fewer& than&50& individuals&per&trial&arm.&As&a&result,&123&trials&that&were&included&in&the&review&by&Law&and&colleagues&were&not&eligible&for&inclusion&in&this&network&meta=analysis.148&&Second,& unlike& previous& reviews,& this& systematic& review& included& trials& with& individuals&regardless&of& their&baseline&LDL&cholesterol&concentrations.&As&a&result,& this&systematic&review&included& trials& such& as& TNT& (Treating& to& New& Targets)& during& which& patients& receiving&atorvastatin& at& 80& mg/day& experienced& an& estimated& 21%& reduction& in& pretreatment& LDL&cholesterol&concentrations.343&This&was&justified&based&on&the&findings&of&previous&reviews&that&showed&that&relative&reductions&are&not&impacted&by&baseline&LDL&cholesterol&levels.335&&Third,&earlier&reviews&excluded&trials&with&titration&designs.&Titration&designs&allowing&clinicians&to&increase&the&dose&of&statin&therapy&to&achieve&target&reductions,&also&known&as&the&‘treat=to=
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target’&model,& continues& to& be& the&most& common&method& of&managing& patients&with& elevated&LDL&cholesterol&levels.&Accordingly,&this&review&included&information&from&titration&design&trials&such&as&IDEAL&(Incremental&Decrease&in&Endpoints&Through&Aggressive&Lipid&Lowering),&which&compared& atorvastatin& (at& 80&mg/day)& and& simvastatin& (starting& at& 20&mg/day,& average& dose&throughout& trial:& 24&mg/day).344&When&extracting&data& from& titration& trials& for& this& systematic&review,& a& careful& approach& was& taken& to& accurately& proportion& patients& into& correct& dose&categories.&Whenever&possible,&data&from&the&fixed&dosing&period&were&used.&If&all&patients&were&force=titrated&to&a&given&dosage,&data&from&the&final&high=dose&period&were&used.&As&an&example,&STAT&(Simvastatin&To&Atorvastatin&switch&Trial)& randomized&patients& to&simvastatin&40&mg&or&atorvastatin&40&mg&for&8&weeks,&after&which&the&atorvastatin&dose&was&increased&to&80&mg&while&the&simvastatin&dose&remained&the&same.345&Per&the&data&extraction&protocol&for&this&systematic&review,&patients&receiving&atorvastatin&in&the&STAT&(whose&LDL&cholesterol&levels&went&down&by&approximately&20%)&were&categorized&as&receiving&a&dose&of&80&mg/day.&Given& the& Bayesian& nature& of& the& analysis,& the& extent& of& potential& heterogeneity& was& not&quantified&using&the&common&I2&statistic.&Instead,&the&between=study&heterogeneity&was&directly&quantified,&which&was&found&to&be&low.&In&addition,&every&attempt&was&made&to&visually&inspect&potential& discrepancies& in& the& reported& results& across& trials.& The& potential& inconsistency&between&direct&and&mixed& findings& in& the&analysis&was&explored&by&comparing& the&95%&CrI&of&estimates&obtained&from&analyses&including&only&direct&(head=to=head)&trials&and&from&those&that&combined& direct& trials& with& placebo=controlled& trials.& Also,& meta=regression& analyses& were&performed&to&evaluate&whether&potential&heterogeneity&or&inconsistency&could&be&explained&by&baseline& LDL& cholesterol& levels& across& trials.& This& statistical& exploration& did& not& find& evidence&that&baseline&LDL&cholesterol&had&an&impact&on&the&relative&treatment&effects.&&The&findings&of&this&comparative&analysis&should&be&interpreted&in& light&of& its& limitations.&First,&there&are&other&important&lipid&outcomes,&which&should&be&evaluated&in&future&analyses.346&One&such&outcome& is&non=HDL&cholesterol.&Recent& research,&published&after& the&work&presented& in&this&chapter&was&completed,&showed&that&there& is&an&association&between&non=HDL&cholesterol&levels& with& the& risk& of& cardiovascular& events& among& patients& treated& with& statin& therapy.347&Second,& as& a& network& meta=analysis& combining& direct& and& indirect& sources& of& evidence,& it&remains&a&possibility&that&potential& imbalances&in&the&occurrence&of&effect&modifiers&across&the&contrasts& impacted& the& results,& potentially& confounding& the& comparative& estimates& between&individual& statins.& However,& this& is& unlikely& given& the& large& body& of& evidence& that& provided&consistent& estimates& from& a& broadly& representative& group& of& individuals& with& different&
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characteristics& across& trials.& In& addition,& meta=regression& analyses& did& not& find& evidence& that&baseline&LDL&cholesterol&levels&had&an&impact&on&the&relative&treatment&effects.&Despite&these&limitations,&this&review&has&important&strengths.&Based&on&256,827&individuals&in&181&randomized&controlled&trials,&this&network&meta=analysis&provides&the&most&comprehensive&evidence& on& the& relative& potency& of& individual& statins& in& reducing& LDL& cholesterol& and& Total&cholesterol,&and&increasing&HDL&cholesterol.& It& included&evidence&from&both&placebo=controlled&and&active=comparator& trials,& considerably&broadening& the&evidence&base& included& in&previous&reviews.& Interestingly,& it& is& the& first& network&meta=analysis& that& includes&more&direct& head=to=head& trials& than& placebo=controlled& trials& in& any& type& of& meta=analysis,10& which& considerably&strengthens& the& statistical& inferences& of& the& findings.& Including& titration& design& trials&considerably& improved& the& generalizability& of& the& findings& as& titration&better& reflects& common&practice& in& cholesterol& management.& As& a& result& of& the& inclusive& approach& taken& for& the&systematic&review,&the&findings&of&the&network&meta=analysis&are&generalizable&to&individuals&in&clinical& practice.& It& included& a& broad& range& of& patients& and& observed& that& the& cholesterol=lowering&effects&of& statins&are&consistent&across&age&groups&and&populations&with&different&co=morbidity&profiles.&&In&conclusion,&this&chapter&reported&the&findings&of&the&most&comprehensive&meta=analysis&of&the&effect& of& statins& on& reductions& in& serum& cholesterol& concentrations,& and& one& of& the& first& to&integrate&direct&head=to=head&comparisons&between&individual&statins.&Overall,&high=dose&statins&were&associated&with&greater&reductions&in&pretreatment&LDL&cholesterol&and&Total&cholesterol&concentrations& as& compared& to& low=dose& regimens& confirming& a& dose=reponse& relationship.&When& individual& statins&were&compared&head=to=head,& several& statins&appeared& to&outperform&other& statins& in& reducing& serum& LDL& cholesterol& and& Total& cholesterol& concentrations.&Atorvastatin,& rosuvastatin& and& simvastatin& ranked& first& in& terms& of& reducing& serum& LDL&cholesterol& and& Total& cholesterol& as& compared& to& the& other& statins& in& the& analysis,& and& were&considered&statistically&equivalent.&The&LDL&cholesterol&reducing&effects&of&some&statins&appear&less&pronounced&than&the&findings&of&previous&meta=analyses.&&




Chapter$5$&Comparative&Benefits&of&Individual&Statins*&!&&The&objective&of&cholesterol=lowering&therapy&with&statin&drugs&is&to&lower&the&risk&of&mortality&and&other&clinically&meaningful&outcomes&such&as&major&coronary&events&(e.g.,&heart&attacks)&and&major& cerebrovascular& events& (e.g.,& strokes).& As& the& number& of& individuals& eligible& for& statin&therapy&continues&to&increase&both&in&primary&and&secondary&prevention,&an&important&question&that& warrants& further& investigation& is& the& comparative& effects& of& individual& statins.& Whether&individual& statins& vary& in& terms& of& their& effect& on& total&mortality& and& clinical& endpoints&when&compared&head=to=head&at&similar&doses&is&unclear&and&has&not&been&studied&in&a&comprehensive&manner&in&previous&meta=analyses.&Information&regarding&the&relative&clinical&value&of&different&statins& in& primary& and& secondary& prevention& of& coronary& heart& disease& is& needed& to& better&inform&patients,&prescribers,&and&other&healthcare&decision&makers.&&A& number& of& prior& meta=analyses& explored& the& comparative& benefits& of& individual& statins& in&terms&of& total&mortality& and& clinical& endpoints& –& each&with& important& limitations.& The& earliest&example,&the&analysis&by&Zhou&and&colleagues&(2006),&aptly&titled&“are&all&statins&created&equal?”,&performed& an& indirect& comparison& to& address& this& question.105& This& analysis& focused& on&atorvastatin,& pravastatin,& and& simvastatin& based& on& published& randomized& placebo=controlled&trials.&Trials&were&eligible&for&inclusion&if&they&enrolled&more&than&1,000&individuals,&and&had&at&least&a&year&of& follow=up.&Based&on& this& limited&sample&of& relevant& trials& (eight& trials& including&63,143&individuals),&authors&did&not&find&a&statistically&significant&difference&between&individual&statins& in& reducing& major& coronary& events.& Similarly,& there& were& no& differences& between&
                                                *&Part&of&the&work&presented&in&this&chapter&was&published&with&the&following&references:&&Naci&H,&Brugts&JJ,&Fleurence&R,&Tsoi&B,&Toor&H,&Ades&AE.&Comparative&benefits&of&statins&in&the&primary&and&secondary&prevention&of&major&coronary&events&and&all=cause&mortality:&a&network&meta=analysis&of&placebo=controlled&and&active=comparator&trials.&Eur&J&Prev&Cardiol.&2013&Aug;20(4):641=57.&Naci& H,& Brugts& JJ,& Fleurence& R,& Ades& AE.& Comparative& effects& of& statins& on& major& cerebrovascular&events:&a&multiple=treatments&meta=analysis&of&placebo=controlled&and&active=comparator&trials.&QJM.&2013&Apr;106(4):299=306.&
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5.1$Empirical$Considerations$As&outlined&in&Chapter&3&(Evidence!Review!and!Synthesis!Methods)&separate&traditional&pair=wise&meta=analyses& and& network& meta=analyses& were& performed& for& all=cause& mortality,& major&coronary& events,& and&major& cerebrovascular& events.&Traditional&pair=wise&meta=analyses&were&based& on& placebo=controlled& trials& whereas& the& network& meta=analyses& combined& placebo=controlled& and& active=comparator& trials.& For& each& endpoint,& three& sets& of& analyses& were&conducted.&First,&to&obtain&an&overall&estimate&of&the&effect&of&statins,&all&primary&and&secondary&prevention&trials&were&pooled&in&addition&to&trials&with&mixed&patient&populations.&Subsequently,&separate& analyses& were& performed& for& the& primary& prevention& and& secondary& prevention&populations.&
Consideration! of! dose! in! the! network! meta;analysis:& For& the& base=case& network&meta=analysis,&trials&with&high&doses&(80&mg/day&for&atorvastatin,&fluvastatin,& lovastatin,&simvastatin,&and&≥40&mg/day& for& rosuvastatin)&were&excluded&and& the&benefits&of& statins&were&evaluated&at&broadly&comparable& LDL& cholesterol=lowering& doses.& This& was& done& to& evaluate& whether& individual&statins&had&different&mortality&and&cardiovascular&benefits&irrespective&of&their&LDL&cholesterol=lowering& effects.& In& a& sensitivity& analysis,& trials& that& evaluated& statins& at& high& doses&were& also&included.&A&dose=specific&analysis&explored&the&effects&of&individual&statins&at&low,&medium,&and&high& doses& separately.& For& the& dose=specific& analysis,& doses& were& categorized& as& low& (≤20&mg/day),& medium& (>20& mg/day& ≤40& mg/day),& and& high& (>40& mg/day)& for& atorvastatin,&fluvastatin,& lovastatin,& pravastatin,& and& simvastatin.& A& different& categorization& scheme& was&adopted& for& rosuvastatin& given& its& considerably& higher& potency& per&mg& as& compared& to& other&statins.&For&rosuvastatin,&doses&≤10&mg/day&were&categorized&as&low,&>10&mg/day&≤20&mg/day&as&medium,& and&>20&mg/day& as& high.& This& categorization& of& doses& deviated& from& that& used& in&Chapters&4&and&6&(which&adopted&a&more&granular&breakdown&of&doses&where&all&possible&statin=dose& combinations& were& considered& separately)& due& to& the& small& number& of& clinical& events&observed&in&the&analyses&presented&in&this&chapter.&&For&the&dose=specific&analysis,&each&statin=dose&combination&was&treated&as&a&different&treatment&and&no&trends&were&fitted&or&assumed.&All&analyses&were&based&on&the&total&number&of&randomly&assigned&participants&if&the&study&authors&did&not&perform&intention=to=treat&analyses.&
Ranking!of! statins! in! the!network!meta;analysis:&The&probability& that& each& statin&was& the&most&efficacious&regimen&was&estimated&by&calculating&the&treatment&effect&for&each&statin&compared&
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with& the& common& comparator& treatment,& and& counting& the& proportion& of& iterations& of& the&Markov&chain&in&which&each&drug&had&the&highest&treatment&effect,&the&second&highest,&and&so&on.&Rank& probabilities& were& separately& estimated& for& all=cause& mortality,& major& coronary& events,&and& major& cerebrovascular& events.& Rankograms& were& developed& to& graphically& present& the&distribution&of&ranking&probabilities.&Also,&cumulative&probability&plots&were&developed&for&each&outcome& and& the& surface& under& the& cumulative& ranking& line& for& each& statin&was& estimated& as&described&in&Chapter&3&(Evidence!Review!and!Synthesis!Methods).324&The&surface&area&under&the&cumulative&ranking& line&provided&a&numerical&summary&of& the&overall&score& for&each&statin& for&each& outcome.& Each& statin& was& scored& with& points& up& to& a& maximum& of& 1.00,& which& was& the&weighted&sum&of&scores&separately&estimated&for&all=cause&mortality,&major&coronary&events,&and&major&cerebrovascular&events.&&
Assessment! of! heterogeneity! and! inconsistency! in! the! network!meta;analysis:&Whether& potential&heterogeneity&and&inconsistency&across&the&evidence&base&could&be&explained&by&differences& in&trial&publication&year,&baseline&LDL&cholesterol&concentration,&and&baseline&mean&age&of&patients&was&investigated&using&meta=regression&analyses.&All&meta=regression&analyses&were&performed&by&allowing&for&a&common&treatment=covariate&interaction&for&each&statin&compared&to&control,&as&described&in&Chapter&3.327&In&addition&to&the&three&study=level&variables&(trial&publication&year,&baseline& LDL& cholesterol& concentration,& and& baseline& mean& age& of& patients),& an& exploratory&analysis&investigated&the&association&between&baseline&risk&(odds&of&an&event&in&the&placebo&arm&of& each& trial)& and& treatment& effect& in& the& placebo=controlled& trials& of& statins.& Baseline& risk&reflected& the& risk& of& outcome& event& for& a& patient& under& the& control& condition& and& indicated&average& risk& of& patient& in& that& trial& if& they&were& not& treated.& Exploration& of& baseline& risk&was&considered&important&and&necessary,&as&baseline&risk&of&study&population&could&modify&the&effect&of&intervention&in&a&given&trial.&&To&further&explore&any&potential&inconsistency&between&direct&and&indirect&evidence,&the&ratio&of&relative&effects&for&indirect&versus&direct&evidence&was&calculated.329&Inconsistency&was&defined&as&the&disagreement&between&direct&and&indirect&evidence&with&a&95%&CI&excluding&1.00.289&
Presentation! of! results:& First,& the& findings& of& the& traditional& pair=wise& meta=analysis& were&presented& along& with& estimates& of& heterogeneity& in& the& pooled& estimates& of& the& identified&placebo=controlled& trials.& Subsequently,& the& findings& of& the& network& meta=analysis& which&combined&evidence&from&placebo=controlled&and&active=comparator&trials&were&presented.&This&was& followed& by& the& presentation& of& meta=regression& results& which& provided& a& statistical&assessment& of& heterogeneity& and& inconsistency& in& the& network& meta=analysis.& The& results& of&
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additional& exploratory& inconsistency& analyses& were& provided& in& the& Appendix,& along& with&additional&detailed&results&that&formed&the&basis&of&the&main&results&presented&in&this&chapter.&&
Goodness!of!fit:&As&described&in&Chapter&3:&Evidence!Review!and!Synthesis!Methods,&the&goodness&of& fit& of& the& network& meta=analysis& models& was& examined& using& the& total& residual& deviance&(posterior& mean& of& the& deviance& under& a& given& model& minus& the& deviance& for& the& saturated&model)&and&deviance&information&criterion&(DIC).&Model&fit&was&considered&to&be&satisfactory&on&the&basis&of&both&measures.& In&each&model,& the&residual&deviance&was&compared&with& the& total&number&of&data&points&in&the&dataset.&Assessment&of&model&fit&for&the&base=case&network&meta=analysis&& Effective&number&of&parameters,&pD& Total&residual&deviance& &DIC&All=cause&mortality&& 94& 205& 873&Major&coronary&events& 78& 143& 737&Major&cerebrovascular&events& 71& 141& 651&
!
Interpretation!of!results:&The&results&of&the&traditional&pair=wise&meta=analyses&were&reported&in&terms& of& odds& ratios& and& 95%& CIs.& Given& the& Bayesian& nature& of& network&meta=analyses,& the&findings&of&these&analyses&were&reported&using&odds&ratios&and&95%&CrIs.&In&traditional&pair=wise&meta=analyses,&the&findings&were&considered& ‘statistically!significant’!when!the&95%&confidence&interval&did&not&include&the&null&value&1.00.&Adopting&the&emerging&convention&in&reporting&and&interpreting& the& findings& of& Bayesian& network&meta=analyses,& 95%&CrIs& that& did& not& cross& the&null&value&of&1.00&were&considered&‘significant’.&Use&of&‘significance’&in&this&way&is&consistent&with&the&latest&network&meta=analyses&that&appeared&in&general&medical&journals.257&
5.2$Systematic$Review$Findings$There&were&103&randomized&controlled&trials&in&the&systematic&review&and&meta=analysis&of&total&mortality&and&clinical&outcomes&(Figure&5.1).&These&trials&included&a&total&of&214,877&individuals.&Overall,&the&average&trial&duration&was&104&weeks&(approximately&2&years).&Fifty=two&trials&had&a&mean&duration&of&one&year&or&longer&and&participants&in&24&trials&were&followed&up&for&less&than&6&months.&Twenty&trials&were&conducted& in&the&primary&prevention&population&compared&with&42&trials&in&the&secondary&prevention&population.&The&remaining&41&trials&included&participants&with& or& without& established& cardiovascular& disease.& Among& these,& there& were& eight& trials& of&
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Figure$ 5.2$ –$ Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&clinical&benefit&outcomes.*&$
&
*&Connecting&lines&indicate&the&direct&pair=wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair=wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.$&
5.3$Outcome$1:$All9Cause$Mortality!
5.3.1!! Benefits!of!Statins!vs.!Control:!Findings!of!the!Traditional!Pair;wise!Meta;analysis!In& the& traditional& pair=wise&meta=analysis& of& statin& therapy& vs.& control& across& all& populations,&169,615& participants& contributed& information& on& 12,398& deaths& across& 60& placebo=controlled&trials& (see& the&Appendix& for& trial=level& results).& There&were& 13& trials& of& atorvastatin& providing&information&on&1,466&deaths&among&27,159&individuals;&six&trials&of&fluvastatin&with&120&deaths&among&4,829&individuals;&eight&trials&of&lovastatin&with&222&deaths&among&17,356&individuals;&22&trials&of&pravastatin&with&4,036&deaths&among&58,653&individuals;&five&trials&of&rosuvastatin&with&3,235&deaths&among&31,997& individuals;&and&six& trials&of&simvastatin&with&3,319&deaths&among&29,621&individuals.&&
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Overall,& as& shown& in& Figure& 5.3,& statin& therapy& was& associated& with& a& reduction& in& all=cause&mortality&(OR:&0.87,&95%&CI:&0.82,&0.92,&I2=22.6%)&(see&Appendix& for&trial=level&results).&Among&statins,&only&fluvastatin&(OR:&0.68,&95%&CI:&0.47,&0.99,&I2=0.0%)&and&pravastatin&(OR:&0.86,&95%&CI:& 0.80,& 0.93,& I2=8.1%)& were& associated& with& a& significant& reduction& in& all=cause& mortality&compared& with& the& control,& while& atorvastatin& (OR:& 0.88,& 95%& CI:& 0.77,& 1.01,& I2=15.2%),&lovastatin&(OR:&1.05,&95%&CI:&0.60,&1.85,& I2=23.6%),&rosuvastatin&(OR:&0.93,&95%&CI:&0.83,&1.05,&




In&the&secondary&prevention&population,&49,936&participants&contributed&information&on&3,823&deaths& across& 32& placebo=controlled& trials.& There& were& six& trials& of& atorvastatin& providing&information&on&878&deaths&among&11,945&individuals;&four&trials&of&fluvastatin&with&109&deaths&among& 3,304& individuals;& five& trials& of& lovastatin&with& 20& deaths& among& 1,385& individuals;& 13&trials&of&pravastatin&with&2,339&deaths&among&27,286&individuals;&and&four&trials&of&simvastatin&with& 477& deaths& among& 6,016& individuals.& There& were& no& trials& of& rosuvastatin& in& this&population.&Among&individuals&with&established&coronary&artery&disease,&statin&therapy&was&associated&with&a& significant& reduction& in& all=cause&mortality& (OR:& 0.82,& 95%&CI:& 0.75,& 0.90,& I2=14.8%)& (Figure&
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5.4).&In&this&population,&only&pravastatin&(OR:&0.82,&95%&CI:&0.75,&0.90,&I2=0.0%)&and&fluvastatin&(OR:&0.66,&95%&CI:&0.45,&0.98,&I2=0.0%)&had&evidence&to&result&in&significantly&fewer&deaths&due&to&any&reason&as&compared&to&control&treatment.&Although&statistically&not&significant,&lovastatin&resulted& in& numerically& more& deaths& than& control& treatment& (OR:& 1.03,& 95%& CI:& 0.40,& 2.40,&
I2=0.0%).& Pooled& estimates& for& atorvastatin& (OR:& 0.83,& 95%& CI:& 0.65,& 1.06,& I2=51.9%)& and&simvastatin& (OR:& 0.72,& 95%& CI:& 0.34,& 1.54,& I2=61.5%)& were& associated& with& considerable&heterogeneity.&&
Figure$ 5.4$ –& Effect& of& statins& compared& to& control& on& all=cause& mortality& in& the& secondary&prevention&population).*&
&
*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&rosuvastatin&among&individuals&with&established&coronary&heart&disease&at&baseline.&&
In& the& primary& prevention& population,& 71,188& participants& contributed& information& on& 2,853&deaths& across& 18& placebo=controlled& trials.& There& were& three& trials& of& atorvastatin& providing&information&on&539&deaths&among&13,997& individuals;&one&trial&of& fluvastatin&with&nine&deaths&among& 294& individuals;& two& trials& of& lovastatin&with& 166& deaths& among& 7,690& individuals;& 10&trials&of&pravastatin&with&1,693&deaths&among&29,975&individuals;&and&two&trials&of&rosuvastatin&with&446&deaths&among&19,232&individuals.&There&were&no&trials&of&simvastatin.&Among&individuals&without&prior&coronary&artery&disease,&statin&therapy&was&associated&with&a&significant&reduction&in&all=cause&mortality&(OR:&0.91,&95%&CI:&0.83,&0.99,&I2=8.9%)&(Figure&5.5).&In& this& population,& only& rosuvastatin& (OR:& 0.80,& 95%& CI:& 0.66,& 0.96,& I2=0.0%)& had& sufficient&evidence& for& a& significant&benefit& on& all=cause&mortality,&while& atorvastatin& (OR:&0.91,&95%&CI:&
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0.74,& 1.12,& I2=23.9%),& fluvastatin& (OR:& 0.80,& 95%& CI:& 0.21,& 3.04,& I2=not& estimated),& and&pravastatin& (OR:& 0.94,& 95%& CI:& 0.84,& 1.04,& I2=3.7%)& did& not.& Lovastatin& was& associated& with&substantial&heterogeneity&(OR:&0.46,&95%&CI:&0.06,&3.57,&I2=75.1%).&
Figure$ 5.5$ –$ Effect& of& statins& compared& to& control& on& all=cause& mortality& in& the& primary&prevention&population).*$
&
*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&simvastatin&among&individuals&with&no&coronary&heart&disease&at&baseline.&&
5.3.2!! Comparative!Benefits!of!Individual!Statins:!Findings!of!the!Network!Meta;analysis!The& network& of& eligible& comparisons& is& shown& in& Figure& 5.6.& In& addition& to& the& placebo=controlled& trials& included& in& the& traditional& pair=wise& meta=analysis,& a& total& of& 41& direct&comparisons& including& 29,643& individuals&were& included& in& the& network&meta=analysis& of& all=cause&mortality.&Generally,&only&small&trials&provided&direct&head=to=head&evidence&on&statins&in&terms&of&all=cause&mortality.&As&a&result&of&the&small&number&of&events&occurring&in&these&direct&head=to=head& comparisons,& there& was& large& uncertainty& around& the& results& in& direct&comparisons.& Atorvastatin& was& directly& compared& to& fluvastatin& in& one& trial& including& 154&individuals&(OR:&0.97,&95%&CI:&0.06,&15.86);&to&lovastatin&in&one&trial&with&156&individuals&(OR:&3.04,& 95%& CI:& 0.17,& 75.75);& to& pravastatin& in& three& trials& involving& 1,698& individuals,& which&demonstrated&that&atorvastatin&was&associated&with&significantly&fewer&deaths&due&to&any&reason&(OR:& 0.36,& 95%&CI:& 0.15,& 0.84);& to& rosuvastatin& in& 13& trials&with& 10,666& individuals& (OR:& 0.93,&95%&CI:&0.44,&2.00);&and&to&simvastatin&in&four&trials&including&12,988&individuals&(OR:&0.75,&95%&CI:& 0.27,& 2.12).& Fluvastatin&was& compared& to& lovastatin& in& one& trial&with& 155& individuals& (OR:&3.04,&95%&CI:&0.13,&73.45).&Rosuvastatin&was&directly&compared&to&pravastatin&in&two&trials&with&
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1,292& individuals& (OR:&0.80,& 95%&CI:& 0.13,& 4.94);& and& to& simvastatin& in& three& trials&with&1,678&individuals& (OR:&1.60,&95%&CI:&0.26,&9.83).&Simvastatin&was&directly&compared&to& fluvastatin& in&one& trial& with& 152& individuals& (OR:& 2.03,& 0.18,& 22.86),& to& lovastatin& in& one& trial& with& 154&individuals& (OR:&0.19,&95%&CI:&0.01,&4.02),&and& to&pravastatin& in&one& trial&with&550& individuals&(OR:&7.06,&95%&CI:&0.36,&137.66).&&
Figure$ 5.6$ –$ Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&all=cause&mortality.*$$
&
*&Connecting&lines&indicate&the&direct&pair=wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair=wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.$&
In& the& base=case& network& meta=analysis,& 64& trials& provided& information& for& the& all=cause&mortality&analyses.&In&total,&161,379&participants&were&included&in&the&base=case&analysis&on&all=cause& mortality,& which& provided& information& on& 11,914& deaths.& The& average& dose& was& 16.7&mg/day&for&atorvastatin&(estimated&mean&change&from&baseline&LDL&cholesterol&as&compared&to&control& as& reported& in&Chapter&4& [Dose;Comparative!Effects! of! Individual! Statins! on!Cholesterol!
Concentrations]:& =48.33& mg/dL,& 95%& CrI:& =67.89,& =36.77)& as& compared& to& 40.0& mg/day& for&fluvastatin& (=35.51&mg/dL,& 95%& CrI:& =60.29,& 0.62),& 39.3&mg/day& for& lovastatin& (=47.15&mg/dL,&
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95%&CrI:&=68.26,&=20.21),&30.9&mg/day&for&pravastatin&(=40.77&mg/dL,&95%&CrI:&=51.68,&=27.00),&14.8& mg/day& for& rosuvastatin& (=69.24& mg/dL,& 95%& CrI:& =85.59,& =38.81),& and& 33.3& mg/day& for&simvastatin& (=54.92&mg/dL,& 95%&CrI:& =74.13,& =39.91).& These&dosing& regimens&were& considered&broadly&similar&in&terms&of&their&LDL&cholesterol&lowering&effects&with&greatly&overlapping&95%&credible&intervals.&&Across&all&populations,&there&were&no&significant&differences&among&statins&in&terms&of&all=cause&mortality& when& all& trials& of& primary& prevention,& secondary& prevention,& and& mixed& patient&populations& were& pooled& (Table& 5.1).& The& statistically& significant& difference& between&atorvastatin&and&pravastatin&was&no& longer&obtained&when&all&populations&were&pooled&(OR&of&atorvastatin& vs.& pravastatin:& 0.91,& 95%& CrI:& 0.72,& 1.11).& Although& these& findings& were& not&statistically& significant,& fluvastatin& was& associated& with& numerically& fewer& deaths& due& to& any&reason&as&compared&to&all&other&statins.&Similarly,&atorvastatin&appeared&to&result&in&numerically&fewer& deaths& than& other& statins,& except& for& simvastatin,& which& appeared& numerically& and&statistically&equivalent&(OR&of&atorvastatin&vs.&simvastatin:&0.99,&95%&CrI:&0.73,&1.28).&&
Table$ 5.1$ –& Comparative& benefits& of& individual& statins& on& all=cause& mortality& across& all&populations.*&
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.11&(0.42,&2.79)& 0.78&(0.52,&1.14)& 0.91&(0.72,&1.11)& 0.85&(0.64,&1.07)& 0.99&(0.73,&1.28)&
Fluvastatin$vs.$ =& 0.71&(0.26,&1.87)& 0.82&(0.33,&2.13)& 0.76&(0.30,&2.00)& 0.89&(0.34,&2.32)&
Lovastatin$vs.$ =& =& 1.16&(0.80,&1.68)& 1.08&(0.73,&1.61)& 1.26&(0.84,&1.89)&
Pravastatin$vs.$ =& =& =& 0.93&(0.75,&1.17)& 1.08&(0.85,&1.39)&
Rosuvastatin$vs.$ =& =& =& =& 1.16&(0.88,&1.53)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&




Table$5.2$–&Comparative&benefits&of& individual& statins&on&all=cause&mortality& in& the&secondary&prevention&population.*&&
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.02&(0.20,&5.00)& 0.93&(0.20,&4.13)& 0.65&(0.24,&1.22)& 0.70&(0.08,&4.18)& 0.68&(0.24,&1.43)&
Fluvastatin$vs.$ =& 0.92&(0.13,&6.56)& 0.62&(0.12,&2.62)& 0.67&(0.05,&7.52)& 0.66&(0.13,&2.74)&
Lovastatin$vs.$ =& =& 0.68&(0.16,&2.56)& 0.72&(0.06,&7.99)& 0.72&(0.16,&2.90)&
Pravastatin$vs.$ =& =& =& 1.09&(0.12,&8.42)& 1.06&(0.52,&2.15)&





Table$ 5.3$ –& Comparative& benefits& of& individual& statins& on& all=cause& mortality& in& the& primary&prevention&population.*&$
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 0.99&(0.18,&5.43)& 0.96&(0.45,&3.47)& 0.97&(0.49,&2.17)& 0.98&(0.32,&2.47)&
Fluvastatin$vs.$ =& 1.01&(0.19,&6.68)& 1.00&(0.19,&5.21)& 0.98&(0.15,&5.53)&
Lovastatin$vs.$ =& =& 1.01&(0.34,&2.00)& 1.02&(0.22,&2.32)&
Pravastatin$vs.$ =& =& =& 1.02&(0.34,&2.17)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&simvastatin&among&individuals&without&established&coronary&heart&disease.&&





& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.22&(0.80,&1.86)& 0.82&(0.57,&1.16)& 0.95&(0.78,&1.13)& 0.91&(0.73,&1.10)& 1.01&(0.73,&1.10)&
Fluvastatin$vs.$ =& 0.66&(0.40,&1.13)& 0.77&(0.51,&1.18)& 0.74&(0.48,&1.15)& 0.82&(0.53,&1.27)&
Lovastatin$vs.$ =& =& 1.16&(0.81,&1.65)& 1.11&(0.77,&1.60)& 1.23&(0.85,&1.80)&
Pravastatin$vs.$ =& =& =& 0.96&(0.78,&1.17)& 1.06&(0.86,&1.32)&
Rosuvastatin$vs.$ =& =& =& =& 1.11&(0.88,&1.40)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
Among& individuals& with& established& coronary& heart& disease,& the& sensitivity& analysis& results&closely& resembled& those& observed& in& the& base=case& analysis.& There& were& no& statistically&significant&differences&between&different&statins&although&fluvastatin&was&again&associated&with&numerically&fewer&deaths&as&compared&to&other&statins&(Table&5.5).&&&
Table$5.5$–&Sensitivity&analysis&results:&Comparative&benefits&of& individual&statins&on&all=cause&mortality&in&the&secondary&prevention&population.*&$
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.20&(0.72,&1.99)& 0.97&(0.42,&2.25)& 0.90&(0.66,&1.15)& 0.49&(0.12,&1.56)& 0.98&(0.68,&1.26)&
Fluvastatin$vs.$ =& 0.82&(0.33,&2.07)& 0.75&(0.44,&1.23)& 0.41&(0.09,&1.39)& 0.82&(0.47,&1.37)&
Lovastatin$vs.$ =& =& 0.92&(0.39,&2.12)& 0.51&(0.09,&1.97)& 1.00&(0.42,&2.33)&
Pravastatin$vs.$ =& =& =& 0.55&(0.13,&1.77)& 1.09&(0.77,&1.50)&
Rosuvastatin$vs.$ =& =& =& =& 1.98&(0.60,&8.40)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
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Including& high=dose& trials& did& not& have& a& qualitative& or& statistical& effect& on& the& results& for& the&primary& prevention&population.& Among& individuals&with& no& history& of& coronary& heart& disease,&there&were&no&significant&differences&between&different&statins&(Table&5.6).&&
Table$5.6$–&Sensitivity&analysis&results:&Comparative&benefits&of& individual&statins&on&all=cause&mortality&in&the&primary&prevention&population.*&&
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.13&(0.25,&5.41)& 1.02&(0.59,&2.33)& 1.00&(0.67,&1.60)& 1.07&(0.51,&1.87)&
Fluvastatin$vs.$ =& 0.93&(0.19,&4.72)& 0.90&(0.19,&4.01)& 0.93&(0.18,&4.34)&
Lovastatin$vs.$ =& =& 0.98&(0.46,&1.65)& 1.06&(0.35,&1.91)&
Pravastatin$vs.$ =& =& =& 1.08&(0.51,&1.75)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&simvastatin&among&individuals&without&established&coronary&heart&disease.&&



















Meta=regression&adjusting&for&publication&year& 0.0839& 0.021&(=0.002,&0.041)&& & &
Figure$ 5.8$ –& Sensitivity& of& base=case& findings& to& meta=regression& analyses& for& all=cause&mortality.*&$




An& exploration& of& the& association& between& baseline& risk& and& treatment& effect& in& the& placebo=controlled& trials& of& statins& suggested& that& baseline& risk& was& not& a& possible& explanation& of&between=study& heterogeneity& in& the& network&meta=analyses& evaluating& all=cause&mortality.& As&shown&in&Figure&5.9&below,&there&was&no&clear&indication&that&baseline&risk&of&study&population&modified&the&effect&of&statins&on&all=cause&mortality&in&the&placebo=controlled&trials.&&&
Figure$5.9$–$Relationship&between&the&observed&event&rate& in&the&control&group&and&observed&odds&ratios&across&the&placebo=controlled&trials&of&statins.&Size&of& the&bubble& is&proportional& to&the&sample&size&in&the&randomized&controlled&trials.&$





 *& Estimates& shown& are& ORs& and& 95%& CrIs.& Base=case& results& are& shown& in& red,& while& the& analysis&adjusted&for&baseline&risk&is&shown&in&white.&
5.4$Outcome$2:$Major$Coronary$Events!




simvastatin& (OR:& 0.73,& 95%&CI:& 0.58,& 0.91,& I2=65.3%)&were& associated&with& significantly& fewer&major& coronary& events& than& control& treatment.& Lovastatin& (OR:& 0.81,& 95%& CI:& 0.55,& 1.19,&
I2=38.2%)&and&rosuvastatin&(OR:&0.63,&95%&CI:&0.36,&1.12,&I2=75.9%)&were&not&associated&with&a&reduction&in&major&coronary&events.&According&to&contour=enhanced&funnel&plots,&there&was&no&evidence& of& differential& effects& between& more& precise& and& less& precise& trials& according& to&contour=enhanced&funnel&plots&(i.e.,&no&evidence&of&small&study&effects)&(see&Appendix).&
Figure$ 5.11$ –& Effect& of& statins& compared& to& control& on& major& coronary& events& across& all&populations.*&
&
*&Estimates&shown&are&ORs&and&95%&CIs.&








Among& individuals& with& no& prior& coronary& artery& disease,& 73,049& participants& contributed&information&on&2,429&major&coronary&events.&There&were& three& trials&of&atorvastatin&with&424&major& coronary& events& among& 15,472& individuals;& two& trials& of& lovastatin& with& 313& events&among& 7,837& individuals;& 8& trials& of& pravastatin&with& 1,592& events& among& 30,854& individuals;&and&two&trials&of&rosuvastatin&with&100&events&among&18,886&individuals.&There&were&no&trials&of&fluvastatin&and&simvastatin&in&this&population.&&In& the&primary&prevention&population,& as& shown& in&Figure&5.13,& statin& therapy&was& associated&with&a&significant&reduction&in&major&coronary&events&(OR:&0.69,&95%&CI:&0.61,&0.79,&I2=40.2%).&Atorvastatin& (OR:& 0.66,& 95%&CI:& 0.54,& 0.81,& I2=0.0%),& lovastatin& (OR:& 0.62,& 95%&CI:& 0.49,& 0.78,&





Figure$5.13$ –& Effect& of& statins& compared& to& control& on&major& coronary& events& in& the& primary&prevention&population.*$
&
*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&fluvastatin&and&simvastatin&among&individuals&with&no&coronary&heart&disease&at&baseline.&&





*&Connecting&lines&indicate&the&direct&pair=wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair=wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.$&
In&the&base=case&network&meta=analysis,&48&trials&provided&information&for&the&major&coronary&events&analyses.&In&total,&there&were&9,363&events&among&151,520&participants.&In&this&analysis,&the&average&dose&was&16.7&mg/day&for&atorvastatin&(estimated&mean&change&from&baseline&LDL&cholesterol& as& compared& to& control& as& reported& in& Chapter& 4& [Dose;Comparative! Effects! of!
Individual!Statins!on!Cholesterol!Concentrations]:&=48.33,&95%&CrI:&=67.89,&=36.77)&as&compared&to&40.0&mg/day&for&fluvastatin&(=34.51,&95%&CrI:&=60.29,&0.61),&39.3&mg/day&for&lovastatin&(=47.15,&95%& CrI:& =68.26,& =20.21),& 30.9&mg/day& for& pravastatin& (=40.77,& 95%& CrI:& =51.68,& =27.00),& 14.8&mg/day& for& rosuvastatin& (=69.24,&95%&CrI:& =85.59,& =38.81),&and&33.3&mg/day& for&simvastatin& (=54.92,&95%&CrI:&=74.13,&=39.91).&&When& all& eligible& trials& were& pooled& (overall& population),& there& were& statistically& significant&differences&between& individual& statins& (Table&5.8).&Rosuvastatin& resulted& in& significantly&more&major&coronary&events&compared&to&atorvastatin&(OR&of&atorvastatin&vs.&rosuvastatin:&0.66,&95%&CrI:& 0.48,& 0.94)& and& fluvastatin& (OR& of& fluvastatin& vs.& rosuvastatin:& 0.59,& 95%& CrI:& 0.36,& 0.95).&Similar&to&the&all=cause&mortality&analysis&findings,&fluvastatin&appeared&to&result&in&numerically&(but&not&statistically)&fewer&major&coronary&events&as&compared&to&other&statins.&
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Table$ 5.8$ –& Comparative& benefits& of& individual& statins& on& major& coronary& events& across& all&populations.*$
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.13&(0.70,&1.85)& 0.83&(0.57,&1.16)& 0.82&(0.65,&1.11)& 0.66&(0.48,&0.94)& 0.83&(0.58,&1.10)&
Fluvastatin$vs.$ =& 0.74&(0.42,&1.20)& 0.73&(0.48,&1.16)& 0.59&(0.36,&0.95)& 0.74&(0.43,&1.15)&
Lovastatin$vs.$ =& =& 0.99&(0.74,&1.47)& 0.79&(0.56,&1.22)& 1.00&(0.69,&1.38)&
Pravastatin$vs.$ =& =& =& 0.81&(0.58,&1.04)& 1.02&(0.68,&1.24)&
Rosuvastatin$vs.$ =& =& =& =& 1.27&(0.82,&1.67)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
Among&participants&with&established&cardiovascular&disease,&as&shown&in&Table&5.9,&atorvastatin&was& associated&with& significantly& fewer&major& coronary& events& compared& to& pravastatin& (OR:&0.65,&95%&CrI:&0.43,&0.99)&and&simvastatin&(OR:&0.68,&95%&CrI:&0.38,&0.98).&&
Table$ 5.9$ –& Comparative& benefits& of& individual& statins& on& major& coronary& events& in& the&secondary&prevention&population.*&
& Lovastatin$ Pravastatin$ Simvastatin$
Atorvastatin$vs.$ 0.65&(0.26,&1.77)& 0.65&(0.43,&0.99)& 0.68&(0.38,&0.98)&
Lovastatin$vs.$ =& 1.01&(0.38,&2.47)& 1.02&(0.36,&2.60)&
Pravastatin$vs.$ =& =& 1.05&(0.61,&1.39)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&fluvastatin&and&rosuvastatin&among&individuals&with&established&coronary&heart&disease.&&




& Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.05&(0.51,&2.27)& 0.90&(0.54,&1.84)& 1.41&(0.59,&3.45)&
Lovastatin$vs.$ =& 0.86&(0.48,&1.81)& 1.35&(0.52,&3.33)&
Pravastatin$vs.$ =& =& 1.55&(0.63,&3.24)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&fluvastatin&and&simvastatin&among&individuals&without&established&coronary&heart&disease.&&
In& the& sensitivity& analysis& inclusive& of& high=dose& trials,& 62& trials& provided& information& for& the&major&coronary&events&analyses.&There&were&10,664&events&among&173,062&participants.&In&the&sensitivity& analysis,& the& average& dose& of& atorvastatin& was& 39.6& mg/day& as& compared& to& 72.3&mg/day& for& fluvastatin,& 40.7&mg/day& for& lovastatin,& 31.2&mg/day& for&pravastatin,& 17.2&mg/day&for&rosuvastatin,&and&33.3&mg/day&for&simvastatin.&&The&findings&of&the&sensitivity&analysis&closely&paralleled&the&findings&of&the&base=case&network&meta=analysis.& There& were& no& significant& differences& in& the& treatment& benefit& among& statins&when& the& trials& of& primary& prevention,& secondary& prevention,& and&mixed& patient& populations&were& pooled& for& major& coronary& events& (Table& 5.11).& Although& rosuvastatin& was& no& longer&statistically& significantly& associated& with& more& major& coronary& events& as& compared& to&atorvastatin&(OR:&0.75,&95%&CrI:&0.57,&1.02)&and&fluvastatin&(OR:&0.67,&95%&CrI:&0.41,&1.09),&it&still&resulted&in&numerically&more&events.&&
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Table$ 5.11$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&coronary&events&across&all&populations.*&$
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.11&(0.72,&1.80)& 0.83&(0.58,&1.11)& 0.84&(0.70,&1.05)& 0.75&(0.57,&1.02)& 0.84&(0.64,&1.01)&
Fluvastatin$vs.$ =& 0.74&(0.42,&1.20)& 0.76&(0.48,&1.18)& 0.67&(0.41,&1.09)& 0.75&(0.44,&1.17)&
Lovastatin$vs.$ =& =& 1.02&(0.77,&1.48)& 0.90&(0.65,&1.40)& 1.01&(0.73,&1.41)&
Pravastatin$vs.$ =& =& =& 0.89&(0.68,&1.17)& 1.00&(0.73,&1.22)&
Rosuvastatin$vs.$ =& =& =& =& 1.12&(0.76,&1.47)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&




Table$ 5.12$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&coronary&events&in&the&secondary&prevention&population.*&&
& Fluvastatin$ Lovastatin$ Pravastatin$ Simvastatin$
Atorvastatin$vs.$ 0.97&(0.67,&1.52)& 0.47&(0.27,&0.83)& 0.77&(0.64,&0.95)& 0.86&(0.67,&1.01)&
Fluvastatin$vs.$ =& 0.48&(0.24,&0.94)& 0.79&(0.52,&1.17)& 0.88&(0.54,&1.29)&
Lovastatin$vs.$ =& =& 1.65&(0.96,&2.90)& 1.82&(1.01,&3.22)&
Pravastatin$vs.$ =& =& =& 1.12&(0.83,&1.34)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&rosuvastatin&among&individuals&with&established&coronary&heart&disease.&&
In& the& sensitivity& analysis& including& high=dose& trials,& there& were& no& detectable& statistical&differences& among& statins& for& participants& without& established& cardiovascular& disease& (Table&5.13).&
Table$ 5.13$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&coronary&events&in&the&primary&prevention&population.*&
& Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.10&(0.65,&1.95)& 0.88&(0.63,&1.43)& 1.44&(0.73,&2.83)&
Lovastatin$vs.$ =& 0.81&(0.51,&1.38)& 1.30&(0.61,&2.70)&
Pravastatin$vs.$ =& =& 1.61&(0.80,&2.98)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&fluvastatin&and&simvastatin&among&individuals&without&established&coronary&heart&disease.&&
In& the&dose=specific&analysis& that& included&all&placebo=controlled,&active=comparator,&and&dose=comparison& trials,& a& total& of& 11,515&major& coronary& events& among& 186,375& participants& in& 69&trials&were&included.&Surprisingly,&there&was&no&general&dose=response&relationship&with&higher&dose& formulations& being& associated& with& greater& coronary& benefits& (Figure& 5.15).& All& statins&
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except& for& low=dose& lovastatin& (OR:&1.67,& 95%&CrI:& 0.76,& 3.95),& high=dose& lovastatin& (OR:&1.42,&95%& CrI:& 0.77,& 2.77),& low=dose& rosuvastatin& (OR:& 0.94,& 95%& CrI:& 0.74,& 1.18),& high=dose&rosuvastatin& (OR:& 0.98,& 95%& CrI:& 0.08,& 19.59),& and& low=dose& simvastatin& (OR:& 0.76,& 95%& CrI:&0.58,& 1.12)& were& associated& with& significantly& fewer& major& coronary& events& as& compared& to&control& treatment.& Higher& doses& of& atorvastatin& and& fluvastatin& had& the& highest& number& of&significant&differences&compared&with&other&statins.&
Figure$ 5.15$ –& Dose=specific& analysis& findings:& comparative& effects& of& individual& statins&compared&to&control&for&major&coronary&events&across&all&populations.*&$
&
*&Estimates&shown&are&ORs&and&95%&CrIs.&&
5.4.3!! Investigation!of!Heterogeneity!and!Inconsistency!in!the!Network!Meta;analysis!Meta=regression&analyses&evaluating&the&impact&of&mean&age&at&baseline,&mean&LDL&cholesterol&concentration& at& baseline,& and& publication& year& could& not& explain& the& potential& heterogeneity&and&inconsistency&in&the&base=case&network&meta=analysis.&Table&5.14&shows&the&between=study&standard& deviations& and& covariate& coefficients& with& base=case& model& as& compared& to& meta=regressions.&Although&the&analysis&that&adjusted&for&the&mean&LDL&cholesterol&concentrations&of&patients& at& baseline& showed& that& this& covariate& was& marginally& significant,& its& impact& on& the&between=study& standard& deviation& was&minimal.& Figure& 5.16& shows& the& sensitivity& of& relative&treatment& effects& of& individual& statins& vs.& control& treatment& to& different& meta=regression&analyses.& According& to& this& figure,& the& comparative& effects& of& individual& statins& on& major&
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Figure$ 5.16$ –$ Sensitivity& of& the& base=case& findings& to& meta=regression& analyses& for& major&coronary&events&.*&$
&
*& Estimates& shown& are& ORs& and& 95%& CrIs.& Base=case& results& are& shown& in& red,& while& the& analysis&adjusted&for&mean&age&of&patients&at&baseline&is&shown&in&green,&the&analysis&adjusting&for&the&mean&LDL&concentration&at&baseline& is&shown&in&yellow,&and&the&analysis&adjusting&for&publication&year& is&shown&in&blue.&
5.5$Outcome$3:$Major$Cerebrovascular$Events&
5.5.1!! Benefits!of!Statins!vs.!Control:!Findings!of!the!Traditional!Pair;wise!Meta;analysis!In& the& traditional& pair=wise&meta=analysis& of& statin& therapy& vs.& control& across& all& populations,&171,731& individuals& contributed& information& on& 4,533&major& cerebrovascular& events& (see& the&
Appendix& for& trial=level& results).&There&were&12& trials&of&atorvastatin&providing& information&on&1,059&major&cerebrovascular&events&among&31,739&individuals;&four&trials&of&fluvastatin&with&18&events& among& 3,166& individuals;& seven& trials& of& lovastatin& with& 56& events& among& 17,869&individuals;&20&trials&of&pravastatin&with&1,658&events&among&63,762&individuals;&three&trials&of&rosuvastatin& with& 509& events& among& 27,896& individuals;& and& four& trials& of& simvastatin& with&1.233&events&among&27,281&individuals.&Overall,& as& shown& in&Figure&5.17,& statin& therapy&was&associated&with&a& reduction& in& the&risk&of&major&cerebrovascular&events&(OR:&0.82,&95%&CI:&0.77,&0.87,&I2=0.0%)&when&compared&to&control&(Figure&5.14)& (see&Appendix& for& trial=level& results).&Among&statins,&atorvastatin& (OR:&0.78,&95%&CI:&0.69,&0.89,&I2=0.0%),&pravastatin&(OR:&0.88,&95%&CI:&0.80,&0.97,&I2=0.0%),&and&simvastatin&(OR:&0.74,& 95%& CI:& 0.66,& 0.83,& I2=0.0%)& were& associated& with& a& significant& reduction& in& major&
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Among& individuals& with& established& disease& (secondary& prevention& population),& 47,378&individuals& contributed& information& on& 1,748& major& cerebrovascular& events.& There& were& six&trials&of&atorvastatin&providing&information&on&696&major&cerebrovascular&events&among&12,283&individuals;& one& trial& of& fluvastatin&with& three& events& among& 1,680& individuals;& three& trials& of&lovastatin& with& five& events& among& 987& individuals;& 11& trials& of& pravastatin& with& 848& events&among& 26,947& individuals;& and& three& trials& of& simvastatin& with& 196& events& among& 5,481&individuals.&In& the& secondary& prevention& population,& statin& therapy& was& associated& with& a& significant&reduction& in& all=cause& mortality& (OR:& 0.82,& 95%& CI:& 0.75,& 0.91,& I2=0.0%)& when& compared& to&control&(Figure&5.18).&Atorvastatin&(OR:&0.83,&95%&CI:&0.70,&0.97,&I2=0.0%),&pravastatin&(OR:&0.86,&95%&CI:&0.75,&0.98,&I2=0.0%),&and&simvastatin&(OR:&0.68,&95%&CI:&0.51,&0.91,&I2=0.0%)&resulted&in&significantly&fewer&events&as&compared&to&control&among&individuals&with&established&history&of&cardiovascular&disease.& Pooled& estimates& for& fluvastatin& (OR:& 1.98,& 95%&CI:& 0.18,& 21.84,& I2=not&
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Figure$ 5.19$ –& Effect& of& statins& compared& to& control& on& major& cerebrovascular& events& in& the&primary&prevention&population.*&
&
*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&simvastatin&among&individuals&with&no&coronary&heart&disease&at&baseline.&&




Figure$ 5.20$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&major&cerebrovascular&events.*&$
&
*&Connecting&lines&indicate&the&direct&pair=wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair=wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.$&





& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.45&(0.32,&7,14)& 1.07&(0.56,&1.98)& 0.87&(0.64,&1.20)& 0.87&(0.64,&1.20)& 1.05&(0.79,&1.47)&
Fluvastatin$vs.$ =& 0.73&(0.13,&3.68)& 0.61&(0.12,&2.73)& 0.60&(0.12,&2.67)& 0.74&(0.15,&3.33)&
Lovastatin$vs.$ =& =& 0.81&(0.46,&1.49)& 0.82&(0.43,&1.55)& 0.99&(0.54,&1.86)&
Pravastatin$vs.$ =& =& =& 1.00&(0.75,&1.30)& 1.21&(0.94,&1.57)&
Rosuvastatin$vs.$ =& =& =& =& 1.21&(0.88,&1.69)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
There&were&no&statistical&differences&among& individual& statins& in& terms&of& reducing& the& risk&of&major& cerebrovascular& events& in& the& secondary& prevention& of& cardiovascular& disease& (Table&5.16).&There&was&considerable&uncertainty&around&the&comparative&estimate&of&atorvastatin&vs.&lovastatin&(OR:&2.84,&95%&CrI:&0.32,&67.75).&&
Table$5.16$–&Comparative&benefits&of&individual&statins&on&major&cerebrovascular&events&in&the&secondary&prevention&population.*&
& Lovastatin$ Pravastatin$ Simvastatin$
Atorvastatin$vs.$ 2.84&(0.32,&67.75)**& 0.94&(0.57,&1.62)& 1.19&(0.65,&2.44)&
Lovastatin$vs.$ =& 0.33&(0.01,&2.91)& 0.42&(0.02,&3.90)&
Pravastatin$vs.$ =& =& 1.27&(0.76,&2.27)&





& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.29&(0.27,&7.24)& 1.21&(0.56,&2.92)& 0.82&(0.57,&1.21)& 1.43&(0.78,&2.65)&
Fluvastatin$vs.$ =& 0.93&(0.16,&5.49)& 0.63&(0.12,&2.98)& 1.13&(0.20,&5.66)&
Lovastatin$vs.$ =& =& 0.68&(0.30,&1.45)& 1.18&(0.47,&2.85)&
Pravastatin$vs.$ =& =& =& 1.75&(0.97,&3.08)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&simvastatin&among&individuals&without&established&coronary&heart&disease.&




Table$ 5.18$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&cerebrovascular&events&across&all&populations.*$
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 0.94&(0.35,&2.26)& 1.08&(0.60,&1.98)& 0.86&(0.70,&1.04)& 0.82&(0.63,&1.05)& 0.99&(0.82,&1.21)&
Fluvastatin$vs.$ =& 1.14&(0.39,&3.82)& 0.91&(0.37,&2.49)& 0.86&(0.36,&2.30)& 1.05&(0.43,&2.90)&
Lovastatin$vs.$ =& =& 0.79&(0.44,&1.44)& 0.76&(0.41,&1.38)& 0.91&(0.50,&1.66)&
Pravastatin$vs.$ =& =& =& 0.95&(0.74,&1.23)& 1.15&(0.94,&1.43)&
Rosuvastatin$vs.$ =& =& =& =& 1.21&(0.93,&1.62)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
Among&individuals&with&established&coronary&heart&disease&(secondary&prevention&population),&as& shown& in&Table&5.19,& there&were&no& significant&differences&between&different& statins.&There&was&substantial&uncertainty&around&the&estimate&comparing&atorvastatin&vs.&lovastatin&(OR:&4.30,&95%&CI:&0.61,&60.86).&&
Table$ 5.19$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&cerebrovascular&events&in&the&secondary&prevention&population.*&
& Lovastatin$ Pravastatin$ Simvastatin$
Atorvastatin$vs.$ 4.30&(0.61,&60.86)& 0.90&(0.64,&1.25)& 0.98&(0.72,&1.40)&
Lovastatin$vs.$ =& 0.21&(0.01,&1.45)& 0.23&(0.02,&1.63)&




There&were&also&no&detectable&statistical&differences&between& individual&statins& in& the&primary&prevention&population&(Table&5.20).&&
Table$ 5.20$ –& Sensitivity& analysis& results:& Comparative& benefits& of& individual& statins& on&major&cerebrovascular&events&in&the&primary&prevention&population.*&
& Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.29&(0.27,&7.24)& 1.21&(0.56,&2.92)& 0.82&(0.57,&1.21)& 1.43&(0.78,&2.65)&
Fluvastatin$vs.$ =& 0.93&(0.16,&5.49)& 0.63&(0.12,&2.98)& 1.13&(0.20,&5.66)&
Lovastatin$vs.$ =& =& 0.68&(0.30,&1.45)& 1.18&(0.47,&2.85)&
Pravastatin$vs.$ =& =& =& 1.75&(0.97,&3.08)&
*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&simvastatin&among&individuals&without&established&coronary&heart&disease.&&




Figure$ 5.21$ –& Dose=specific& analysis& findings:& comparative& effects& of& individual& statins&compared&to&control&for&major&coronary&events&across&all&populations.*$
&
*&Estimates&shown&are&ORs&and&95%&CrIs.&&












Meta=regression&analysis&adjusting&for&publication&year& 0.0734& 0.021,&(=0.005,&0.047)&& & &
Figure$ 5.22$ –$ Sensitivity& of& the& base=case& findings& to& meta=regression& analyses& for& major&coronary&events.*&$
&
*& Estimates& shown& are& ORs& and& 95%& CrIs.& Base=case& results& are& shown& in& red,& while& the& analysis&adjusted&for&mean&age&of&patients&at&baseline&is&shown&in&green,&the&analysis&adjusting&for&the&mean&LDL& cholesterol& concentration& at& baseline& is& shown& in& yellow,& and& the& analysis& adjusting& for&publication&year&is&shown&in&blue.&
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5.6$ Overall$ Rankings$ of$ Individual$ Statins$ in$ terms$ of$ Benefit$ Outcomes$ Across$ All$






5.7$Summary$of$Findings$This& network&meta=analysis& of& 103& randomized& trials& including& 214,877& individuals& provided&evidence& on& the& statistically& and& clinically&meaningful& benefits& of& statins& in& both& primary& and&secondary&prevention&of&all=cause&mortality,&major&coronary&events,&and&major&cerebrovascular&events.& Overall,& statins& were& associated& with& an& 18%& reduction& in& relative& odds& of& all=cause&mortality& among& patients& with& cardiovascular& disease.& In& primary& prevention,& statin& therapy&resulted&in&a&modest&but&significant&9%&reduction&in&relative&odds&of&all=cause&mortality.&Benefits&of&statins&in&reducing&the&relative&odds&of&major&coronary&events&by&31%&were&consistent&across&primary&and&secondary&prevention&populations.&Similarly,&there&was&a&consistent&18%&reduction&in& the& relative& odds& of& major& cerebrovascular& events& across& primary& prevention,& secondary&prevention,& and& overall& populations.& Across& all& populations,& the& base=case& analysis& provided&evidence&to&suggest&that&individual&statins&are&statistically&equivalent&in&terms&of&their&benefits&on&total&mortality&and&major&cerebrovascular&events,&but& that& there&may&be&differences&among&individual&statins&for&preventing&major&coronary&events.&Among&individual&statins,&atorvastatin,&fluvastatin,& and& simvastatin& were& likely& to& be& ranked& superior& to& their& alternatives& at&comparable&doses&across&all&populations.&
5.7.1!! Comparative!Benefits!of!Statins!on!Total!Mortality!and!Major!Coronary!Events!The&base=case&network&meta=analysis&detected&statistically&significant&differences&among&statins.&Doses&considered&in&the&base=case&analysis&were&broadly&comparable&and,&as&expected,&resulted&in& approximately& 30=40%& reductions& from& baseline& LDL& cholesterol& levels.& Atorvastatin& and&fluvastatin&performed&significantly&better&than&rosuvastatin&in&terms&of&reducing&major&coronary&events& across& all& populations.& Atorvastatin& and& fluvastatin& had& a& strong& effect& in& reducing&mortality& and& morbidity& among& individuals& with& established& coronary& heart& disease.& Among&individuals&with&established&disease,&atorvastatin&resulted& in&marginally& fewer&major&coronary&events&as&compared&with&pravastatin&and&simvastatin.&Relative&treatment&effects&for&statins&were&not& sensitive& to& the& findings& of& the&meta=regression& analysis& and& the& sensitivity& analysis& that&included& intensive& dose& trials.& In& the& sensitivity& analysis,& atorvastatin& was& significantly& more&effective& than& lovastatin& and& pravastatin& in& reducing&major& coronary& events& in& the& secondary&prevention& setting.& Also,& fluvastatin& was& more& effective& than& lovastatin& in& reducing& major&coronary& events.& Unfortunately,& fluvastatin& and& simvastatin& had& insufficient& evidence& in& the&primary&prevention&setting&as&there&was&no&trial&for&either&statin&that&provided&information&for&their&effectiveness&in&high=risk&individuals&without&established&disease.&&
160 
 
The& dose=specific& analysis& paralleled& the& findings& of& previous&meta=analyses& in& that& statins& at&higher&doses&do&not&reduce&all=cause&mortality&more&so&than&statins&at&lower&doses.240&Similar&to&previous& meta=analyses,& there& was& a& general& dose=response& relationship& across& placebo=controlled&and&active=comparator& trials& in& terms&of& reducing&major&coronary&events.&However,&this& relationship& was& not& apparent& for& all& statins.& For& instance,& low=dose& and& high=dose&formulations& of& lovastatin& fared& worse& than& the& medium=dose& formulation.257& Similarly,&currently&available&randomized&evidence&is&not&adequate&to&suggest&that&high=dose&rosuvastatin&is& beneficial& in& reducing& major& coronary& events.349=351& Although& high=dose& formulations& of&atorvastatin& and& fluvastatin& have& not& been& compared& directly& in& trials,& the& findings& of& the&network&meta=analysis&provided&compelling&evidence&that&these&agents&are&equally&effective& in&reducing&the&occurrence&of&major&coronary&events.&Placebo=controlled&trials&of&atorvastatin&and&fluvastatin& were& comparable& in& terms& of& known& relative& treatment& effect& modifiers& and&individuals& in& the& placebo& arms& experienced& major& coronary& events& at& similar&rates.134,183,193,352,353&Given&the&greatly&differing& incremental&LDL&cholesterol& lowering&effects&of&high=dose&atorvastatin&and& fluvastatin,& this&analysis& suggests& that& incremental&LDL&cholesterol&reducing&effects&alone&may&not&be&responsible&for&the&comparative&benefits&of&statins.&&
5.7.2!! Comparative!Benefits!of!Statins!on!Major!Cerebrovascular!Events!The&overall&findings&of&the&network&meta=analysis&presented&in&this&chapter&reinforce&and&extend&the& results& of& previous& meta=analyses& on& statin& therapy.& Previous& reviews& elucidated& the&importance&of&lipid&management&with&statins&in&the&prevention&of&strokes&and&found&consistent&evidence&that&would&warrant&advocating&statin&use&for&the&prevention&of&incident&strokes.354,355&Clinical&practice&guidelines&also&recommend&statin&therapy&in&secondary&prevention&of&stroke&for&patients&with&non=cardioembolic& stroke.356,357& Since& SPARCL& (Stroke&Prevention&by&Aggressive&Reduction& in&Cholesterol&Levels)&was& the&only& trial& that& investigated& the&benefits&of& statins& for&the&secondary&prevention&of&strokes&in&individuals&with&a&history&of&transient&ischemic&attack&or&stroke,&the&analysis&presented&in&this&chapter&did&not&explore&the&comparative&benefits&of&statins&in&this&population&separately.358&The&base=case&analysis&in&individuals&with&or&without&a&history&of& established& coronary& heart& disease& did& not& detect& significant& differences& among& individual&statins.&&Although&there&were&no&statistical&differences,& this&review&suggested&that& the&randomized&trial&evidence&base&for&some&statins&was&more&robust&and&consistent&than&it&was&for&others.&This&was&particularly& the& case& for& atorvastatin& and& simvastatin.& There& was& essentially& no& detectable&heterogeneity&across&the&trials&of&atorvastatin&and&simvastatin&with&consistent&evidence&for&their&
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benefits& in& the& prevention& of&major& cerebrovascular& events.& Unlike& simvastatin&which& did& not&have&evidence&in&individuals&with&no&history&of&coronary&heart&disease,&atorvastatin&was&able&to&reach&statistical&significance&in&both&primary&and&secondary&prevention&populations&(as&well&as&across& all& populations)& as& compared& to& control& treatment.& & Trial& evidence& for& fluvastatin& and&lovastatin& was& inconsistent& across& individuals& with& and& without& coronary& heart& disease& and&there& was& large& uncertainty& around& the& benefits& of& these& agents& in& the& prevention& of& major&cerebrovascular& events.& Finally,& there& was& substantial& heterogeneity& in& the& evidence& base& for&rosuvastatin.&Given&the&small&number&of&trials,&JUPITER&appeared&to&drive&the&pooled&estimates&for&rosuvastatin,&specifically&for&individuals&without&a&history&of&coronary&heart&disease.257&
5.7.3!! Conclusions!and!Implications!for!Clinical!Practice!The&primary&findings&of&this&network&meta=analysis&suggested&that&fluvastatin,&which&is&among&the& least& potent& statins& in& terms& of& lowering& LDL& cholesterol& concentrations,& appeared& to&perform&equally&well&with&more&potent&statins&such&as&atorvastatin&and&simvastatin&in&terms&of&preventing& total& mortality,& major& coronary& events,& and& major& cerebrovascular& events& at&therapeutic& doses.& Indeed,& in& the& secondary&prevention& setting,& fluvastatin&was&more& effective&than&rosuvastatin&in&terms&of&reducing&the&risk&of&major&coronary&events&(OR:&0.59,&95%&CI:&0.36&to& 0.95)& on& the& basis& of& the& existing& randomized& trial& evidence& available& in& the& published&literature.& Across& all& populations,& fluvastatin&was& ranked& as& the& best& treatment& option& for& the&prevention&of&total&mortality&and&clinical&outcomes.&&Previous&reviews&have&shown&that&the&cardiovascular&benefits&of&statins&are&directly&attributable&to& their& LDL& cholesterol& lowering& effects,&with& greater& reductions& in& baseline& LDL& cholesterol&levels&resulting&in&greater&risk&reductions.175,239,359&However,&these&analyses&compared&high&dose&formulations&to&low&dose&formulations&without&differentiating&between&individual&statins.&When&dose=response&relationships&of&individual&statins&are&explored,&as&shown&in&this&chapter,&strong&inferences&cannot&be&made.&&The&analyses&presented&in&this&chapter&have&a&number&of&relevant&limitations.&First,&there&were&only&a&few&head=to=head&trials&of&individual&statins&that&were&prospectively&designed&to&capture&differences& in& clinical& outcomes& as& primary& endpoints.& Second,& there& was& an& apparent&asymmetry& in& the&evidence&network&where&specific& interventions&appeared& to&be&avoided&(e.g.&fluvastatin),&which&may&be&indicative&of&a&biased&clinical&research&agenda.&Third,&between=study&heterogeneity&ranged& from& low&to&moderate&across&various& traditional&pairwise&meta=analyses&of&statins&vs.&control.&Hence,& it&remains&a&possibility& that& this&analysis&did&not& fully&account& for&heterogeneity&due&to&unobserved&or&unmeasured&factors.&However,&random=effects&models&took&
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Chapter$6$&Comparative&Harms&of&Individual&Statins*&&&As&shown&in&the&previous&chapter,&statins&are&effective&in&the&primary&and&secondary&prevention&of&all=cause&mortality,&major&coronary&events,&and&major&cerebrovascular&events.&The&findings&of&the&previous&chapter&also&demonstrate&that&trial&participants&receiving&fluvastatin,&simvastatin,&and& atorvastatin& appear& to& incur& greater& clinical& benefit& than& those& receiving& lovastatin,&pravastatin,& and& rosuvastatin.& Based& on& these& findings,& should& fluvastatin,& simvastatin,& and&atorvastatin& be& prioritized& given& their& favorable& effect& on& important& clinical& outcomes?& This&question&should&be&addressed&in&light&of&the&potentially&harmful&adverse&events&associated&with&statin& therapy& as& a& drug& class,& and& different& statins& individually.& An& evaluation& of& the&comparative&harm&profiles&of&individual&statins&forms&the&basis&of&the&empirical&work&presented&in&this&chapter.&&Statin&therapy&is&associated&with&a&predominantly&favorable&safety&profile.&Although&rare,&muscle&toxicity&remains&the&biggest&concern&with&statin&therapy.360&Muscle&toxicity&attributable&to&statin&therapy&can&range& from&muscle&pain&(termed&myalgia&when&unaccompanied&by&an&evidence&of&muscle& damage)& to& more& severe& conditions,& the& most& severe& of& which& is& a& potentially& fatal&condition&called&rhabdomyolysis,&which&is&defined&as&a&sharp&increase&in&serum&concentrations&of& creatine& kinase& accompanied& by& muscle=related& symptoms.361& Elevations& in& serum&concentrations&of&creatine&kinase&is&a&potential&indication&of&muscle&damage.362&The&mechanism&of& statin=induced& muscle& toxicity& remains& elusive& but& appears& to& be& exacerbated& by& old& age,&certain&co=morbidities,&and&the&interaction&of&statins&with&other&drugs.363,364&Another& potential& concern& with& statin& drugs& is& related& to& their& effect& on& liver& enzymes.365&Individuals&receiving&statins&often&experience&asymptomatic&elevations&in&liver&enzymes,&which&
                                                *& Part& of& the& work& presented& in& this& chapter& was& published& with& the& following& reference:& Naci& H,&Brugts& JJ,&Ades&AE.&Comparative& tolerability& and&harms&of& individual& statins:& a& study=level&network&meta=analysis&of&246&955&participants&from&135&randomized,&controlled&trials.&Circ&Cardiovasc&Qual&Outcomes.&2013&Jul;6(4):&390=9.&&
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are& typically& reversible& and& appear& to& be& unrelated& to& an& increased& risk& for& hepatoxicity.366&Nonetheless,& continuing& statin& therapy& in& the& presence& of& elevated& hepatic& enzymes& poses& a&therapeutic&dilemma& for&prescribers& and&patients,& and& represents& an& important& risk& factor& for&treatment&discontinuation.367&Statin&therapy& is&also&associated&with&a&slightly& increased&risk&of&new=onset&diabetes&across&all&populations.368,369& Although& the& reasons& for& this& increase& in& risk& are& not& clear,& one& hypothesis&postulates& that& statins& may& adversely& affect& the& glucose& metabolism& by& impairing& insulin&secretion.370& It& is& also& possible& that& the& observed& risk& represents& a& chance& finding& or& residual&confounding& in& randomized& controlled& trials& of& statins.& Whatever& the& cause,& statin=induced&diabetes& risk,& which& surfaced& only& in& 2010,& has& resulted& in& a& flurry& of& media& coverage& and&academic& debate.371=377& In& response,& the& United& States& Food& and&Drug& Administration& in& 2012&added&information&on&drug&labels&concerning&an&effect&of&statins&on&incident&diabetes.378&&Although&statin&therapy&is& increasingly&common&among&individuals&with&relatively& low&risk&for&developing& cardiovascular& disease,& there& has& not& been& any& comprehensive& analysis& on& the&comparative& adverse& event& profiles& of& different& statins& across& all& populations,& and& in& sub=populations&of&primary&and&secondary&prevention.&At&the&population& level,& the&nonrandomized&observational& evidence& that& linked& statin& use& to& increased& risks& of& moderate& or& serious& liver&dysfunction,&acute&renal&failure,&and&moderate&or&serious&myopathy&suggested&that&the&adverse&effects& appeared& to& be& similar& across& individual& statins& for& each& outcome& except& for& liver&dysfunction&where&risks&were&highest&for&fluvastatin.379&In&a&more&recent&retrospective&analysis&of& administrative& data& from& Canada,& the& United& Kingdom& and& United& States,& the& use& of& high&potency& statins& was& associated& with& an& increased& rate& of& acute& kidney& injury& in& hospital&admissions&compared&with&low&potency&statins.380&&A&number&of&previous&reviews&of&randomized&controlled&trials&focused&on&statins&as&a&class&and&established& their& favorable& safety& profile.381=383& Large=scale& meta=analyses& of& randomized&controlled&trials&confirmed&that&the&frequency&of&clinically&significant&side&effects&associated&with&statin& therapy& is& low,& concluding& that& “by& any& standard,& statins& are& remarkably& safe&drugs.”384&However,& these& previous& reviews& did& not& consider& the& totality& of& the& existing& randomized&controlled&trial&evidence&base:&they&either&pooled&only&placebo=controlled&trials&or&only&a&sub=set&of& active=comparator& trials.& In& addition,& previous& reviews& did& not& consider& all& clinically&meaningful& and& patient=centered& outcomes.& Therefore,&more& research& is& needed& to& synthesize&the&evidence&on&a&more&diverse&range&of&outcomes&that&are&important&for&individuals&receiving&statins.&These&range&from&previously&studied&outcomes&such&as&cancer&385=387&and&diabetes368,388&
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to& lesser& studied& outcomes& such& as&muscle& aches& and& clinically&meaningful& elevations& in& liver&enzymes,& which& may& be& among& factors& contributing& to& nonadherence& to& long& term& statin&therapy.389,390&The&impact&of&statins&on&these&outcomes&is&needed&to&better&inform&patients&and&prescribers&about&the&harms&associated&with&statin&therapy.&&What& is& particularly& lacking& in& the& literature& is& evidence& on& the& relative& harms& of& individual&statins.&The&existing&literature&provides&only&piecemeal&information&on&the&side&effect&profiles&of&individual& statins.& For& example,& one& meta=analysis& evaluated& the& harms& of& atorvastatin& and&concluded&that&the&side&effects&observed&in&trial&participants&receiving&atorvastatin&were&similar&in& frequency& to& those& observed& in& individuals& receiving& placebo.391& Another& meta=analysis&pooled& the& direct& head=to=head& comparisons& of& atorvastatin& and& rosuvastatin& and& found& the&adverse&effect&profiles&of& these&agents& to&be&similar&at&all&doses.339&There&was&also&a& relatively&recent& network&meta=analysis& that& indirectly& compared& different& statins& to& each& other.392& The&findings&of&this&previous&network&meta=analysis&suggested&that&statins&exert&a&similar&risk&across&individual& drugs.& An& important& limitation& of& this& analysis&was& its& focus& on& placebo=controlled&trials,&which&did&not&take&into&account&evidence&from&a&large&number&of&trials&with&direct&head=to=head&comparisons&of&statins.&Equally&important,&this&previous&network&meta=analysis&did&not&assess&differences& in&dosages&of& individual& statins&across&populations.&Thus,& there& is& a&need& to&explore&and&quantify&the&relative&tolerability&and&harms&of&different&statins&in&the&prevention&of&cardiovascular&disease.&The& objective& of& the& empirical&work&presented& in& this& chapter& is& to& systematically& review&and&synthesize& the& totality& of& the& randomized& controlled& trial& evidence& on& different& statins,& and&determine& their& comparative& tolerability& and& harms& across& a& range& of& populations& eligible& for&statin&therapy.&This&chapter&reports&the&findings&of&a&comprehensive&network&meta=analysis&that&combines& evidence& from& both& placebo=controlled& and& active=comparator& trials& of& statins& on&tolerability& and& harm& outcomes.& The& overall& effect& of& statins& on& these& outcomes& across& all&populations,& in& addition& to& secondary& and& primary& prevention& of& coronary& heart& disease,& is&evaluated.& The& effects& of& individual& statins& head=to=head& in& these& patient& populations& are&compared,&taking&into&account&dose&differences&across&the&included&set&of&included&trials.&
6.1$Empirical$Considerations$As& described& in& Chapter& 3& (Evidence! Review! and! Synthesis!Methods)& separate& traditional& pair=wise& meta=analyses& and& network& meta=analyses& were& performed& for& tolerability& (number& of&participants& who& discontinued& the& study& medication& due& to& adverse& events),& elevations& in&hepatic& transaminases& (number& of& participants&with& clinically&meaningful& elevations& in& either&
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alanine&aminotransferase,&ALT,&or&aspartate&aminotransferase,&AST,&three&times&baseline&values&as& commonly& defined& by& trial& investigators),& elevations& in& creatine& kinase& (number& of&participants& with& clinically& meaningful& increases& in& baseline& creatine& kinase,& CK,& levels& as&defined& by& trial& investigators,& ranging& from& three& to& 10& times& higher& than& baseline&concentrations),& myalgia& (number& of& individuals& with& muscle& pain,& as& defined& by& trial&investigators),&myopathy&(number&of&participants&with&10&times&baseline&creatine&kinase&levels&associated&with&muscle& symptoms),& and& rhabdomyolysis& (number& of& participants&with& severe&muscle& damage,& as& diagnosed& by& trial& investigators).& In& addition,& separate& analyses& were&conducted&on&the&incidence&of&cancer&and&diabetes&mellitus&(as&defined&by&trial&investigators).&&Traditional& pair=wise& meta=analyses& were& based& on& placebo=controlled& trials& whereas& the&network& meta=analyses& combined& placebo=controlled& and& active=comparator& trials.& For& each&endpoint,& three& sets&of& analyses&were& conducted.& First,& to&obtain& a& comprehensive& estimate&of&the&effect&of&statins,&all&primary&and&secondary&prevention&trials&were&pooled&in&addition&to&trials&with& mixed& patient& populations.& Subsequently,& separate& analyses& were& performed& for& the&primary& prevention& and& secondary& prevention& populations.& These& separate& analyses& were&performed&for&the&four&primary&outcomes,&which&had&the&most&abundant&data& in&the& identified&trials.& These& outcomes& were& discontinuations& due& to& adverse& events,& myalgia& occurrence,&transaminase&elevations,&and&creatine&kinase&elevations.&&
Consideration! of! dose! in! the! network! meta;analysis:& For& the& base=case& network&meta=analysis,&comparisons&were&performed&at&the&drug=level,&comparing&individual&statins&to&each&other&(e.g.,&atorvastatin& vs.& simvastatin)& by& pooling& all& available& doses& in& the& identified& set& of& trials.& A&separate& dose=specific& analysis& explored& the& effects& of& individual& statins& at& all& available& doses,&using&a&similar&dose&grouping&as&in&Chapter&4&(Dose;Comparative!Effects!of!Individual!Statins!on!
Cholesterol!Concentrations).&In&this&analysis,&each&possible&statin=dose&combination&was&treated&as&a&different&treatment&and&no&trends&were&fitted&or&assumed.&The&following&daily&doses&were&considered&for&atorvastatin,& lovastatin,&pravastatin,&and&simvastatin:&≤10&mg,&>10&and&≤20&mg,&>20&and&≤40&mg,&and&>40&mg.&For& fluvastatin,&daily&doses&were&≤20&mg,&>20&and&≤40&mg,&and&>40& mg.& Given& the& different& potency& of& rosuvastatin,& a& different& dosing& categorization& was&adopted:&the&daily&doses&for&rosuvastatin&were&categories&as&≤5&mg,&>5&and&≤10&mg,&>10&and&≤20&mg,&and&>20&mg.&All&analyses&were&based&on&the&total&number&of&randomly&assigned&participants.&
Ranking! of! statins! in! the! network!meta;analysis:& The&probability& that& each& statin&was& the& least&harmful& regimen&was& estimated& by& calculating& the& treatment& effect& for& each& statin& compared&with& the& control& treatment,& and& counting& the& proportion& of& iterations& of& the&Markov& chain& in&
167 
 
which& each& drug& had& the& lowest& treatment& effect,& the& second& lowest,& and& so& on.& Rank&probabilities& were& separately& estimated& for& discontinuations& due& to& adverse& events,& myalgia&occurrence,&hepatic&transaminase&elevations,&and&creatine&kinase&elevations.&Rankograms&were&developed& to& graphically& present& the& distribution& of& ranking& probabilities.& Also,& cumulative&probability& plots& were& developed& for& each& outcome& and& the& surface& under& the& cumulative&ranking& line& for& each& statin& was& estimated& as& described& in& Chapter& 3& (Evidence! Review! and!
Synthesis!Methods).324&The&surface&area&under&the&cumulative&ranking&line&provided&a&numerical&summary& of& the& overall& score& for& each& statin& for& each& outcome.& Each& statin& was& scored& with&points&up&to&a&maximum&of&1.00,&which&was&the&weighted&sum&of&scores&separately&estimated&for&discontinuations& due& to& adverse& events,&myalgia& occurrence,& hepatic& transaminase& elevations,&and&creatine&kinase&elevations.&&
Assessment! of! heterogeneity! and! inconsistency! in! the! network!meta;analysis:&Whether& potential&heterogeneity&and&inconsistency&across&the&evidence&base&could&be&explained&by&differences& in&trial&publication&year,&baseline&LDL&cholesterol&concentration,&and&baseline&mean&age&of&patients&was&investigated&using&meta=regression&analyses.&All&meta=regression&analyses&were&performed&by&allowing&for&a&common&treatment=covariate&interaction&for&each&statin&compared&to&control,&as&described&in&Chapter&3.327&To&further&explore&any&potential&inconsistency&between&direct&and&indirect& evidence,& the& ratio& of& relative& effects& for& indirect& versus& direct& evidence& was&calculated.329& Inconsistency& was& defined& as& the& disagreement& between& direct& and& indirect&evidence&with&a&95%&CI&excluding&1.00.289&
Goodness!of!fit:&As&described&previously&(Chapter&3:&Evidence!Review!and!Synthesis!Methods),&the&goodness& of& fit& of& the& network& meta=analysis& models& was& examined& using& the& total& residual&deviance& (posterior& mean& of& the& deviance& under& a& given& model& minus& the& deviance& for& the&saturated&model),& and&was&considered& to&be&satisfactory.& In&each&model,& the& residual&deviance&was&compared&with&the&total&number&of&data&points&in&the&dataset.&As&expected,&models&could&not&predict&a&zero&cell&since&probabilities&at&zero&or&one&were&ruled&out,&which&resulted&in&the&total&residual&deviance&estimates&to&appear&large&when&there&were&a&large&number&of&zero&cells.&&




Presentation! of! results:& First,& the& findings& of& the& traditional& pair=wise& meta=analysis& were&presented& along& with& estimates& of& heterogeneity& in& the& pooled& estimates& of& the& identified&placebo=controlled& trials.& Subsequently,& the& findings& of& the& network& meta=analysis,& which&combined&evidence&from&placebo=controlled&and&active=comparator&trials&were&presented.&This&was& followed& by& the& presentation& of& meta=regression& results,& which& provided& a& statistical&assessment& of& heterogeneity& and& inconsistency& in& the& network& meta=analysis.& The& results& of&additional& exploratory& inconsistency& analyses& were& provided& in& the& Appendix,& along& with&additional&detailed&results&that&formed&the&basis&of&the&main&results&presented&in&this&chapter.&&
Interpretation! of! results:& As& previously,& the& results& of& the& traditional& pair=wise& meta=analyses&were&reported&in&terms&of&odds&ratios&and&95%&CIs.&Given&the&Bayesian&nature&of&network&meta=analyses,& the& findings& of& these& analyses& were& reported& using& odds& ratios& and& 95%& CrIs.& In&traditional&pair=wise&meta=analyses,&the&findings&were&considered&‘statistically!significant’!when!the& 95%& confidence& interval& did& not& include& the& null& value& 1.00.& Adopting& the& emerging&convention&in&reporting&and&interpreting&the&findings&of&Bayesian&network&meta=analyses,&95%&CrIs&that&did&not&cross&the&null&value&of&1.00&were&considered&‘significant’.&Use&of&‘significance’&in&this& way& was& considered& consistent& with& the& latest& network& meta=analyses& that& appeared& in&general&medical&journals.257&
6.2$Systematic$Review$Findings$There& were& 133& randomized& controlled& trials& in& the& systematic& review& and& meta=analysis& of&tolerability&and&harm&outcomes&(Figure&6.1).&These&trials&included&a&total&of&233,783&individuals.&Overall,&the&average&trial&duration&was&68&weeks&(approximately&1.3&years).&Twenty=nine&trials&were&conducted&in&the&primary&prevention&population&compared&with&37&trials&in&the&secondary&prevention& population.& The& remaining& 67& trials& included& participants& with& or& without&established&cardiovascular&disease.&Among&these,& there&were&eight&trials&of&patients&with&acute&coronary&syndromes,&two&trials&that&primarily&included&participants&with&heart&failure,&and&two&trials&with&metabolic&syndrome.&Figures& 6.2& and& 6.3& show& the& network& of& eligible& pair=wise& comparisons& for& tolerability& and&harm& outcomes& (discontinuations& due& to& adverse& events,& myalgia& occurrence,& hepatic&transaminase&elevations,& creatine&kinase&elevations,&new=onset&diabetes,& cancer& incidence,&and&rhabdomyolysis&events)&in&placebo=controlled&and&active=comparator&trials&of&individuals&across&all&populations.&Of&the&15&possible&pair=wise&comparisons&between&the&six&statins&(in&the&base=case& analysis& of& drug=level& comparison),& 13& were& available& in& the& identified& literature.& The&
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Figure$ 6.2$ –$ Network& of& available& comparisons& in& the& base=case& drug=level& network& meta=analysis&of&tolerability&and&harm&outcomes.*$
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6.3.1%% Tolerability%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%In& the& traditional& pair1wise&meta1analysis& of& statin& therapy& vs.& control& across& all& populations,&76,462& participants& contributed& information& on& 5,149& discontinuations& across& 44& placebo1controlled& trials.& There& were& 10& trials& of& atorvastatin& providing& information& on& 1,302&discontinuations&due&to&adverse&events&among&18,014&trial&participants;&five&trials&of&fluvastatin&with& 492& events& among& 4,644& individuals;& three& trials& of& lovastatin& providing& information& on&1,342&events&among&15,097&participants;&16&trials&of&pravastatin&with&784&events&among&20,869&individuals;&four&trials&of&rosuvastatin&with&890&events&among&10,838&individuals;&and&six&trials&of&simvastatin&with&339&events&among&7,000&individuals.&&Overall,&as&shown&in&Figure&6.4,&statin&therapy&was&not&associated&with&a&significant&increase&in&discontinuations&due&to&adverse&events&(OR:&0.95,&95%&CI:&0.83,&1.08,& I2=21.9%)&(see&Appendix&for& trial1level& results).& Among& statins,& pravastatin& resulted& in& significantly& fewer&discontinuations&due& to&adverse&events& (OR:&0.74,&95%&CI:&0.56,&0.98,& I2=53.3%).&Although&not&statistically& significant,& individuals& receiving& atorvastatin& had& numerically& more&discontinuations&(OR:&1.29,&95%&CI:&0.86,&1.92,& I2=79.4%).&Fluvastatin&(OR:&0.89,&95%&CI:&0.67,&1.18,&I2=21.9%);&lovastatin&(OR:&0.92,&95%&CI:&0.79,&1.07,&I2=19.7%);&rosuvastatin&(OR:&1.03,&95%&CI:& 0.75,& 1.40,& I2=69.5%);& and& simvastatin& (OR:& 1.05,& 95%& CI:& 0.83,& 1.33,& I2=0.0%)& were& not&associated&with&a&significant&increase&or&decrease&in&treatment&discontinuations&due&to&adverse&events.&According&to&contour1enhanced&funnel&plots,&there&was&no&evidence&of&small&study&effects&(see&Appendix).&




In&the&secondary&prevention&population,&22,472&participants&contributed&information&on&1,692&discontinuations& due& to& adverse& events& across& 14& placebo1controlled& trials.& There& were& four&trials& of& atorvastatin& contributing& information& on& 848& discontinuations& among& 8,918&participants;& three& trials& of& fluvastatin&with& 404& events& among& 2,876& individuals;& one& trial& of&lovastatin& with& 9& events& among& 247& individuals;& four& trials& of& pravastatin& with& 152& events&among&5,366&individuals;&and&two&trials&of&simvastatin&with&279&events&among&5,065&individuals.&Among&individuals&with&established&coronary&artery&disease,&statin&therapy&was&not&associated&with& an& increase& in& discontinuations& due& to& adverse& events& (OR:& 1.20,& 95%& CI:& 0.86,& 1.68,&




In& the& primary& prevention& population,& 20,864& trial& participants& contributed& information& on&1,623& discontinuations& due& to& adverse& events& across& 10& trials& (see& Appendix& for& trial1level&results).& There& were& two& trials& of& atorvastatin& providing& information& on& 338& discontinuation&events& among& 5,248& trial& participants;& one& trial& of& lovastatin& with& 904& events& among& 6,605&
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individuals;&six& trials&of&pravastatin&with&280&events&among&8,027& individuals;&and&one& trial&of&rosuvastatin&with&101&events&among&984&individuals.&&Among& individuals& without& prior& coronary& artery& disease,& statin& therapy& was& not& associated&with& a& significant& increase& in& discontinuations&due& to& adverse& events& (OR:& 0.96,& 95%&CI:& 0.80,&1.15,& I2=36.4%)& (Figure& 6.6).& Numerically& more& discontinuations& occurred& among& trial&participants& randomized& to& receive& rosuvastatin& (OR:& 1.50,& 95%& CI:& 0.91,& 2.46,& I2=0.0%)& as&compared&to&those&receiving&control.&In&this&population,&neither&atorvastatin&(OR:&0.82,&95%&CI:&0.66,&1.03,&I2=0.0%)&nor&lovastatin&(OR:&0.98,&95%&CI:&0.85,&1.13,&I2=0.0%)&differed&from&control&in&terms&of&their&effect&on&treatment&discontinuations&due&to&adverse&events.&&
Figure$ 6.6$ –& Effect& of& statins& compared& to& control& on& all1cause& mortality& in& the& primary&prevention&population.*$
&*&Estimates&shown&are&ORs&and&95%&CIs.&&
6.3.2%% Comparative%Tolerability%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The& network& of& eligible& comparisons& is& shown& in& Figure& 6.7.& In& addition& to& the& placebo1controlled& trials& included& in& the& traditional& pair1wise& meta1analysis,& a& total& of& 84& direct&comparisons& including& 73,030& individuals& were& included& in& the& network& meta1analysis& of&discontinuations&due&to&adverse&events.‡‡‡&&Atorvastatin&was&directly&compared&to&fluvastatin&in&two&trials&including&1,733&individuals&(OR:&0.85,&95%&CI:&0.62,&1.16,& I2=0.0%);& to& lovastatin& in& four& trials& including&3,347& individuals& (OR:&0.77,& 95%& CI:& 0.55,& 1.07,& I2=0.0%);& to& pravastatin& in& seven& trials& including& 6,126& individuals,&
                                                ‡‡‡&The&number&of&trial&participants&outlined&in&the&following&section&does&not&add&up&to&this&total&due&to&double&counting&of&multi1arm&trials&that&included&two&or&more&active&comparators.&&
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which& showed& that& individuals& randomized& to& atorvastatin& were& more& likely& to& discontinue&treatment&due&to&adverse&events&(OR:&1.41,&95%&CI:&1.07,&1.82,&I2=14.4%);&to&rosuvastatin&in&25&trials& including& 17,615& individuals& (OR:& 0.96,& 0.79,& 1.16,& I2=17.1%);& and& to& simvastatin& in& 16&trials& including& 25,501& individuals,&which& demonstrated& that& atorvastatin&was&marginally& less&tolerable&than&simvastatin&(OR:&1.37,&95%&CI:&1.00,&1.89,&I2=75.3%).&Fluvastatin&was&compared&to&lovastatin&in&three&trials&including&1,945&individuals&(OR:&1.61,&95%&CI:&1.15,&2.27,&I2=0.0%);&to&pravastatin& in& one& trial& including& 939& individuals,& which& indicated& that& fluvastatin& was&associated&with& significantly&more& discontinuations& due& to& adverse& events& (OR:& 3.42,& 95%&CI:&2.04,& 5.76,& I2=0.0%);& and& to& simvastatin& in& two& trials& including& 1,097& individuals,& which&demonstrated&that&fluvastatin&was&less&tolerable&than&simvastatin&(OR:&1.72,&95%&CI:&1.14,&2.56,&




Figure$ 6.7$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&discontinuations&due&to&adverse&events.*$
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
In&the&base1case&network&meta1analysis,&96&trials&provided&information&for&the&discontinuations&due&to&adverse&events&analyses.&In&total,&128,842&participants&contributed&information&on&7,626&events& (6%& of& all& participants).& Across& all& populations,& there& were& no& significant& differences&among& statins& in& terms& of& discontinuations& due& to& adverse& events& when& all& trials& of& primary&prevention,&secondary&prevention,&and&mixed&patient&populations&were&pooled&(Table&6.1).&&
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Table$6.1$ –& Comparative& tolerability& of& individual& statins& in& terms& of& discontinuations& due& to&adverse&events&across&all&populations.*&&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 0.95&(0.63,&1.45)& 1.24&(0.84,&1.87)& 1.46&(1.11,&1.92)& 1.01&(0.82,&1.25)& 1.32&(1.05,&1.68)&
Fluvastatin$vs.$ 1& 1.30&(0.81,&2.10)& 1.53&(0.98,&2.34)& 1.06&(0.68,&1.63)& 1.39&(0.88,&2.14)&
Lovastatin$vs.$ 1& 1& 1.17&(0.77,&1.78)& 0.81&(0.53,&1.25)& 1.06&(0.69,&1.63)&
Pravastatin$vs.$ 1& 1& 1& 0.69&(0.51,&0.94)& 0.91&(0.67,&1.24)&
Rosuvastatin$
vs.$
1& 1& 1& 1& 1.31&(1.00,&1.73)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&




Table$ 6.2$ –& Comparative& tolerability& of& individual& statins& in& terms& of& discontinuations& due& to&adverse&events&in&the&secondary&prevention&population.*&&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 2.06&(0.75,&5.57)& 3.26&&(0.71,&15.92)& 1.12&&(0.46,&2.38)& 1.06&&(0.58,&1.98)& 1.68&&(0.84,&3.41)&
Fluvastatin$vs.$ 1& 1.59&&(0.32,&8.51)& 0.54&&(0.17,&1.59)& 0.52&&(0.16,&1.69)& 0.82&&(0.28,&2.40)&
Lovastatin$vs.$ 1& 1& 0.34&&(0.06,&1.69)& 0.33&&(0.06,&1.72)& 0.52&&(0.1,&2.42)&
Pravastatin$vs.$ 1& 1& 1& 0.95&&(0.36,&2.85)& 1.50&&(0.6,&4.39)&
Rosuvastatin$vs.$ 1& 1& 1& 1& 1.58&&(0.62,&4.01)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
Consistent&with&the&findings&in&the&secondary&prevention&population,&individual&statins&appeared&statistically&equivalent&to&each&other&in&terms&of&their&effects&on&treatment&discontinuations&due&to& adverse& events& among& trial& participants& with& no& prior& history& of& coronary& heart& disease&(Table&6.3).&&
Table$6.3$ –& Comparative& tolerability& of& individual& statins& in& terms& of& discontinuations& due& to&adverse&events&in&the&primary&prevention&population.*&&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.28&&(0.54,&3.23)& 1.34&&(0.71,&2.43)& 1.02&&(0.60,&1.71)& 1.05&&(0.44,&2.65)& 1.1&&(0.41,&3.04)&
Fluvastatin$vs.$ 1& 1.05&&(0.42,&2.32)& 0.79&&(0.29,&2.01)& 0.82&&(0.25,&2.68)& 0.86&&(0.23,&3.07)&
Lovastatin$vs.$ 1& 1& 0.76&&(0.38,&1.57)& 0.78&&(0.32,&2.15)& 0.82&&(0.28,&2.59)&
Pravastatin$vs.$ 1& 1& 1& 1.04&&(0.43,&2.71)& 1.09&&(0.40,&3.04)&
Rosuvastatin$vs.$ 1& 1& 1& 1& 1.05&&(0.35,&3.07)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
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In&the&dose1specific&analysis& that& included&all&placebo1controlled,&active1comparator,&and&dose1comparison& trials,& a& total& of& 8,523& discontinuations& due& to& adverse& events& among& 148,566&participants& in&111& trials&were& included.&Atorvastatin& at&>20&and&≤40&mg/day& (OR:&2.50,& 95%&CrI:& 1.48,& 4.32)& and& at& >40&mg/day& (OR:& 1.66,& 95%& CrI:& 1.17,& 2.38)& led& to& significantly& more&discontinuations&as&compared&to&control.&Similarly,&individuals&receiving&fluvastatin&at&>20&and&≤40&mg/day&were&more& likely& to& discontinue& treatment& as& compared& to& control& as& a& result& of&experiencing& adverse& events& (OR:& 2.26,& 95%& CrI:& 1.07,& 4.90).& Conversely,& lovastatin& at& ≤10&mg/day&led&to&fewer&discontinuations&due&to&adverse&events&as&compared&to&control&treatment&(OR:&0.24,&95%&CrI:&0.07,&0.77).&Although&atorvastatin&and&simvastatin&appeared&to&have&a&dose1response&relationship,&surprisingly,&there&was&not&a&strong&dose1response&relationship&for&most&statin1dose& combinations& (higher& doses& did& not& necessarily& result& in& higher& discontinuation&rates)&(Figure&6.8).&&
Figure$6.8$–&Dose1specific&analysis&findings:&Comparative&effects&of&individual&statins&compared&to&control&for&discontinuations&due&to&adverse&events&across&all&populations.*&&
&*&Estimates&shown&are&ORs&and&95%&CrIs.&There&were&no&trials&of&fluvastatin&at&>20&and&≤40&mg/day&among&individuals&with&and&without&prior&coronary&heart&disease&(overall&population).&&
6.3.3%% Investigation%of%Heterogeneity%and%Inconsistency%in%the%Network%Meta<analysis%Meta1regression& analyses& evaluating& the& impact& of& mean& age& at& baseline,& mean& LDL1C&concentration& at& baseline,& and& publication& year& could& not& explain& the& potential& heterogeneity&and&inconsistency& in&the&base1case&network&meta1analysis.&Table&6.4&shows&the&between1study&standard& deviations& and& covariate& coefficients& with& base1case& model& as& compared& to& meta1regressions.&Figure&6.9&shows&the&sensitivity&of&relative&treatment&effects&of&statins&vs.&control&to&
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different& meta1regression& analyses.& According& to& this& figure,& the& comparative& effects& of&individual&statins&on&discontinuations&due&to&adverse&events&were&not&sensitive&to&mean&age&at&baseline,&mean&LDL&cholesterol&concentrations,&and&publication&year.&Neither&the&magnitude&of&the& relative& treatment& effects& nor& their& uncertainty& changed& materially& in& various& meta1regression& analyses.& There& was& no& statistically& detectable& inconsistency& between& direct& and&indirect&evidence&(see&Appendix).&&











Figure$ 6.9$ –& Sensitivity& of& the& base1case& findings& to& meta1regression& analyses& for&discontinuations&due&to&adverse&events.*& &&
&*& Estimates& shown& are& ORs& and& 95%& CrIs.& Base1case& results& are& shown& in& red,& while& the& analysis&adjusted&for&mean&age&of&patients&at&baseline&is&shown&in&green,&the&analysis&adjusting&for&the&mean&LDL&concentration&at&baseline&in&shown&in&yellow,&and&the&analysis&adjusting&for&publication&year&is&shown&in&blue.&&
6.4&Outcome$2:$Myalgia$
6.4.1%% Harms%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%Across& all& populations,& 43,531& participants& contributed& information& on& 952& myalgia& events.&There& were& three& trials& of& atorvastatin& with& 9,979& individuals& experiencing& 458& events;& two&trials& of& fluvastatin&with&14& events& among&2,063& individuals;& two& trials& of& lovastatin&with&177&events& among& 8.492& individuals;& six& trials& of& pravastatin& with& 123& events& among& 16,428&individuals;&two&trials&of&rosuvastatin&with&167&events&among&5,558&individuals;&and&two&trials&of&simvastatin&including&1,011&individuals&experiencing&13&myalgia&events.&&Overall,&as&shown&in&Figure&6.10,&statin&therapy&as&a&class&was&not&associated&with&an&increase&in&the&risk&of&myalgia&occurence&(OR:&1.07,&95%&CI:&0.89,&1.29,&I2:&22.1%)&(see&the&Appendix&for&trial1level&results).&According&to&pair1wise&meta1analyses,&atorvastatin&(OR:&1.05,&95%&CI:&0.72,&1.54,&












Figure$ 6.11$ –& Effect& of& statins& compared& to& control& on&myalgia& occurrence& in& the& secondary&prevention&population.*&
&*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&rosuvastatin&among&individuals&with&established&coronary&heart&disease.&&
Among& individuals& with& no& prior& coronary& heart& disease,& 13,262& participants& contributed&information& on& 358& myalgia& events.& There& were& two& trials& of& atorvastatin& with& 188& events&among&5,248& individuals;& three& trials&of&pravastatin&with&47&events&among&7,030&participants;&and&one&trial&of&rosuvastatin&with&123&events&among&984&trial&participants.&There&were&no&trials&of&fluvastatin,&lovastatin,&and&simvastatin&in&this&population.&&As&shown&in&Figure&6.12,&statin&therapy&was&not&associated&with&a&significant&increase&in&the&risk&of& incident&myalgia&events& in&the&primary&prevention&population&(OR:&1.08,&95%&CI:&0.81,&1.44,&









Figure$ 6.12$ –& Effect& of& statins& compared& to& control& on& myalgia& occurrence& in& the& primary&prevention&population.*&
&*& Estimates& shown& are& ORs& and& 95%& CIs.& There& were& no& trials& of& fluvastatin,& lovastatin,& and&simvastatin&among&individuals&with&no&established&coronary&heart&disease&at&baseline.&&
6.4.2%% Comparative%Harms%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The&network&of&eligible&comparisons&for&this&analysis&is&shown&in&Figure&6.13.&In&addition&to&the&placebo1controlled&trials&included&in&the&pair1wise&meta1analyses,&there&were&45&direct&head1to1head&comparisons&between&statins&including&1,295&events&among&52,046&individuals&that&were&not& included& in&previous&comparisons& in& the& literature.&Atorvastatin&was&directly& compared& to&fluvastatin& in& one& trial& including& 2,379& individuals& (OR:& 0.88,& 95%&CI:& 0.47,& 1.65,& I2=0.0%);& to&lovastatin& in&two&trials& including&3,027&individuals&(OR:&0.86,&95%&CI:&0.46,&1.51,&I2=11.7%);&to&pravastatin&in&five&trials& including&8,122&individuals&(OR:&1.12,&95%&CI:&0.84,&1.49,&I2=0.0%);&to&rosuvastatin& in& 21& trials& including& 13,354& individuals& (OR:& 0.88,& 95%&CI:& 0.72,& 1.61,& I2=1.4%);&and& to& simvastatin& in& eight& trials& including& 16,479& individuals& (OR:& 1.29,& 95%& CI:& 0.74,& 2.22,&





Figure$ 6.13$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&myalgia&occurrence.*&&
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
In& the& base1case& network&meta1analysis,& 53& trials& provided& information& on&myalgia& events.& In&total,&82,769&individuals&were&included&in&the&base1case&analysis,&which&provided&information&on&1,884&events.&In&the&base1case&analysis,&there&were&no&significant&differences&between&statins&in&terms&of&their&effect&on&incident&myalgia&events&when&all&trials&of&primary&prevention,&secondary&prevention,& and& mixed& patient& populations& were& pooled& (overall& population)& (Table& 6.5).&Although& the&direction&and&magnitude&of& the&difference&between& rosuvastatin&and&simvastatin&observed&in&the&base1case&network&meta1analysis&was&consistent&with&the&finding&from&the&pair1wise&meta1analysis,& there&was& greater& variability& around& this& estimate&when& all& eligible& direct&and& indirect& trials& were& combined;& there& was& no& statistically& detectable& difference& between&these& two&agents& (OR&of& rosuvastatin&vs.& simvastatin:&1.46,&95%&CrI:&0.98,&2.14).&Although&not&statistically& significant,& simvastatin& appeared& to& result& in&numerically& fewer&myalgia& events& as&compared&to&other&statins.&&
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Table$ 6.5$ –& Comparative& tolerability& of& individual& statins& on& myalgia& events& across& all&populations.*$
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.08&&(0.56,&2.17)& 0.87&&(0.54,1.46)& 1.10&(0.77,&1.53)& 0.88&&(0.71,&1.08)& 1.28&&(0.88,&1.80)&
Fluvastatin$vs.$ 1& 0.81&&(0.37,&1.71)& 1.02&&(0.48,&2.02)& 0.82&&(0.40,&1.58)& 1.19&&(0.56,&2.37)&
Lovastatin$vs.$ 1& 1& 1.26&&(0.70,&2.15)& 1.00&&(0.58,&1.68)& 1.46&&(0.80,&2.54)&
Pravastatin$vs.$ 1& 1& 1& 0.80&&(0.55,&1.19)& 1.17&&(0.74,&1.82)&
Rosuvastatin$vs.$ 1& 1& 1& 1& 1.46&&(0.98,&2.14)&*&Estimates&shown&are&0Rs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
There& were& no& statistically& detectable& differences& among& individual& statins& in& terms& of&increasing& the& risk& of& incident& myalgia& events& in& the& secondary& prevention& of& cardiovascular&disease& (Table& 6.6).& There&was& considerable& uncertainty& around& the& comparative& estimates& of&lovastatin&due&to&the&very&few&number&of&data&points&available&for&this&statin.&&
Table$ 6.6$ –$ Comparative& effects& of& individual& statins& on& myalgia& events& in& the& secondary&prevention&population.*&$
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 0.40&&(0.06,&3.13)& 0.16&&(0.00,&5.37)*& 0.72&&(0.23,&1.98)& 0.94&&(0.56,&1.54)& 1.62&&(0.82,&2.95)&
Fluvastatin$vs.$ 1& 0.39&&(0.00,&18.45)*& 1.80&&(0.17,&14.78)& 2.36&&(0.28,&17.49)& 4.04&&(0.47,&30.42)&
Lovastatin$vs.$ 1& 1& 4.38&&(0.11,&1346.8)*& 5.88&&(0.17,&1737.32)*& 9.88&&(0.29,&2902.76)*&
Pravastatin$vs.$ 1& 1& 1& 1.30&&(0.43,&4.55)& 2.23&&(0.69,&8.21)&
Rosuvastatin$vs.$ 1& 1& 1& 1& 1.73&&(0.73,&3.74)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&too&few&data&points&to&obtain&reliable&estimates&for&the&comparative&effects&of&lovastatin.&&
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There&were&also&no&statistically&detectable&differences&among& individual&statins& in& the&primary&prevention&population&(Table&6.7).&Data&were&particularly&sparse&for&this&analysis&with&no&trials&of&fluvastatin,&lovastatin,&and&simvastatin&among&individuals&without&coronary&heart&disease.&&








Figure$ 6.14$ –& Dose1specific& analysis& findings:& comparative& effects& of& individual& statins&compared&to&control&for&myalgia&occurrence&across&all&populations.*&
&*& Estimates& shown& are& ORs& and& 95%& CrIs.& There& was& no& available& data& for& the& lowest& doses& of&fluvastatin,&lovastatin,&and&pravastatin.&Similarly,&no&data&was&available&for&pravastatin&at&higher&than&40&mg/day.&&




















6.5.1%% Harms%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%Across& all& populations,& 122,665& participants& contributed& information& on& 1,619& transaminase&elevations.& There& were& six& trials& with& 190& events& among& 14,973& individuals;& three& trials& of&fluvastatin&with& 31& events& among& 3,225& individuals;& four& trials& of& lovastatin&with& 286& events&among&15,501&individuals;&10&trials&of&pravastatin&with&737&events&among&33,232&participants;&five& trials& of& rosuvastatin& with& 158& events& among& 28,640& individuals;& and& six& trials& of&simvastatin&with&217&events&among&27,094&participants.&&Overall,& as& shown& in&Figure&6.16,& statin& therapy&was&associated&with&an& increase& in& the&risk&of&transaminase&elevations&(OR:&1.51,&95%&CI:&1.24,&1.84,&I2=52.3%)&when&compared&to&control&(see&the& Appendix& for& trial1level& results).& Atorvastatin& (OR:& 2.50,& 95%& CI:& 1.25,& 5.02,& I2=69.5%);&fluvastatin& (OR:& 4.21,& 95%& CI:& 1.72,& 10.32,& I2=0.0%);& lovastatin& (OR:& 1.88,& 95%& CI:& 1.34,& 2.63,&





Among& individuals& with& established& coronary& heart& disease,& 27,336& individuals& contributed&information& on& 639& transaminase& elevations.& There& were& two& trials& of& atorvastatin& with& 69&events& among& 6,331& individuals;& two& trials& of& fluvastatin& with& 19& events& among& 1,996&individuals;& two& trials& of& lovastatin& with& nine& events& among& 651& individuals;& three& trials& of&pravastatin&with&292&events&among&13,293&participants;&and&two&trials&of&simvastatin&with&130&events&among&5,065&individuals.&There&were&no&trials&of&rosuvastatin&in&this&population.&&In& the& secondary& prevention& population,& statin& therapy& was& associated& with& a& significant&increase&in&the&risk&of&transaminase&elevations&(OR:&1.60,&95%&CI:&1.02,&2.51,&I2=69.0%).&Among&individual&statins,&atorvastatin&(OR:&5.00,&95%&CI:&2.66,&9.46,&I2=0.0%)&and&fluvastatin&(OR:&3.77,&95%& CI:& 1.24,& 11.43,& I2=0.0%)&were& significantly& associated&with& an& increase& in& transaminase&elevations& whereas& lovastatin& (OR:& 1.98,& 95%& CI:& 0.48,& 8.15,& I2=0.0%);& pravastatin& (OR:& 1.01,&95%&CI:&0.81,&1.26,&I2=0.0%);&and&simvastatin&(OR:&0.51,&95%&CI:&0.06,&4.64,&I2=76.0%)&were&not&(Figure&6.17).&&
Figure$6.17$–&Effect&of&statins&compared&to&control&on&transaminase&elevations&in&the&secondary&prevention&population.*&
&*&Estimates&shown&are&ORs&and&95%&CrIs.&&
Among& individuals& with& no& prior& coronary& heart& disease,& 45,838& individuals& contributed&information& on& 554& transaminase& elevations.& There& were& two& trials& of& atorvastatin& with& 62&events&among&5,248&participants;&one&trial&of&lovastatin&with&29&events&among&6,605&individuals;&and&four&trials&of&pravastatin&with&394&events&among&15,199&participants.&There&were&no&trials&of&fluvastatin&and&simvastatin&in&this&population.&&
193 
 
In& the& primary& prevention& population,& as& shown& in& Figure& 6.18,& statin& therapy& was& not&associated&with&a& significant& increase& in& the& risk&of& transaminase&elevation& (OR:&1.12,&95%&CI:&0.95,&1.33,&I2=0.0%)&as&compared&to&control&treatment.&Among&statins,&individuals&randomized&to&atorvastatin& (OR:& 1.24,& 95%&CI:& 0.78,& 1.98,& I2=0.0%);& lovastatin& (OR:& 1.64,& 95%&CI:& 0.77,& 3.49,&
I2=0.0%);&and&pravastatin&(OR:&1.03,&95%&CI:&0.84,&1.26,&I2=0.0%)&did&not&have&an&increase&in&the&odds&of&experiencing&transaminase&elevations&as&compared&to&those&randomized&to&control.&&
Figure$6.18$–&Effect&of&statins&compared&to&control&treatment&on&transaminase&elevations&in&the&primary&prevention&population.*&
&*& Estimates& shown& are& ORs& and& 95%& CIs.& There& were& no& trials& of& fluvastatin,& rosuvastatin,& and&simvastatin&among&individuals&with&no&established&coronary&heart&disease.&&
6.5.2%% Comparative%Harms%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The&network&of&eligible&comparisons&for&this&analysis&is&shown&in&Figure&6.19.&In&addition&to&the&placebo1controlled& trials& included& in& the& traditional& pair1wise& meta1analyses,& there& were& 46&direct& head1to1head& comparisons& between& statins& including& 44,755& individuals& that& were& not&included& in& previous& analyses& available& in& the& literature.& Atorvastatin& was& compared& to&fluvastatin& in& one& trial& including& 154& individuals& (OR:& 0.19,& 95%& CI:& 0.01,& 4.02,& I2=0.0%);& to&lovastatin&in&one&trial&including&749&individuals,&which&suggested&that&individuals&randomized&to&atorvastatin& experienced& significantly& fewer& transaminase& elevations& as& compared& to& those&receiving&lovastatin;&however&this&finding&was&based&only&on&four&events&(OR:&0.07,&95%&CI:&0.00,&0.71,& I2=0.0%);& to& pravastatin& in& four& trials& including& 6,321& participants,&which& demonstrated&that&atorvastatin&resulted&in&significantly&higher&odds&of&transaminase&elevations&as&compared&to&pravastatin& (OR:& 3.70,& 95%& CI:& 1.35,& 10.00,& I2=61.3%);& to& rosuvastatin& in& 17& trials& including&
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11,283& individuals& (OR:& 1.35,& 95%& CI:& 0.75,& 2.44,& I2=37.0%);& and& to& simvastatin& in& 12& trials&including&20,825& individuals&(OR:&1.64,&95%&CI:&0.76,&3.44,& I2=52.9%).&Fluvastatin&was&directly&compared& to& lovastatin& in& one& trial& including& 154& trial& participants& (OR:& 5.27,& 95%& CI:& 0.25,&111.56,& I2=0.0%),& and& to& simvastatin& in&one& trial& including&152& individuals& (OR:&5.13,& 95%&CI:&0.24,& 108.75,& I2=0.0%).& Lovastatin&was&directly& compared& to& pravastatin& in& one& trial& including&672&individuals&(OR:&0.33,&95%&CI:&0.03,&3.12,&I2=0.0%),&and&to&simvastatin&in&one&trial&(the&direct&comparison&between& lovastatin&and&simvastatin& included&zero&events& therefore& the&number&of&trial& participants& were& not& counted& towards& the& total).& Pravastatin& was& directly& compared& to&rosuvastatin&in&one&trial&including&366&individuals&(OR:&0.18,&95%&CI:&0.01,&3.45,&I2=0.0%),&and&to&simvastatin& in& one& trial& including& 265& individuals& (OR:& 0.19,& 95%& CI:& 0.01,& 3.93,& I2=0.0%).&Rosuvastatin& was& directly& compared& to& simvastatin& in& four& trials& including& 3,904& individuals&(OR:&1.05,&95%&CI:&0.35,&3.13,&I2=0.0%).&&
Figure$ 6.19$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&transaminase&elevations.*&
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
In& the& base1case& network&meta1analysis,& 70& trials& provided& information& on& the& occurrence& of&transaminase&elevations.&In&total,&there&were&2,051&elevations&among&163,248&trial&participants.&When& all& eligible& trials& were& pooled& (overall& population),& there& were& statistically& detectable&
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differences& between& individual& statins& (Table& 6.9).& Individuals& randomized& to& receive&atorvastatin& were& more& likely& to& experience& transaminase& elevations& as& compared& to& those&randomized&to&receive&pravastatin&(OR:&2.55,&95%&CrI:&1.54,&4.14);&rosuvastatin&(OR:&1.60,&95%&CrI:& 1.06,& 2.38);& and& simvastatin& (OR:& 2.20,& 95%& CrI:& 1.36,& 3.52).& Fluvastatin& appeared& to&significantly&increase&the&odds&of&transaminase&elevations&as&compared&to&pravastatin&(OR:&5.19,&95%&CrI:&1.75,&16.73);&rosuvastatin&(OR:&3.25,&95%&CrI:&1.08,&10.50);&and&simvastatin&(OR:&4.50,&95%&CrI:&1.49,&14.19).&Although&not& statistically& significant,& fluvastatin& resulted& in&numerically&more&transaminase&elevations&than&&atorvastatin&(OR:&2.04,&95%&CrI:&0.70,&6.66)&(the&reciprocal&is&provided&in&Table&6.9).&&
Table$ 6.9$ –& Comparative& effects& of& individual& statins& on& transaminase& elevations& across& all&populations.*&&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$
vs.$
0.49&&(0.15,&1.42)& 1.26&&(0.57,&2.73)& 2.55&&(1.54,&4.14)& 1.60&&(1.06,&2.38)& 2.20&&(1.36,&3.52)&
Fluvastatin$
vs.$
1& 2.58&&(0.76,&9.03)& 5.19&&(1.75,&16.73)& 3.25&&(1.08,&10.50)& 4.50&&(1.49,&14.19)&
Lovastatin$
vs.$
1& 1& 2.03&&(0.90,&4.56)& 1.27&&(0.55,&2.93)& 1.76&&(0.75,&4.12)&
Pravastatin$
vs.$
1& 1& 1& 0.63&&(0.36,&1.10)& 0.87&&(0.47,&1.57)&
Rosuvastatin$
vs.$
1& 1& 1& 1& 1.38&&(0.79,&2.38)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&




Table$ 6.10$ –& Comparative& effects& of& individual& statins& on& transaminase& elevations& in& the&secondary&prevention&population.*&&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$
vs.$
0.60&&(0.10,&2.99)& 1.94&&(0.28,&12.95)& 3.97&&(1.25,&12.55)& 2.19&&(0.67,&7.16)& 4.04&&(1.37,&11.73)&
Fluvastatin$
vs.$
1& 3.21&&(0.42,&28.98)& 6.55&&(1.21,&42.32)& 3.63&&(0.49,&31.82)& 6.67&&(1.21,&43.33)&
Lovastatin$
vs.$
1& 1& 2.02&&(0.29,&14.71)& 1.12&&(0.12,&11.27)& 2.09&&(0.29,&15.35)&
Pravastatin$
vs.$
1& 1& 1& 0.55&&(0.10,&2.91)& 1.02&&(0.25,&4.12)&
Rosuvastatin$
vs.$
1& 1& 1& 1& 1.83&&(0.37,&9.05)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
As& shown& in& Table& 6.11,& there& were& no& statistically& detectable& differences& among& individual&statins.&Although&atorvastatin&appeared& to&result& in&numerically&more& transaminase&elevations&than&lovastatin&(OR:&1.12,&95%&CrI:&0.29,&5.86),&pravastatin&(OR:&1.92,&95%&CrI:&0.97,&6.84),&and&rosuvastatin& (OR:&1.27,&95%&CrI:&0.62,&3.14),& these& findings&were&associated&with&considerable&uncertainty&due&to&the&very&small&number&of&events&included&in&this&analysis.&&
Table$ 6.11$ –& Comparative& effects& of& individual& statins& on& transaminase& elevations& in& the&primary&prevention&population.*&
$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 1.12&&(0.29,&5.86)& 1.92&&(0.97,&6.84)& 1.27&&(0.62,&3.14)&
Lovastatin$vs.$ 1& 1.72&&(0.47,&8.86)& 1.13&&(0.24,&4.98)&
Pravastatin$vs.$ 1& 1& 0.66&&(0.20,&1.47)&*&Estimates&shown&are&0Rs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of&fluvastatin&and&simvastatin&among&individuals&without&established&coronary&heart&disease.&&
In& the& dose1specific& analysis& for& clinically& meaningful& elevations& in& hepatic& transaminases&included&all&placebo1controlled,&active1comparator,&and&dose1comparison&trials,&there&was&a&total&of&2,287&transaminase&elevations&among&185,600&participants&in&84&trials.&A&number&of&statins&at&
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high& doses& were& associated& with& significantly& higher& odds& of& transaminase& elevations& as&compared& to& control& treatment& (Figure& 6.20):& atorvastatin& at& >20& and& ≤40&mg/day& (OR:& 2.42,&95%& CrI:& 1.10,& 5.50)& and& at& >40& mg/day& (OR:& 5.25,& 95%& CrI:& 3.89,& 7.24);& fluvastatin& at& >40&mg/day& (OR:& 4.16;& 95%&CrI:& 1.60,& 14.36);& lovastatin& at& >40&mg/day& (OR:& 1.80,& 95%&CrI:& 1.06,&2.97);&and&simvastatin&at&>40&mg/day&(OR:&2.83,&95%&CrI:&1.47,&5.87).&Surprisingly,&simvastatin&at&≤10&mg/day&resulted&in& lower&odds&of&transaminase&elevations&as&compared&to&control&(OR:&0.41,& 95%& CrI:& 0.18,& 0.85).& There& was& a& general& dose1response& relationship,& which& was&particularly&clear&with&atorvastatin,&rosuvastatin,&and&simvastatin,&with&higher&doses&resulting&in&higher&odds&of&transaminase&elevations.&
Figure$ 6.20$ –& Dose1specific& analysis& findings:& comparative& effects& of& individual& statins&compared&to&control&for&transaminase&elevations&across&all&populations.*&
&*&Estimates&shown&are&ORs&and&95%&CrIs.&There&were&no& trials&of& fluvastatin&at& low&and&moderate&doses;&lovastatin&at&low&doses;&and&pravastatin&at&high&doses.&&




















6.6.1%% Harms%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%In& the& traditional& pair1wise&meta1analysis& of& statin& therapy& vs.& control& across& all& populations,&101,324& participants& contributed& information& on& 463& creatine& kinase& elevations& (see& the&
Appendix& for& trial1level& results).& There& were& two& trials& of& atorvastatin& with& 14& events& among&7,569& individuals;& four& trials& of& fluvastatin& with& eight& events& among& 2,646& individuals;& three&trials&of&lovastatin&with&72&events&among&15,254&individuals;&seven&trials&of&pravastatin&with&281&events& among& 20,690& individuals;& five& trials& of& rosuvastatin& with& 58& events& among& 28,640&individuals;&and&five&trials&of&simvastatin&with&30&events&among&26,525&trial&participants.&&Overall,&as&shown&in&Figure&6.22,&statin&therapy&was&not&associated&with&an&increase&in&the&risk&of&creatine&kinase&elevations& (OR:&1.13,&95%&CI:&0.85,&1.51,& I2=20.4%)&when&compared& to&control&(Figure&6.22)&(see&the&Appendix&for&trial1level&results).&None&of&the&individual&statins&resulted&in&significantly& higher& odds& of& creatine& kinase& elevations:& atorvastatin& (OR:& 0.75,& 95%& CI:& 0.03,&17.61,&I2=71.6%);&fluvastatin&(OR:&0.31,&95%&CI:&0.07,&1.33,&I2=0.0%);&lovastatin&(OR:&0.75,&95%&CI:&0.55,&1.63,& I2=9.2%);&pravastatin& (OR:&1.22,&95%&CI:&0.96,&1.55,& I2=0.0%);& rosuvastatin& (OR:&1.62,& 95%&CI:& 078,& 3.39,& I2=14.6%);& and& simvastatin& (OR:& 0.74,& 95%&CI:& 0.17,& 3.28,& I2=57.7%).&According&to&contour1enhanced& funnel&plots,& there&was&no&evidence&of&small&study&effects&(see&
Appendix).&




Among&individuals&with&established&coronary&heart&disease&(secondary&prevention&population),&15,895& trial& participants& contributed& information& on& 35& clinically& meaningful& creatine& kinase&elevations.&There&was&one&trial&of&atorvastatin&with&two&events&among&4,731&participants;&three&trials& of& fluvastatin& with& seven& events& among& 2,361;& one& trial& of& pravastatin& with& 19& events&among& 4,159& participants;& and& one& trial& of& simvastatin& with& seven& events& among& 4,444&participants.&Lovastatin&and&rosuvastatin&did&not&have&any&trials&in&this&population.&&In& the& secondary& prevention& population,& statin& therapy& was& not& associated& with& a& significant&increase&in&the&risk&of&creatine&kinase&elevations&(OR:&1.36,&95%&CI:&0.51,&3.61,&I2=22.4%)&(Figure&6.23).& None& of& the& individual& statins& resulted& in& significantly& higher& odds& of& creatine& kinase&elevations:&atorvastatin&(OR:&5.01,&95%&CI:&0.24,&104.53,&I2=0.0%);&fluvastatin&(OR:&0.31,&95%&CI:&0.06,&1.56,& I2=0.0%);&pravastatin& (OR:&1.72,&95%&CI:&0.67,&4.37,& I2=0.0%);&and&simvastatin& (OR:&6.02,&95%&CI:&0.72,&50.04,&I2=0.0%).&In&general,&these&results&were&associated&with&considerable&uncertainty&due&to&the&scarcity&of&events&and&the&small&number&of&trials&eligible&for&inclusion&in&this&analysis.&&
Figure$ 6.23$ –& Effect& of& statins& compared& to& control& on& creatine& kinase& elevations& in& the&secondary&prevention&population.*&
&*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&rosuvastatin&among&individuals&with&established&coronary&heart&disease&at&baseline.&&
Among& individuals& with& no& prior& coronary& heart& disease& (primary& prevention& population),&43,713& trial& participants& contributed& information&on&339& clinically&meaningful& creatine&kinase&elevations.&There&was&one&trial&of&atorvastatin&with&12&events&among&2,838&individuals;&one&trial&of& fluvastatin& with& one& event& among& 285& individuals;& one& trial& of& lovastatin& with& 42& events&among&6,605& individuals;& four& trials&of&pravastatin&with&238&events&among&15,199& individuals;&
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and&two&trials&of&rosuvastatin&with&46&events&among&18,786&participants.&There&were&no&trials&of&simvastatin&in&this&population.&&Consistent& with& the& findings& obtained& in& the& overall& and& secondary& prevention& populations,&statin& therapy& was& not& associated& with& a& significant& increase& in& the& risk& of& creatine& kinase&elevations& (OR:& 1.11,& 95%&CI:& 0.78,& 1.59,& I2=26.8%)& as& compared& to& control& treatment& (Figure&6.24).&Similarly,&fluvastatin&(OR:&0.33,&95%&CI:&0.01,&8.25,&I2=0.0%);&lovastatin&(OR:&1.00,&95%&CI:&0.54,&1.83,&I2=0.0%);&pravastatin&(OR:&1.15,&95%&CI:&0.89,&1.49,&I2=0.0%);&and&rosuvastatin&(OR:&1.93,& 95%&CI:& 0.96,& 3.87,& I2=0.0%)& did& not& result& in& higher& odds& of& creatine& kinase& elevations.&Surprisingly&atorvastatin&was&associated&with&a&significant&decrease&in&the&risk&of&creatine&kinase&elevations&in&this&population&(OR:&0.20,&95%&CI:&0.04,&0.90,&I2=0.0%).&&
Figure$6.24$–&Effect&of&statins&compared&to&control&on&creatine&kinase&elevations&in&the&primary&prevention&population.*&
&*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&simvastatin&among&individuals&with&no&established&coronary&heart&disease&at&baseline.&&
6.6.2%% Comparative%Harms%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The&network&of&eligible&comparisons&is&shown&in&Figure&6.25.&In&addition&to&the&trials&included&in&the& pair1wise& comparisons& of& statin& therapy& vs.& control,& there& were& 30& direct& head1to1head&comparisons&among&individual&statins,&providing&information&on&229&events&among&31,090&trial&participants.&Atorvastatin&was&directly&compared&to&pravastatin&in&three&trials&with&127&events&among&7,028&individuals&(OR:&1.19,&95%&CI:&0.84,&1.69,&I2=0.0%);&to&rosuvastatin&in&16&trials&with&56&events&among&12,030&individuals&(OR:&1.25,&95%&CI:&0.72,&2.17,&I2=0.0%);&and&to&simvastatin&in& five& trials&with& 37& events& among&6,555& individuals& (OR:& 0.77,& 95%&CI:& 0.48,& 1.92,& I2=0.0%).&Pravastatin& was& directly& compared& to& rosuvastatin& in& one& trial& with& one& event& among& 1,059&
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individuals& (OR:& 0.34,& 95%& CI:& 0.01,& 8.45,& I2=0.0%);& and& to& simvastatin& in& one& trial& with& two&events&among&550&individuals&(OR:&0.19,&95%&CI:&0.00,&4.16,&I2=0.0%).&Finally,&rosuvastatin&was&directly& compared& to& simvastatin& in& four& trials&with& six& events& among& 3,868& trial& participants&(OR:&2.44,&95%&CI:&0.53,&11.11,&I2=0.0%).&&
Figure$ 6.25$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&creatine&kinase&elevations.*&
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
In& the&base1case&network&meta1analysis,&49&trials&provided& information& for& the&creatine&kinase&analysis.& In& total,&124,935& individuals&were& included& in& the&base1case&analysis,&which&provided&information& on& 708& individuals& with& clinically& meaningful& creatine& kinase& elevations.& In& the&base1case&analysis&that&pooled&all&trials&of&primary&prevention,&secondary&prevention,&and&mixed&patient&populations,&individuals&randomized&to&fluvastatin&appeared&to&have&significantly&lower&odds& of& experiencing& creatine& kinase& elevations& as& compared& to& those& randomized& to&atorvastatin& (OR:&0.17,&95%&CrI:&0.04,&0.82)& (the&reciprocal&of& this& finding& is& reported& in&Table&6.13);&pravastatin&(OR:&0.20,&95%&CrI:&0.04,&0.88);&rosuvastatin&(OR:&0.18,&95%&CrI:&0.04,&0.81);&and&simvastatin&(OR:&0.20,&95%&CrI:&0.04,&0.94).&Although&fluvastatin&appeared&to&result&in&fewer&individuals& experiencing& creating& kinase& elevations& than& lovastatin,& this& finding& was& not&
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statistically& significant& (OR:& 0.24,& 95%& CrI:& 0.05,& 1.17).& There& were& no& other& statistically&detectable&differences&among&statins&(Table&6.13).&&
Table$6.13$–&Comparative&effects&of& individual& statins&on&creatine&kinase&elevations&across&all&populations.*&
$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$
vs.$
5.59&&(1.22,&25.52)& 1.32&&(0.54,&2.88)& 1.13&&(0.65,&1.78)& 0.99&&(0.64,&1.53)& 1.13&&(0.65,&1.97)&
Fluvastatin$
vs.$
1& 0.24&&(0.05,&1.17)& 0.20&&(0.04,&0.88)& 0.18&&(0.04,&0.81)& 0.20&&(0.04,&0.94)&
Lovastatin$
vs.$
1& 1& 0.84&&(0.39,&1.94)& 0.76&&(0.34,&1.85)& 0.86&&(0.37,&2.23)&
Pravastatin$
vs.$
1& 1& 1& 0.89&&(0.51,&1.63)& 1.01&&(0.55,&2.00)&
Rosuvastatin$
vs.$
1& 1& 1& 1& 1.14&&(0.62,&2.19)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
There&were&too&few&events&for&a&reliable&analysis&in&the&secondary&prevention&population.&Small&number& of& events& was& also& a& complication& for& the& network& meta1analysis& in& the& primary&prevention& population,& with& a& number& of& analyses& failing& to& converge& due& to& the& very& small&number& of& data& points& available& for& analysis.& This& was& particularly& the& case& for& comparisons&involving&fluvastatin&and&simvastatin.&There&were&no&statistically&detectable&differences&among&individual&statins& in& terms&of& the&odds&of&creating&kinase&elevations& in& the&primary&prevention&population&(Table&6.14).&&
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Table$ 6.14$ –& Comparative& effects& of& individual& statins& on& creatine& kinase& elevations& in& the&primary&prevention&population.*&
$ Lovastatin$ Pravastatin$ Rosuvastatin$
Atorvastatin$vs.$ 0.75&&(0.03,&18.56)& 0.60&&(0.05,&5.79)& 0.55&&(0.11,&2.64)&
Lovastatin$vs.$ 1& 0.82&&(0.04,&14.81)& 0.74&&(0.03,&17.57)&
Pravastatin$vs.$ 1& 1& 0.90&&(0.11,&9.07)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&There&were&no&trials&of& fluvastatin& and& simvastatin& among& individuals& with& no& established& coronary& heart& disease& at&baseline.&&In& the&dose1specific&analysis& that& included&all&placebo1controlled,&active1comparator,&and&dose1comparison&trials,&a&total&of&758&individuals&with&clinically&meaningful&creatine&kinase&elevations&among&134,676& trial& participants& in&58& trials&were& included.&There&were&no& available&data& for&fluvastatin&at&low&doses,&lovastatin&at&moderate&doses,&and&pravastatin&at&high&doses.&There&was&a& dose1response& relationship& with& simvastatin,& with& higher& doses& resulting& in& higher& odds& of&creatine& elevations& (Figure& 6.26).& Simvastatin& at& >40& mg/day& resulted& in& significantly& higher&odds& of& experiencing& elevations& as& compared& to& control& treatment& (OR:& 4.14,& 95%& CrI:& 1.08,&16.24).&&
















Figure$ 6.27$ –& Sensitivity& of& the& base1case& findings& to& meta1regression& analyses& for& creatine&kinase&elevations.*&&






6.7.1.1% % Harms%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%The& pair1wise&meta1analysis& of& placebo1controlled& trials& of& statins& included& 5,514& individuals&with& incident& cancers& among& 100,523& trial& participants& in& 21& trials.& There&were& two& trials& of&atorvastatin& providing& information& on& 194& individuals& with& incident& cancers& among& 5,280&participants;& two& trials& of& fluvastatin&with&123& individuals&with& incident& cancers& among&1,996&trial& participants;& two& trials& of& lovastatin& with& 522& individuals& with& incident& cancers& among&6,852&participants;&10&trials&of&pravastatin&with&2,048&individuals&with&incident&cancers&among&38,516&participants;&two&trials&of&rosuvastatin&with&773&individuals&with&incident&cancers&among&22,645&participants;&and&three&trials&of&simvastatin&providing&information&on&1,824&individuals&with&incident&cancers&among&25,234&trial&participants.&&Overall,&as&shown&in&Figure&6.28,&statin&therapy&was&not&associated&with&a&significant&increase&in&the&risk&of&incident&cancers&(OR:&0.96,&95%&CI:&0.91,&1.02,&I2=0.0%).&None&of&the&individual&statins&appeared&to&significantly&increase&the&risk&of&incident&cancers&as&compared&to&control&treatment&in&placebo1controlled&trials:&atorvastatin&(OR:&0.81,&95%&CI:&0.60,&1.80,&I2=0.0%);&fluvastatin&(OR:&0.89,&95%&CI:&0.61,&1.28,&I2=0.0%);&lovastatin&(OR:&0.97,&95%&CI:&0.82,&1.17,&I2=0.0%);&pravastatin&(OR:&0.94,&95%&CI:&0.86,&1.03,&I2=0.0%);&rosuvastatin&(OR:&0.97,&95%&CI:&0.84,&1.12,&I2=0.0%);&and&simvastatin&(OR:&1.01,&95%&CI:&0.92,&1.11,&I2=0.0%).&&




6.7.1.2% % Comparative%Harms%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The& network& of& eligible& comparisons& is& shown& in& Figure& 6.29.& In& addition& to& the& placebo1controlled&trials&included&in&the&traditional&pair1wise&meta1analysis,&the&network&meta1analysis&included&a& total&of& four&direct& comparisons& including&219& incident& cancers&among&11,520& trial&participants.&In&total,&there&were&26&trials&including&112,045&participants&providing&information&on&5,733&incident&cancers.&&In& the& network& meta1analysis,& there& were& no& statistically& detectable& differences& among&individual&statins&(Table&6.16).&&
Figure$ 6.29$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&the&risk&of&incident&diabetes.*&





$ Fluvastatin$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$
vs.$
0.94&&(0.59,&1.47)& 0.86&&(0.60,&1.2)& 0.90&&(0.69,&1.20)& 0.84&&(0.62,&1.16)& 0.84&&(0.66,&1.08)&
Fluvastatin$
vs.$
1& 0.91&&(0.58,&1.43)& 0.97&&(0.65,&1.45)& 0.90&&(0.58,&1.39)& 0.90&&(0.6,&1.37)&
Lovastatin$
vs.$
1& 1& 1.06&&(0.81,&1.42)& 0.99&&(0.73,&1.36)& 0.98&&(0.75,&1.34)&
Pravastatin$
vs.$
1& 1& 1& 0.94&&(0.73,&1.19)& 0.93&&(0.77,&1.15)&
Rosuvastatin$
vs.$
1& 1& 1& 1& 0.99&&(0.78,&1.30)&*&Estimates&shown&are&ORs&and&95%&CrIs.&Table&should&be&read&from&left&to&right.&&
6.7.2%% Diabetes%




Figure$6.30$–& Effect& of& statins& compared& to& control& on& the& risk&of& incident&diabetes& across& all&populations.*&
&*&Estimates&shown&are&ORs&and&95%&CIs.&&




Figure$ 6.31$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&the&risk&of&new1onset&diabetes.*&
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
Table$6.17$–&Comparative&effects&of&individual&statins&on&the&risk&of&incident&diabetes&across&all&populations.*&
$ Lovastatin$ Pravastatin$ Rosuvastatin$ Simvastatin$
Atorvastatin$vs.$ 1.18&&(0.71,&1.99)& 1.12&&(0.79,&1.62)& 1.01&&(0.69,&1.47)& 1.06&&(0.72,&1.57)&
Lovastatin$vs.$ 1& 0.95&&(0.62,&1.46)& 0.85&&(0.54,&1.33)& 0.9&&(0.56,&1.41)&
Pravastatin$vs.$ 1& 1& 0.90&&(0.7,&1.12)& 0.94&&(0.72,&1.21)&
Rosuvastatin$
vs.$





6.7.3.1% % Harms%of%Statins%vs.%Control:%Findings%of%the%Traditional%Pair<wise%Meta<analysis%There&were&very& few&data&points& available& for& this& analysis.& In& the& traditional&pair1wise&meta1analysis& of& statin& therapy& vs.& control& across& all& populations,& 60,605& participants& contributed&information&on&only&20&individuals&with&rhabdolymyosis&events.&There&were&four&trials&with&nine&events& among& 17,551& individuals;& one& trial& of& pravastatin& with& a& single& event& among& 326&individuals;&one& trial&of& rosuvastatin&with&one&event&among&17,802& trial&participants;& and& two&trials&of&simvastatin&with&nine&events&among&24,986&individuals.&&As&shown&in&Figure&6.32,&statin&therapy&was&no&associated&with&a&significant&increase&in&the&odds&of&rhabdolymyosis&events&as&compared&to&control&(OR:&1.17,&95%&CI:&0.51,&2.72,&I2=0.0%).&None&of&the&individual&statins&resulted&in&statistically&significantly&higher&odds&of&rhabdolymysosis&as&compared&to&control:&atorvastatin&(OR:&1.14,&95%&CI:&0.33,&4.00,&I2=0.0%);&pravastatin&(OR:&0.33,&95%& CI:& 0.01,& 8.19,& I2=0.0%);& rosuvastatin& (OR:& 1.84,& 95%& CI:& 0.50,& 6.79,& I2=0.0%);& and&simvastatin&(OR:&1.84,&95%&CI:&0.50,&6.79,&I2=0.0%).&&
Figure$ 6.32$ –& Effect& of& statins& compard& to& control& on& the& risk& of& rhabdolymyosis& across& all&populations.*&
&*&Estimates&shown&are&ORs&and&95%&CIs.&There&were&no&trials&of&fluvastatin&and&lovastatin&reporting&rhabdomyolysis&outcomes.&&
6.7.3.2% % Comparative%Harms%of%Individual%Statins:%Findings%of%the%Network%Meta<analysis%The& network& of& eligible& comparisons& is& shown& in& Figure& 6.33.& In& addition& to& the& placebo1controlled&trials&included&the&traditional&pair1wise&meta1analysis,&there&was&one&direct&head1to1
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head& comparison& between& atorvastatin& and& simvastatin,& which& provided& information& on& five&individuals&with&rhabdolymyosis&events.&In&total,&nine&trials&including&69,493&participants&were&included&in&the&base1case&network&meta1analysis,&which&provided&information&on&25&individuals&who& experienced& rhabdolymyosis.& However,& this& analysis& failed& to& converge& due& to& the&extremely&small&numbers&of&events.&&
Figure$ 6.33$ –& Network& of& available& comparisons& for& determining& the& comparative& effects& of&individual&statins&on&rhabdolymyosis&events.*& &
&*&Connecting&lines&indicate&the&direct&pair1wise&comparisons&between&two&treatments.&The&width&of&the& lines& is&proportional& to& the&number&of&pair1wise&comparisons&between&two&treatments,&and&the&size&of&every&node&is&proportional&to&the&number&of&participants&receiving&the&named&statin.&
6.8$ Overall$ Rankings$ of$ Individual$ Statins$ in$ Terms$ of$ Harm$ Outcomes$ Across$ All$
Populations$Network&meta1analyses&presented& in& this&chapter&detected&a&number&of&statistically&significant&differences&among& individual& statins& in& terms&of& their& comparative&effects&on&discontinuations&due& to& adverse& events,& myalgia,& transaminase& elevations,& and& creatine& kinase& elevations.& In&addition&to&statistically&detectable&differences,& the&magnitude&of&comparative&effects&as&well&as&their&uncertainty&varied&considerably.&&Combining&the&results&of& the&network&meta1analyses&on&the&outcomes&with&the&most&abundant&data& (trial& discontinuations& due& to& adverse& events& [tolerability],& myalgia& occurrence,&transaminase&elevations,&and&creatine&kinase&elevations),&the&overall&rankings&for&the&individual&
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statins& are& shown& in& Figure& 6.34.& In& addition& to& the& overall& score& for& each& statin,& the& relative&contribution& of& each& outcome& (discontinuations,& myalgia,& transaminase,& and& creatine& kinase&elevations)&to&the&overall&score&is&also&shown.&&Pravastatin&ranked&first&with&an&overall&score&of&0.71& out& of& 1.00,& followed& by& simvastatin& (0.70),& and& lovastatin& (0.50),& suggesting& that& these&statins&had&the&most&favorable&tolerability&and&harm&profile&on&the&basis&of&discontinuations&due&to& adverse& events,& myalgia,& transaminase& elevations,& and& creatine& kinase& elevations& (Figure&6.34).& As& expected,& control& treatment& ranked& very& favorably&with& a& total& score& of& 0.70& out& of&1.00.&&
Figure$ 6.34$ –& Ranking& of& individual& statins& on& the& basis& of& discontinuations& due& to& adverse&events,&myalgia,&transaminase&elevations,&and&creatine&kinase&elevations.&&
$
$
6.9$Summary$of$Findings$$This& network&meta1analysis& of& 233,783&participants& provided& comprehensive& evidence& on& the&comparative& tolerability& and& harms& of& individual& statins& using& both& placebo1controlled& and&active1comparator& trials.& Overall,& statins& as& a& class&were& associated&with& an& increased& risk& of&diabetes&and&hepatic&transaminase&elevations&with&no&statistically&detectable&effect&on&myalgia,&myopathy,&rhabdomyolysis,&and&cancer.&Across&the&totality&of&the&evidence&base,&higher&doses&of&some& statins& resulted& in& higher& odds& of& experiencing& discontinuations& due& to& adverse& events,&transaminase& elevations& and& creatine& elevations.& When& compared& head1to1head& in& network&meta1analyses,& there& were& differences& among& individual& statins,& with& pravastatin& and&simvastatin&likely&to&be&ranked&superior&to&their&alternatives&in&terms&of&their&safety&profile.&&
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The&findings&of&the&empirical&work&presented&in&this&chapter&contribute&to&two&ongoing&debates&about&the&effect&of&statins&on&diabetes&and&cancer&incidence.&First,&this&review&and&meta1analysis&confirmed& the& findings& of& previous& pair1wise& meta1analyses& in& that& statins& as& a& class& are&associated&with& higher& odds& of& developing& diabetes368& Interestingly,& rosuvastatin& remains& the&only& statin& that& has& an& independent& association& with& an& increased& risk& in& incident& diabetes&among& individual& statins.& While& the& findings& of& network& meta1analyses& cannot& distinguish&between&rosuvastatin&and&other& statins& in& terms&of& their&effects&on&new&onset&diabetes&due& to&generally&wide&credible& intervals&around&relative& treatment&effects,& this&should&be& the& focus&of&future&prospective&studies.&&Another&widely&disputed&issue&relates&to&whether&statins&cause&or&prevent&cancer.3931396&Duncan&and&colleagues&hypothesized&that&statins&may&be&able&to&promote&the&growth&of&cancer&cells&due&to&their&effect&on&the&HMG1CoA&reductase&metabolism.397&However,&almost&unequivocal&evidence&from& randomized& and& non1randomized& studies& suggested& that& statins& either& do& not& have& an&effect&on&cancer&incidence&or&may&be&protective&against&certain&types&of&cancers.3851387,3981404&The&findings& of& the& review& and& meta1analysis& presented& in& this& chapter& confirmed& the& lack& of&evidence&that&statins&are&associated&with&an&increased&risk&of&developing&cancers.&These&findings&may& even& suggest& that& atorvastatin& is& protective& against& cancer& (although& not& statistically&significant).&&A& challenging& issue& for& prescribers& is& the& association& of& statin& use& with& elevations& in& liver&enzymes.&This&review&confirmed&that&statins&are&associated&with&clinically&meaningful&elevations&in& hepatic& transaminase& concentrations.405& These& are& asymptomatic& and& (mostly)& reversible&elevations&in&liver&enzymes&called&transaminases,&which&may&be&indicative&of&liver&toxicity&if&they&reach&very&high&levels.&Although&drug1induced&hepatic&toxicity&is&possible&among&some&patients&(as&with&any&drug),&this&risk&is&extremely&low&with&statins.&Prescribers&routinely&evaluate&hepatic&transaminases&(and&other&enzymes&such&as&creatine&kinase)&in&individuals&who&may&be&at&risk&of&experiencing&such&elevations.&The&findings&presented&in&this&chapter&provide&further&assistance&to& prescribers& in& selecting& the& statins& that& are& associated& with& lower& odds& of& hepatic&transaminase&elevations.&&Although&this&review&did&not& find&statistical&evidence&of&myalgia,& this&may&be&due&to&an&under1detection& of&muscle& toxicity& and& its& associated&muscle& aches& in& clinical& trials.4061408& Similar& to&previous&reviews&of&randomized&controlled&trials,& the&frequency&of&these&adverse&events& in&the&randomized&controlled&trial& literature&is&extremely& low.&However,& the&occurrence&of&myalgia& in&actual&clinical&practice&remains&a&common&side&effect&associated&with&the&use&of&statins.&&
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An&important&motivation&for&undertaking&this&empirical&work&was&that&available&statins&differ&to&a&various&extent&in&pharmacological&properties&and&it&would&be&expected&that&they&differ&in&terms&of& their& side& effects.87,104& Nonetheless,& their& comparative& harms& had& not& been& evaluated& in& a&comprehensive& manner& in& previous& reviews.& The& findings& of& the& review& and& meta1analysis&presented& this& chapter& showed& that& there& are& statistically& detectable& differences& between&individual&statins&in&terms&of&their&tolerability&and&harms:&across&populations,&differences&were&observed& in& discontinuations& due& to& adverse& events,& hepatic& transaminase& elevations,& and&creatine&kinase&elevations.&At& the&drug1level,& individuals& receiving&simvastatin&and&pravastatin&appeared& to& have& the& lowest& odds& of& experiencing& discontinuations& due& to& adverse& events,&myalgia,& and& transaminase&and&creatine&kinase&elevations.&These& findings&were&not& influenced&by& study1level& characteristics,& which& were& evaluated& in& the& meta1regression& analyses.&Specifically,&baseline&mean&age,&LDL&cholesterol&concentration,&and&trial&publication&year&did&not&have&an&impact&on&the&observed&findings.&&&Among&individuals&with&established&coronary&heart&disease&(secondary&prevention&population),&atorvastatin&was&more&likely&to&result&in&hepatic&enzyme&elevations&as&compared&to&pravastatin&and& simvastatin;& fluvastatin& led& to& more& transaminase& elevations& than& pravastatin& and&simvastatin.& Generally,& similar& trends& were& apparent& in& the& primary& prevention& population;&however,& these& findings& were& associated& with& considerable& uncertainty& due& to& the& smaller&number& of& data& points& available& for& the& analysis.& Unfortunately,& there& were& no& trials& of&fluvastatin&among&individuals&without&established&coronary&heart&disease.&&The& dose1specific& analysis& paralleled& the& findings& of& previous& meta1analyses& in& that& more&intensive&statin&therapy&is&associated&with&greater&risk&of&harm&and&less&favorable&tolerability&as&compared&to&lower&doses.382,4091411&Similar&to&previous&studies,&there&was&a&weak&dose1response&relationship&across&placebo1controlled&and&active1comparator&trials&in&terms&of&discontinuations&due&to&adverse&events,&transaminase&elevations,&and&creatine&kinase&elevations.&&The&findings&of&this&comparative&analysis&should&be&interpreted&in& light&of& its& limitations.&First,&the&randomized&controlled& trials&of&statins& included& in& this&review&did&not&report&acute&kidney&failure,&which&is&a&rare&but&important&harmful&side&effect&associated&with&statin&therapy.&Recent&observational& analyses& evaluated& the& effects& of& statins& on& this& outcome.380& Second,& although&there&was&no&evidence&of&small1study&effects,&there&was&an&apparent&asymmetry&in&the&evidence&network&where&specific& interventions&seemed& to&be&avoided&(eg,& fluvastatin).&For& instance,& the&relative& effect& of& fluvastatin& on& creatine& kinase& elevations&was& estimated& on& the& basis& of& only&eight&events&observed& in& four& trials.& Similarly,& there&were&only& four& trials&of& fluvastatin,&which&
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reported&hepatic& transaminase& elevations.&Third,& there&was& considerable&heterogeneity& across&various& traditional& pairwise& meta1analyses& of& statins& versus& control,& particularly& for& hepatic&transaminase& elevations.& It& remains& a& possibility& that& the& analyses& did& not& fully& account& for&heterogeneity& as& a& result& of& unobserved& or& unmeasured& factors.& However,& the& random1effects&model& took& into& account& potential& unexplained& heterogeneity& across& the& studies.& Also,& meta1regression& analyses& further& evaluated& heterogeneity& and& inconsistency& and& did& not& detect& a&significant&effect&of&study1level&covariates&such&as&baseline&mean&LDL&cholesterol&concentrations,&publication&year,&and&baseline&mean&age&of&patients.&Despite& these& limitations,& the& empirical& work& presented& in& this& chapter& has& important&methodological&strengths.&First,& this&review& is& the& largest&meta1analysis&on& the&harms&of&statin&therapy& to& date,& including& almost& a& quarter1million& trial& participants.& Second,& this& review&incorporated&data&from&a&comprehensive&list&of&trials,&irrespective&of&placebo&or&active&controls,&including& all& clinically& used& statins.& In& total,& there& were& 78& active1comparator& trials& with& or&without& a& placebo& or& usual& care& arm.& Third,& the& empirical&work& in& this& chapter& evaluated& the&dose1comparative&harms&of&individual&statins.&




Chapter$7$&Methodological&Quality&and&Risk&of&Industry&Sponsorship&Bias&in&the&Randomized&Controlled&Trials&of&Statins*&&&Over& the& past& 25& years,& large& placebo1controlled& trials& of& statins& informed& influential& clinical&practice& guidelines,& which& in& turn& progressively& expanded& the& limits& of& statin& therapy& to&populations&at&lower&risk&of&developing&cardiovascular&disease.&In&addition&to&placebo1controlled&trials,& a& large& number& of& head1to1head& randomized& controlled& trials& evaluated& the& dose1comparative&effects&of&individual&statins,&and&established&some&statins&as&more&efficacious&than&others.&Network&meta1analyses&presented&in&Chapters&416&of&this&thesis&combined&the&findings&of&these&placebo1controlled& and& active1comparator& trials& of& statins& to& examine& their& comparative&benefit& and& harm& profiles& to& inform& future& prescribing& decisions.& The& findings& of& such&comparative&assessments&can&be&jeopardized&due&to&potential&bias&in&the&randomized&controlled&trials&of& individual&statins.&Of&particular&concern&are&bias& that&can&be&attributed&to&(1)&flaws& in&the&methodological&quality&of&trials&and&(2)&industry&sponsorship.&If&present,&bias&can&render&the&findings&of& comparative&analyses& invalid.&Therefore,& this& chapter&evaluates& the&methodological&quality&and&risk&of&industry&sponsorship&bias&in&the&randomized&controlled&trials&of&statins.&&
7.1$Methodological$Quality$The&fact&that&the&comprehensive&meta1analyses&presented&in&the&previous&chapters&were&based&on&randomized&controlled&trials&has&significant&implications&for&the&credibility&of&their&findings.&Randomized&controlled&trial&designs&are&considered&the&gold&standard&for&determining&whether&a&health&intervention&works&or&is&more&effective&than&another&treatment.&As&discussed&in&Chapter&3& (Evidence% Review% and% Synthesis% Methods),& such& designs& have& high& internal& validity,& i.e.,& can&




ensure&that&the&observed&treatment&effect&can&be&attributed&to&the&experimental&treatment.&The&internal& validity& of& randomized& controlled& trials& is& achieved& by& two& key& design& features.412,413&First,&by&randomly&allocating&patients&to&treatment&groups,&researchers&can&ensure&that&there&are&no& systematic& differences& in& patient& groups& at& baseline& in& terms& of& known& (and& unknown)&factors&that&may&influence&outcomes.&Second,&by&carefully&establishing&a&controlled&environment&where& patients& receive& care,& researchers& ensure& that& there& are& no& systematic& differences&between&treatment&groups&in&terms&of&how&they&receive&treatment&and&are&followed&up.&&Although& typically& placed& at& the& top& of& evidence& hierarchies,414& causal& inferences& from&randomized& trials& can&be& jeopardized&by& limitations& in&methodological& quality& in& their& design,&conduct,& analysis,& and& reporting,& leading& to& underestimation& or& overestimation& of& the& true&intervention&effect,&i.e.,&bias.4151419&In&1995,&a&seminal&quantitative&study&by&Schulz&and&colleagues&showed&that&inadequate&methodological&approaches&in&randomized&trials&were&associated&with&systematically& different& (and& often& exaggerated)& treatment& effects.420& In& particular,& this& study&provided& empirical& evidence& on& the& association& between& four& dimensions& of& methodological&quality& (allocation& concealment,& sequence& generation,& blinding,& and& incomplete& data)& and& the&magnitude&of&treatment&effects.&In&later&years,&other&studies&provided&empirical&evidence&on&the&association& between& treatment& effects& and& sequence& generation,421& allocation& concealment,422&blinding&of&participants&and&personnel,422&blinding&of&outcome&assessment,422&selective&reporting&of&outcomes,423&incomplete&outcome&data,424&and&selective&outcome&reporting.4251427&Consistent&with& the&empirical& findings&of& this&body&of& literature&evaluating& the&methodological&biases& in& randomized& controlled& trials,& the& Cochrane& Collaboration& recently& categorized& the&potential& biases& in& randomized& controlled& trials& as& selection& bias,& performance& bias,& attrition&bias,& detection& bias& and& reporting& bias.428& These& biases& are& outlined& in& Table& 7.1& along& with&methodological&approaches&to&prevent&them.&&In& recent&meta1epidemiological& studies& (i.e.,&meta1analyses& of&meta1analyses),& blinding& of& trial&participants&and&personnel&was&shown&to&have&the&strongest&effect&on&observed&study&outcomes&in& randomized& controlled& trials,& followed& by& allocation& concealment.429& However,& the& average&bias&associated&with&limitations&in&the&methodological&quality&of&randomized&trials&appeared&to&vary&with&the&type&of&outcome:&there&was&no&statistically&detectable&bias&for&objective&outcomes&such&as&all1cause&mortality&and&laboratory&measures.&In&the&largest&meta1epidemiologic&study&to&date,&Savovic&and&colleagues&found&that&lack&of,&or&unclear&double1blinding&(vs.&double1blinding),&was&associated&with&an&average&of&13%&exaggeration&of&treatment&effects,&which&was&also&driven&primarily& by& trials& with& subjective& outcomes.430& However,& there& was& no& evidence& that& other&
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Performance%bias% Systematic&differences&between&groups&in&care&provided& • Blinding&of&personnel&and&participants&
Detection%bias% Systematic&differences&between&groups&in&how&outcomes&are&determined& • Blinding&of&outcome&assessment&
Attrition%bias% Systematic&differences&between&groups&in&withdrawals&from&a&study,&resulting&in&incomplete&outcome&data&
• Properly&dealing&with&incomplete&data&(e.g.,&conduct&intention1to1treat&analysis,&ensure&balance&of&withdrawals&in&treatment&groups,&impute&data&using&appropriate&techniques,&ensure&missing&data&are&not&associated&with&true&outcome)&
Reporting%bias% Systematic&differences&between&reported&and&unreported&findings& • Reporting&findings&on&all&pre1specified&outcomes&*&Adapted&from&the&Cochrane&Collaboration's&tool&for&assessing&risk&of&bias&in&randomized&trials.415&&




by& industry,431& and& findings& from& industry1sponsored& research& are& increasingly& the& most&influential,& i.e.,& the&most& frequently& cited.432&There&are& clear& financial& conflicts&of& interest&with&pharmaceutical& company& sponsorship& of& randomized& controlled& trials.& Unsurprisingly,&pharmaceutical& companies& may& not& wish& to& risk& unfavorable& trial& results,& which& would& have&significant&financial&implications.&Irrespective&of&financial&interests,&academic&investigators&may&be&willing& to&be& funded&by& the& industry& to&advance& their&professional& recognition&and&become&“key& opinion& leaders”& (or& “thought& leaders”)& for& pharmaceutical& companies.433& Over& time,&industry& sponsorship&may& influence& researchers’& attitudes& and& habits& of& thought& towards& the&pharmaceutical& industry& and& its& products& –& potentially& jeopardizing& the& validity& of& findings&obtained&from&industry1sponsored&randomized&trials.434&&The& question& of& whether& the& conflicts& of& interest& that& intertwine& industry& sponsors& and&investigators& influence& the& outcome& of& randomized& trials& is& of& great& academic& interest.& Three&comprehensive& (and& influential§§§)& studies& conducted& over& the& past& decade&provided& evidence&that& research& sponsored& by& the& pharmaceutical& industry& is& more& likely& to& favor& the& product&developed&by&the&company&sponsoring&the&research&than&research&funded&by&other&sources.&&First,&Bekelman&and&colleagues&systematically&documented&the&nature&and&influence&of&financial&conflicts&of&interest&in&biomedical&research.435&Reviewing&quantitative&studies&on&the&extent&and&impact& of& financial& conflicts& of& interest,& Bekelman& and& colleagues& showed& that& studies& that&compared& the& outcome& of& industry1sponsored& vs.& nonindustry1sponsored& studies& were& over&three&times&more&likely&to&report&favorable&results&for&the&sponsored&product&(OR:&3.60,&95%&CI:&2.63,&4.91).&When&they&stratified&their&results&and&focused&specifically&on&randomized&controlled&trials&(as&opposed&to&including&other&study&types&such&as&economic&evaluation&analyses),&studies&funded&by&the&industry&had&over&four&times&the&odds&of&yielding&pro1industry&conclusions&(OR:&4.14,&95%&CI:&2.72,&6.32).&&Second,& Lexchin& and& colleagues& performed& another& study& to& examine& the& link& between&pharmaceutical& industry& sponsorship& and& research& outcome.436& Across& a& broad& range& of&therapeutic& conditions,& patient& populations,& and& outcomes,& this& analysis& included& sixteen&reviews&that&investigated&the&relationship&between&funding&source&and&the&outcomes&of&clinical&trials&and&meta1analyses.&Studies&sponsored&by&pharmaceutical&companies&were&more& likely&to&have&outcomes&favoring&the&sponsor&than&were&studies&with&other&sponsors&(OR:&4.05,&95%&CI:&
                                                §§§& At& the& time& of&writing& this& thesis,& these& landmark& analyses& evaluating& the& presence& of& industry&sponsorship&bias&in&randomized&controlled&trials&were&collectively&cited&over&2,500&times.&
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2.98,& 5.51),& which& led& the& authors& to& conclude:& “there& is& some& kind& of& systematic& bias& to& the&outcome&of&published&research&funded&by&the&pharmaceutical&industry.”436&&Third,& a& recent& systematic& review&by& the&Cochrane&Collaboration& appeared& to& corroborate& the&findings&of&previous&reviews.437&This&review&showed&that&the&number&of&studies&with&favorable&results&was& higher& among& industry1sponsored& studies& compared&with& nonindustry1sponsored&studies& (RR:& 1.24,& 95%&CI:& 1.14,& 1.35).438& Similarly,& the& reports& of& industry1sponsored& studies&presented&more& favorable& overall& conclusions& compared& with& nonindustry1sponsored& studies&(RR:&1.31,&95%&CI:&1.20,&1.44).& In& industry1sponsored&head1to1head&comparisons,&the&drug&that&compared&favorably&was&most&often&the&drug&manufactured&by&the&study&sponsor.&&In&2007,&Bero&and&colleagues&published&an&analysis&examining&the&association&between&industry&sponsorship,& study& design& characteristics,& and& reported& conclusions& in& head1to1head&comparisons&of& individual& statins& and&other&drugs.439&Consistent&with& the& findings&of&previous&analyses& on& industry& sponsorship& bias,& Bero& and& colleagues& –& aptly& titled:&Why% Some% Statins%
Appear% More% Efficacious% than% Others& –& showed& that& head1to1head& comparisons& of& statins& and&other&drugs&were&more& likely&to&report&results&and&conclusions&favoring&the&sponsor's&product&compared&to&the&comparator&drug,&suggesting&the&presence&of&industry&sponsorship&bias.&These&findings& led& the& authors& to& conclude:& “This& bias& in& drug–drug& comparison& trials& should& be&considered&when&making&decisions&regarding&drug&choice.”439&&There& are& two& potential& explanations& for& the& observed& relationship& between& industry&sponsorship& and& research& outcome.& These& explanations,& if& supported& empirically,&would& offer&alternative&(yet&potentially&complementary)&mechanisms&of&industry&sponsorship&bias&in&clinical&research.& The& first& suggests& that& pharmaceutical& companies& introduce& bias& into& individual&randomized& controlled& trials,& rendering& their& findings& invalid.& Indeed,& it& was& originally&hypothesized& that& pharmaceutical& companies& conducted& poor& quality& research,& resulting& in&findings& that& favored& their& own& products.& However,& there& is& now& conclusive& evidence& from&systematic&reviews&that&the&methodological&quality&of& industry1sponsored&studies& is&at& least&as&good& as& (and& sometimes& better& than)& those& of& nonindustry1funded& studies.435,436,440& Using& a&comprehensive&list&of&studies,&the&recent&Cochrane&Collaboration&review&confirmed&that&there&is&generally&no&difference&between&industry&and&nonindustry1sponsored&studies&in&methodological&quality& that& may& increase& the& risk& of& bias,& such& as& randomization& sequence,& allocation&concealment,& and& follow1up.& To& the& contrary,& industry& sponsored& studies& generally& report&adequate&blinding&more&often&than&nonindustry1sponsored&studies.438&&
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The&second&oft1cited&potential&explanation&for&the&observed&link&between&industry&sponsorship&and& exaggerated& research& outcomes& refers& to& what& is& commonly& termed& “design& bias”,& i.e.,&limitations& in& the& planning& and& design& considerations& preceding& the& conduct,& analysis,& and&reporting& of& trials.434& For& example,& Lexchin& and& colleagues& suggested& that& pharmaceutical&companies&may&ask& the& “right”&questions&and&preferentially& sponsor& trials&on&a&drug& that& they&consider&to&be&superior&to&its&alternatives.436&In&a&similar&fashion,&industry&may&selectively&design&trials& that& favor&positive&results,&such&as&the&use&of&placebo&comparisons.434&As&an&extension&of&this& potential& design& bias,& in& head1to1head& trials,& industry& sponsors&may& exclusively& compare&their&products&to&active&treatments&known&to&be&inferior,&or&use&too&low&a&dose&of&a&competitor&drug,& deliberately& reducing& its& observed& efficacy.441,442& Although& the& findings& of& industry1sponsored&trials&with&‘straw1man&comparators’&may&still&have&high&internal&validity,&such&design&biases&would&distort&the&evidence&base&in&favor&of&industry1sponsored&products.&&While& these& explanations& are& plausible,& and& consistent& with& anecdotal& evidence& put& forth& in&recent&popular&books&on&the&pharmaceutical&industry,433,4431446&studies&in&the&scholarly&literature&provided& limited& empirical& evidence& supporting& these& hypotheses.& First,& the& previous& finding&that&industry1sponsored&trials&have&high&methodological&quality&does&not&necessarily&mean&that&companies&do&not&bias&individual&trials&through&their&influence&on&other&domains&not&covered&by&traditional&risk&of&bias&assessments.&Empirical&evidence&for&an&industry&sponsorship&bias&would&show& that& industry1sponsored& trials&produce&systematically&exaggerated& findings& compared& to&those&obtained&from&identical&(or&at&least&comparable)&trials&funded&by&nonindustry&sources.447&However,&such&comparability&has&rarely&been&established&in&previous&studies:&the&existing&body&of& literature& did& not& take& into& account& the& important& differences& across& industry1& and&nonindustry1sponsored&studies.&These& include&actual&differences& in&drug& interventions,&patient&populations,&and&dosing&regimens,&which&collectively&influence&the&observed&treatment&effects&in&randomized&trials.&In&addition,&previous&analyses&demonstrated&a&statistical&association&between&industry& sponsorship& and& trial& conclusions,& rather& than& differences& in& the&magnitude& of& effect&sizes& between& industry1& and& nonindustry1sponsored& trials.448& Therefore,& previous&comprehensive&analyses&did&not&provide&sufficient&evidence&either&for&or&against&the&presence&of&industry&sponsorship&bias&in&individual&randomized&controlled&trials.&&For&a&collective&set&of&trials,& there&is&also&limited&empirical&evidence&for&the&presence&of&design&bias.&Currently,&it&is&not&clear&by&which&mechanism&design&bias&would&operate,&and&how&it&would&influence& a& complex& evidence& network& including& a& large& number& of& placebo1controlled& and&active1comparator& trials.& One& possibility& is& that& the& share& of& randomized& trials& with& placebo&comparisons& is& higher& among& industry1sponsored& trials& as& compared& to& trials& funded& by&
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nonindustry& sources.& In& a& systematic& analysis& of& the& clinical& trial& registry& ClinicalTrials.gov,&Lathyris& and& colleagues& showed& that& the& large& majority& of& industry1sponsored& trials& was&placebo1controlled&and&examined&a&single&drug&owned&by&the&sponsoring&company.449&However,&whether& a& similar& majority& of& nonindustry1sponsored& trials& was& placebo1controlled& is& not&known.&Another&way&to&conceive&of&design&bias& is& that& industry1sponsored&trials& include&(drug&and&dose)&comparisons&that&are&almost&exclusively&different&than&those&included&in&nonindustry1sponsored&trials.&For&example,&Heres&and&colleagues&showed&that&industry&sponsors&selectively&used& suboptimal& comparators& in& the& trials& of& antipsychotics.450& While& acknowledging& the&challenges& associated& with& choosing& dosing& schedules& for& antipsychotic& agents,& Heres& and&colleagues& suggested& that&pharmaceutical& companies&did&not& always&use& the& appropriate&dose&range& and& titration& schedule& for& their& competitors’& products& in& head1to1head& comparisons,&primarily& because& in& numerous& trials& dose& ranges& were& determined& according& to& the&manufacturer’s&package& insert,&which&often&did&not& reflect& the& latest& state&of&knowledge&about&proper&dosing.&Whether&similar& ‘straw1man’&comparators&were&used&in&nonindustry1sponsored&trials&is&not&known.&Taken&together,&although&the&existing&body&of& literature&on&industry&sponsorship&bias&provides&seemingly&unequivocal&evidence&for&the&exaggeration&of&results&(favoring&sponsoring&company’s&product)& in& industry1sponsored& trials,& it& is& not& clear& whether& (or& to& what& extent)& industry&involvement& in& the& randomized& trials&of& statins&affected& the& findings&of& the&empirical& analyses&presented& in& Chapters& 416& of& this& thesis.& The& objective& of& this& chapter& was& to& explore& the&methodological&quality&and&risk&of&industry&sponsorship&bias&in&a&systematically&identified&set&of&placebo1controlled&and&active1comparator&trials&of&statins.&&
7.3$Empirical$Considerations$As& outlined& in& Chapter& 3& (Evidence% Review% and% Synthesis% Methods),& a& network& meta1analytic&approach&was&used&to&examine&the&methodological&quality&and&risk&of&industry&sponsorship&bias&in&the&randomized&trials&of&statins.&By&taking&into&account&actual&differences&in&the&effectiveness&of& individual&statins&at&different&doses,&network&meta1analysis&provided&an&analytic&framework&for&the&exploration&of&bias.451&The&network&analyses&presented&in&this&chapter&pooled&all&primary&and&secondary&prevention&trials& in&addition&to& trials&with&mixed&patient&populations,& including&all& placebo1controlled& and& active1comparator& trials& eligible& for& inclusion& in& the& systematic&review.&&The&primary&outcome&of&interest&was&&the&mean&change&from&baseline&in&serum&LDL&cholesterol&levels& between& two& comparator& treatments& for& a& given& dose& (change& from& baseline& in& the&
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treatment&group&minus&that&in&the&control&group).&Accordingly,&both&the&methodological&quality&and& risk&of& bias&were& evaluated&on& the&basis& of& the&mean& change& from&baseline& in& serum&LDL&cholesterol& levels.& Mean& LDL& cholesterol& reduction& from& baseline& was& the& most& frequently&reported&outcome&in&the&randomized&controlled&trials&of&statins.&Another&important&advantage&of&using& this& outcome& was& its& objective& nature.& As& previous& meta1epidemiological& studies& have&shown,& objective& outcomes& such& as& laboratory& assessments& are& largely& immune& to& biases&resulting&from&methodological&quality&deficits&in&trials.429,430&&Consistent&with&the&network&meta1analyses&presented&in&Chapter&4&(Dose<Comparative%Effects%of%
Individual% Statins% on% Cholesterol% Concentrations),& all& analyses&were& dose1specific& and& explored&the&effects&of&individual&statins&at&different&doses&separately.&Each&statin1dose&combination&was&considered& as& a& different& treatment& and& no& trends&were& fitted& or& assumed.& All& analyses&were&based& on& the& total& number& of& randomly& assigned& participants& regardless& of& how& the& study&authors&analysed&the&data.&&
Definition%of%bias:&Two&sources&of&bias&were&explored.&First&was&quality1related&bias,&which&was&defined&as&the&potential&underestimation&or&overestimation&of&the&true&intervention&effect&due&to&flaws& in& the& methodological& attributes& of& randomized& controlled& trials.415& Second,& industry&sponsorship& bias,&which& could& occur&when& a& pharmaceutical& company& sponsor& favors& its& own&drug& in& placebo1controlled& or& active1comparator& trials,& or& the& highest& dose& of& its& own&drug& in&dose1comparator&trials,&was&explored.451&&As&described&previously&in&Chapter&3&(Evidence%Review%and%Synthesis%Methods)&six&attributes&of&methodological& quality& were& considered& in& the& evidence& review& conducted& for& this& thesis.415&These& were& blinding& (i.e.,& did& the& investigators& blind& trial& participants& and& researchers& from&knowledge&of&which&treatment&a&trial&participant&received?);&random&sequence&generation&(i.e.,&were& the& methods& for& allocation& sequence& reported& to& determine& whether& it& produced&comparable& groups?);& allocation& concealment& (i.e.,& were& the& methods& used& to& conceal& the&allocation&sequence&reported&to&determine&whether&group&allocations&could&have&been&foreseen&before& or& during& treatment& initiation?);& blinding& of& outcome& assessment& (i.e.,& did& trial&investigators& blind& outcome& assessment& from& knowledge& of& which& intervention& a& participant&received?);& indications& of& incomplete& outcome& data& (i.e.,& did& the& investigators& report&completeness&of&outcome&data& for&LDL&cholesterol& lowering,& including&attrition&and&exclusions&from&the&analysis?);&and&indications&of&selective&reporting&(i.e.,&did&the&investigators&fail&to&report&tolerability& and& harm& outcomes& commonly& reported& in& randomized& trials& of& statins& [e.g.,&
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withdrawals&due&to&adverse&events,&creatine&kinase&elevations,&hepatic&transaminase&elevations,&or&myalgia]?&Also,&were&there&deviations&in&trial&outcomes&from&published&protocols?).&&On& each& methodological& attribute,& each& study& was& given& a& rating& of& high,& low,& or& uncertain&quality.&For&each&trial,&one&point&was&assigned&for&each&item&with&‘‘high&quality”&to&calculate&the&overall&methodological&quality& score& ranging& from&0& (worst&methodological&quality)& to&6& (best&methodological& quality).& Trials& did& not& receive& any& points& for& methodological& attributes& with&“low&quality”&or& “uncertain&quality.”&Using& this& information,& the&distribution&of&methodological&quality& of& different& comparisons& across& the& evidence& network& was& evaluated& (e.g.,& explored&whether& trials& comparing& simvastatin& vs.& control& had& on& average& a& higher& or& lower&methodological&quality&score&than&those&comparing&atorvastatin&vs.&rosuvastatin).&&
Mechanism% of% bias:& For& the& exploration& of& industry& sponsorship& bias,& one& statin& (at& a& specific&dose)&per&trial&was&coded&as&“potentially&biased.”&Two&a%priori&hypotheses&were&considered&for&this&designation&by&which&industry&sponsorship&bias&could&occur&in&individual&randomized&trials&(scenarios&1& and&2).&The& first& (scenario&1)&was& that& a&pharmaceutical& sponsor&would& favor& its&own&drug&in&placebo1controlled&or&active1comparator&trials&of&statins&or&the&highest&dose&of& its&own&drug&if&different&doses&were&being&considered.452&Accordingly,&one&arm&per&trial&was&labeled&as& potentially& biased& in& the& industry1sponsored& trials& of& statins.& In& scenario& 2,& the& hypothesis&was&that&a&sponsor&would&favor&its&own&drug&in&placebo1controlled&or&active1comparator&trials&of&statins,& but& that& it& would& neither& differentiate& between& different& doses& of& its& own& drug& nor&differentiate&between&its&older&and&newer&products.&Accordingly,&one&arm&per&trial&was&labeled&as&potentially&biased&in&the&industry1sponsored&trials&of&statins&unless&a&given&trial&compared&the&same&statin&at&different&doses.&&To&explore&the&presence&of&design&bias,&the&percentage&of&industry1sponsored&trials&with&placebo&controls& was& compared& to& the& corresponding& percentage& in& nonindustry1sponsored& trials.& In&addition,& the& type& of& drug& and& dose& comparisons& was& contrasted& between& industry1& and&nonindustry1sponsored&trials.&&As&mentioned&in&Chapter&3&(Evidence%Review%and%Synthesis%Methods),&in&cases&where&trial&funding&source&was& not& clearly& reported,& studies& with& industry1affiliated& authors& were& categorized& as&industry1sponsored.& Also,& trials& with& industry,& government,& and/or& academic& institution& co1sponsorship&were& categorized& as& industry1sponsored& unless& the& trial& investigators& included& a&statement&suggesting&that&the&funding&body&had&no&involvement&in&trial&design,&conduct,&analysis&or&reporting&(seven&of&the&industry1sponsored&trials&included&a&statement&indicating&that&study&sponsors& did& not& have& any& involvement& in& the& trial& design,& conduct,& analysis,& and& reporting;&
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these& trials&were& labeled&as&nonindustry1sponsored& for& the&evaluation&of& industry&sponsorship&bias&and&they&were&labeled&as&industry1sponsored&for&the&evaluation&of&design&bias).&&
Assessment% of% methodological% quality:& To& evaluate& the& sensitivity& of& base1case& network& meta1analysis& findings&on&study1level&methodological&quality&attributes,&six&sets&of&separate&analyses&were&conducted,&excluding&studies&with&low&quality&on&the&following&methodological& items:&(1)&blinding& of& personnel& and& participants,& (2)& random& sequence& generation,& (3)& allocation&concealment,& (4)&blinding&of&outcome&assessment,& (5)& indications&of& incomplete&outcome&data,&and&(6)&indications&of&selective&reporting.&&
Statistical% exploration% of% industry% sponsorship% bias:& Industry& sponsorship& bias& was& first&qualitatively&evaluated&by&comparing&the&dose1comparative&effects&of&individual&statins&obtained&from& an& analysis& including& only& industry1sponsored& trials& vs.& those& obtained& from&an& analysis&including& only& nonindustry1sponsored& trials.& The& consistency& of& the& relative& treatment& effects&obtained& from& the& two& sets& of& analyses& were& visually& inspected& for& potential& differences.& As&described& in&Chapter&3,&meta1regression&analyses&were&subsequently&conducted& to&statistically&evaluate& potential& industry& sponsorship& bias.4521454&Meta1regression& analyses&were& performed&by& allowing& for& a& common& treatment1bias& interaction& for& each& statin1dose& compared& to&control.327& In& addition& to& assuming& that& each& trial& estimated&a& study1specific& bias,&which& came&from& a& common& bias& distribution& (i.e.,& random1effects& model& for& bias),& a& separate& analysis&assumed&that&all&studies&estimated&the&same&bias&parameter&(i.e.,&fixed1effect&model&for&bias).&&
Goodness% of% fit:& The& relative& goodness&of& fit& of& fixed1effect& and& random1effects&models& for&bias&was&formally&evaluated&using&the&total&residual&deviance&(posterior&mean&of&the&deviance&under&a&given&model&minus&the&deviance&for&the&saturated&model)&along&with&the&deviance&information&criterion& (sum& of& the& posterior& mean& of& the& residual& deviance& and& the& effective& number& of&parameters),&as&described& in&Chapter&3.320&Due&to&better& fit,&only&the&results&obtained&from&the&fixed1effect&model&for&bias&were&reported&(total&residual&deviance&for&the&fixed1effect&model&was&228.20&as&compared&to&229.20&for&the&random1effects&model).&&




Interpretation%of%results:&Given&the&Bayesian&nature&of&network&meta1analyses,&the&findings&of&the&statistical&analyses&were&presented&as&mean&changes&from&baseline&and&95%&CrIs.&As&previously,&if& a& 95%& CrI& did& not& include& the& null& value& 0.00,& this& was& interpreted& as& indicating& <5%&probability& that& there&was&no&difference&between& the& two&comparisons.&For& the&exploration&of&industry& sponsorship& bias,& a& negative& meta1regression& coefficient& indicated& the& presence& of&industry& sponsorship& bias.& The& findings& were& considered& ‘statistically& significant’& if& 95%& CrIs&excluded&the&null&value&0.00.&&


























&Figure&7.2&shows&the&network&of&eligible&pair1wise&comparisons&for&LDL&cholesterol&reductions&from& baseline& in& placebo1controlled& and& active1comparator& trials& of& individuals& across& all&populations.&As&outlined&previously&in&Chapter&4&(Dose<Comparative%Effects%of%Individual%Statins%







7.5!Methodological!Quality!of!Randomized!Controlled!Trials!of!Statins!Out# of# a# total# of# 183# randomized# controlled# trials# included# in# this# network#meta9analysis,#112# were# double9blind# (rated# as# high# quality)# while# 58# were# open9label# and# two# were#single9blind#(rated#as#low#quality).#Blinding#was#not#clear#for#the#remaining#11#trials.#54#of#the#included#trials#were#were#rated#as#high#quality#in#terms#of#random#sequence#generation;#the#corresponding#numbers#were#24#for#allocation#concealment;#70#for#blinding#of#outcome#assessment;# 95# for# incomplete# outcome# data;# and# 127# for# selective# reporting.# A# large#number# of# trials# were# considered# to# have# uncertain# methodological# quality:# 94# trials# for#random# sequence# generation;# 77# for# allocation# concealment;# 46# for# blinding# of# outcome#assessment;#48#for#incomplete#outcome#data;#and#11#for#selective#reporting.###On# average,# the# included# set# of# randomized# controlled# trials# had# between# two# and# three#methodological# attributes# with# high# quality# (average# methodological# quality# score# across#the# included# set# of# trials# was# 2.65).# There# were# 14# trials# that# did# not# have# any#methodological#attributes#with#high#quality;#38#trials#had#one;#37#had#two,#38#had#three;#30#had# four;# and# 14# had# five.# Only# 11# trials# were# rated# as# having# high# quality# on# all# six#methodological#quality#attributes.##
7.5.1%% Distribution%of%Methodological%Quality%in%the%Evidence%Network%Figure# 7.3# shows# the# distribution# of# methodological# quality# scores# among# the# eligible#comparisons#of#statins#and#control#treatment.#The#majority#of#comparisons#had#an#average#methodological# score# between# two# and# three# (depicted# in# black# lines# in# Figure# 7.3).# On#average,# placebo9controlled# trials# of# rosuvastatin# and# simvastatin# had# higher#methodological# quality# than# other# comparisons# (average#methodological# quality# score# for#both# comparisons# >3).# Trials# comparing# atorvastatin# and# fluvastatin# (two# trials,# average#methodological# quality# score:# 1.50);# atorvastatin# and# rosuvastatin# (34# trials,# score:# 1.97);#atorvastatin# and# simvastatin# (24# trials,# score:# 1.79);# fluvastatin# and#pravastatin# (one# trial,#score:#1.00);#fluvastatin#and#simvastatin#(two#trials,#score:#1.30);#lovastatin#and#simvastatin#(three#trials,#score:#1.66);#and#pravastatin#and#simvastatin#(10#trials,#score:#1.80)#were#rated#as#having#very#low#methodological#quality.##
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!
Figure!7.3! –#Distribution#of#methodological# quality# in# the#network#of# available# statin# and#control#comparisons.*##
 *#Connecting#lines#indicate#the#direct#pair9wise#comparisons#between#two#treatments.#The#width#of#the#lines#is#proportional#to#the#number#of#pair9wise#comparisons#between#two#treatments,#and#the#size#of#every#node#is#proportional#to#the#number#of#participants#receiving#the#named#statin.#Color#of#the#line#connecting#the#nodes#is#indicative#of#the#average#methodological#quality#of#the#trials# directly# comparing# the# two# treatments:# red# denotes# very# low# quality# (average#methodological# quality# score# of# trials# <2);# black,# low# quality# (average#methodological# score# of#trials:#≥2#and#<3);#and#green,#moderate#quality#(average#methodological#score#of#trials#≥3).##
7.5.2## Influence%of%Methodological%Quality%Attributes%on%DoseAComparative%Effects%Figure# 7.4# shows# the# sensitivity# of# the# dose9comparative# effects# of# individual# statins# to#different#trial9level#methodological#quality#attributes.#Overall,#the#magnitude#of#cholesterol9lowering# effects# of# statin# therapy# vs.# control#was# consistent# when# trials# with# low# quality#were# excluded# in# various# sensitivity# analyses.# The# degree# to# which# the# magnitude# of#cholesterol# reduction# varied# across# analyses# depended# greatly# on# the# amount# of# the# data#available# for# a# given# analysis.# In# cases# where# there# were# few# data# points# available# (for#example,# fluvastatin#at#all#dose# formulations;# lovastatin#at#≤10#mg/day;#and#pravastatin#at#>40#mg/day),#there#was#considerable#uncertainty#around#the#observed#treatment#effects.#In#all#analyses,#95%#CrIs#greatly#overlapped#across#base9case#and#sensitivity#analyses.#####
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Figure! 7.4! –# Sensitivity# of# network# meta9analysis# findings# to# methodological# quality#attributes#of#randomized#controlled#trials#of#statins.*#
#*# Figure# shows# mean# change# from# baseline# LDL# cholesterol# levels# with# individual# statins# at#different#doses#as# compared# to# control# (95%#credible# intervals);# lower# (more#negative)#values#favor#statin#treatment#over#control.#In#addition#to#the#findings#of#the#base9case#analysis#shown#in#red# (circles),# findings# of# separate# sensitivity# analyses# excluding# trials# with# low# quality# on# the#following# methodological# quality# attributes# are# shown:# blinding# (green# squares);# random#sequence# generation# (yellow# circles);# allocation# concealment# (blue# diamonds);# blinding# of#outcome# assessment# (black# circles);# incomplete# outcome# data# (white# circles);# and# selective#reporting#(purple#triangles).#
#
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7.6!Risk!of!Industry!Sponsorship!Bias!in!the!Randomized!Controlled!Trials!of!Statins!A#total#of#136#randomized# trials#were#sponsored#by# the#pharmaceutical# industry.#17# trials#were# sponsored# by# governmental# agencies,# and# eight# were# funded# by# academic# research#centers.# The# remaining# 15# trials# did# not# report# the# funding# source.# Out# of# a# total# of# 136#industry9sponsored#trials,#58#were#placebo9controlled#(42.6%).#The#corresponding#number#for#the#nonindustry9sponsored#trials#was#17#(42.5%).#There#were#31#multi9armed#industry9sponsored# trials# as# compared# to# eight#multi9armed#nonindustry9sponsored# trials.#Out# of# a#total# of# 66# statin# and# dose# comparisons# available# in# 40# nonindustry9sponsored# trials#(including#multiple#comparisons#in#multi9armed#trials),#39#were#unique#comparisons.#33#of#the#unique#comparisons#were#also#available#in#industry9sponsored#trials#(Table#7.2).##There# were# no# systematic# differences# between# the# findings# obtained# from# industry9sponsored#and#nonindustry9sponsored#trials#(Figure#7.5).#While#the#network#meta9analysis#of# industry9sponsored# trials# estimated# a# larger# treatment# effect# for# some# statin9dose#combinations# as# compared# to# the# network# meta9analysis# of# nonindustry9sponsored# trials#(for#example,# the#mean#reduction#from#baseline#with#atorvastatin#>20#and#≤40#mg/day#vs.#control# was# an# estimated# 63.34# mg/dL# as# compared# to# an# estimated# 50.96# mg/dL# in#nonindustry9sponsored#trials),#the#opposite#was#true#in#other#cases#(for#example,#the#mean#reduction# from#baseline#with#atorvastatin#≤10#mg/day#vs.# control#was#an#estimated#45.19#mg/dL# in# industry9sponsored# trials# as# compared# to# an# estimated# 55.74# mg/dL# in#nonindustry9sponsored# trials).# There# was# generally# greater# uncertainty# around# the#cholesterol9lowering#effects#of#individual#statins#in#nonindustry9sponsored#trials,#reflecting#the# smaller# number# of# randomized# controlled# trials# that# were# funded# by# nonindustry#sources.# Overall,# point# estimates# and# 95%# credible# intervals# greatly# overlapped# for# all#statin9dose#combinations#included#in#both#sets#of#network#meta9analyses.###
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Table! 7.2! –# Availability# of# statin9dose# comparisons# in# industry# and# nonindustry9funded#trials.#
Unique!comparisons!available!in!nonindustryKsponsored!trials! Availability!in!industryK




#*# Findings# from# industry9sponsored# trials# are# shown# in#white# and# findings# from# nonindustry9sponsored# trials# are# shown# in# red.# Estimates# shown# are# mean# changes# from# baseline# (95%#credible#intervals)#in#serum#LDL#cholesterol#concentrations#as#compared#to#control#treatment.##




!*#Findings#of#scenario#1#are#shown#in#red#and#findings#of#scenario#2#are#shown#in#white.#Figure#shows#the#extent#to#which#mean#change#from#baseline#LDL#cholesterol#levels#was#exaggerated#in#trials# with# industry9favored# statins# (95%# credible# intervals);# lower# (more# negative)# values#suggest#greater#bias.!
7.7!Summary!and!Discussion!The#Cochrane#Collaboration#defines#bias#as#a#systematic#deviation#from#the#truth,#in#results#or# inferences# of# studies.455# In# other#words,# bias# refers# to# systematic% error,# suggesting# that#multiple#replications#of#the#same#trial#would#reach#the#wrong#answer#on#average.#Although#randomized#research#designs#are#largely#immune#to#many#biases#that#affect#weaker#forms#of#evidence# obtained# from#nonrandomized# studies,# important# deficits# in# the# design,# conduct,#analysis,# and# reporting# may# still# lead# to# bias# in# randomized# controlled# trials.415# The#empirical# work# presented# this# chapter# explored# the# methodological# quality# and# risk# of#industry#sponsorship#bias#in#the#randomized#controlled#trials#of#statins.##Consistent# with# the# literature# evaluating# the# risk# of# bias# due# to# reported# design#characteristics# of# randomized# trials,429,430# the# analyses# presented# in# this# chapter# did# not#detect# any# effect# of#methodological# flaws#on# an#objective# laboratory#outcome.# Specifically,#the#magnitude#of#LDL#cholesterol9lowering#effects#of#individual#statins#was#consistent#when#trials# with# low# methodological# quality# attributes# were# excluded# from# various# sensitivity#analyses.##There# is# now# a# long# history# of# studies# evaluating# industry# sponsorship# bias,# which#unequivocally# conclude# that# industry# sponsorship# biases# study# outcomes# in# favor# of# the#sponsoring# company’s# product.4359438,440,456# As# Bero# put# it,# “Decision# makers# should# take#sponsorship# into# account#when# evaluating#whether# they# should# base# clinical# practice# and#reimbursement# on# the# results# of# a# trial.”438# Sismondo# added:# “Funding# introduces# a#systematic# bias# that# cannot#be# corrected#by# simple#methodological# strictures.”434#He#went#
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even# further# and# concluded# that# there# was# no# more# need# for# research# to# establish# that#funding#affects#published#results.##Previous# reviews#outlined# a#number#of# potential#mechanisms#by#which# industry# sponsors#can# influence# the# outcome# of# a# study,# including# how# the# trial# is# designed,# conducted,#analyzed,# and# reported.# Given# the# conclusive# evidence# that# the# methodological# quality# of#industry9sponsored# trials# is# at# least# as# good# as# (and# often# times# better# than)# those#sponsored# by# nonindustry# sources,437# the# observed# “industry# sponsorship# bias”# may# be#attributable#of#factors#that#cannot#be#explained#by#standard#risk#of#bias#assessment#tools.##Unlike# the# findings#of# the#previous#reviews,# the#analyses#presented# in# this#chapter#did#not#find# empirical# evidence# of# industry# sponsorship# bias# in# a# systematically# identified# set# of#placebo9controlled# and# active9comparator# trials# of# statins.# First,# the# mean# change# from#baseline# LDL# cholesterol# levels# achieved# in# industry9sponsored# trials# closely# paralleled# in#magnitude#the#reductions#observed#in#nonindustry9sponsored#trials:#there#was#no#evidence#that# pharmaceutical# sponsors# favored# their# own# drugs# in# placebo9controlled# or# active9comparator# trials#of#statins.#As#shown# in#Chapter#4#(DoseAComparative%Effects%of%Statins%on%
Cholesterol%Levels),#there#were#actual#differences#in#the#effectiveness#of#individual#statins#at#different# doses# that,# when# taken# into# account,# explained# previously# observed# differences#between# industry9# and# nonindustry9sponsored# trials.# Second,# there# was# limited# evidence#that#pharmaceutical#companies#addressed#research#questions#that#were#drastically#different#than# those# asked# by# other# funders.# For# example,# a# similar# share# of# industry9and#nonindustry9sponsored#statin#trials#was#placebo9controlled.#In#addition,#out#of#a#total#of#39#unique# statin9dose# comparisons# available# in# nonindustry9sponsored# trials,# 33# were# also#available# in# industry9sponsored# trials,# potentially# reflecting# the# relevance# of# research#conducted#by#industry#sponsors.##The# assessment# of# industry# sponsorship# bias# presented# in# this# chapter# differed# from#previous#reviews#in#the#literature#in#the#following#ways:#
1. Comparison% of% like% with% like.! Previous# studies# did# not# limit# their# comparisons# to# a#homogenous#set#of#studies.#The#analyses#presented#in#this#chapter#paid#particular#attention#to#the#comparability#of#patient#populations,#interventions,#and#doses#across#the#identified#set#of#trials.447#As#discussed#in#Chapter#3#(Evidence%Review%and%Synthesis%Methods),#a#systematic#review#was#performed# to# identify# randomized# controlled# trials#of# atorvastatin,# fluvastatin,#lovastatin,#pravastatin,#rosuvastatin,#and#simvastatin#if# they#had#more#than#50#participants#per# trial# arm,# lasted# longer# than# four# weeks,# and# reported# the# outcomes# of# interest# as#defined#in#a#protocol#that#was#developed#prior#to#the#review.#Included#trials#were#those# in#patient# populations#with# and#without# coronary# heart# disease# at# baseline.# Unlike# previous#analyses,#which# explored# the# potential# effect# of# industry# sponsorship# on# a# heterogeneous#
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range# of# objective# and# subjective# outcomes,# the# current# review# adopted# mean# LDL#cholesterol# reduction# from# baseline# as# the# primary# outcome# of# interest# to# ensure#consistency# across# the# included# set# of# trials.# Also,# mean# LDL# cholesterol# reduction# from#baseline#was# the#most# frequently# reported#outcome# in# the# randomized#controlled# trials#of#statins.# Another# important# advantage# of# using# this# outcome# was# its# objective# nature.# As#previous# meta9epidemiological# studies# have# shown,429,430# objective# outcomes# such# as#laboratory#assessments#are#largely#immune#to#biases#resulting#from#methodological#quality#deficits#in#trials.#!
2. Exploration% of% the% mechanism% of% potential% bias.! Previous# studies# did# not# explore# the#potential#mechanism# of# potential# bias.# Gartlehner# and# colleagues#were# among# the# first# to#point# out# the#difficulty# in#determining#how# industry#biases# from#multiple# funding# sources#would#influence#a#complex#body#of#evidence,#with#different#companies#sponsoring#different#products.448# In# a# best9case# scenario,# they# postulated# that# biases# from# multiple# funding#sources#would#act#in#opposing#directions#and#cancel#each#other#out.#In#a#worst9case#scenario,#Gartlehner#and#colleagues#paralleled#the#notions#put#forth#by#Barden#and#colleagues#in#that#if#industry#bias#exists,#a#drug#would#perform#better#in#trials#sponsored#by#its#manufacturer#and# worse# as# a# comparator# in# trials# funded# by# a# competitor.447# Applying# these#considerations#to#the#statin#evidence#network,#analyses#presented#in#this#chapter#evaluated#the#particular#mechanism#of#potential#industry#sponsorship#bias.#Specifically,#the#hypothesis#tested# in# this# chapter# was# that# industry# sponsorship# bias# would# occur# when# a#pharmaceutical#sponsor#favored#its#own#product#in#placebo9controlled#or#active9comparator#trials,#or#the#highest#dose#of#its#own#drug#in#a#trial#comparing#multiple#doses.#Based#on#these#analyses,# there#was# no# evidence# that# the# pharmaceutical# companies# intentionally# favored#their#products#in#the#randomized#controlled#trials#of#statins.#!
3. Comparison%of%effect%sizes.!Previous#influential#reviews#did#not#evaluate#the#magnitude#of#effect# sizes.# They# showed# that# there# was# a# statistical# association# between# industry#sponsorship#and#positive#results.4359437#Positive#results#observed#in#earlier#studies#referred#to# a# dichotomous# outcome# of# either# reporting# statistically# significant# findings# or# positive#conclusions# that# were# favorable# for# the# sponsoring# company.# These# approaches# may# be#subject# to# important# limitations.#For#the# former,# industry#sponsorship#may#result# in# larger#and#better9designed#studies#(as#shown#in#the#trials#in#psychiatry),457#with#greater#statistical#power#to#identify#significant#differences#if#such#differences#exist.#For#the#latter,#Als9Nielsen#and# colleagues# showed# that# source# of# funding# is# a# good# predictor# of# the# strength# of#published# recommendations# (also# referred# to# as# ‘interpretation# bias’).456# (As# discussed#under#item#4#below,#the#question#of#whether#favorable#conclusions#are#inappropriate#cannot#be# addressed# without# taking# into# account# actual# treatment# differences# between# statins.)#Strictly#speaking,#the#difference#in#the#frequency#of#either#statistically#significant#findings#or#
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favorable#conclusions#observed#between#industry9#and#nonindustry9sponsored#trials#should#not#be#referred#to#as#bias.#Bias#is#the#underestimation#or#overestimation#of#true#intervention#effects.# Therefore,# any# bias# assessment# would# need# to# evaluate# the# magnitude# of# the#intervention#effect#(as#well#as#its#uncertainty).##Indeed,#when#the#magnitude#of#the#intervention#effect#was#taken#into#account,#the#empirical#work#presented#in#this#chapter#showed#that#industry9sponsored#trials#of#statins#resulted#in#the#same#degree#of#cholesterol#reduction,#as#did#nonindustry9funded#trials.##
4. Consideration% of% actual% effectiveness% differences% between% treatments% and% doses.!Previous#reviews#did#not#test#differences#in#effectiveness#that#can#be#explained#by#different#drugs#and#their#dosages.#Heres# and# colleagues# showed# that#previous# comparisons#of# the# same# set# of#antipsychotic# drugs# led# to# contradictory# overall# conclusions,# depending# on# the# sponsor# of#the#study.450#Safer#and#colleagues#reported#that#in#trials#of#psychiatric#drugs#the#comparator#drug#was#often#given#in#doses#outside#the#usual#range#or#there#was#a#rapid#and#substantial#dose# increase# in# the# drug# not# manufactured# by# the# sponsoring# company,# indicating#deliberate# scientific#misconduct.458#As#Lexchin#noted,# higher#doses#may#bias# the# results# in#favor#of#effectiveness#of# the#manufacturer’s#product.436#These#previous#analyses#suggested#that#treatment#and#dose#differences#should#be#taken#into#account#in#analyses#exploring#bias.#Network#meta9analysis#provides#a#methodological#framework#for#dose#and#different#statins#being# used.451,452# The# analyses# presented# in# this# chapter# allowed# for# the# incorporation# of#actual# differences# in# the# effectiveness# of# individual# statins# at# different# doses.# When# such#differences# were# taken# into# account,# there# was# no# evidence# of# industry# sponsorship# bias#within#individual#trials.#!
7.7.1% %Generalizability%of%Findings%An#important#consideration#is#whether#the#findings#of#this#chapter#are#generalizable#to#the#assessment# of# industry# sponsorship# bias# in# other# therapeutic# areas.# Certainly,# there# are#unique# aspects# of# the# statin# evidence# base# that# complicate# comparisons# with# other#therapeutic# areas.# Lathyris# and# colleagues# previously# suggested# that# the# more# favorable#results#of#industry9sponsored#trials#might#be#due#to#design#issues,#in#particular#the#choice#of#comparators#that#are#either#inactive#or#suboptimal.449#Unlike#other#therapeutic#areas#where#the# influence# of# dose# on# treatment# effectiveness# may# not# be# widely# known# outside# of#industry# researchers,# statin# drugs# have# a# widely# established# dose9response# relationship#with# higher# doses# resulting# in# greater# cholesterol# lowering# effects.# It# is# possible# that# this#relationship#might#have#made# it# difficult# for#pharmaceutical# companies# to# introduce#overt#design#biases#in#randomized#controlled#trials#using#dose#as#a#design#factor.#This#may#explain#why# the# comparators# in# industry9# and#nonindustry9sponsored# trials# greatly# overlapped# in#the# statin# evidence# network.# Out# of# a# total# of# 39# unique# comparisons# available# in#
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nonindustry9sponsored# trials,# 33# were# also# available# in# industry9sponsored# trials.#Interestingly,# fluvastatin# at# ≤10mg/day,# one# of# the# least# effective# statins,# was# avoided# in#industry9sponsored#trials.##Previous# studies# have# shown# that# each# pharmaceutical# company# generates# a# clinical#research#agenda#that#is#strongly#focused#on#its#own#products,#while#comparisons#involving#different# interventions# from# different# companies# are# uncommon.# Indeed,# Lathyris# and#colleagues# showed# that# the# large# majority# of# industry9sponsored# randomized# research# is#sponsored# by# a# single# company# and# examines# a# single# intervention# owned# by# this#company.449# In# addition,# according# to# the# review#by# Lathyris# and# colleagues# head9to9head#comparisons# of# interventions# owned# by# different# companies# are# a# small# minority# of#industry9sponsored#trials.#However,#this#was#not#the#case#in#the#clinical#literature#evaluating#the# effectiveness# of# statin# therapy,# which# may# limit# the# generalizability# of# the# findings#presented# in# this# chapter# to# other# therapeutic# areas.# There#were# a# large# number# of# trials#where# pharmaceutical# companies# compared# their# products# against# licensed# regimens#belonging# to# other# companies.# However,# consistent# with# the# findings# of# the# review# by#Lathyris# and# colleagues,449# in# head9to9head# trials# of# statins,# the# company# owning# the#established#comparator#was#usually#not#involved.##More#problematic#is#the#pharmaceutical#company#behavior#in#terms#of#publication#delays#and#data#withholding,#contributing#to#time9lag#and#publication#biases.459,460#In#recent#years,#pharmaceutical#companies#have#attempted#to#prevent#studies#with#unfavorable#results#from#being#published,#and#to#publish#positive#results#more#than#once#in#high#profile#cases.441,461#Such#practices,#which#do#not#appear#to#be#prevalent#in#the#statin#literature,462#may#partly#explain#the#previous#findings#of#bias#in#favor#of#outcomes#of#research#funded#by#industry.461##
7.7.2%% Bias%in%an%Individual%Trial%vs.%a%Collection%of%Trials%The# findings# of# this# chapter# suggested# that# the# research# questions# asked# by# industry#sponsors# seem# to# parallel# those# asked# by# nonindustry# sources,# and# the# findings# obtained#from#these#trials#appear#similar#in#magnitude#as#those#in#nonindustry#sources.#Nonetheless,#as# shown# in# previous# reviews,# pharmaceutical# companies# exclusively# sponsor# trials# that#have#favorable#conclusions#for#its#products.#This#has#clear#implications#for#those#reviewing#and# making# decisions# based# on# the# existing# evidence.# Industry# sponsorship# creates#asymmetries# in# the# evidence# base,# with# some# companies# selectively# comparing# their#products#against#others#that#they#deem#strategic#competitors.#For#example,#all#of#the#direct#head9to9head#comparisons#between#rosuvastatin,#which#entered#the#United#States#market#in#2003# (sponsoring# company:# Astra# Zeneca),# and# atorvastatin,# which# was# approved# by# the#Food#and#Drug#Administration#in#1996#(sponsoring#company:#Pfizer),#were#funded#by#Astra#Zeneca.# In# a# similar# fashion,# Pfizer# sponsored# the# majority# of# head9to9head# trials# of#
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!Evidence9Based#Decision9Making:##Going#from#Evidence#to#Prescribing*###As#outlined#in#Chapter#1#(Introduction:#The#Concept%of%Quality%in%Prescription%Drug%Therapy),#defining# prescribing# quality# on# the# basis# of# comparative# evidence# requires# prescribers# to#appraise#all#available#evidence#prior#to#reaching#a#conclusion#about#which#drug#to#prescribe.#In# principle,# quantitative# comparative# effectiveness# data# have# the# potential# to# provide#prescribers# with# valuable# evidence# to# make# an# effective# choice# out# of# several# apparently#similar#drugs.#The#empirical#work#presented# in# this# thesis# focused#on# the# role#of#evidence#review# and# synthesis# methods# to# generate# comparative# evidence# on# individual# statins,#which# can# subsequently# be# used# to# guide# and# evaluate# the# quality# of# statin# prescribing#decisions.#This#chapter#reflects#on#the#potential#utility#of#comparative#evidence#to#decision9making,#and#outlines#a#number#of#considerations#to#apply#such#evidence#in#prescription#drug#therapy,# i.e.,# to# fill# the# existing# gaps# in# clinical# practice# guidelines;# and# facilitate# evidence9based# decision9making.# Specifically,# this# chapter# brings# together# the# empirical# findings# of#the#previous#chapters#and#addresses#the#following#questions:##1. What#are# the# limitations#and#strengths#of# the#methods#underpinning# the#empirical#findings?#2. Should#prescribers#recommend#statin#therapy?#3. Which#statin(s)#should#be#favored#in#clinical#practice?#4. What# are# some# generalizability# considerations# when# applying# the# findings# of# this#systematic#review#and#network#meta9analysis#to#individuals#in#clinical#practice?#The#first#part#of#this#chapter#summarizes#the#methods#underpinning#the#empirical#findings#of#this#thesis,#and#lists#their#limitations#and#strengths.#The#second#part#provides#a#discussion#on#the#primary#clinical#practice#implications#of#the#findings,#and#explores#the#potential#role#




8.1!Summary!of!Empirical!Considerations!The#systematic#review#of#the#clinical#literature#on#statins,#which#forms#the#empirical#basis#of#this# thesis,# included# randomized# controlled# trials# of# atorvastatin,# fluvastatin,# lovastatin,#pravastatin,# rosuvastatin,# and# simvastatin# if# they# had#more# than# 50# participants# per# trial#arm,#lasted#longer#than#four#weeks,#and#reported#the#outcomes#of#interest#as#defined#in#the#study#protocol.#Of#particular#interest#were#the#effects#of#individual#statins#in#the#primary#and#secondary# prevention# of# all9cause# mortality,# major# coronary# events,# and# major#cerebrovascular#events,#and#discontinuations#due#to#adverse#events,#myalgia,#transaminase#elevations,#and#creatine#kinase#elevations.#As#described# in#Chapter#3#(Evidence%Review%and%
Synthesis% Methods)# the# statistical# analyses# predominantly# consisted# of# Bayesian# network#meta9analysis#methods#to#synthesize#the#available#direct#and#indirect#evidence#on#individual#statins.284##Overall,# the# systematic# review# of# the# published# literature# included# 184# randomized#controlled# trials# with# 260,630# individuals# with# or# without# cardiovascular# disease# at#baseline.# Although# a# large# number# of# existing# trials# were# placebo9controlled# (n# =# 85),# 99#head9to9head# trials# compared# statins# at# different# doses# and# investigated# the# comparative#benefits#and#harms#of#individual#statins.#There#was#an#apparent#asymmetry#in#the#evidence#network# where# specific# interventions# were# more# commonly# evaluated# (e.g.# atorvastatin)#than#others#(e.g.#fluvastatin).#Most#frequent#comparisons#occurred#between#pravastatin#and#placebo,# atorvastatin# and# placebo,# and# rosuvastatin# and# atorvastatin.# No# trial# directly#compared#all#six#statins#to#each#other.#The#network#meta9analysis#approach#used#to#determine#the#comparative#benefits#and#harms#of#individual#statins#assumed#similarity#and#consistency#in#the#evidence#base.#Underpinning#both# of# these# considerations# was# the# assumption# that# there# was# no# interaction# between#heterogeneity# and# treatment# comparisons.# This# implies# that# heterogeneity# that# is#unexplained# or# unaccounted# for# may# introduce# bias# if# it# influences# different# statins# to# a#different#extent.288#As#described#by#Jansen#and#Naci,#any#imbalances#across#studies#in#terms#of# unmeasured#or#unknown# relative# effect#modifiers#would#bias# the# results.308#Hence,# any#comparison#of#individual#statins#should#be#tempered#by#the#differences#that#may#result#from#imbalances#in#the#distribution#of#relative#treatment#effect#modifiers#across#different#trials.##In#order# to#ensure#similarity#and#consistency#across# the#entire#set#of# trials# included# in# the#systematic# review,# both# statistical# and# qualitative# approaches# were# adopted.# First,# all#analyses# were# based# on# random9effects# models,# which# took# into# account# potential#
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Figure! 8.1! –# Dose9comparative# absolute# effects# of# statins# on# serum# LDL# cholesterol#concentrations.*#
#*#Estimates#shown#are#absolute#reductions#at#all#dose#combinations#standardized#to#the#average#pretreatment#LDL#cholesterol#concentration#in#the#included#set#of#trials#(mean,#95%#CrIs).#!
8.2!Limitations!and!Strengths!of!Methods!Network# meta9analyses# reported# in# this# thesis# were# not# without# limitations.# First,# as# a#literature9based#meta9analysis,#the#empirical#findings#shared#the#limitations#of#the#published#evidence# base.# Using# the# Cochrane# Collaboration’s# tool# for# assessing# the# risk# of# bias# in#randomized# trials,415# only# a# few# trials# were# rated# as# high# quality# on# all# methodological#quality# attributes.#Overall,# the# quality# of# reporting# for# the# included# randomized# trials#was#well#below#an#acceptable# level,#which# complicated# the#assessment#of# their#methodological#conduct# and#validity.465#Accordingly,# as# reported# in#Chapter#7# (Methodological%Quality%and%
Risk% of% Industry% Sponsorship% Bias% in% the% Randomized% Controlled% Trials% of% Statins),# a# large#number#of#trials#were#rated#as#“uncertain#quality”:#it#was#challenging#to#distinguish#between#methodological#factors#that#were#missing#(such#as#lack#of#allocation#concealment)#and#those#that#were#simply#not#reported#–#a#commonly#encountered#problem#in#systematic#reviews#of#the# literature.88990# Given# that# standardized# reporting# checklists# for# randomized# trials# are#relatively# new# (e.g.# Consolidated# Standards# of# Reporting# Trials,# [CONSORT]466),# older#randomized#controlled#trials#may#not#have#reported# important#design#features,#even#when#they#were#carried#out.#In#this#regard,#it#may#not#be#fair#to#apply#the#same#quality#criteria#to#older#clinical#trials#that#were#conducted#in#a#period#during#which#reporting#standards#were#different# (or# not# as# detailed).# The# systematic# review# conducted# for# this# thesis# was#particularly#prone#to#this#limitation#given#the#long#history#of#statin#trials,#spanning#over#25#years.##
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Irrespective# of# methodological# quality# assessments,# however,# the# fundamental#consideration#in#a#network#meta9analysis#is#whether#an#estimate#of#treatment#effect#is#near#the#“true”#value#for#a#given#outcome,#across#studies.#It#is#significant#to#consider#the#extent#to#which#results#of#included#trials#(and#their#synthesis#across#a#complex#evidence#network)#are#trustworthy# and# should# be# believed.# The# analysis# presented# in# Chapter# 7# (Methodological%
Quality%and%Risk%of%Bias%in%Randomized%Controlled%Trials%of%Statins)#showed#that#the#findings#of# the# randomized# trials# of# statins# did# not# appear# to# be# influenced#by# reported#deficits# in#trial# methodology.# Also,# there# was# no# qualitative# or# statistical# evidence# to# suggest# that#industry9sponsorship#resulted#in#a#systematic#underestimation#or#overestimation#of#the#true#intervention#effect#across#the#evidence#network.#Second,#while#there#were#several#active9comparator#trials#comparing#statins#in#terms#of#LDL#cholesterol# lowering#effects#or#harm#outcomes,# there#were#only#a# few#direct#head9to9head#trials# of# statins# that#were# prospectively# designed# to# capture# differences# in# clinical# benefit#outcomes#as#primary#endpoints.#Related#to#this#point,#there#was#an#apparent#asymmetry#in#the# evidence# network#where# specific# interventions# appeared# to# be# avoided.# In# particular,#there#was#a#paucity#of#existing#data#on#benefits#and#harms#for#fluvastatin.#For#instance,#the#relative#effect#of#fluvastatin#on#creatine#kinase#elevations#was#estimated#on#the#basis#of#only#eight#events#observed#in#four#trials# including#2,646#participants.#Similarly,#there#were#only#four# trials# of# fluvastatin,# which# reported# hepatic# transaminase# elevations,# introducing#considerable# uncertainty# (as# evident# in# extremely# wide# 95%# credible# intervals)# into# the#comparative# treatment#effects#of# this#agent.#When#present,#such#uncertainly#weakened#the#conclusions# that# could# be# drawn# on# the# comparative# benefits# and# harms# of# individual#statins.##Third,# there# was# inadequate# data# for# a# meaningful# comparison# of# individual# statins# in#primary#and#secondary#prevention.#For#instance,#there#was#no#available#all9cause#mortality#data#on#simvastatin#among#individuals#without#established#coronary#heart#disease;#no#data#on#the#effect#of#fluvastatin#and#simvastatin#on#major#coronary#events#in#primary#prevention;#and# no# data# on# the# effect# of# fluvastatin# and# rosuvastatin# on# major# coronary# events# in#secondary# prevention.# Also,# the# total# number# of# trial# participants# eligible# for# inclusion# in#sub9group# analyses# by# coronary# heart# disease# status#was# considerably# less# than# the# total#number# of# eligible# participants# included# in# base9case# analyses# including# all# populations#(overall# population).# As# a# result,# there# was# considerable# uncertainty# in# the# relative#treatment# effects# in# sub9groups# with# correspondingly# wide# 95%# credible# intervals# and#unstable#ranking#probabilities#–#again#potentially#weakening# the#clinical# interpretability#of#network#meta9analysis#findings.###
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Finally,# as# with# any# meta9analysis,# it# remains# a# possibility# that# the# analysis# did# not# fully#account#for#heterogeneity#due#to#unobserved#or#unmeasured#factors.#Given#the#large#volume#of# available# studies# in# the# literature,# the# network# meta9analyses# did# not# use# individual#patient9level# data,# which# would# have# advantages# when# exploring# potential# differences#across# relative# treatment#effect#modifiers.470#Having#access# to# individual#patient9level#data#would#offer#additional#benefits,#as#discussed#in#Chapter#9:#Future%Research%Directions,%Policy%
Implications,%and%Conclusions.##In# spite# of# these# limitations,# the# empirical# work# presented# in# this# thesis# had# important#strengths.#This#systematic#review#of#the#literature#was#the#largest#and#most#comprehensive#meta9analysis# on# statin# therapy,# and# the# first# to# investigate# the# comparative# effects# of#different#statins#using#both#placebo9controlled#and#active9comparator#trials.#Using#network#meta9analysis# methods# were# particularly# helpful# in# two# important# ways.# First,# these#methods# facilitated# the# incorporation# of# the# totality# of# the# existing# data# obtained# from#identified# randomized# controlled# trials,# allowing# for# an# in9depth# investigation# of# the#comparative# benefits# and# harms# of# individual# statins.# Second,# network# meta9analyses#allowed#for#ranking#individual#statins#on#the#basis#of#both#benefit#and#harm#outcomes.##This#analyses#presented#in#this#thesis#differed#from#previous#network#meta9analyses#in#three#important#aspects.#First,#it#incorporated#data#from#a#comprehensive#list#of#trials#irrespective#of# placebo# or# active# controls.# Although# a# large# number# of# randomized# controlled# trials#compared#statins#head9to9head,#until#the#empirical#work#presented#in#this#thesis,#findings#of#these#active9comparator#trials#were#neither#systematically#identified#nor#combined#with#the#findings# of# placebo9controlled# trials.# Previous# meta9analyses# were# pair9wise# in# nature,#which,# by# definition,# compared# two# alternatives# at# a# time.# Even# previous# attempts# at#analyzing# the# comparative# benefits# and# harms# of# multiple# statins# did# not# identify# and#include#active9comparator# trials.105,214,348,359,392#Over# the#quarter9century#history#of# statins,#there#had#not#been#any#comprehensive#review#of#the#existing#literature#evaluating#whether#individual#statins#(irrespective#of#their#cholesterol9lowering#effects)#are#different#in#terms#of#their#benefit#and#harm#profiles.##Second,#although#limited#by#data#availability,#this#review#attempted#to#provide#comparative#estimates#separately#for#the#primary#and#secondary#prevention#populations.#This#was#a#key#strength#of#the#analyses#presented#in#this#thesis#because#statin#therapy,#initially#focused#on#patients#with#established#coronary#heart#disease,#has#become#widely#common#as#the#limits#of# treatment# expanded# over# time# to# include# persons# at# progressively# lower# risk# of#developing# cardiovascular# events.# As# the# number# of# people# eligible# for# statin# therapy#continues#to#increase,#information#regarding#the#relative#clinical#value#of#statins#is#needed#to#better# inform# patients# and# prescribers.# It# is# particularly# difficult# to# determine# the# exact#
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threshold#of#the#level#of#baseline#risk#for#cardiovascular#events#at#which#to#start#prescription#or#tailor#therapy#to#patients#most#likely#to#benefit#from#statin#treatment.#Findings#presented#in#this#thesis#provide#additional#evidence#to#support#decision9making#in#clinical#practice.##
Third,# the# comparative# efficacy# and# side# effects# of# individual# statins# were# evaluated# at#different# doses.# The# majority# of# previous# meta9analyses# did# not# explicitly# address# the#potential#impact#of#dose#on#the#clinical#efficacy#and#safety#of#statins.#The#empirical#findings#presented#in#this#thesis#provide#essential#information#to#prescribers#about#the#comparative#benefits#and#harms#of#individual#statins.##
8.3!Benefits!and!Harms!of!Statins!as!a!Class:!Whether!to!Prescribe!Statins?!The# empirical# analyses# presented# in# this# thesis# provide# relevant# evidence# not# only# to#investigate# the# comparative# benefits# and# harms# of# individual# statins# but# also# to# answer#important#questions#not#fully#addressed#in#previous#reviews.#One#such#question#is#whether#statins#should#be#prescribed#for#individuals#without#established#coronary#disease#(primary#prevention# population).# Although# the# therapeutic# value# of# statins# in# the# secondary#prevention#setting#are#well#documented,# their#effectiveness# in# individuals# free#of#coronary#heart# disease# is# disputed.237# The# empirical# work# presented# in# Chapter# 5# (Comparative%
Benefits% of% Individual% Statins)# showed# that# all9cause# mortality# benefits# of# statins# were#clinically# and# statistically# significant# in# this# population.#With# reductions# estimated# at# 9%,#this# analysis# confirmed# the# survival# benefit# of# statin# therapy# observed# in# some# of# the#previous#meta9analyses.257# In#contrast# to#recent#reviews,221# this#analysis#achieved#a#higher#precision#around# the# survival#benefit# (with# statistical# significance)# as# a# result# of# including#trials#with# very# few# events# that#were# not# considered# previously.# This# finding# also# closely#paralleled# the# most# recent# individual# patient9level# meta9analysis# performed# by# the#Cholesterol#Treatment#Trialists#that#showed#that#using#statins#was#effective#in#the#primary#prevention# setting,238# providing# empirical# evidence# in# support# of# the# emerging# consensus#among#experts471#that#statins#should#be#prescribed#to#individuals#who#have#a#moderate9to9high# 109year# risk# of# developing# coronary# heart# disease,# as# estimated# by# risk# assessment#tools#commonly#used#by#prescribers#in#clinical#practice.472##While# the# findings# reported# in# Chapter# 5# (Clinical% Benefits% of% Individual% Statins)# provided#supporting#evidence#for#initiating#statin#therapy#in#individuals#who#are#at#an#increased#risk#of#developing#cardiovascular#disease,#findings#reported#in#Chapter#6#(Comparative%Harms%of%
Individual% Statins)# suggested# that# expanding# the# limits# of# statin# therapy# to# a# wider#population# of# individuals# without# cardiovascular# disease# might# have# important# safety#implications.#Although#rare,#adverse#events#associated#with#statin#therapy#range#from#mild#to#moderate,# and# appear# to# increase#with# treatment# intensity.#With# notable# exceptions,473#
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randomized# trial# evidence#on# the# long9term#safety#of# individual# statin# treatments# remains#limited.# At# the# population# level,#mortality# and# cardiovascular# benefits# of# statin# therapy# in#primary# prevention# greatly# outweigh# its# potential# harms# –# even# taking# into# account# the#recent# finding# that# statin# use# is# associated# with# a# modest# increase# in# diabetes# incidence#(Approximately#260#individuals#would#need#to#be#treated#with#statins#for#about#four#years#for#one#case#of#diabetes#to#develop.#In#contrast,#an#estimated#50#individuals#would#need#to#be# treated# for#about# four#years# to#prevent#one#major# coronary#event).371#At# the# individual#level,#however,#there#may#be#a#risk#of#exposing#a#large#group#of#individuals#to#the#(primarily#minor)#harms#of#statin#therapy#for#the#benefit#of#a#smaller#number#of#individuals.#In#addition#to#new9onset#diabetes,#statins#use# is# linked#to#(asymptomatic#and#reversible)# liver#enzyme#elevations.# At# high# doses,# statins# are# not# very# tolerable# with# patients# discontinuing#treatment#due#to#adverse#events#such#as#reversible#enzyme#elevations#potentially#indicative#of#muscle# injury#or#damage.#Although#the#risk#of#developing#diabetes# is# low,#what#this#risk#would#amount#to#over#time#is#simply#not#known#based#on#the#existing#evidence#base.#Taken#together,# the# empirical# findings# reported# in# this# thesis# suggest# that# statins# should# not# be#enthusiastically# recommended# for# individuals# at# low# risk# of# developing# coronary# heart#disease.161# In# addition,# compelling# evidence# suggests# that# non9pharmacological#interventions# may# be# as# effective# as# drug# therapy# in# many# chronic# illnesses,# including#coronary#heart#disease.474#Such#interventions#may#substitute#or#complement#drug#therapy#in#individuals#at#low#risk#of#developing#coronary#heart#disease.#!
8.4!Comparative!Benefits!and!Harms!of!Individual!Statins:!Which!Statin!to!Prescribe?!“What#is#the#drug#of#choice#for#condition#x?”#is#among#the#most#commonly#asked#questions#in# primary# care.475# Reflecting# the# complexity# of# prescribing# decisions,# answering# this#question#requires#a#difficult#trade9off#between#the#benefits#and#harms#of#multiple#drugs#for#a#given#condition.# In# the#case#of# statin# therapy# for# the#primary#and#secondary#prevention#of#coronary# heart# disease,# there# are# several# important# benefit# and# harm# outcomes,# which#include#all9cause#mortality,#major#coronary#events,#major#cerebrovascular#events#(in#terms#of# benefit# outcomes),# and# discontinuations# due# to# adverse# events,# myalgia,# hepatic#transaminase#elevations,#creatine#kinase#elevations,#and#most#recently,#new9onset#diabetes#(in#terms#of#harm#outcomes).##One# conceivable#way# to# simplify# therapeutic# considerations# for# choosing# among# different#statin# options# would# be# to# prioritize# major# coronary# events# and# discontinuations# due# to#adverse# events# over# other# benefit# and# harm# outcomes.# Such# an# approach# (albeit#hypothetical)#would#be#justifiable#on#the#grounds#that#prevention#of#major#coronary#events#is#among#the#fundamental#goals#of#statin#therapy:#although#not#always#fatal,#major#coronary#events#often#result#in#severe#pain#and#lifelong#disability.#In#a#similar#fashion,#monitoring#and#
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minimizing# discontinuations# due# to# adverse# events# is# an# important# aspect# of# prescription#drug# therapy# since# this# outcome# is# indicative# of# the# acceptability# and# tolerability# of#pharmacological#treatment#and#encompasses#a#range#of#reasons#for#withdrawing#treatment#because#of#side#effects.##According# to# the# findings# presented# in# Chapters# 5# (Comparative% Benefits% of% Individual%
Statins)#and#6#(Comparative%Harms%of%Individual%Statins),#there#were#a#number#of#statistically#detectable#differences#among#individual#statins#in#terms#of#both#major#coronary#events#and#discontinuations# due# to# adverse# events# (Table# 8.1).# For# example,# individuals# receiving#fluvastatin#(OR:#0.59,#95%#CrI:#0.36,#0.95)#and#atorvastatin#(OR:#0.66,#95%#CrI:#0.48,#0.94)#had# lower# odds# of# experiencing# major# coronary# events# as# compared# to# those# receiving#rosuvastatin.# Individuals# randomized# to# rosuvastatin#were# also#more# likely# to#discontinue#treatment# due# to# experiencing# adverse# events# as# compared# to# those# receiving#pravastatin#(OR:# 1.45,# 95%#CrI:# 1.06,# 1.96# –# the# reciprocal# of# this# finding# is# reported# in# Table# 1)# and#simvastatin#(OR:#1.31,#95%#CrI:#1.00,#1.73).#There#was#statistical#evidence#that#atorvastatin#was# less# tolerable# than#other#statins:# individuals#receiving#atorvastatin#had#higher#odds#of#discontinuing# treatment#due# to#adverse#events#as#compared#to# those#receiving#pravastatin#(OR:#1.46,#95%#CrI:#1.11,#1.92)#and#simvastatin#(OR:#1.32,#95%#CrI:#1.05,#1.68).###Considering# these# findings# in# terms# of# ranking# probabilities,# fluvastatin# had# the# most#favorable#efficacy#profile#followed#by#atorvastatin#based#on#the#available#evidence#on#major#coronary# events# (Figure# 8.2):# fluvastatin# and# atorvastatin# had# the# highest# probability# of#ranking# best# and# second# best# treatments,# respectively.# This# reflected# the# statistically#detectable# differences# among# individual# statins,# favoring# atorvastatin# and# fluvastatin# at#comparable#doses#(Table#8.1).#Unsurprisingly,#the#findings#suggested#that#control#treatment#had#the#highest#probability#of#ranking#last#in#terms#of#its#effect#in#reducing#major#coronary#events.#While#pravastatin#and#simvastatin#had#the#most#favorable#tolerability#profile#among#statins,# i.e.,# had# the# highest# probability# of# ranking# best# in# terms# of# their# effect# on#discontinuations# due# to# adverse# events,# atorvastatin# and# rosuvastatin# had# similarly# high#probabilities#of#ranking#last#on#this#outcome.##Taking# into# account# additional# outcomes# complicate# the# therapeutic# considerations# for#choosing#among#different#options,#as#individual#statins#differ#in#terms#of#their#comparative#effects#on#different#benefit#and#harm#outcomes.#For#example,#trial#participants#randomized#to# fluvastatin# appeared# to# experience# numerically# fewer#major# cerebrovascular# events# as#compared# to# those# randomized# to# other# statins# although# this# finding#was# not# statistically#significant#(Table#8.1).#While#fluvastatin#performed#worse#than#pravastatin#(OR:#5.19,#95%#CrI:#1.75,#16.70),# rosuvastatin# (OR:#3.25,#95%#CrI:#1.08,#10.50),# and# simvastatin# (OR:#4.50,#95%#CrI:#1.49,#14.20)#in#terms#of#hepatic#transaminase#elevations,#it#performed#better#than#
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atorvastatin# (OR:# 0.18,# 95%# CrI:# 0.04,# 0.82# –# the# reciprocal# of# this# finding# is# reported# in#Table#8.1),#pravastatin#(OR:#0.20,#95%#CrI:#0.04,#0.88),#rosuvastatin#(OR:#0.18,#95%#CrI:#0.04,#0.81),#and#simvastatin#(OR:#0.20,#95%#CrI:#0.04,#0.94)#in#terms#of#creatine#kinase#elevations.#Finally,# individuals# receiving# atorvastatin# had# higher# odds# of# experiencing# hepatic#transaminase# elevations# than# those# receiving# pravastatin# (OR:# 2.55,# 95%# CrI:# 1.54,# 4.14),#rosuvastatin#(OR:#1.60,#95%#CrI:#1.06,#2.38),#and#simvastatin#(OR:#2.20,#95%#CrI:#1.36,#3.52).#
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Table&8.1&–&Comparative.benefits.and.harms.of.individual.statins.according.to.network.meta;analyses.across.all.populations.*.
& Fluvastatin& Lovastatin& Pravastatin& Rosuvastatin& Simvastatin& Outcome& Outcome&&
Atorvastatin&
vs.&
1.11.(0.42,.2.79). 0.78.(0.52,.1.14). 0.91.(0.72,.1.11). 0.85.(0.64,.1.07). 0.99.(0.73,.1.28). Total.mortality. Benefit.1.13.(0.70,.1.85). 0.83.(0.57,.1.16). 0.82.(0.65,.1.11). 0.66$(0.48,$0.94)$ 0.83.(0.58,.1.10). Major.coronary.events.1.45.(0.32,.7.14). 1.07.(0.56,.1.98). 0.87.(0.64,.1.20). 0.87.(0.64,.1.20). 1.05.(0.79,.1.47). Major.cerebrovascular.events.0.95.(0.63,.1.45). 1.24.(0.84,.1.87). 1.46$(1.11,$1.92)$ 1.01.(0.82,.1.25). 1.32$(1.05,$1.68)$ Discontinuations.due.to.adverse.events. Harm.1.08.(0.56,.2.17). 0.87.(0.54,1.46). 1.10.(0.77,.1.53). 0.88.(0.71,.1.08). 1.28.(0.88,.1.80). Myalgia.0.49.(0.15,.1.42). 1.26.(0.57,.2.73). 2.55$(1.54,$4.14)$ 1.60$(1.06,$2.38)$ 2.20$(1.36,$3.52)$ Transaminase.elevations.
5.59$(1.22,$25.5)$ 1.32.(0.54,.2.88). 1.13.(0.65,.1.78). 0.99.(0.64,.1.53). 1.13.(0.65,.1.97). Creatine.kinase.elevations.
Fluvastatin&
vs.& ;.
0.71.(0.26,.1.87). 0.82.(0.33,.2.13). 0.76.(0.30,.2.00). 0.89.(0.34,.2.32). Total.mortality. Benefit.0.74.(0.42,.1.20). 0.73.(0.48,.1.16). 0.59$(0.36,$0.95)$ 0.74.(0.43,.1.15). Major.coronary.events.0.73.(0.13,.3.68). 0.61.(0.12,.2.73). 0.60.(0.12,.2.67). 0.74.(0.15,.3.33). Major.cerebrovascular.events.1.30.(0.81,.2.10). 1.53.(0.98,.2.34). 1.06.(0.68,.1.63). 1.39.(0.88,.2.14). Discontinuations.due.to.adverse.events. Harm.0.81.(0.37,.1.71). 1.02.(0.48,.2.02). 0.82.(0.40,.1.58). 1.19.(0.56,.2.37). Myalgia.2.58.(0.76,.9.03). 5.19$(1.75,$16.7)$ 3.25$(1.08,$10.5)$ 4.50$(1.49,$14.2)$ Transaminase.elevations.0.24.(0.05,.1.17). 0.20$(0.04,$0.88)$ 0.18$(0.04,$0.81)$ 0.20$(0.04,$0.94)$ Creatine.kinase.elevations.
Lovastatin&vs.& ;. ;.
1.16.(0.80,.1.68). 1.08.(0.73,.1.61). 1.26.(0.84,.1.89). Total.mortality. Benefit.0.99.(0.74,.1.47). 0.79.(0.56,.1.22). 1.00.(0.69,.1.38). Major.coronary.events.0.81.(0.46,.1.49). 0.82.(0.43,.1.55). 0.99.(0.54,.1.86). Major.cerebrovascular.events.1.17.(0.77,.1.78). 0.81.(0.53,.1.25). 1.06.(0.69,.1.63). Discontinuations.due.to.adverse.events. Harm.1.26.(0.70,.2.15). 1.00.(0.58,.1.68). 1.46.(0.80,.2.54). Myalgia.2.03.(0.90,.4.56). 1.27.(0.55,.2.93). 1.76.(0.75,.4.12). Transaminase.elevations.0.84.(0.39,.1.94). 0.76.(0.34,.1.85). 0.86.(0.37,.2.23). Creatine.kinase.elevations.
Pravastatin&
vs.& ;. ;. ;.
0.93.(0.75,.1.17). 1.08.(0.85,.1.39). Total.mortality. Benefit.0.81.(0.58,.1.04). 1.02.(0.68,.1.24). Major.coronary.events.1.00.(0.75,.1.30). 1.21.(0.94,.1.57). Major.cerebrovascular.events.
0.69$(0.51,$0.94)$ 0.91.(0.67,.1.24). Discontinuations.due.to.adverse.events. Harm.0.80.(0.55,.1.19). 1.17.(0.74,.1.82). Myalgia.0.63.(0.36,.1.10). 0.87.(0.47,.1.57). Transaminase.elevations.0.89.(0.51,.1.63). 1.01.(0.55,.2.00). Creatine.kinase.elevations.
Rosuvastatin&
vs.& ;. ;. ;. ;.
1.16.(0.88,.1.53). Total.mortality. Benefit.1.27.(0.82,.1.67). Major.coronary.events.1.21.(0.88,.1.69). Major.cerebrovascular.events.
1.31$(1.00,$1.73)$ Discontinuations.due.to.adverse.events. Harm.1.46.(0.98,.2.14). Myalgia.1.38.(0.79,.2.38). Transaminase.elevations.1.14.(0.62,.2.19). Creatine.kinase.elevations.
*.Estimates.shown.are.ORs.and.95%.CrIs,.as.previously.presented.in.Chapters.5.and.6..Table.should.be.read.from.left.to.right..
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Figure& 8.2& –. Distribution. of. ranking. probabilities. for. individual. statins. for. major. coronary. events. and. discontinuations. due. to. adverse. events.*..
.*.Ranking.for.each.treatment.indicates.the.probability.to.be.the.best.treatment,.the.second.best,.the.third.best,.and.so.on..For.simplicity,.this.figures.provides.the.relative.ranking.probabilities.for.only.two.outcomes..Tolerability.depicts.discontinuations.due.to.adverse.events.whereas.efficacy.refers.to.primary.and.secondary.prevention.of.major.coronary.events..
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Given) the) difficulty) in) interpreting) the) findings) from) multiple) network) meta;analyses) on)several)benefit)and)harm)outcomes,)Table)8.2)shows)the)overall)ranking)of)individual)statins)for)each)benefit)and)harm)outcome.))
Table&8.2&–)Overall)ranking)of)individual)statins)by)their)probability)to)be)the)best)treatment)in)terms)of)benefit)and)harm)outcomes.*))
) Atorva& Fluva& Lova& Prava& Rosuva& Simva&
All;cause)mortality) 3) 1& 6) 4) 5) 2)Major)coronary)events) 2) 1& 5) 4) 6) 3)Major)cerebrovascular)events) 4) 2) 3) 5) 6) 1&Discontinuations)due)to)adverse)events) 6) 5) 3) 1& 4) 2)Myalgia) 4) 2) 5) 3) 6) 1&Transaminase)elevations) 5) 6) 4) 1& 3) 2)Creatine)kinase)elevations) 6) 1& 2) 3) 5) 4)*) Atorva:) atorvastatin;) Fluva:) fluvastatin;) Lova:) lovastatin;) Prava:) pravastatin;) Rosuva:)rosuvastatin;)Simva:)simvastatin.))
Figure)8.3)presents)the)combined)benefit)and)harm)profiles)of)individual)statins)where)the)ranking) probabilities) for) individual) statins) on) different) outcomes) are) summarized) into) a)single) number) (surface) under) the) cumulative) ranking) line,) SUCRA),324) showing) the)contribution) of) each) outcome) to) the) overall) benefit) and) harm) score) for) each) statin.)According) to) this) figure,) fluvastatin) ranked) first) in) terms) of) its) clinical) efficacy) with) an)overall) score)of)0.83)out)of)1.00,) followed)by)atorvastatin)with)0.71,) and) simvastatin)with)0.65.) When) ranked) on) the) basis) of) combined) harm) outcomes,) pravastatin) (0.71)) and)simvastatin)(0.70))appeared)to)perform)better)than)other)statins.))Putting)both)benefit)and)harm)outcomes)together,)Figure)8.4)shows)the)overall)comparative)benefit)and)harm)profiles)of) six)statins)where) the)size)of)each)circle) is)proportional) to) the)number)of)randomized)participants)included)in)the)published)placebo;controlled)and)active;comparator)trials)of)statins.)According)to)this)figure,)simvastatin)appeared)to)have)the)most)favorable) benefit;harm) profile:) although) both) fluvastatin) and) atorvastatin) had) higher)combined) benefit) scores,) simvastatin) had) a) considerably) higher) combined) harm) score)(Figure) 8.4).) This) figure) also) highlights) the) paucity) of) available) data) on) some) statins.) In)particular,)considerably)fewer)individuals)received)fluvastatin)and)lovastatin)as)compared)to)other)statins.))An) important) limitation)of) summarizing) the)empirical) findings)of) the)previous)chapters)as)presented)in)Figure)8.4)is)the)underlying)assumption)that)all)benefit)and)harm)outcomes)are)
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equally) important,)and)hence)contribute)equally) to) the)combined)benefit)and)harm)scores.)Considering) the) types) of) outcomes) evaluated) in) the)network)meta;analyses) (ranging) from)minor)reversible)liver)enzyme)irregularities)to)deaths),)this)assumption)does)not)hold.)It) is)possible)that)prescribers)initiating)statin)therapy)in)individuals)with)high)cholesterol)levels)would) consider) long;term) benefits) to) be)more) important) than) short;to;intermediate) term)harms.)As)such,)prescribers)may)select)fluvastatin)given)its)favorable)benefit)score)for)long;term) benefits.) Alternatively,) prescribers) prioritizing) harm) outcomes) (for) example) among)frail)elderly)patients))may)prefer)pravastatin)given)its)favorable)harm)profile.)))
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 *) (A)) all;cause) mortality,) major) coronary) events,) and) major) cerebrovascular) events,) and) (B))discontinuations) due) to) adverse) events,)myalgia,) transaminase) elevations,) and) creatine) kinase)elevations.) Each) statin) was) scored) with) points) up) to) a) maximum) of) 1.00,) with) higher) scores)indicating)better)benefit)and)harm)profiles,)taking)into)account)the)magnitude)and)uncertainty)of)the)cumulative)probability)of)being)the)best)treatment.)Each)benefit)outcome)contributed)1/3)of)the)total)benefit)score,)and)each)harm)outcome)contributed)1/4)of)the)total)harm)score.)
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Figure&8.4&–)Comparative)benefit;harm)profiles)of)individual)statins)on)the)basis)of)placebo;controlled)and)active;comparator)trials.*) )
)*)The)figure)combines)the)overall)benefit)(all;cause)mortality,)major)coronary)events,)and)major)cerebrovascular) events)) and) harm) (discontinuations) due) to) adverse) events,) myalgia,)transaminase)elevation,)and)creatine)kinase)elevation))scores)for)each)statin)estimated)based)on)cumulative)probabilities)of)being)the)best)treatment.)The)size)of)each)circle)is)proportional)to)the)number) of) randomized) participants) according) to) the) systematic) review) of) published) placebo;controlled)and)active;comparator)trials)of)statins.)
Insofar)as)the)systematic)review)and)network)meta;analysis)reported)in)this)thesis)provided)much;needed) answers) regarding) the) comparative) effects) of) individual) statins,) it) also)highlighted) the) challenging)nature)of)making) sense)of) the) existing)evidence)on)harms)and)benefits)of)multiple)alternatives,)and) their) trade;offs.)Although) it)provided)evidence)of) the)benefits)and)harms)comparatively,)synthesizing)a)large)volume)of)complex)information,)this)comprehensive) review) did) not) conclusively) distinguish) between) individual) statins,)complicating)the)decision)around)which)statin)should)be)preferred)as)the)first)drug)of)choice)in)clinical)practice,)and)underscoring)the)challenges)facing)prescribers)who)are)charged)with)basing) their) decisions) on) this) body)of) evidence.) Compounding) this) problem,) there)was)no)clear) winner) among) statins) (i.e.,) no) statin) outperformed) its) competitors) in) terms) of) both)benefit)and)harm)outcomes),)leaving)it)up)to)the)prescriber)to)decide)whether)–)and)to)what)extent)–)long;term)clinical)benefits)seemed)to)outweigh)more)intermediate;term)harms)for)any)given)statin.)&The)complexity)of)prescription)drug)therapy)stems)from)the)difficulty) in)making)trade;offs)between)the)benefits)and)harms)of)two)or)more)options.)Frustrating)for)prescribers,)there)is)a) lack) of) a) conceptual) framework) with) regard) to) balancing) the) benefits) and) harms) of)
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prescription)drugs.)Increasingly,)however,)researchers)are)turning)to)multi;criteria)decision)analysis)for)these)kinds)of)decision)problems,476)which)is)a)formal)framework)for)analysis)of)complex)decision)problems)involving)trade;offs)between)multiple)outcomes.477)An)attractive)feature) of) multi;criteria) decision) analysis) is) that) it) applies) qualitative) preferences) on)different)outcomes,)allowing)for)a)transparent)judgment)on)their)relative)importance.478,479))Combining) network) meta;analysis) with) multi;criteria) decision) analysis) could) potentially)greatly) improve) the) interpretability) of) existing) evidence) by) making) explicit) the) difficult)trade;offs) between) outcomes.) When) applied) to) prescription) drug) therapy,) multi;criteria)decision) analysis) consists) of) four) key) elements.477) First) is) choosing) the) alternatives) to) be)appraised) (e.g.,)multiple) drugs) in) a) given) class).) Second) is) deciding) on) the) criteria) against)which) the) alternatives) are) appraised) (e.g.,) different) benefit) and) harm) outcomes).) Third) is)estimating) the) comparative) performance) of) each) alternative) on) each) criterion) (e.g.,)comparative)effects)of)each)drug)on)different)benefit)and)harm)outcomes).)Finally,)fourth)is)determining) the) criteria) weights) that) indicate) the) relative) values) of) each) criterion) as)compared)to)others)(e.g.,)preferences)about)the)relative)importance)of)different)benefit)and)harm)outcomes).))An)important)advantage)of)potentially)combining)network)meta;analysis)with)multi;criteria)decision)analysis)is)that)this)combined)approach)would)allow)prescribers)to)weight)different)outcomes)differently)and)see)how)drug)rankings)change)according)to)individual)preferences.)Such)explicit)trade;offs)would)be)necessary)when)incorporating)the)empirical)findings)of)this)thesis) to)clinical)practice)guidelines,) thereby)translating) the)current)best)evidence) to)high;quality)prescribing)decisions)in)clinical)practice.)First,)clinical)practice)guideline)developers)may) consider) incorporating) the) findings) of) this) systematic) review) and) network) meta;analysis) alongside) multi;criteria) decision;analysis) to) make) explicit) trade;offs) between)multiple)clinical)benefit)and)harm)outcomes.486)Second,)the)summary)of)the)existing)clinical)literature)on)statins)can)be)combined)with)prescriber)knowledge)and)patient)preferences)at)point;of;care)settings)when)making)prescribing)decisions.)For)example) this)might) take) the)form) of) a) decision) support) tool) that) relies) on) the) findings) of) published) network) meta;analyses,)which)can)then)be)considered)in)light)of)user)knowledge)and)preferences.487)A)key)advantage) of) this) approach) would) be) that) preferences) used) to) determine) the) relative)importance) of) different) benefit) and) harm) outcomes) can) reflect) those) of) patients.488)Considering) patient) values) would) facilitate) shared) decision;making) between) patients) and)prescribers)in)choosing)among)multiple)drugs.)
8.5&Generalizability&of&Findings:&To&Whom&Do&the&Results&Apply?&Another) important) consideration) for)prescribers) is)deciding)whether) (and) to)what)extent))the)findings)of)this)review)apply)to)individuals)in)clinical)practice,)and)if)so,)which)groups)of)
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individuals.!Generalizability) of) the) findings) of) the) network)meta;analysis) depends) on) the)external) validity) of) the) individual) randomized) controlled) trials) included) in) the) analysis.)External) validity) is) the) relevance)of) a) trial’s) results) to) clinical) practice) and) the) confidence)with)which)the)results) from)a)specific) trial)population)can)be)applied) to)other)populations)and)settings.489)For)instance,)there)is)concern)that)older)adults)enrolled)in)clinical)trials)may)not) be) representative) of) the) general) population) of) older) adults,) potentially) limiting) the)application)of) the) findings)to)broader)categories)of)patients.)This) is)primarily)attributed)to)the) co;morbid) conditions) and) the) burden) of)multiple) other)medications) in) older) adults.49)However,)due)to)the)comprehensive)nature)of)the)systematic)review)that)forms)the)basis)of)the) network)meta;analysis) presented) in) this) thesis,) the) findings)would) be) expected) to) be)generalizable) to) the)majority) of) patients) in) clinical) practice.) This) review) included) a) broad)range)of)patients)and)the)benefits)of)statins)appeared)consistent)in)studies)with)populations)that)varied) in)age,)geographic)region,)and)severity)of)underlying) illness,)which)adds) to) the)strength)of)the)overall)inferences.))From) a) clinical) standpoint,) pre;defined) inclusion) and) exclusion) criteria) ensured) that) the)trials) identified) in) the)review)(and) included) in) the)statistical)analysis))were)comparable) in)terms) of) important) baseline) characteristics.) Given) the) continuous) relationship) between)cholesterol) concentrations) and) coronary) heart) disease) risk,) no) definite) threshold) exists)above)which)patients)must)be) treated) –) and) the)decision) to) treat) “high”) cholesterol) levels)depends)more)on)the)expected)risk)reduction.)As)a)result,) there)were)potential)differences)across)patient)populations)included)in)the)network)meta;analysis.)Randomized)trials)varied)considerably) in) terms)of)entry)criteria)and)patients)differed) in) terms)of) their)co;morbidity)profiles.)Including)trials)with)variable)patient)populations)was)justified)on)the)grounds)that)the)benefits) of) statins) are) consistent) across) a)wide) range)of) populations)with)diverse) risk)profiles.) For) instance,) the) largest) randomized) trial) ever) conducted) on) statins,) the)Medical)Research) Council/British) Heart) Foundation)Heart) Protection) Study) (HPS),)which) included)over) 10,000) individuals,) showed) that) the) benefits) of) statins) extended) to) a) wide) range) of)patients)at)risk)from)cardiovascular)events,)including)those)with)peripheral)vascular)disease,)cerebrovascular)disease,)diabetes,)and)hypertension,)with)no)detectable)differences)between)different)age)groups)and)genders.139))Similar) to) previous) reviews,) the) network) meta;analysis) presented) in) this) thesis) did) not)differentiate) between) individuals) with) and) without) diabetes) (no) separate) sub;group)analyses)were)conducted) for)groups)of) individuals)with)and)without)diabetes).)Diabetes) is)considered)as)a)coronary)heart)disease)risk)equivalent.154)The)risk)of)myocardial)infarction)in) patients) with) diabetes) without) a) history) of) myocardial) infarction) is) as) high) as) that) in)patients)without)diabetes)who)have)had)a)myocardial)infarction.)The)meta;analysis)by)Costa)and) colleagues) showed) that) (in) trials)with) at) least) three) years) of) follow;up)) reductions) in)
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&Future)Research)Directions,)Policy)Implications,)and)Conclusions*)))Statins)are)among)the)most)widely)prescribed)classes)of)drugs,)used)to)prolong)survival)and)reduce) the) risk) of) deaths,) heart) attacks,) strokes,) and) other) coronary) events.220,238,493,494) In)addition)to)their)favorable)clinical)effects,)statins)are)also)generally)safe)with)regards)to)rare)adverse) events.381,382) Although) a) large) number) of) published) randomized) controlled) trials)compared) statins) head;to;head,) findings) of) these) active;comparator) trials) were) neither)systematically) identified) nor) combined) with) the) findings) of) placebo;controlled) trials.)Previous)meta;analyses)were) pair;wise) in) nature,) i.e.,) compared) two) treatments) at) a) time)(e.g.,) atorvastatin) vs.) placebo).) As) discussed) in) Chapter) 3) (Evidence! Review! and! Synthesis!
Methods),)traditional)pair;wise)meta;analysis)is)incapable)of)comparing)multiple)treatments)simultaneously.95)Even)previous)attempts)at)analyzing)the)comparative)benefits)and)harms)of)multiple)statins)did)not)identify)and)include)active;comparator)trials.105,214,348,359,392)Thus,)over)the)quarter)century)history)of)statins,)there)has)not)been)any)comprehensive)review)of)the) existing) literature) evaluating) whether) –) and) to) what) extent) –) individual) statins) at)comparable) doses) (with) similar) LDL) cholesterol) lowering) effects)) are) interchangeable) in)terms)of)their)benefit)and)harm)profiles.))Although) the) systematic) review) and) network) meta;analysis) provides) comprehensive)evidence)on)the)comparative)benefits)and)harms)of)individual)statins,)as)with)any)research)endeavor,) the) empirical) work) presented) in) this) thesis) constitutes) an) unfinished) research)agenda.) Future) research) directions) are) several,) and) include) further) investigating) the)potential) mechanisms) underpinning) the) observed) comparative) effectiveness) of) individual)statins;) exploring) how) best) to) incorporate) patient) preferences) into) statin) prescribing)decisions)in)clinical)practice;)and)developing)a)framework)for)future)evaluations)of)industry)sponsorship)bias)in)cardiovascular)diseases)and)beyond.))
                                                *)Part)of)the)contents)of)this)chapter)has)been)was)published)with)the)following)reference:)Naci)H,)O’Connor) AB.) Assessing) comparative) effectiveness) of) new) drugs) before) approval) using)prospective)network)meta;analyses.)J)Clin)Epidemiol.)2013)Aug;66(8):812;6.)
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9.1&Future&Research&Directions&A) number) of) questions) about) the) comparative) benefits) of) individual) statins) remain)unanswered.) First,) the) observed) effects) of) statins) on) all;cause) mortality,) major) coronary)events,)and)major)cerebrovascular)events)(as)reported)in)Chapter)5:)Comparative!Benefits!of!
Individual! Statins)) are) not) entirely) commensurate) with) their) LDL) cholesterol;lowering)effects,)suggesting)that)mechanisms)beyond)cholesterol;lowering)may)be)responsible)for)the)cardiovascular) risk) reduction) associated) with) statin) therapy.) Supporting) this) view,) other)products) (such) as) ezetimibe)) that) successfully) lower) LDL) cholesterol) have) failed) to)convincingly) reduce) the) risk) of) all;cause) mortality,) major) coronary) events,) and) major)cerebrovascular)events.495;498))Researchers) have) previously) suggested) that) statins) have) pleiotropic) effects) beyond) their)LDL)cholesterol) lowering)effects.499;501)Based)on)a)review)of)the)experimental) literature)on)the) antiatherosclerotic) and) antithrombotic) effects) of) fluvastatin,) for) example,) Corsini)concluded) that) the) effects) of) fluvastatin) may) extend) beyond) cholesterol) lowering.502) In)addition,) a) recent) meta;analysis) by) Broekholdt) and) colleagues) showed) that) non;HDL)cholesterol) had) a) more) important) role) than) LDL) cholesterol) in) preventing) the) risk) for)cardiovascular)events.347)In)a)similar)fashion,)emerging)evidence)suggests)that)statins)have)anti;inflammatory) effects) that) that) may) be) partially) responsible) for) their) efficacy) in)preventing) coronary) heart) disease.503;505) Whether) these) potential) pleiotropic) and) anti;inflammatory) effects) –) and) cholesterol) lowering) effects) that) extend) beyond) LDL) –) are)responsible)for)the)finding)that)less)potent)statins)are)equivalent)or)better)than)more)potent)alternatives) needs) further) examination.) Potential) future) research) opportunities) include)exploring)the)comparative)anti;inflammatory,)antithrombotic,)and)non;HDL;lowering)effects)of) individual) statins) and) investigating) the) relationship) between) these) factors) and)cardiovascular)disease)risk.))Similarly,)further)investigation)is)warranted)on)the)comparative)harms)of)individual)statins.)For) each) of) the) tolerability) and) harm) outcomes) that) were) evaluated) in) Chapter) 6)(Comparative!Harms!of! Individual!Statins),) information)was)available) in) less)than)half)of)all)randomized)participants)across)all)randomized)controlled)trials)of)statins.)This)is)consistent)with)other)therapeutic)areas)where)reporting)of)harmful)adverse)events)remains)stubbornly)inadequate.506,507)In)addition,)outcomes)in)each)trial)were)extracted)as)they)were)originally)reported)in)the)published)accounts)of)the)trials)(i.e.,)as)defined)by)trial)investigators),)which)potentially)introduced)variability)in)outcome)definitions.)To)build)upon)the)empirical)work)presented)in)Chapter)6,)an)important)research)opportunity,)devised)in)collaboration)with)Dr.)John) P.) Ioannidis) of) Stanford) University,) is) to) seek) individual) patient;level) data) on)standardized)tolerability)and)harm)outcomes)from)the)investigators)of)all)identified)placebo;
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controlled)and)active;comparator)trials)of)statins)reporting)tolerability)and)harm)outcomes.)Performing)more)detailed)network)meta;analyses)using)individual)patient;level)data)would)yield)new)insights)about)the)comparative)harms)of)individual)statins,)with)the)possibility)to)explore)additional)outcomes,)such)as)acute)kidney) injury)associated)with)statin)therapy,380)that)were)rarely)reported)in)the)published)literature.))Using)individual)patient;level)data)would)have)additional)benefits,508)particularly)to)evaluate)whether)patient;level) characteristics,) such) as)different) comorbidity)profiles,) are) related) to)statin) efficacy.509) Previous) studies) have) shown) that) incorporating) individual) patient;level)data) into) network) meta;analyses) produces) markedly) more) accurate) treatment;covariate)interaction) estimates) than) an) analysis) using) aggregate) study;level) data) alone.470) Methods)exist)to)synthesize)both)individual)patient;level)and)aggregate)study;level)data,)allowing)for)an) exploration) of) potential) relative) treatment) effect) modifiers) that) are) available) in) a)combination) of) individual) patient;level) and) study;level) aggregate) data.510)Using) individual)patient;level) data) would) also) facilitate) a) more) standardized) analysis) of) outcomes.) The)majority)of)the)included)statin)trials)reported)their)results)as)composite)endpoints.)Although)composite)end)points)increased)the)event)rate)and)thus)the)statistical)power)of)trial)results,)they) have) previously) been) criticized) as) they) may) provide) misleading) information) if)component)end)points)are)of)widely)differing)importance)to)patients,)and)the)magnitude)of)effect) differs) markedly) across) components.467;469) Given) the) paucity) of) more) granular)outcome) information) in) the) published) accounts) of) randomized) controlled) trials,) a) careful)examination) of) disaggregated) endpoints) (e.g.,) fatal) vs.) non;fatal) myocardial) infarctions))would)be)possible)with)access)to)individual)patient;level)data.))Another)future)research)opportunity)relates)to)the)important)yet)largely)unfulfilled)promise)of) evidence;based)prescribing.)As)highlighted) throughout) this) thesis,)prescribing)decisions)are)complex)and) incorporating)scientific)evidence) into)such)decisions)remains)challenging.)Even) in) cases)when) comparative) evidence) on) drugs) exists,) prescribers) and) patients) often)struggle) to)weigh) the) relative)benefits) and)harms)of)multiple) alternatives.)As)discussed) in)Chapter)8)(Evidence=Based!Decision=Making:!Going!from!Evidence!to!Prescribing),)there)is)an)opportunity) to) adopt) a) more) formal) framework) to) help) prescribers) and) patients) in)identifying) a) first) line) drug) among) multiple) alternatives.) One) option) is) to) adopt) decision)analysis)methods) to) encourage) and) facilitate) shared)decision)making)between)prescribers)and) patients,) by) specifically) combining) network)meta;analysis) and)multi;criteria) decision)analysis.)However,)considerable)research)is)required)before)this)vision)can)become)reality.)Important)questions)that)remain)unanswered)are)several,)and)include:)Can)patients)reliably)distinguish)between)different)outcomes?)What)is)the)best)forum)for)sharing)the)findings)of)network)meta;analyses)with)patients)(e.g.,)decision)support)tools,)online)education)portals,)printed)materials)?)What) is) the) ideal)setting)to)engage)patients)and)seek)their)preferences)
 266 
about)different)outcomes)(e.g.,)clinical)practice,)home,)other)community)setting)?)Combining)network) meta;analysis) and) multi;criteria) decision) analysis) would) also) allow) for) the)incorporation) of) additional) considerations) that) would) influence) the) interpretation) of)existing)evidence.)For)example,)one)possibility)would)be)to)put)less)weight)on)the)treatments)that)have)only)minimal)evidence.))Finally,) findings) of) Chapter) 7) (Methodological! Quality! and! Risk! of! Bias! in! Randomized!
Controlled!Trials!of!Statins))highlight) the)need)for) further)research) into)the)empirical)basis)for) industry) sponsorship) biases,) and) the) importance) of) adopting) study) designs,) such) as)network)meta;analysis,)which)are) capable)of)distinguishing)between) industry) sponsorship)bias)and)actual)differences)between) treatments)and)doses.)For) the)analyses)presented) in)Chapter) 7) of) this) thesis,) statins) provided) an) excellent) case) study) to) explore) industry)sponsorship) bias:) all) six) statins) are) manufactured) by) competing) pharmaceutical)companies) and) each) company) conducted)head;to;head) trials) of) their) products) against)alternative) agents) sponsored) by) other) companies.)As) empirically) shown) in) Chapter) 4)(Dose=Comparative! Effects! of! Individual! Statins),) there) are) actual) differences) in) the)effectiveness) of) individual) statins) that,) when) taken) into) account,) explain) previous)findings)of)industry)sponsorship)bias.)Future)empirical)evaluations)should)investigate)the)validity) of) previously) observed) associations) between) industry) sponsorship) and) study)findings)and)conclusions)in)other)therapeutic)areas.)The)particular)mechanisms)underlying)the)phenomenon)of)sponsorship)bias)needs)further)research.)One)such)possibility)would)be)to)put)less)weight)on)treatment)options)that)have)relatively)minimal)evidence)as)compared)to)their)alternatives,)which)might)reflect)a)biased)research)agenda.))
9.2&Policy&Implications&In) the) absence) of) comparative) evidence,) marketing) claims) have) historically) driven) statin)prescriptions) –) with) sales) of) five) statins) trailing) behind) those) of) atorvastatin) (Lipitor®,)Pfizer).)In)recent)years,)Pfizer’s)continued)marketing)efforts)on)atorvastatin)despite)cheaper)generic) competition) helped) it) become) the) best;selling) medication) in) history.511) Indeed,)atorvastatin)in)its)brand)formulation)is)the)most)commercially)successful)drug)of)all)time)in)terms)of)peak)annual)performance,) lifetime) sales,) and) cumulative) sales)during) the) first)10)years)of)availability.512)Over)the)course)of)its)lifetime,)atorvastatin)has)generated)global)sales)of)almost)$150)billion.513)Between)2004)and)2010,)it)was)the)best)selling)medication)in)the)US)in)terms)of)the)number)of)units)sold.514)In)2010,)its)sales)in)the)United)States)totaled)$7.2)billion.515))Even) by) the) pharmaceutical) industry’s) standards,) Pfizer’s) marketing) strategy) has) been)exceptional) in) its) scope) and) magnitude,) making) atorvastatin) a) blockbuster) statin) shortly)
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after) its)market) entry.) ) As) reported)by) the)USA)Today) in)2011)before) atorvastatin) lost) its)patent)protection:516))Pfizer)spent)tens)of)millions)of)dollars)on)sales)and)marketing)efforts,)including)on)the)popular)drama)"ER,")first)urging)patients)to)"Know)Your)Numbers")and)then)showing)patients)discussing)how)Lipitor)helped)them)get)their)cholesterol)numbers)below)guideline)goals.)The)Lipitor)promotion)team)set)new)standards)for) a) marketing) campaign.) They) repeatedly) visited) family) doctors) as) well) as)cardiologists,)and)blanketed)patients)with)data)showing)that)Lipitor)was)best)at)lowering) cholesterol.) They) stressed) to) doctors) nervous) about) safety) that)Lipitor's) lowest) dose)worked) as) well) as) rivals') highest) doses.) They) gave) free)samples) of) the)white) pills) and) sometimes) bought) lunch) for) the) office) staff.) In)another) savvy) move,) Lipitor) was) priced) below) rival) drugs.) The) company)continued) research) on) Lipitor,) through) [2011]) conducting) more) than) 400)studies,)costing)roughly)$1)billion)and)including)more)than)80,000)patients.)The)studies)have)shown)how)Lipitor)helped)patients)with)heart)problems,)diabetes,)stroke) risk) and)other) conditions,) by)preventing)heart) attacks) and) strokes)and)reducing)plaque)buildup)in)arteries.)
What)made)the)success)story)of)atorvastatin)even)more)remarkable)was)the)wider)context)of)the)statin)market)over)the)past)decade.)Simvastatin)(Zocor®,)Merck),)the)second)best;selling)statin) in) the)United)States,) lost)patent)protection)and)became)generically)available) in)mid;2006.)What)followed)was)the)widespread)adoption)of)incentives)by)insurers)and)pharmacy)benefit)managers)to)switch)patients)on)atorvastatin)to)simvastatin.517)This)typically)took)the)form) of) formulary) design) changes) by) moving) atorvastatin) to) the) highest) copayment) tier)(with) considerable) cost) sharing)) and) placing) simvastatin) to) the) lowest) tier) (with)minimal)cost) sharing).) Despite) these) incentive) mechanisms) put) in) place) to) deter) atorvastatin)prescribing,)by)the)end)of)2006,)more)than)two;thirds)of)statins)prescribed)were)still)brands)with)atorvastatin)leading)the)way,)even)though)three)generic)statins)were)already)available)including)simvastatin.517)Until) its)market)expiry) in)2011,)Pfizer)continued)to)spend)heavily)to)promoting)atorvastatin)on)advertising)in)print,)on)television)and)online,)which)totaled)a)$271.9)million)yearly)budget.518)Following)its)patent)expiry)in)2011,)atorvastatin)sales)were)at)$7.7)billion)globally.519))Are) the)historical) statin)prescribing) trends)–)and)atorvastatin’s)exceptional)performance)–)evidence;based) according) to) the) empirical) findings) presented) in) previous) chapters) of) this)thesis?) As) Chapter) 4) (Dose=Comparative! Effects! of! Individual! Statins)) showed,) when) the)totality) of) randomized) controlled) trial) evidence) base)was) taken) into) account,) simvastatin)and) atorvastatin) had) similar) cholesterol;lowering) effects) even) at) their) highest) doses.) In)addition,) the) effects) of) simvastatin) and) atorvastatin) on) clinically) meaningful) benefit)outcomes)were)similar)with)no)statistically)detectable)differences)in)various)network)meta;analyses) presented) in) Chapter) 5) (Comparative! Benefits! of! Individual! Statins).) However,) as)Chapter) 6) showed) (Comparative! Harms! of! Individual! Statins),) simvastatin) appeared) to)outperform) atorvastatin) in) terms) of) tolerability) and) harm) outcomes.) Under) alternative)
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scenarios)where)benefit)and)harm)outcomes)were)combined)and)weighted)using)qualitative)preference)statements)(Chapter)8:)Evidence=Based!Decision=Making:!Going! from!Evidence!to!
Prescribing),)atorvastatin)rarely)surpassed)other)statins)in)terms)of)its)comparative)benefit)and)harm)profile.) In) summary,) atorvastatin’s) sales) performance)over) the)past) decade)was)not)based)on)the)current)best)evidence)according)to)the)empirical)findings)presented)in)this)thesis.))Clearly,) and) perhaps) unsurprisingly,) factors) beyond) comparative) evidence) motivated) the)historical) statin) prescribing) patterns) in) the) United) States.) The) extent) to) which) evidence)influences)prescribing)decisions) is)difficult) to)assess)as) there) is)a)wide)array)of)competing)factors)underlying)prescribing)behavior.)These) include) the)effectiveness)of)pharmaceutical)promotion) practices,520) and) attractiveness) of) using) newer) drugs) compared) to) those)recommended) as) a) result) of) scientific) evidence) so) that) prescribers) are) considered) up;to;date.521) Information) overload) is) also) an) important) factor,) as) prescribers) find) the) current)volume)of)scientific)information)unmanageable)and)instead)rely)on)information)provided)by)sales) and) marketing) teams) of) pharmaceutical) companies.42,53,522,523) Also,) regulatory)mechanisms)may)play)an)indirect)role)in)prescribing)decisions.))An)important)consideration)in)generating)comparative)evidence)is)its)timing.)If)the)goal)is)to)guide)prescribing)decisions,)comparative)effectiveness)evidence)needs)to)be)generated)prior)to)the)widespread)adoption)of)a)drug.)This)is)because)once)clinical)practice)is)established;)it)may) be) particularly) difficult) to) change) prescribing) patterns.) For) example,) the) federally)funded) ‘Antihypertensive) and) Lipid;Lowering) Treatment) to) Prevent) Heart) Attack) Trial’)(ALLHAT),)which)showed)that)older)and)cheaper)antihypertensive)drugs)were)as)effective)as)their) newer) and) more) expensive) alternatives,) had) only) a) modest) impact) on) prescribing)patterns.524)Therefore)comparative)evidence)that)forms)the)basis)of)high)quality)prescribing)decisions)should)be)assembled)early)on)–) ideally)at)the)drug)approval)stage.)Currently,) the)United) States) Food) and)Drug)Administration) does) not) require) the) inclusion) of) statements)regarding) a) drug’s) comparative) effectiveness) in) product) labels.525) The) current) lack) of)consideration)for)comparative)effectiveness)evidence)at)the)time)of)drug)approval)plays)an)indirect) role) in) guiding) prescribing) decisions.) Concomitant) with) Food) and) Drug)Administration’s) approval) to) prescribe) a) new) drug) for) an) indication,) drug)manufacturers)initiate)a)plethora)of)marketing)campaigns)to)enhance)the)product)awareness)of)prescribers.)In) the) case) of) rosuvastatin) (Crestor®),) AstraZeneca) launched) an) extensive) marketing)campaign)immediately)following)market)entry)to)promote)the)drug)as)the)most)potent)statin)available,)which)led)to)a)debate)about)the)dangers)of)widely)promoting)a)drug)with)no)safety)record.526))
&
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9.3&An&Opportunity&for&Regulatory&Reform&The)current)regulatory)environment)constitutes)an)opportunity)to)raise)the)bar)for)market)authorization) of) new) drugs.) One) important) component) of) potential) regulatory) reform) is)requiring) comparative) evidence) at) the) time) of) drug) approvals.) Such) a) requirement)would)have)significant)benefits.)As)described)in)detail)by)Sorenson)and)colleagues,527)evidence)on)the)comparative)benefits)and)harms)of)new)drugs)is)needed)by)a)range)of)decision)makers)upon) market) entry.) Comparative) evidence) can) help) regulatory) agencies) to) ensure) that)products) that)are) inferior) to)existing)alternatives)are) identified)early)on,) allow) third;party)payers)make)coverage)and)reimbursement)decisions)based)on)the)best)available)evidence)on)different) treatment) options,) and) aid) prescribers) and) patients) understand) what) therapies)work)best.)A)related)limitation)of)the)existing)regulatory)framework)for)new)drugs)is)that)judgments)of)efficacy)are)often)based)on)surrogate)outcome)measures,)not)clinical)endpoints,)which)can)complicate) the) assessment) of) benefits) and) harms) at) the) time) of) market) entry.528) Use) of)surrogate) endpoints) may) sometimes) be) warranted) on) the) basis) that) they) are) strong)predictors)of) long;term)clinical)outcomes.529)Surrogate)endpoints)facilitate)efficiency)in)the)drug)evaluation)process)by)effectively)reducing)the)size)and)duration)of)trials.)For)example,)lowering) LDL) cholesterol) levels) strongly) correlate) with) a) reduction) in) coronary) heart)disease)and)mortality)risk.)However,)surrogate)endpoints)can)also)yield)findings)that)suggest)benefit)when)no)such)effect) in)clinical)outcomes)exists.)Recent)years)have)revealed)several)problems) with) drugs) evaluated) and) approved) on) the) basis) of) surrogate) measures) alone.)While) some) drugs) were) outright) harmful) (rosiglitazone,) which) was) shown) to) cause)cardiovascular) events,) was) originally) approved) based) on) its) ability) to) reduce) short;term)hemoglobin) A1c) levels) in) patients) with) diabetes),530) others) like) ezetimibe) failed) to)convincingly) show) evidence) to) reduce) the) risk) of) major) coronary) events) and) mortality)despite)evidence)of)cholesterol;lowering)effects.495,496,498,531)Thus,)approving)products)on)the)basis)of)surrogate)measures)may)not)meet)the)information)needs)of)prescribers.))Regulatory) experts) have) recently) called) for) requiring) comparative) evidence) on) clinically)meaningful)outcomes)(e.g.,)mortality,)heart)attacks,)strokes).)Although)an)estimated)half)of)new)drugs)approved)in)the)United)States)over)the)last)decade)had)some)comparative)efficacy)data)available)at)the)time)of)market)authorization,532)there)remains)a)paucity)of)meaningful)comparative)evidence)available)on)clinical)outcomes)at) the)time)of)new)drug)approval)and)beyond.)Even)if)comparative)evidence)for)market)approvals)becomes)the)norm,)the)ultimate)health) impact)of)new) therapies)approved)on) the)basis)of) surrogate)endpoints)may) remain)unknown)until)post;market)evidence.)In)general,)commentators)have)pushed)for)basing)drug)approvals) on) trials) that) measure) clinical) outcomes.) Yet,) despite) calls) to) raise) the) bar) for)
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market) entry,) previous) licensing) decisions) appear) to) set) a) precedent) in) the) regulatory)setting:)all)six)of) the)currently)marketed)statins)were)granted)market)authorization)on)the)basis)of)their)LDL)cholesterol)lowering)effects)as)opposed)to)their)effect)on)reducing)the)risk)for) clinical) events.) In) the) case) of) atorvastatin,) for) example,) a) regulatory) comparison)with)simvastatin)on)mortality)outcomes)would)have)potentially)shown)the)lack)of)superiority)of)this)agent)over)simvastatin,)and)might)have)curbed)some)of)the)widespread)enthusiasm)that)stemmed)from)Pfizer’s)subsequent)sales)and)marketing)efforts.))Although) pharmaceutical) companies) are) vehemently,) and) understandably,) opposed) to)making)comparative)evidence)on)clinical)outcomes) the)default)evidentiary) standard)at) the)regulatory)setting,)raising)the)bar)for)market)entry)does)not)seem)to)have)a)negative)impact)on)drug)approval)rates.) In)fact,)since)the)1962)regulatory)requirement)in)the)United)States)for) pharmaceutical) companies) to) establish) evidence) of) safety) and) effectiveness,) there) has)been)an)increase,)rather)than)decrease)in)the)number)of)products)reaching)the)market)over)the) long;run.) An) analysis) by) Munos) showed) that) the) rate) of) drug) approvals) has) been)constant) over) the) past) 60) years) with) a) slight) upward) trend) from) the) period) 1980;1995)(culminating)in)53)approvals)in)1996).533)Further,)during)a)period)where)various)aspects)of)regulatory)expectations)for)evidence)increased,)the)number)of)innovative)drugs)entering)the)United)States)market) increased.534) Indeed,)as)discussed)by)Naci)and)colleagues,)raising)the)evidentiary)threshold)could)guide)pharmaceutical)industry’s)priorities)and)encourage)more)efficient)allocation)of)research)investment.535)By)requiring)comparative)evidence)for)market)entry,)common)sense)dictates)that)pharmaceutical)companies)would)be)more)likely)to)invest)in)therapeutic)areas)with)few)or)no)existing)treatment)options)rather)than)investing)in)areas)with)existing)alternatives.))Recent)calls) for)reform)at)the)Food)and)Drug)Administration)focused)on)the) importance)of)active) comparator) trials) for) generating) comparative) evidence.) However,) there) are)considerable)challenges)to)formally)requiring)these)types)of)trials)at)the)time)of)regulatory)approvals.536) Active) comparator) trials) may) be) unfeasibly) large) and) costly) when) multiple)comparators) are) included) –) particularly)when) evidence) on) long;term) clinical) outcomes) is)required.) Even) if) active) comparator) trials) were) required,) it) would) not) be) possible) to)compare)new)drugs)to)all)available)alternatives)(in)the)case)of)statins,)this)would)require)a)randomized) controlled) trial)with) seven) arms) comparing) all) available) statins) to) each)other)and)to)control).)Nevertheless,)the)Food)and)Drug)Administration)is)committed)to)emphasize)the) importance) of) active) comparator) trials) and) continue) to) collaborate) with) independent)consultants) to)define) the) clinically) relevant) comparators,)meaningful) short;) and) long;term)outcomes,) dosing) regimens,) and) margins) of) superiority,) equivalence,) and) non;inferiority)necessary)in)these)study)designs)in)cases)where)they)are)warranted,)for)example)when)there)are) only) two)drugs) available) in) a) class.537) In) cases)where) active;comparator) trials) are)not)
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feasible)to)compare)all)available)drugs)in)a)given)class,)however,)an)alternative)option)is)to)establish) a) formal) role) for) prospectively) designed) network) meta;analysis) before) market)entry.) Prospectively) designed) network) meta;analysis) can) be) used) to) determine) the)comparative)clinical)benefit)and)harm)profiles)of)drugs)at)the)time)of)market)authorization)decisions.))
9.4&Obtaining&Comparative&Evidence&Before&Market&Entry&Using&Prospective&Network&
MetaXanalysis&Evidence) review) and) synthesis) methods) such) as) meta;analyses) are) already) used) in) the)regulatory) setting,) for) example) to) address) essential) safety)questions.538) In) a) recent) case,) a)series) of) traditional) pair;wise) meta;analyses) were) pivotal) in) raising) safety) signals) for)rosiglitazone)(Avandia®).539,540) In) the)United)States,) these)concerns)also)contributed) to) the)Food)and)Drug)Administration’s)2008)Guidance)for)Industry)on)“Evaluating)Cardiovascular)Risk) in) New) Antidiabetic) Therapies) to) Treat) Type) 2) Diabetes”,) which) encourages)manufacturers)of)new)antidiabetic)drugs)to)perform)prospective)traditional)pair;wise)meta;analyses)to)evaluate)cardiovascular)events)associated)with)their)products)relative)to)control)treatment) and) explore) similarities) and/or) differences) in) subgroups.541) As) discussed) in)Chapter)3)(Evidence!Review!and!Synthesis!Methods),)in)conditions)with)several)drug)options,)pair;wise)meta;analysis) is) limited)by)the)relatively)small)number)(or)the)complete) lack))of)trials)that)directly)compare)a)particular)pair)of)drugs.)By)definition,)pair;wise)meta;analysis)is)incapable)of)comparing)multiple)active)comparators)simultaneously.!)Unlike) pair;wise) meta;analysis,) network) meta;analysis) is) capable) of) evaluating) the)comparative)benefits)and)harms)of)two)or)more)drugs,)even)when)the)drugs)are)not)directly)compared) to) each) other) in) randomized) trials.97) In) the) regulatory) setting,) network) meta;analysis) allowing) the) comparison) of) multiple) drugs) can) help) to) estimate) the) benefit) and)harm) profiles) of) new) drugs) relative) to) existing) alternatives) at) the) time) of) market) entry)before) prescribing) patterns) are) established.) Specifically,) network) meta;analysis) could) be)used) as) a) basis) for) estimating) effect) sizes) for) clinical) efficacy) and) safety) endpoints) during)regulatory)assessment)for)market)authorization)of)new)drugs.))A) simplified) overview) of) the) current) regulatory) process) for) market) authorization) of) new)drugs) is) provided) in) Figure) 9.1.) There) are) three) phases) of) experimentation) prior) to) the)regulatory)assessment)of)new)drugs)for)market)entry.542)In)Phase)1,)an)investigational)drug)is) tested) in) a) small) number) of) healthy) volunteers) to) explore) its) safety) profile) in) terms) of)toxicity.) In) Phase) 2,) tests) are) performed) on) a) larger) number) of) individuals) with) a) given)condition) to) assess) whether) the) drug) provides) intended) clinical) benefits,) and) to) monitor)short;term)side)effects.)In)Phase)3,)the)drug)is)tested)in)a)larger)group)of)individuals)with)a)
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given)condition)to)evaluate)its)clinical)efficacy)and)safety.)Regulatory)assessment)for)market)authorization)follows)the)completion)of)Phase)3.))As)shown)in)Figure)9.1,)regulatory)agencies)are)heavily)involved)in)the)clinical)development)of)new)drugs.)In)the)case)of)the)Food)and)Drug)Administration,)an)“end;of;Phase)2)meeting”)is)arranged) to)determine) the)safety)of)proceeding) to)Phase)3,) to)evaluate) the)Phase)3) trial)plan) and) protocols) and) the) adequacy) of) current) studies,) and) to) identify) any) additional)information)necessary)to)support)regulatory)assessment)following)the)completion)of)Phase)3.543) Following) the) completion)of) Phase)3,) regulators) and)pharmaceutical) companies) have)another)opportunity)to)discuss)a)number)of)topics) in)regards)to)the)marketing)application,)including)the)appropriate)methods)for)statistical)analysis)of)the)data,)and)to)discuss)the)best)approach)to)the)presentation)of)data)in)the)marketing)application.))
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Figure& 9.1& –) A) simplified) overview) of) regulatory) involvement) during) the) phased)experimentation)of)drug)development)and)potential)outcomes)of)market)entry)assessment.*)
)
*)Figure)adapted)from)Naci)H)and)O’Connor)AB.)Assessing)the)comparative)effectiveness)of)new)drugs) using) pre;planned) network) meta;analysis.) Journal) of) Clinical) Epidemiology.) 2013)Aug;66(8):812;6.544)
At)the)time)of)regulatory)assessment)for)market)authorization)(following)the)completion)of)Phase)3) trials),) network)meta;analysis) could)be)used) to) estimate) the) comparative) efficacy)and)safety)of)the)new)drug)and)its)existing)alternatives.)In)cases)where)no)active;comparator)trials) exist,) network) meta;analysis) could) generate) estimates) of) comparative) efficacy) and)safety.)In)cases)where)active;comparator)trials)exist,)network)meta;analysis)could)combine)the)findings)of)the)direct)comparisons)with)those)from)indirect)comparisons)for)support)of)superiority,) equivalence,) or) non;inferiority) claims.) In) cases)where) only) active;comparator)trials) exist,) these) could) be) combined) in) network) meta;analysis) as) long) as) drugs) are)compared)to)each)other)in)a)network.))
9.4.1! !Network!Meta=analysis!and!Market!Authorization!Decisions!At) the) time) of) regulatory) assessments) for) market) entry,) network) meta;analysis) could)potentially) suggest) that) a) new) drug) is) superior,) equivalent,) or) inferior) to) one) or) more)existing)alternatives.)Superiority)could)be)determined)via)more)beneficial)(e.g.,)more)efficacy)at) the) primary) endpoint)) and/or) less) harmful) effects) (e.g.,) less) discontinuation) due) to)adverse) events).) Similarly,) inferiority) could) be) determined) via) less) beneficial) (e.g.,) less)
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efficacy)at) the)primary)endpoint))and/or)more)harmful)effects)(e.g.,)more)discontinuations)due)to)adverse)events).))Prospectively) designed) network) meta;analysis) would) offer) important) benefits) at) the)regulatory)setting.) )A)prospective)network)meta;analysis)can)be)defined)as)a)meta;analysis)of) trials) that) are) identified,) evaluated) and) determined) to) be) eligible) for) the)meta;analysis)before) the) results) of) any) of) those) studies) are) known.549) Phase) 3) trials) submitted) to)regulatory) agencies) for) market) authorization) assessment) could) form) the) basis) for)performing)network)meta;analyses)at)the)time)of)new)drug)approval.))The) keys) to) performing) network) meta;analyses) are) having) trials) of) comparable)characteristics) with) similar) patient) populations) (i.e.,) balanced) distribution) of) relative)treatment) effect) modifiers) across) treatment) comparisons) in) the) evidence) network).) The)Food) and) Drug) Administration) could) help) emphasize) the) use) of) similar) trial) designs) and)patient) populations) for) different) drugs) seeking) approval) for) a) shared) indication) in)anticipation) of) future) network) meta;analysis.) Whenever) possible,) trials) for) a) specific)indication) can) conform) in) terms) of) patient) populations,) outcomes,) outcome) assessment)techniques,) follow;up) time) points,) and) dosing) regimens.) In) addition,) regulators) and)pharmaceutical) companies) could) work) together) to) identify) relative) treatment) effect)modifiers)to)ensure)that)potential)sources)of)heterogeneity)can)be)explored)across)trials.))Regulatory)agency) involvement) in) the)design)of) the)trials)would)help)minimize)design)and)population) differences) between) trials,) reducing) the) risk) for) bias) when) comparing) across)trials)by)ensuring)that)trials)are)comparable)in)terms)of)relative)treatment)effect)modifiers.)Similar) to)current) collaborative)efforts) in)determining)acceptable) surrogate)endpoints)and)time)points)for)follow;up)assessments)of)randomized)trials,)pharmaceutical)companies)and)regulators) could) collaborate) on) pre;determining) non;inferiority,) equivalence,) and)superiority)margins)when)two)or)more)active)comparators)are)evaluated)in)network)meta;analyses.550)Reaching) consensus)a!priori) on)how) to) evaluate) the)balance)between)benefits)and) harms) would) be) particularly) important) given) the) existing) challenges) in) objectively)quantifying) side) effects) in) relation) to) clinical) effects,) which) form) the) basis) of) regulatory)decisions.551)Having)access)to)the)individual)patient;level)data)from)the)clinical)trials)would)considerably)strengthen)the)utility)of)network)meta;analyses)at)the)regulatory)setting.)In)the)case)of)the)Food)and)Drug)Administration,)regulatory)agency)statisticians)have)access)to)all) individual)patient;level) data) from) clinical) trials,) whether) published) or) not,) which) include) large,)computerized)dataset)for)each)randomized)controlled)trial)as)well)as)its)protocol)and)clinical)study) report.) Although) not) required,) network) meta;analysis) with) individual) patient;level)data) would) be) desirable) when) taking) into) account) the) distribution) of) relative) treatment)
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effect) modifiers) across) treatment) comparisons.470) Using) data) sources) that) are) to) a) great)extent)not)available)to)the)wider)public,)regulators)can)perform)their)own)analyses)assessing)the)comparability)of)trials,)sources)of)potential)bias,)and)so)forth.)Accordingly,)the)Food)and)Drug)Administration)could)then)incorporate)network)meta;analysis)results)into)its)decision;making)and)into)product)labelling,)helping)to)better)inform)the)public)about)new)treatments)before) treatment) patterns) are) established.) This) would) not) only) allow) for) performing)comparative) assessments) at) the) regulatory) level,) but) also) facilitate) downstream) ‘after;approval’) evaluations) of) drugs) by) public) and) private) insurers,) and) pharmacy) benefit)managers.))
9.4.2!! Challenges!Ahead!Planning)future)trials)to)inform)future)network)meta;analyses)would)go)against)the)current)(perceived))practice)of)planning)each)individual)trial)in)isolation)from)the)others.538)Although)pharmaceutical) companies) may) be) understandably) opposed) to) designing) their) trials) to)mirror) those) of) their) competitors,) the) Food) and) Drug) Administration) already) provides)comprehensive)scientific)guidance)to)ensure)that)separate)trials)submitted)at)different)time)points) by) different) pharmaceutical) companies) are) sufficiently) comparable) clinically) to)warrant) the) same) indication.) Given) its) current) level) of) involvement,) the) Food) and) Drug)Administration) could) play) a) greater) role) in) guiding) the) design) of) Phase) 3) trials) to) allow)future)network)meta;analyses) to)be)done.) In)attempts) to)arrive)at)a) feasible)approach,) the)Food)and)Drug)Administration)and)pharmaceutical)companies)can)continue)collaborating)on)issues)related)to)trial)design,)selection)of)appropriate)comparators,)and)ensure)that)patient)populations) are) as) similar) as) possible) across) Phase) 3) trials) in) terms) of) relative) treatment)effect)modifiers.))Certain)aspects)of)this)proposal)may)require)legislative)action.)At)the)moment,)the)Food)and)Drug) Administration) is) not) required) to) consider) comparative) evidence) in) its) market)authorization) decisions.) Although) the)European)Medicines)Agency) is) increasingly) favoring)the)submission)of)comparative)data)for)market)entry)considerations,552)the)Food)and)Drug)Administration)prefers)to)consider)it)on)a)case;by;case)basis.553)Further,)the)Food)and)Drug)Administration)may)not)be)allowed)to)use)individual)patient;level)data)from)the)marketing)application) of) one) drug) in) the) evaluation) of) another,) which) would) prevent) it) from)performing) analyses)with) datasets) that) are) not) available) to) the) research) community.) It) is)important) to) note,) however,) that) the) data) access) landscape) is) quickly) changing) with)widespread) enthusiasm) to)make) individual) patient;level) data) from) randomized) controlled)trials) of) drugs) available.554;557) Such) an) approach) would) also) have) benefits) for) the)pharmaceutical) industry.558) Acknowledging) this) potential,) GlaxoSmithKline) has) made) a)commitment)to)release)individual)patient;level)data)from)its)clinical)trials.559))
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9.5& Implications& of& Regulatory& Reform& for& Market& Authorization& of& CholesterolX
Lowering&Drugs&In)August)2009,) the)Food)and)Drug)Administration)approved)pitavastatin)(Livalo®)) for)the)indication)of)cholesterol)lowering,)making)it)the)seventh)statin)currently)available)for)sale)in)the)United)States.)As)Gagne)and)Choudhry)observed)“This)approval)[came])almost)a)quarter)century) after) that) for) the) first)member) of) the) class,) lovastatin,) [eight]) years) after) generic)lovastatin) was) approved) and) [four]) years) after) [two]) additional) statins,) pravastatin) and)simvastatin,) lost) patent) protection) and) generic) versions) of) them) entered) the) market.”560)Pitavastatin) was) approved) based) on) its) non;inferior) LDL) cholesterol) lowering) ability)compared)with)atorvastatin,)simvastatin,)and)pravastatin.)Four)years)after)its)market)entry,)information)on)whether)–)and)the)extent)to)which)–)pitavastatin)lowers)the)risk)of)coronary)and) cerebrovascular) events) and) deaths) remains) unknown.) In) a) similar) fashion,) how)pitavastatin)fares)against)existing)statins)has)not)been)evaluated.))If) the) potential) regulatory) reform) proposed) in) this) chapter) was) in) place) at) the) time) of)pitavastatin’s) market) entry,) rather) than) approving) pitavastatin) on) the) basis) of) its)cholesterol;lowering)effects,)the)Food)and)Drug)Administration)could)have)required)a)large)active;comparator) non;inferiority) trial) evaluating) the) impact) of) pitavastatin) on) major)coronary) and) cerebrovascular) events) as) compared) to) a) suitable) competitor) such) as)simvastatin.)A)non;inferiority)trials)could)evaluate)whether)pitavastatin)was)not)worse)than)an) active) control) by) more) than) a) specified) “non;inferiority”) margin.545) In) contrast) to)superiority)designs,)non;inferiority)designs)require)external)information)to)confirm)that)the)active)control)had)its)expected)effect)in)the)study)(also)termed)assay)sensitivity,)which)refers)to) the) ability) to) distinguish) an) effective) from) an) ineffective) drug) on) the) basis) of) its)superiority) to) placebo).546)Although) assay) sensitivity) is) achievable) in) non;inferiority) trials)with) three) arms) (placebo) and) two) active) comparators),) the) use) of) placebo) is) no) longer)ethical)in)statin)trials.)In)such)scenarios,)network)meta;analysis)can)be)particularly)helpful.)Regulators)could)determine)the)comparative)benefit)and)harm)profile)of)pitavastatin)versus)other)statins)using)network)meta;analysis.))Availability) of) comparative) data) is) particularly) relevant) for) the) new) class) of) powerful)cholesterol;lowering) drugs) that) are) currently) in) the) pharmaceutical) research) and)development) pipeline.) Given) the) potential) of) these) products) (PCSK9) inhibitors)) to) lower)cholesterol)concentrations)to)levels)not)possible)with)statins,)pharmaceutical)companies)are)currently) competing) to) bring) them) to) market.561) Sanofi) and) Regeneron) Pharmaceuticals)have)recently)reported)the)findings)of)their)early;stage)investigations562)and)have)reportedly)initiated) a) Phase) 3) trial) involving) 18,000) patients) with) a) recent) heart) attack) or) angina)pectoris)who)cannot)lower)their)cholesterol)levels)with)statin)therapy)alone.)Amgen)has)also)
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reported)Phase)1)trial)results)and)has)begun)Phase)3)trials.563)Other)companies)with)drugs)in)mid;stage)clinical)trials)include)Pfizer,)Roche,)Eli)Lilly)&)Company,)and)Alnylam.)))Regulatory) involvement) during) this) stage) of) clinical) development,) already) underway,) is)essential) to) ensure) that) the) trials) designed) by) these) pharmaceutical) and) biotechnology)companies)are)adequately)similar)in)terms)of)important)relative)treatment)effect)modifiers)to) allow) for) their) combination) in) future)network)meta;analyses.) Important) considerations)include) the) use) of) similar) comparator) groups) (e.g.,) simvastatin) at) 20mg/day);) patient)populations) (e.g.,) individuals) with) established) coronary) heart) disease,) secondary)prevention);) and) clinical) endpoints) (e.g.,) major) coronary) and) cerebrovascular) events) and)deaths).))Regulatory)agency)involvement)might)help)to)avert)a)highly)undesirable)–)yet)all)too)likely)–)scenario)whereby)pharmaceutical)companies)that)are)currently)developing)PCSK9)inhibitors)separately) conduct) clinical) trials) on) slightly) different) populations) and) use) different)comparator) groups,) which) might) not) allow) for) a) credible) comparison) of) their) products’)comparative) efficacy) and) safety.) Lack) of) comparative) evidence)would) leave) prescribers) in)the)dark)about)the)comparative)benefits)and)harms)of)this)new)class)of)therapies)relative)to)statins,) and) once) again) create) a) significant) information) gap) for) evidence;based) decision;making) in) clinical) practice,) setting) off) yet) another) marketing) race) among) pharmaceutical)companies.))
9.6&Conclusion&Comparative)data)on)clinically)meaningful)benefit) and)harm)outcomes) is) critical) to)ensure)evidence;based) prescribing) decisions) in) clinical) practice.) Despite) their) limitations,) the)empirical) findings)presented) in) this) thesis)provide) the)most) comprehensive)assessment)of)the) comparative) benefit) and) harm) profiles) of) individual) statins) to) guide) high;quality)prescribing)decisions.)Using)184)randomized)controlled)trials)including)260,630)individuals)with) or) without) cardiovascular) disease,) this) thesis) made) four) major) contributions) to) the)literature) on) the) comparative) effectiveness) and) safety) of) individual) statins,) showing) the)following:)(1))cholesterol;lowering)effects)of)statins)are)less)pronounced)than)suggested)by)the)previous)reviews)focusing)on)small)placebo;controlled)trials)alone;)(2))individual)statins)potentially) differ) in) terms) of) their) comparative) effects) on) clinically) meaningful) outcomes)such)as)all;cause)mortality,)major)coronary)events,)and)major)cerebrovascular)events,)with)less) potent) statins) performing) equally) well) with) those) capable) of) achieving) more) LDL)cholesterol) reductions) per)mg) dose;) (3)) harms) associated)with) statins) are) rare;) but) some)statins) such) as) simvastatin) and)pravastatin) are) safer) than)others;) and) (4)) unlike)previous)findings)in)the)literature,)the)research)questions)asked)by)industry)sponsors)seem)to)parallel)
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those) asked) by) nonindustry) sources,) and) the) findings) obtained) from) these) trials) appear)similar)in)magnitude)as)those)in)nonindustry)sources.))Based)on)these)findings,)statin)prescribing)patterns)over)the)past)decade)–)and)in)particular)atorvastatin’s) exceptional) sales) performance) –) are) not) supported) by) the) current) best)evidence.)Among)many)significant)factors,)the)lack)of)comparative)effectiveness)evidence)at)the)time)of)market)entry)may)have)played)an)indirect)role)in)determining)statin)prescribing)patterns.)To)meet)the)information)needs)of)prescribers,)regulators)should)consider)requiring)comparative) evidence) at) the) time) of) new) drug) approval.) Regulatory) agencies) such) as) the)Food) and) Drug) Administration) are) uniquely) positioned) to) oversee) the) drug) development)process) and) influence) the) nature) of) clinical) evidence) at) an) early) stage.) During) clinical)development,)regulators)and)pharmaceutical)companies)have)an)opportunity)to)collaborate)to) choose) comparators,) determine) sample) sizes) of) future) trials,) and) identify) relative)treatment) effect) modifiers) for) exploration) of) heterogeneity.) Although) requiring) active)comparator)trials)remains)to)be)the)ultimate)goal,)it)is)not)conceivable)that)new)drugs)will)be)compared)to)all)existing)alternatives) in)randomized)controlled) trials)–)at) least) in) the)short)term.)By)allowing) for)a) comparison)of) all) relevant)drugs)–) even)when) they)are)not) trialed)against) each) other) –conducting) prospectively) designed) network) meta;analyses) would)facilitate) the) “comparative”) aspect) of) an) expanded) comparative) effectiveness) research)agenda.) Network) meta;analysis) can) inform) approval) decisions,) may) help) decrease) the)likelihood) of) inferior) treatments) being) approved,) and) would) help) focus) downstream)comparative) effectiveness) research) efforts) by) streamlining) the) information) needs) of)regulators,)insurers,)prescribers,)and)patients.))
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Med.!Apr)11)2011;171(7):619.)248.) Minder)CM,)Blaha)MJ,)Tam)LM,)et)al.)Making)the)Case)for)Selective)Use)of)Statins)in)the) Primary) Prevention) Setting.) Arch! Intern! Med.! September) 26,) 2011)2011;171(17):1593;1594.)249.) Sutton)A,)Abrams)K,)Jones)D,)Sheldon)T,)Song)F.)Methods!for!Meta=Analysis!in!Medical!
Research.)London,)UK:)Wiley;)2000.)
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Cardiovascular! disease! (CVD)! is! the! leading! cause! of! death! and! a! major! cause! of! disability!






(atorvastatin,! fluvastatin,! lovastatin,! pravastatin,! rosuvastatin,! simvastatin)! marketed! in! the!
United! States! for! the! almost! identical! indication! of! “reducing! elevated! total\cholesterol,! low\
density! lipoprotein\C,! apolipoprotein\B,! non\high\density! lipoprotein\C,! and! triglyceride! levels!
and!increasing!high\density!lipoprotein!in!patients!with!primary!hypercholesterolemia.”5!!
Statins! are! used! for! the! secondary! prevention! of! cardiovascular! events! in! patients! with! CVD!
(including! a! history! of! angina! or! acute! myocardial! infarction,! peripheral! arterial! disease,! or! a!
history! of! stroke)! and! for! primary! prevention! in! patients! who! are! at! increased! risk! of!
cardiovascular! events! because! of! factors! such! as! smoking,! hypertension! and! diabetes.! It! is!
recommended! that! statins! are! used! in! conjunction! with! lifestyle! measures! (diet,! smoking!
cessation! and! exercise)! and! other! appropriate! interventions! (e.g.! adequate! control! of! chronic!
conditions!such!as!hypertension!and!diabetes).!
Statin!therapy,!initially!focused!on!patients!with!established!cardiovascular!disease,!has!become!
widely! common! as! the! limits! of! treatment! expanded! over! time! to! include! persons! at!
progressively! lower! risk! of! developing! cardiovascular! events.4,! 6! As! the! number! of! patients! in!
need!for!statin!therapy!continues!to!increase,!information!regarding!the!relative!clinical!value!of!
statins! is! needed! to! better! inform! not! only! patients! and! prescribers,! but! also! payers.! It! is!
particularly! difficult! to! determine! the! exact! threshold! of! the! level! of! baseline! risk! for!
cardiovascular!events!at!which! to! start!prescription!or! tailor! therapy! to!patients!most! likely! to!
benefit!from!statin!treatment.!
A! large!body!of! literature!has! demonstrated! the! clinical! efficacy! and! safety! of! statins! for! both!
primary!and!secondary!prevention!of!CVD!events.4,! 6\12!There!are! three!main! limitations!of! the!
literature!synthesizing!the!evidence!on!the!efficacy!and!safety!of!statin!therapy:!
1. The!majority!of!published!metaRanalyses!include!only!direct!evidence.!!




placebo\controlled! trials!has! limitations!as! there! is! a! large!number!of! active\comparator! statin!
trials,! which! can! contribute! to! the! evidence! base.! It! is! therefore! important! to! synthesize! the!
totality!of!the!evidence!base!on!statins.!
2. The! extent! to!which! individual! statins! differ! in! terms!of! efficacy! and! acceptability! is!
unclear.!!
Although!prescribers!and!guideline!developers!widely!believe!that!similar!drugs!do!not!differ! in!







the! fact! that! most! randomized! clinical! trials! have! not! tested! different! statins! head\to\head.!
Additionally,!almost!all!of!the!meta\analyses!‘lumped’!all!statins!together!as!one!intervention.4,!7\
11,!21\23!!




doses! have! similar! clinical! efficacy.! This! assumption! cannot! be! validated! and! has! not! been!
verified!in!clinical!data.!!
Overcoming!the!limitations!of!the!literature!
Combination! of! direct! and! indirect! evidence:!Methodological! advances! in! statistical! synthesis!
approaches,! called! mixed! treatment! comparisons! (also! known! as! network! meta5analyses),!
facilitate! the! combination! of! direct! and! indirect! evidence! by! incorporating! both! direct! (when!
statins! are! compared! to! each! other!within! a! trial)! and! indirect! comparisons! (when! statins! are!
compared!between!trials!with!a!common!comparator!treatment,!which!is!often!placebo).24\26!
Evaluation!of!the!comparative!efficacy!and!acceptability!of!individual!statins:!By!implication!of!






as! well! as! an! estimate! of! incoherence! (that! is,! a!measure! of! how!well! the! entire! network! of!
statins! fits! together).! Mixed! treatment! comparison! methods! have! been! used! successfully! in!
other!fields!of!medicine!and!resulted!in!influential!publications.29!!
Evaluation!of! the! impact!of! dose!on! the! comparative! efficacy! and!acceptability! of! individual!
statins:!Meta\regression! techniques! can! incorporate! the! impact! of! dose! on! the! efficacy! and!




document! the! comparative! clinical! efficacy! of! statins! on! the! basis! of! both! direct! and! indirect!
evidence.!!
Statistical!analyses!will!be!conducted!to!rank!the!available!statins!in!terms!of!their!efficacy!and!







surrogate! outcomes! independently! of! the! effect! on! clinical! outcomes! in! primary!
prevention,!secondary!prevention,!and!mixed!patient!populations?!
2. What!is!the!comparative!clinical!efficacy!and!safety!of!individual!statins!on!the!basis!of!




The! systematic! review! will! be! conducted! based! on! the! most! up\to\date! NHS! Centre! for!
Dissemination! and!Review!guidelines.33! Search! terms!will! be!pre\defined,! and! searches!will! be!
conducted! in! MEDLINE,! Cochrane! Database! of! Systematic! Reviews! (CDSR),! Cochrane! Central!
Register! of! Controlled! Trials! (CCTR),! Database! of! Abstracts! of! Reviews! of! Effects! (DARE),! NHS!





cholesterol,! cardiovascular! disease,! and! Hydroxymethylglutaryl5CoA! Reductase!
Inhibitors/therapeutic!use.!A!manual!search!will!also!be!performed!using!the!authors'!reference!
files!and!reference!lists!from!original!communications!and!review!articles.! Identified!qualitative!
and! quantitative! systematic! reviews! (meta\analyses)!will! be!manually! reviewed! to! cross! check!
references!and!confirm!the!comprehensiveness!of!study!identification!and!selection.!!
Trial!databases!of!regulatory!agencies!(the!Food!and!Drug!Administration!(FDA)!in!the!USA,!the!
Medicines! and! Healthcare! products! Regulatory! Agency! (MHRA)! in! the! UK! and! the! European!
Medicines! Agency! (EMA)! in! the! EU)! and! ongoing! trial! registers! (clinicaltrials.gov! in! the! USA,!













• Studies!not! reporting!detailed!dosing! regimens! received!by!patients!on!all! comparator!







• Patients! in! at! least! one! arm! of! the! trial! must! receive! atorvastatin,! fluvastatin,!
losuvastatin,! pravastatin,! rosuvastatin,! and! simvastatin! (either! generic! or! brand\name!
formulations)!
• The! patients! of! interest! are! patients! at! least! 18! years! of! age! with,! or! at! risk! of!
developing,!CVD!(primary!and!secondary!prevention!populations)!
• To! be! included! in! the! statistical! analysis,! each! selected! study! must! report! either!
surrogate! endpoints! (e.g.! reductions! in! blood! cholesterol! levels),! or! clinical! events! of!
interest!(e.g.!reductions!in!the!risk!of!developing!CVD!events).!Outcomes!of!interest!are!
also!listed!below.!!
Trials! with! crossover! design! will! only! be! included! if! results! are! available! from! the! first!
randomized!period.! Studies! that! compared!multiple!doses!of! the! same! statin!will! be! included.!
Both!fixed\dose!and!titration!trials!will!be!included.!!
Titles!and!abstracts!of!studies!identified!from!the!searches!described!above!will!be!screened!by!
one! researcher! based! on! the! exclusion! criteria! (Level! 1! screening;! Figure! below).! Full! texts! of!
studies!accepted!at!Level!1!will!be!further!reviewed!by!two!researchers!at!Level!2!employing!the!
inclusion! criteria! (Figure).! At! Level! 2,! if! there! is! an! uncertainty! on! the! study! relevance,! the!
reviewers!will!resolve!the!issue!by!consensus.!!



































Once! the! list! of! included! studies! is! finalized,! two! researchers!will! extract! data! independently.!




trials.! Primary! prevention! trials! are! those! that! assessed! the! efficacy! and! safety! of! statins! in!
patients!free!of!CVD!at!baseline.!Secondary!prevention!trials!are!those!that!evaluated!statins!in!
patients! with! established! CVD.! Given! that! a! number! of! trials! will! include! both! primary! and!
secondary! prevention! populations,! these! trials! will! be! categorized! as! having! a! mixed! patient!
population.!In!cases!where!study!authors!reported!data!separately!on!a!sole!primary!prevention!
or!secondary!prevention!group!within!a!mixed!trial,!this!information!will!be!recorded!for!use!in!
respective! statistical! analysis.! To!account! for! the!possibility! that! the!efficacy!of! statins!may!be!





trial! characteristics! are!provided,! the! trial! authors!will! be! contacted! in! order! to!obtain! further!
information.!As!with!data!extraction,!potential!disagreements!will!be!resolved!by!consensus.!!
Statistical!Analysis!








Included! trials! will! first! be! summarized! in! terms! of! patient! and! trial! characteristics.! Trial! and!
patient!population! characteristics!will! be! tabulated,! describing! the! types!of! direct! and! indirect!














in!WinBUGS.24\27,! 37! This!will! be!based!on!modeling! the!outcomes! in! every! treatment! group!of!
every! study,! and! specifying! the! relations! among! the! relative! effects! across! studies! making!
different! comparisons.! The! probability! that! each! statin! is! the!most! efficacious! regimen!will! be!






Relative! treatment! effects!will! be! determined! using! an! “unconstrained”!model! for! the! control!
arm!rate!of!the!studies.25!Thus,!the!analysis!will!not!allow!one!study’s!placebo!rate!to!give!any!





into! account! potential! heterogeneity,! will! assume! that! every! trial! has! an! identical! underlying!
mean! effect,! but! some! degree! of! variation!may! be! present.! The! choice! of! a! fixed! or! random!
effect!meta\analysis!model!will!be!made!by!comparing!models!regarding!their!goodness!of!fit!to!
the! data.! The! goodness! of! fit! will! be! estimated! by! calculating! the! difference! between! the!
deviance! for! the! fitted!model! and! the! deviance! for! the! saturated!model! (which! fits! the! data!
perfectly).!!
To! estimate! inconsistency! between! direct! and! indirect! evidence,!we!will! calculate! the! ratio! of!
relative! effects! for! indirect! versus! direct! evidence.! Inconsistency! will! be! defined! as! the!
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disagreement!between!direct!and!indirect!evidence!with!a!95%!CI!excluding!1.38!More!formally,!
we! will! adopt! the! node\split! method.! In! the! node\split! method,! a! model! that! assumes!
consistency!across!the!entire!set!of!comparisons!in!the!treatment!network!will!be!compared!with!
one! that! relaxes! the! consistency! assumption! for! the! individual! comparison! (node)! being!
assessed.39! Using! this! method,! the! amount! of! agreement! between! the! direct! and! indirect!
evidence!will!be!formally!measured.!!
A! systematic! procedure! will! be! followed! to! ensure! that! the! choice! of! initial! values! used! in!
WinBugs!models!do!not!have!a!substantial!impact!on!the!findings.!The!convergence!of!models!in!
WinBugs! will! be! initially! challenged! by! performing! 3\chain! analyses! with! widely! dispersed!
starting! values! and! evaluating! their! convergence! using! the! Brooks\Gelman\Rubin! (BGR)!
diagnostic!plots.!
Consideration!of!Dose!
In!contrast! to! the!approach!adopted!by!earlier!statin!meta\analyses,!studies! that!used!variable!
doses!(titrating)!will!not!be!excluded.7! Instead,!where!trials!provided!data!on!the!proportion!of!
patients!at!each!dose,!the!number!in!the!treatment!arm!will!be!proportioned!out!to!the!correct!
dosage! (and! hence! included! in! the! analysis).40! Even! where! trials! did! not! provide! data! on! the!
proportion!of!patients!at!each!dose,!trials!will!be!categorized!as!‘titration!trials’!and!included!in!
the!analysis.!!
Four! sets! of! analyses! will! be! conducted! to! explicitly! consider! the! impact! of! dose! on! the!
comparative!treatment!effects!of!statins.!The!first!set!of!analyses!will!pool!trials!with!fixed\dose!
and! titration! designs! to! evaluate! the! comparative! efficacy! and! safety! of! statins! irrespective! of!
dose.!Secondary!analyses!will!include!only!titration!trials.!!
The! effect! of! dose! on! comparative! treatment! effects! will! be! an! essential! consideration! in!
additional!statistical!analyses.!As!the!literature!does!not!provide!a!clear!answer!as!to!how!dose!
should! be! taken! into! account,! two! types! of! analyses! will! be! conducted.! One! set! of! mixed!
treatment! comparison! analyses! will! be! conducted! for! the! dose\specific! comparators! (e.g.!
rosuvastatin!10\20mg!vs.!atorvastatin!10\20mg).!Therefore,!drug!efficacy!will!be!defined!as!the!
reduction! in! cholesterol! concentration! (or! the! reduction! in! CVD! event! occurrence)! for! a! given!
dose.!This!analysis!will!compare!all!potential!drug\dose!combinations! (comparing!18!dose\drug!
combinations! to! each! other:! 6! statins,! each! with! low\medium\high! dosages).! Another! set! of!
analyses!will!be!conducted!for!comparisons!at!the!drug\level!(e.g.!rosuvastatin!vs.!atorvastatin)!
and! will! compare! six! statins.! The! drug\level! analysis! will! use! a! meta\regression! to! take! into!













4. Priors:!Sensitivity!of! the! findings! to!prior!distributions!will!be!evaluated!by!varying! the!
prior!distributions!from!less! informative!to!more!informative!values!and!examining!the!
variability! observed! in! the! credibility! intervals! of! point! estimates.! One! prior! will! be!
extremely! vague,! while! the! other! (to! be! employed! in! the! base\case! analyses)! will! be!
vague!but!slightly!informative.!!
5. Population:! Sensitivity! of! the! findings! to! patient! populations! (primary! prevention,!
secondary! prevention,! mixed)! will! be! assessed! in! comprehensive! analyses! by! first!
pooling!all!trials!together!and!then!introducing!meta\regression!coefficients!to!take!into!
account!potential!differences!across!patient!populations.!!
6. Publication!year:!Sensitivity!of! the! findings! to!publication!year! (as!a!proxy! for!evolving!
trial! protocols! and! potentially! different! patient! populations! over! the! years)! will! be!
assessed! by! incorporating! publication! year! as! a! meta\regression! coefficient! in! the!
analysis.!!
7. Blinding!in!trials:!It!is!possible!that!the!findings!obtained!in!double\blind!trials!differ!than!
those! from! open\label! trials.! To! test! the! sensitivity! of! the! findings! to! the! blinding! in!
trials,!separate!analyses!will!be!conducted!for!double\blind!and!open\label!trials.!!
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Appendix! Figure! 3! –$ Statistical$ assessment$ of$ inconsistency$ in$ first6order$ loops$ in$ the$treatment$ network$ for$ (A)$ all6cause$ mortality,$ (B)$ major$ coronary$ events,$ (C)$ major$cerebrovascular$events,$(D)$discontinuations,$(E)$myalgia,$(F)$transaminase$elevations,$and$

































Legend.$ a:$ Control,$ b:$ Atorvastatin,$ c:$ Fluvastatin,$ d:$ Lovastatin,$ e:$ Pravastatin,$ f:$ Rosuvastatin,$ g:$Simvastatin$
 403 
-4.00 -2.00 0.00 2.00 4.00











0.21 [ -2.86 , 3.28 ]
0.90 [ -1.26 , 3.06 ]
0.10 [ -0.92 , 1.12 ]
1.07 [ -1.22 , 3.35 ]
0.32 [ -1.54 , 2.19 ]
0.02 [ -0.38 , 0.42 ]
0.37 [ -1.47 , 2.22 ]
0.01 [ -0.66 , 0.69 ]
0.56 [ -0.70 , 1.83 ]






































-4.00 0.00 2.00 4.00 6.00








0.54 [ -3.48 , 4.56 ]
0.20 [ -3.45 , 3.86 ]
0.87 [ -0.98 , 2.72 ]
0.55 [ -2.01 , 3.11 ]
1.00 [ -1.56 , 3.55 ]
0.06 [ -0.59 , 0.72 ]
0.41 [ -2.26 , 3.08 ]
 405 
-2.00 0.00 1.00 2.00 3.00



























0.07 [ -1.06 , 1.19 ]
0.20 [ -0.42 , 0.83 ]
0.05 [ -1.54 , 1.64 ]
0.48 [ -0.59 , 1.56 ]
0.57 [ -0.98 , 2.13 ]
0.81 [ -0.64 , 2.25 ]
0.34 [ -0.79 , 1.46 ]
0.20 [ -0.56 , 0.96 ]
0.75 [ -0.58 , 2.08 ]
0.36 [ -0.58 , 1.30 ]
0.29 [ -0.96 , 1.55 ]
0.70 [ -0.84 , 2.25 ]
0.14 [ -0.95 , 1.22 ]
0.89 [ -0.17 , 1.96 ]
0.47 [ -0.34 , 1.28 ]
0.29 [ -0.51 , 1.10 ]
0.60 [ -0.42 , 1.62 ]
0.34 [ -0.39 , 1.08 ]
0.48 [ -0.56 , 1.52 ]
0.50 [ -0.39 , 1.39 ]
0.61 [ -0.34 , 1.56 ]
0.34 [ -0.50 , 1.19 ]
1.13 [ -0.05 , 2.31 ]
0.16 [ -0.80 , 1.13 ]
0.18 [ -0.63 , 1.00 ]



































-4.00 -2.00 0.00 2.00 4.00 6.00



























0.00 [ -2.12 , 2.12 ]
1.34 [ -0.26 , 2.93 ]
1.05 [ -0.54 , 2.63 ]
0.35 [ -1.85 , 2.55 ]
0.70 [ -0.65 , 2.05 ]
0.88 [ -1.32 , 3.08 ]
0.88 [ -1.29 , 3.05 ]
0.00 [ -2.19 , 2.19 ]
0.66 [ -1.70 , 3.02 ]
0.57 [ -0.61 , 1.76 ]
0.46 [ -1.21 , 2.13 ]
0.17 [ -1.49 , 1.83 ]
0.20 [ -1.33 , 1.72 ]
0.51 [ -1.51 , 2.53 ]
0.63 [ -2.87 , 4.13 ]
1.14 [ -2.23 , 4.52 ]
1.61 [ -0.34 , 3.56 ]
0.82 [ -0.69 , 2.33 ]
0.22 [ -1.11 , 1.55 ]
0.63 [ -2.54 , 3.80 ]
0.09 [ -0.81 , 0.99 ]
0.17 [ -1.63 , 1.96 ]
0.28 [ -1.46 , 2.01 ]
0.87 [ -2.48 , 4.21 ]
0.65 [ -1.09 , 2.38 ]




















-5.00 0.00 5.00 10.00

















0.06 [ -3.52 , 3.64 ]
0.79 [ -2.01 , 3.59 ]
0.47 [ -3.06 , 4.00 ]
0.10 [ -1.27 , 1.48 ]
0.63 [ -2.11 , 3.37 ]
5.06 [  0.89 , 9.23 ]
2.18 [ -0.48 , 4.84 ]
0.24 [ -2.59 , 3.07 ]
0.82 [ -0.72 , 2.37 ]
1.29 [ -1.19 , 3.78 ]
0.76 [ -0.63 , 2.15 ]
0.63 [ -0.79 , 2.05 ]
0.99 [ -1.75 , 3.72 ]
0.04 [ -1.03 , 1.10 ]
1.63 [ -0.66 , 3.93 ]


































1.23 [ -0.38 , 2.84 ]
1.48 [ -2.24 , 5.19 ]
1.51 [ -1.18 , 4.20 ]
1.18 [ -1.49 , 3.86 ]
0.02 [ -2.18 , 2.22 ]
0.43 [ -3.20 , 4.07 ]
0.64 [ -2.69 , 3.97 ]
2.42 [ -0.53 , 5.37 ]
0.96 [ -1.74 , 3.66 ]



































XML Template (2013) [21.3.2013–2:05pm] [1–13]
//blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/CPRJ/Vol00000/130189/APPFile/SG-CPRJ130189.3d (CPR) [PREPRINTER stage]
EU RO PEAN
SOCIETY O F
CARDIOLOGY ®Original scientific paper
Dose-comparative effects of different
statins on serum lipid levels: a network
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Abstract
Aims: The extent to which individual statins vary in terms of their impact on serum lipid levels has been studied mainly
on the basis of placebo-controlled trials. Our objective was to review and quantify the dose-comparative effects of
different statins on serum lipid levels using both placebo- and active-comparator trials.
Methods: We systematically reviewed randomized trials evaluating different statins in participants with, or at risk of
developing, cardiovascular disease. We performed random-effects Bayesian network meta-analyses to quantify the the
relative potency of individual statins across all possible dose combinations using both direct and indirect evidence. Dose-
comparative effects were determined by estimating the mean change from baseline in serum lipids as compared to
control treatment. (systematic review registration: PROSPERO 2011:CRD42011001470).
Results: We included 181 placebo-controlled and active-comparator trials including 256,827 individuals. There were 83
two-armed placebo-controlled trials and the remaining 98 were two- or multi-armed active-comparator trials. All statins
reduced serum LDL and total cholesterol levels: higher doses resulted in higher reductions in pretreatment LDL and
total cholesterol concentrations. In absolute terms, all statins significantly reduced LDL cholesterol levels as compared to
control treatment from average baseline levels of approximately 150mg/dl, except for fluvastatin at !20mg/day and
lovastatin at !10mg/day. Atorvastatin, rosuvastatin, and simvastatin were broadly equivalent in terms of their LDL
cholesterol-lowering effects. Dose-comparative effects of indivudual statins were not different between those with
and without coronary heart disease at baseline. According to meta-regression analyses, LDL cholesterol-lowering effects
of individual statins were not impacted by differences across trials in terms of baseline mean age and proportion of
women as trial participants. Pretreatment LDL cholesterol concentrations had a marginally statistically significant effect
on LDL cholesterol change from baseline. Mean differences from baseline in HDL cholesterol as compared to control
treatment was not significant for any statin-dose combination.
Conclusions: The findings of this comprehensive review provide supporting evidence for the dose–response relation-
ship of statins in reducing LDL and total cholesterol. The LDL cholesterol-reducing effects of some statins appear less
pronounced than the findings of previous meta-analyses, which is particularly the case for the high-dose formulations of
atorvastatin and rosuvastatin. The most consistent evidence for a combined reduction in both LDL and total cholesterol
was achieved with atorvastatin at >40mg/day, rosuvastatin at >10mg/day, and simvastatin at >40mg/day, which appear
equivalent in terms of their LDL and total cholesterol-reducing effects.
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Introduction
Statins eﬀectively lower low-density lipoprotein choles-
terol (LDL-C) and total cholesterol (Total-C), while
resulting in modest increases in high-density lipoprotein
cholesterol (HDL-C), reducing the risk of cardiovascu-
lar morbidity and mortality.1 Clinical practice guide-
lines recommend using statins as the drugs of first
choice in patients with hypercholesterolaemia or com-
bined hyperlipidaemia.2
Dose-comparative eﬀects of statins on serum lipid
levels have been previously studied.3 One of the most
comprehensive of these studies, conducted by Law and
colleagues,4 was a meta-analysis of 164 short-term trials
which typically lasted a few weeks and included
approximately 24,000 individuals. Other examples
include a review by Edwards and colleagues5 that
included double-blind trials that lasted longer than 12
weeks and included approximately 43,000 individuals.
An important limitation of previous meta-analyses is
that they relied solely on placebo-controlled trials with-
out taking into account a large number of head-to-head
trials which resulted in an enormous loss of valuable
data. Although a limited number of direct (head-
to-head) meta-analyses have been performed, these stu-
dies focused on two statins at a time – without a clear
indication of the dose-comparative eﬀects of all statins
simultaneously.6,7 For example, the comprehensive
Drug Class Review included 102 head-to-head com-
parisons of diﬀerent statins but did not perform a
formal statistical analysis to estimate the pooled eﬀects
of each statin-dose combination and the statistical
uncertainty around these estimates.1 As previous stu-
dies have shown, qualitatively reviewing and comparing
findings from diﬀerent studies results in a biased inter-
pretation of relative eﬀectiveness.8
To date, there is no comprehensive analysis of the
dose-comparative eﬀects of statins that builds on the
totality of the randomized trial evidence. This has
important implications for clinical practice as clinicians
do not have adequate evidence on the comparative
eﬀects of diﬀerent statins on serum lipids based on
direct head-to-head meta-analyses. Our objective in
this study was to perform a systematic review of the
statin literature and quantify the dose-comparative
eﬀects of statins on serum lipid levels by combining
both placebo-controlled and active-comparator trials.
Given the suboptimal lipid control in clinical prac-
tice,9–11 this information is necessary as the foundation
for evidence-based decision making.
In this paper, we report the findings of our multiple-
treatments meta-analysis and meta-regression on the
eﬀect of diﬀerent statins on serum LDL-C, Total-C,
and HDL-C levels. By doing so, we address the follow-
ing questions: What is the estimated lipid change from
baseline that can be expected with various doses of dif-
ferent statins? Is the estimated lipid change from base-
line sensitive to patient characteristics such as age, sex,




We searched MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews, and Cochrane
Central Register of Controlled Trials to identify studies
published between 1 January 1985 and 1 January 2011.
To identify the relevant literature, we developed a
search strategy using the search terms atorvastatin, flu-
vastatin, simvastatin, lovastatin, pravastatin, rosuvas-
tatin, cholesterol, cardiovascular disease, and
hydroxymethylglutaryl-CoA reductase inhibitors/
therapeutic use. We also performed manual searches
using the authors’ files and reference lists from original
communications and review articles to cross check ref-
erences. Two researchers (BT, HT) independently per-
formed abstract, title, and full-text screening. A third
researcher approved study selection (HN).
We included open-label and double-blind rando-
mized controlled trials comparing one statin with
another at any dose or with control (placebo, diet, or
usual care) for adults with, or at risk of developing,
cardiovascular disease. We included trials of atorvasta-
tin, fluvastatin, lovastatin, pravastatin, rosuvastatin,
and simvastatin if they had more than 50 participants
per trial arm, lasted longer than 4 weeks, and reported
one of the three surrogate outcomes of interest: LDL-
C, HDL-C, or Total-C. Both fixed-dose and titration
designs were included. Per pre-defined criteria, we
excluded trials conducted in patients with renal
insuﬃciency.
Whenever possible, we categorized included trials as
primary prevention, secondary prevention, or mixed
patient population. Trials that included at least 80%
of participants without established coronary heart dis-
ease or reported data separately on a sole primary pre-
vention group were categorized as primary prevention.
Trials that included at least 80% of participants with
established coronary heart disease or reported data sep-
arately on a sole secondary prevention group were cate-
gorized as secondary prevention. All remaining trials
were categorized as having a mixed patient population.
The primary outcome of interest was the mean
change from baseline in serum LDL-C levels between
two comparator treatments for a given dose (change
from baseline in the treatment group minus that in
the control group). Secondary outcomes were HDL-C
and Total-C levels between two comparator treatments
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for a given dose. We used a structured form developed
in MS Excel to extract data on trial and patient popu-
lation characteristics, and outcomes. A full list of data
extraction elements can be found in our publicly avail-
able protocol.12 One researcher extracted data (HN)
and another independently checked for accuracy (BT).
Statistical analysis
We first qualitatively summarized included trials,
describing the types of direct and indirect comparisons
and important clinical and methodological variables.
To determine the comparative eﬀects of statins at dif-
ferent doses, we conducted network meta-analyses,
which are generalizations of indirect comparisons
with more than two (or multiple pairs of) treatments
being compared indirectly and at least one pair of treat-
ments compared both directly and indirectly.13,14 This
type of analysis allowed for combining the direct
within-trial comparisons between two treatments (e.g.
atorvastatin vs. control) with indirect comparisons con-
structed from trials that had one treatment in common
(e.g. atorvastatin vs. control and simvastatin vs. con-
trol).15 This analysis preserved the within-trial rando-
mized treatment comparison of each trial while
combining all available comparisons between treat-
ments. We combined study-level relative treatment
eﬀects using Bayesian Markov chain Monte Carlo
methods in WinBUGS version 1.4.3.16 We used the
model developed by Dias and colleagues17 for the
National Institute of Health Clinical Excellence
Decision Support Unit in the UK. This was based on
modelling the outcomes in every treatment group of
every study and specifying the relations among the rela-
tive eﬀects across studies making diﬀerent comparisons,
while taking into account the correlations between
treatment eﬀects within multi-arm trials.
Both fixed- and random-eﬀects models were run.
The fixed-eﬀects model assumed that there was no
between-study heterogeneity. The random-eﬀects
model took into account potential heterogeneity by
assuming that each treatment at each dose was drawn
from the same distribution, whose mean and variance
were estimated from the data.18 Model fit was better
with the random-eﬀects model (for the primary out-
come, the total residual deviance for the random-eﬀects
model was 216.4 for 214 unconstrained data points as
compared to 219.1 for the fixed-eﬀects model) and only
the results from the random-eﬀects model are
presented.
The diﬀerence between treatments was assessed on
the basis of 95% credible intervals (CI), which may be
interpreted as Bayesian equivalents of 95% confidence
intervals. The 95% CI can be interpreted as indicating a
95% probability that the true mean change falls within
this range. If a 95% CI does not include the null value
0.00, this can be interpreted as indicating <5% prob-
ability that there is no diﬀerence between the two com-
parators. Given the Bayesian nature of the statistical
analyses, p-values are not provided.
We assessed the probability that each statin-dose
combination is best by calculating its treatment eﬀect
compared with control treatment, and counting the
proportion of iterations for which each statin has the
highest treatment eﬀect, the second highest, and so on.
This approach took into account the magnitude of the
estimated treatment eﬀect as well as the uncertainty
around it. We developed rankograms and cumulative
probability plots to graphically present the distribution
of ranking probabilities, and estimated the surface
under the cumulative ranking line for each statin.19
The surface under the cumulative ranking line for
each statin would be 1.0 (or 100%) when a treatment
is certain to be the best and 0.0 (0%) when a treatment
is certain to be the worst.
To obtain a comprehensive estimate of the compara-
tive eﬀect of statins at diﬀerent doses on serum lipid
levels, our network meta-analysis pooled all primary
and secondary prevention trials in addition to trials
with mixed patient populations, including all placebo-
controlled and active-comparator trials eligible for
inclusion in this review. For the primary outcome of
LDL-C changes from baseline, we also performed sep-
arate analyses for the primary and secondary preven-
tion populations, as categorized by the criteria
mentioned above.
Trials that allowed variable dosing regimens
(titrating) were included in the statistical analysis.
Whenever possible, data from the fixed dosing period
were used for titration designs. If all patients were
force-titrated to a given dosage, data from the final
high-dose period were used. Where trials provided
data on the proportion of patients at diﬀerent doses,
the number in the treatment arm was proportioned out
to the correct dosage.
All analyses were dose-specific and explored the
eﬀects of individual statins at diﬀerent doses separately.
Each statin-dose combination was treated as a diﬀerent
treatment and no trends were fitted or assumed. The
following daily doses were considered for atorvastatin,
lovastatin, pravastatin, and simvastatin: !10mg (10),
11–20mg (20), 21–40mg (40), and >40mg (80). For
fluvastatin, daily doses were !20mg (20), 21–40mg
(40), and >40mg (80). For rosuvastatin, the daily
doses were !5mg (5), 6–10mg (10), >11–20mg (20),
and >20mg (40). !2 test for linear trend was performed
to test for the linearity of the dose–response relation-
ship. All analyses were based on the total number of
randomly assigned participants regardless of whether
the study authors perform intention-to-treat analyses.
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We investigated whether potential heterogeneity and
inconsistency across the evidence base in the network
meta-analysis could be explained by mean age at base-
line, mean LDL-C concentration at baseline, or the
proportion of women included in the trial using meta-
regression analyses. We performed all meta-regression
analyses by allowing for a common treatment-covariate
interaction for each statin compared to control.20 We
also qualitatively evaluated the consistency of relative
treatment eﬀects obtained from an analysis of head-
to-head trials (i.e. direct evidence) with those obtained
from an analysis combining both placebo-controlled
and active-comparator trials (i.e. mixed evidence).
We visually inspected the consistency of the relative
treatment eﬀects for potential diﬀerences between esti-
mates obtained from two sets of analyses (i.e. direct and
mixed estimates).
Results
We included 181 trials (Figure 1, see supplementary
material for references of included trials and trial and
population characteristics, available online only). There
were 83 two-armed placebo-controlled trials and
the remaining 98 were two- or multi-armed active-
comparator trials, and 112 trials were double-blind
Titles identified through MEDLINE, EMBASE, and 
COCHRANE databases 
(n=19,837)
Abstracts screened after duplicates removed 
(n=18,540)
Full-text articles assessed for eligibility 
(n=450)
Trials included in meta-analysis
(n=181)
Trials in secondary prevention (n=52)
Trials in primary prevention (n=41)
Trials in acute coronary syndrome (n=10)
Trials in heart failure (n=4)
Trials in metabolic syndrome (n=3)
Trials in hypercholesterolemia with or without 





Full-text articles excluded 
(n  = 269)
Not randomized trial (n=24)
Not used in cardiovascular disease (n=7)
Duration <4 weeks (n=19)
Sample size <50 per arm (n=35)
Combination therapy (n=46)
Kin publications (n=73)
Outcome not reported (n=65)
Figure 1. Flow diagram of trial identification and selection.
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while 55 were open-label and two were single-blind.
Blinding was not clear for the remaining 12 trials.
Overall, the average trial duration was 66 weeks, with
53 trials reporting serum lipid levels after at least 1 year
of follow up. Figure 2 shows the network of eligible
comparisons when all populations were pooled. Most
frequent comparisons occurred between pravastatin
and placebo, and rosuvastatin and atorvastatin. No
trial directly compared all statin-dose combinations to
each other.
Diﬀerential dose-comparative eﬀects of individual sta-
tins on serum lipid levels are shown in Figure 3 and Table
1. Figure 4 shows the estimated percentage reductions
from an average baseline concentration of 150mg/dl
(3.88mmol/l, approximate average of pretreatment
LDL-C level in included trials). Regarding LDL-C reduc-
tion, higher statin doses were associated with greater rela-
tive reductions in pretreatment LDL-C (!2 test for linear
trend for all statins except for rosuvastatin in lowering
LDL-C: p< 0.00; rosuvastatin: p¼ 0.08). Similarly,
except for lovastatin (p¼ 0.09) and pravastatin
(p¼ 0.11), there was a general linear dose–response rela-
tionship for reducing Total-C from baseline as compared
to control. According to the network meta-
analysis results, atorvastatin, pravastatin, rosuvastatin,
and simvastatin were significantly better than control
treatment in terms of reducing baseline concentrations
of LDL-C. However, fluvastatin (at "40mg/day) and
lovastatin (at "10mg/day) did not result in significant
reductions from baseline LDL-C levels as compared to
control treatment. Considering Total-C reduction,
fluvastatin (at all doses), lovastatin (at "10mg/day and
21–40mg/day), and pravastatin (at >40mg/day) did not
have adequate evidence to demonstrate superiority over
control treatment in terms of lowering pretreatment
levels. Statin-dose combinations resulted in only modest
increases in baseline HDL-C levels, and were not signifi-
cantly better than control treatment. Higher doses of sta-
tins were not associated with greater increases in baseline
HDL-C concentrations.
Figure 5 shows the dose-comparative eﬀects of indi-
vidual statins on pretreatment LDL-C levels in primary
Atorva ≤ 10
Placebo
Atorva >10 and ≤ 20
Atorva >20 and ≤ 40
Atorva > 40
Fluva ≤ 10
Fluva >20 and ≤ 40
Fluva >10 and ≤ 20
Fluva > 40
Lova ≤ 10
Lova >10 and ≤ 20
Lova >20 and ≤ 40
Lova > 40
Prava ≤ 10
Prava >10 and ≤ 20
Prava >20 and ≤ 40
Prava > 40
Rosuva ≤ 5
Rosuva > 5 and ≤ 10
Rosuva >10 and ≤ 20
Rosuva > 20
Simva ≤ 10
Simva >10 and ≤ 20
Simva >20 and ≤ 40
Simva > 40
Figure 2. Network of available comparisons. Connecting lines indicate the direct pair-wise comparison between two treatments.
The width of the lines is proportional to the number of pair-wise comparisons between two treatments, and the size of every node is
proportional to the number of participants.
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and secondary prevention populations separately.
Generally, higher statin doses were associated with
greater relative reductions in pretreatment LDL-C but
this dose response relationship was not as clear as in the
base-case analysis including all populations. With greatly
overlapping 95% credible intervals, there was no statis-
tical diﬀerence between the LDL-C-reducing eﬀects of
individual statins between populations with and without
coronary heart disease at baseline.
Figure 6 shows the ranking of individual statin-dose
combinations in terms of lowering both baseline LDL-
C and Total-C concentrations. Ranking first, simvasta-
tin (>40mg/day), atorvastatin (>40mg/day), and
rosuvastatin (>10mg/day) resulted in the highest
reductions in baseline LDL-C and Total-C concentra-
tions as compared to other statins.
Figure 7 reports the findings from all three sets of
meta-regression analyses. According to the meta-
regression analyses, baseline mean age (b¼ 0.54, 95%
CI "0.76, 2.13) and proportion of women included in
the trials (b¼ 0.05, 95% CI "0.43, 0.60) did not explain
heterogeneity in the analysis. Baseline mean LDL-C
concentration was marginally statistically significant
(b¼"0.23, 95% CI "0.49, "0.05) but its impact on
the reduction of pretreatment LDL-C concentrations
in meta-regressions were not materially diﬀerent. Also,
there was no detectable inconsistency between direct and
indirect estimates. Between-study heterogeneity was low
(standard deviation¼ 1.71, 95% CI 0.25, 4.64).
Discussion
This network meta-analysis of 256,827 individuals dem-
onstrates the dose-comparative eﬀects of individual sta-
tins on serum lipid concentrations. Overall, high-dose
statins were associated with greater reductions in
Atorva ≤ 10
LDL-C Reduction (mg/dl)
–150.0 –100.0 –50.0 0.0 50.0 –40.0 –20.0 –0.0 20.0 40.0
–3.8 –2.5 –1.2 0.0 1.2–1.0 –0.5 0.0
mmol/l mmol/l
0.5 1.0–3.8 –2.5 –1.2
mmol/l
0.0 1.2
HDL-C Difference (mg/dl) Total-C Reduction (mg/dl)
Atorva >10 and ≤ 20
Atorva >20 and ≤ 40
Atorva > 40
Fluva ≤ 20
Fluva >20 and ≤ 40
Fluva > 40
Lova ≤ 10
Lova >10 and ≤ 20
Lova >20 and ≤ 40
Lova > 40
Prava ≤ 10
Prava >10 and ≤ 20
Prava >20 and ≤ 40
Prava > 40
Rosuva ≤ 5
Rosuva > 5 and ≤ 10
Rosuva >10 and ≤ 20
Rosuva > 20
Simva ≤ 10
Simva >10 and ≤ 20
Simva >20 and ≤ 40
Simva > 40
–150.0 –100.0 –50.0 0.0 50.0
Figure 3. Dose-comparative effects of statins on serum lipid levels.
Values are mean (95% credible interval). Estimates shown are mean changes from baseline in serum lipid concentrations as compared
to control treatment. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol, Total-C, total chol-
esterol; atorva, atorvastatin; fluva, fluvastatin; lova, lovastatin; prava, pravastatin; rosuva, rosuvastatin; simva, simvastatin.
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Table 1. Dose-comparative effects of statins on serum lipid levels in serum lipid LDL-C, HDL-C, and Total-C concentrations
Dose !5 6–10 11–20 21–40 >40
Low-density lipoprotein cholesterol
Atorvastatin
mg/dl – "43.16 ("58.77, "34.08) "48.33 ("67.89, "36.77) "54.79 ("70.88, "38.63) "60.82 ("80.06, "50.86)
mmol/l – "1.11 ("1.51, "0.88) "1.24 ("1.75, "0.95) "1.41 ("1.83, "0.99) "1.57 ("2.07, "1.31)
Fluvastatin
mg/dl – – "15.46 ("45.66, 4.62) "34.51 ("60.29, 0.62) "52.80 ("87.54, "15.10)
mmol/l – – "0.39 ("1.18, 0.11) "0.89 ("1.55, 0.01) "1.36 ("2.26, "0.39)
Lovastatin
mg/dl – "20.33 ("57.98, 18.02) "34.37 ("56.22, "17.54) "47.15 ("68.26, "20.21) "53.41 ("81.61, "25.38)
mmol/l – "20.33 ("57.98, 18.02) "34.37 ("56.22, "17.54) "47.15 ("68.26, "20.21) "53.41 ("81.61, "25.38)
Pravastatin
mg/dl – "20.41 ("40.62, "4.98) "31.12 ("45.85, "12.91) "40.77 ("51.68, "27.00) "47.14 ("79.49, "7.10)
mmol/l – "0.52 ("1.05, "0.12) "0.80 ("1.18, "0.33) "1.05 ("1.33, "0.69) "1.21 ("2.05, "0.18)
Rosuvastatin
mg/dl "47.37 ("68.37, "31.64) "56.85 ("71.45, "37.59) "69.24 ("85.59, "38.81) "67.54 ("96.74, "32.46) –
mmol/l "1.22 ("1.76, "0.81) "1.47 ("1.84, "0.97) "1.79 ("2.21, "1.00) "1.74 ("2.50, "0.83) –
Simvastatin
mg/dl – "36.98 ("54.78, "19.25) "41.69 ("60.71, "27.42) "54.92 ("74.13, "39.91) "66.87 ("87.66, "33.99)
mmol/l – "0.95 ("1.41, "0.49) "1.07 ("1.56, "0.70) "1.42 ("1.91, "1.03) "1.72 ("2.26. "0.87)
High–density lipoprotein cholesterol
Atorvastatin
mg/dl – 2.01 ("2.89, 6.41) 2.38 ("4.47, 7.76) 1.88 ("6.57, 10.35) 2.58 ("4.51, 8.78)
mmol/l – 0.05 ("0.07, 0.16) 0.06 ("0.11, 0.20) 0.04 ("0.16, 0.26) 0.06 ("0.11, 0.22)
Fluvastatin
mg/dl – – 1.03 ("10.77, 12.58) 1.33 ("14.28, 16.65) 0.27 ("14.22, 16.23)
mmol/l – – 0.02 ("0.27, 0.32) 0.33 ("0.36, 0.43) 0.00 ("0.36, 0.41)
Lovastatin
mg/dl – 1.48 ("17.17, 19.72) 1.76 ("8.80, 10.52) 0.36 ("10.15, 10.89) 3.00 ("10.16, 16.47)
mmol/l – 0.03 ("0.44, 0.50) 0.04 ("0.22, 0.27) 0.00 ("0.26, 0.28) 0.07 ("0.26, 0.42)
Pravastatin
mg/dl – 1.23 ("9.43, 11.65) 1.10 ("6.93, 8.81) 2.81 ("3.77, 7.30) "1.63 ("21.24, 16.61)
mmol/l – 0.03 ("0.24, 0.30) 0.02 ("0.17, 0.22) 0.07 ("0.09, 0.18) 0.04 ("0.54, 0.42)
Rosuvastatin
mg/dl 2.15 ("8.81, 10.40) 3.16 ("2.81, 9.79) 2.16 ("5.94, 12.03) 4.91 ("8.24, 19.86) –
mmol/l 0.05 ("0.22, 0.26) 0.08 ("0.07, 0.25) 0.05 ("0.15, 0.31) 0.12 ("0.21, 0.51) –
Simvastatin
mg/dl – 2.39 ("7.37, 8.89) 1.79 ("4.25, 7.66) 2.77 ("5.30, 11.43) 1.69 ("5.32, 10.56)
mmol/l – 0.06 ("0.19, 0.22) 0.04 ("0.10, 0.19) 0.07 ("0.13, 0.29) 0.04 ("0.13, 0.27)
Total cholesterol
Atorvastatin
mg/dl – "49.49 ("63.63, "37.82) "66.75 ("88.38, "47.49) "71.55 ("94.70, "41.28) "79.22 ("101.20, "57.75)
mmol/l – "1.27 ("1.64, "0.97) "1.72 ("2.28, "1.22) "1.85 ("2.44, "1.06) "2.04 ("2.61, "1.49)
Fluvastatin
mg/dl – – "19.82 ("61.95, 10.99) "26.27 ("72.20, 20.00) "28.41 ("80.73, 5.70)
mmol/l – – "0.51 ("1.60, 0.28) "0.67 ("1.86, 0.51) "0.73 ("2.08, 0.14)
Lovastatin
mg/dl – "34.66 ("75.46, 22.64) "40.21 ("60.72, "16.24) "24.94 ("60.82, "0.54) "67.26 ("105.60, "30.90)
mmol/l – "0.89 ("1.95, 0.58) "1.03 ("1.57, "0.41) "0.64 ("1.57, "0.01) "1.73 ("2.73, "0.79)
Pravastatin
mg/dl – "30.07 ("44.94, "9.58) "38.61 ("50.52, "17.02) "41.16 ("54.05, "27.39) "27.28 ("77.76, 6.41)
mmol/l – "0.77 ("1.16, "0.24) "0.99 ("1.30, "0.44) "1.06 ("1.39, "0.70) "0.70 ("2.01, 0.16)
(continued)
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pretreatment LDL-C and Total-C concentrations as
compared to low-dose regimens. In terms of increasing
HDL-C, all statin-dose combinations failed to result in
clinically and statistically meaningful increases in pre-
treatment HDL-C levels and higher doses were not
associated with better HDL improvements.
When individual statins were compared head-
to-head, several statins appeared to outperform other
statins in reducing serum LDL-C and Total-C concen-
trations. In our meta-analysis, atorvastatin, rosuvasta-
tin and simvastatin ranked first in terms of reducing
serum LDL-C and Total-C as compared to the other
statins. High-dose formulations of atorvastatin, rosu-
vastatin, and simvastatin were broadly equivalent.
Fluvastatin, lovastatin, and pravastatin, on the other
hand, were associated with significantly less reductions
in pretreatment LDL-C and Total-C concentrations
relative to other statins. Low-dose regimens of fluvas-
tatin and lovastatin did not lower pretreatment choles-
terol levels over and above the reduction observed in
control treatment.
This analysis is the first to quantitatively evaluate the
dose-comparative eﬀects of diﬀerent statins on serum
lipids across all populations. Previous comprehensive
reviews such as the Drug Class Review did not perform
statistical analyses. The statin dose conversion/equiva-
lence tables that stem from previous reviews do not
take into account the statistical uncertainty around
the dose-comparative eﬀects of statins. As a result,
existing dose conversion tables give the false impression
that prescribers should expect narrow ranges of LDL-C
reductions at various statin doses.
Based on our findings, we developed a revised ‘Statin
Prescribing Reference’ table (Table 2) to report the stat-
istically equivalent doses of statins and the percentage
LDL-C changes that can be expected when prescribing
them. Also included are statements about the consist-
ency of the evidence associated with the preferred
agents, which reflect the variability (and uncertainty)
in the evidence base.
The findings of our analysis are novel and diﬀer
from previous reviews in important ways. First, the
Table 1. Continued
Dose !5 6–10 11–20 21–40 >40
Rosuvastatin
mg/dl "29.03 ("52.01, "8.91) "61.49 ("77.06, "47.58) "72.14 ("100.20, "54.28) "87.75 ("113.9, "55.32) –
mmol/l "0.75 ("1.34, "0.23) "1.59 ("1.99, "1.23) "1.86 ("2.59, "1.40) "2.26 ("2.94, "1.43) –
Simvastatin
mg/dl – "49.48 ("67.77, "30.16) "56.93 ("72.62, "40.93) "60.26 ("83.73, "44.15) "81.94 ("103.90, "53.73)
mmol/l – "1.27 ("1.75, "0.77) "1.47 ("1.87, "1.05) "1.55 ("2.16, "1.14) "2.11 ("2.68, "1.38)
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Figure 4. Dose-comparative effects of statins on serum LDL-C concentrations.
Values are mean (95% credible interval). Estimates shown are absolute reductions at all dose combinations standardized to the average
pretreatment LDL-C concentration in the included set of trials.
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traditionally considered ‘more powerful’ statins not-
ably rosuvastatin which is not generic, and atorvastatin
which has recently been released as a generic – are not
found to be statistically superior to simvastatin in their
maximum LDL-C-lowering doses. Second, the extent
to which some statins lower pretreatment LDL-C
levels appears to be less pronounced in our review com-
pared to earlier estimates. This was particularly the case
for atorvastatin and rosuvastatin at high doses. For
instance, according to previous analyses, high-dose
atorvastatin (at 80mg/day) lowers pretreatment LDL-
C levels by 55% (and 60% according to manufacturer’s
prescribing information).1,4,21 We found that high-dose
atorvastatin lowers baseline LDL-C concentrations by
an estimated 45% (95% CI 35, 54%). Similarly, accord-
ing to manufacturer’s prescribing information, high-
dose rosuvastatin lowers pretreatment LDL-C levels
by 63%. However, the findings of our analysis sug-
gested that high-dose rosuvastatin resulted in a 46%
mean reduction from baseline, which was associated
with considerable uncertainty (95% CI 23, 66%). This
diﬀerence was also observed for other statin-dose com-
binations: 20mg/day of fluvastatin (!22% per prescrib-
ing information vs.!11% in our analysis), 20mg/day of
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Figure 5. Sub-group analysis results.
Values are mean (95% credible interval). Estimates shown are mean changes from baseline in LDL-C concentrations as compared to
control treatment. Results are provided separately for primary prevention (A) and secondary prevention (B) populations.
LDL-C, low-density lipoprotein cholesterol, atorva, atorvastatin; fluva, fluvastatin; lova, lovastatin; prava, pravastatin; rosuva, rosuvas-
tatin; simva, simvastatin.
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pravastatin (!32% per prescribing information vs.
!22% in our analysis). LDL-C-lowering eﬀects of sim-
vastatin according to our analyses appeared consistent
with previous findings.
We attribute this diﬀerence to three main factors.
First, previous assessments of dose-comparative eﬀects
of statins were based on small studies, which tend to
evaluate highly-selected patients in strictly controlled
environments, which may not be representative of the
conditions in actual clinical practice. Our review
excluded trials that included fewer than 50 individuals
per trial arm. Second, unlike previous reviews, our
review included trials with indivuduals regardless of
their baseline LDL-C concentrations. Third, earlier
reviews exluded trials with titration designs. Titration
designs allowing clinicians to increase the dose of statin
therapy to achieve target reductions, also known as the
‘treat-to-target’ model, continues to be the most
common method of managing patients with elevated
LDL cholesterol levels. Accordingly, we included infor-
mation from titration design trials.
Our analysis combined direct and indirect evidence
and compared all available statin-dose combinations.
This methodology diﬀers from traditional pair-wise
meta-analysis in that it combines placebo-controlled
and active-comparator trials, facilitating the compari-
son of multiple interventions.22 Increasingly used to
compare more than two health interventions simultan-
eously, network meta-analyses provide information
that can be used to rank treatments, which helps clin-
icians, patients, and other healthcare decisionmakers
when making prescribing decisions.23 We previously
used this methodology to compare the benefits of indi-
vidual statins in the primary and secondary prevention
of all-cause mortality,24 major coronary events, and
major cerebrovascular events.25
The findings of our analysis should be interpreted in
light of its limitations. First, our review did not evalu-
ate the comparative costs and harms of individual sta-
tins, which should be taken into consideration when
making prescribing decisions.26 This is particularly
important given our finding that generic statins such
as simvastatin perform equally well as other branded
statins in terms of lowering pretreatment LDL-C levels.
There is a paucity of evidence on the comparative
harms of individual statins. Future studies should
focus on addressing this important gap in the literature.
Equally important, there are other important lipid out-
comes, which should be evaluated in future analyses.27
For instance, recent analyses have shown the associ-
ation between non-HDL cholesterol levels with the
risk of cardiovascular events among patients treated
with statin therapy.28
Second, our literature-based meta-analysis shares
the limitations of the published literature. Given the
large volume of randomized trial evidence available
from the published literature, we did not make an
attempt to contact study authors and obtain individual
patient-level information. An individual patient-level
data meta-analysis such as that produced by the
Cholesterol Treatment Trialists’ Collaboration may
provide a more nuanced examination of the compara-
tive eﬀects of statins in specific subgroups – such as
those with or without established cardiovascular dis-
ease, diﬀerent age groups, and diabetes status. Third,
as a network meta-analysis combining direct and indir-
ect sources of evidence, it remains a possibility that
potential imbalances in the occurrence of eﬀect
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Figure 6. Dose-comparative ranking and equivalence of statins
in terms of both LDL-C and Total-C reduction.
Estimates shown are based on the surface under the cumulative
ranking (SUCRA) plots by combining LDL-C (left-part of the
stacked bars) and Total-C (right-part of the stacked bars) -redu-
cing effects of individual statins. Statin-dose combinations are
ranked out of a total of 1.0 (0.5 for LDL-C and 0.5 for Total-C).
LDL-C, low-density lipoprotein cholesterol, Total-C, total chol-
esterol; atorva, atorvastatin; fluva, fluvastatin; lova, lovastatin;
prava, pravastatin; rosuva, rosuvastatin; simva, simvastatin.
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modifiers across the contrasts impacted the results,
potentially confounding the comparative estimates
between statins. However, this is unlikely given the
large body of evidence that provided consistent esti-
mates from a broadly representative group of individ-
uals with diﬀerent characteristics across trials.
Given the Bayesian nature of the analysis, we did not
quantify the extent of potential heterogeneity using the
commonly used I2 statistic. Instead, we directly quanti-
fied the between-study heterogeneity, which was found
to be low. In addition, we made every attempt to visu-
ally inspect potential discrepancies in the reported
results across trials. We assessed the consistency of
direct and mixed findings in the analysis by comparing
the 95%CI of estimates obtained from analyses including
only direct (head-to-head) trials and from those that com-
bined direct trials with placebo-controlled trials. We also
performed meta-regression analyses to evaluate whether
potential heterogeneity or inconsistency could be
explained by baseline LDL-C levels across trials. This
statistical exploration did not find evidence that baseline
LDL-C had an impact on the relative treatment eﬀects.
This review has important strengths. Based on
256,827 individuals in 181 randomized controlled
trials, this network meta-analysis provides the most
comprehensive evidence on the relative potency of indi-
vidual statins in reducing LDL-C and Total-C, and
increasing HDL-C. We included evidence from both
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Figure 7. Dose-comparative effects of statins on serum lipid levels according to meta-regression analyses.
Values are mean (95% credible interval). Estimates shown are mean changes from baseline in serum lipid concentrations as compared
to control treatment, as adjusted in meta-regression analyses. Findings are shown separately for meta-regressions adjusting for
baseline age (A), proportion of women (B), and baseline mean LDL-C concentration (C).
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placebo-controlled and active-comparator trials, con-
siderably broadening the evidence base considered in
previous reviews. To the best of our knowledge, ours
is the first network meta-analysis that included more
direct head-to-head trials than placebo-controlled
trials, considerably strengthening the statistical infer-
ences of our findings. Including titration design trials
considerably improved the generalizability of our find-
ings as titration better reflects common practice in chol-
esterol management. As a result of our inclusive
approach, our findings are generalizable to individuals
in clinical practice. We included a broad range of
patients and observed that the cholesterol-lowering
eﬀects of statins are consistent in studies with popula-
tions that varied in age, geographic region, and severity
of underlying illness, which adds to the strength of our
overall inferences. The findings of the meta-regression
analyses provide supportive evidence to suggest that the
LDL-lowering eﬀects of individual statins do not diﬀer
by diﬀerences across the literature in age, sex, baseline
LDL-C concentration, and existing coronary heart
disease.
In conclusion, this report is the most comprehensive
meta-analysis of the eﬀect of statins on reductions in
serum lipids, and one of the first to integrate direct
head-to-head comparisons between statins. Most inter-
estingly we report the findings of our multiple-treat-
ments meta-analysis on the eﬀect of diﬀerent statins
on serum LDL-C, Total-C, and HDL-C levels.
Overall, high-dose statins were associated with greater
reductions in pretreatment LDL-C and Total-C con-
centrations as compared to low-dose regimens
confirming a dose–reponse relationship. When individ-
ual statins were compared head-to-head, several statins
appeared to outperform other statins in reducing serum
LDL-C and Total-C concentrations. In our meta-ana-
lysis, atorvastatin, rosuvastatin, and simvastatin
ranked first in terms of reducing serum LDL-C and
Total-C as compared to the other statins in the analysis.
The LDL-C-reducing eﬀects of some statins appear less
pronounced than the findings of previous meta-ana-
lyses. Surprisingly, in terms of increasing HDL-C, all
statins have only a modest eﬀect on HDL irrespective
of dose. The statin prescribing reference table devel-
oped in this study will help those in clinical practice
to make evidence-based decisions about initiating
statin therapy.
Disclosure statement
Dr Rachael Fleurence currently works for the Patient
Centered Outcomes Research Institute. The views expressed
in this article do not necessarily represent those of the Patient
Centered Outcomes Research Institute.
Acknowledgements
The authors thank Bernice Tsoi and Harleen Toor for their
assistance with abstract and full-text review, data extraction,
and quality review of extracted data for accuracy.
Funding
This research received no specific grant from any
funding agency in the public, commercial, or not-for-profit
sectors.
Table 2. Statistically equivalent doses of statins and expected LDL-C changes




High Prescribers can expect an approximately 45% reduction from pretreatment LDL-C
levels with 95% of reductions ranging from 23% to 66%







Simva >10 and !40mg
Medium Prescribers can expect an approximately 38% reduction from pretreatment LDL-C
levels with 95% of reductions ranging between 6% and 61%
The uncertainty is due in large part to the variability in the evidence base for
fluvastatin and pravastatin (at their highest doses)
Evidence is most consistent for atorvastatin, rosuvastatin, and simvastatin. These





Low Prescribers can expect an approximately 20% reduction from pretreatment LDL-C
levels. In 95% of the cases, patients are estimated to experience changes
between 10% increase* and 42% decrease in their baseline LDL-C
concentrations
*Lowest doses of fluvastatin and lovastatin may at times not result in reductions in
baseline LDL-C levels
Evidence is most consistent for pravastatin and simvastatin. These agents should be
preferred to initiate therapy
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Comparative benefits of statins
in the primary and secondary prevention
of major coronary events and all-cause
mortality: a network meta-analysis
of placebo-controlled and
active-comparator trials
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Abstract
Background: The extent to which individual statins vary in terms of clinical outcomes across all populations, in addition
to secondary and primary prevention has not been studied extensively in meta-analyses.
Methods: We systematically studied 199,721 participants in 92 placebo-controlled and active-comparator trials com-
paring atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin in participants with, or at risk of
developing, cardiovascular disease. We performed pairwise and network meta-analyses for major coronary events and
all-cause mortality outcomes, taking into account the dose differences across trials. Systematic review registration:
PROSPERO 2011:CRD42011001470.
Results: There were only a few trials that evaluated fluvastatin. Most frequent comparisons occurred between pravas-
tatin and placebo, atorvastatin and placebo, and rosuvastatin and atorvastatin. No trial directly compared all six statins to
each other. Across all populations, statins were significantly more effective than control in reducing all-cause mortality
(OR 0.87, 95% credible interval 0.82–0.92) and major coronary events (OR 0.69, 95% CI 0.64–0.75). In terms of reducing
major coronary events, atorvastatin (OR 0.66, 95% CI 0.48–0.94) and fluvastatin (OR 0.59, 95% CI 0.36–0.95) were
significantly more effective than rosuvastatin at comparable doses. In participants with cardiovascular disease, statins
significantly reduced deaths (OR 0.82, 95% CI 0.75–0.90) and major coronary events (OR 0.69, 95% CI 0.62–0.77).
Atorvastatin was significantly more effective than pravastatin (OR 0.65, 95% CI 0.43–0.99) and simvastatin (OR 0.68, 95%
CI 0.38–0.98) for secondary prevention of major coronary events. In primary prevention, statins significantly reduced
deaths (OR 0.91, 95% CI 0.83–0.99) and major coronary events (OR 0.69, 95% CI 0.61–0.79) with no differences among
individual statins. Across all populations, atorvastatin (80%), fluvastatin (79%), and simvastatin (62%) had the highest
overall probability of being the best treatment in terms of both outcomes. Higher doses of atorvastatin and fluvastatin
had the highest number of significant differences in preventing major coronary events compared with other statins. No
significant heterogeneity or inconsistency was detected.
Conclusions: Statins significantly reduce the incidence of all-cause mortality and major coronary events as compared to
control in both secondary and primary prevention. This analysis provides evidence for potential differences between
individual statins, which are not fully explained by their low-density lipoprotein cholesterol-reducing effects.
The observed differences between statins should be investigated in future prospective studies.
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Introduction
Statins are widely used to prolong survival and reduce
the occurrence of coronary and cerebrovascular events
in patients with cardiovascular disease. Prior meta-
analyses have demonstrated the eﬀectiveness of statins
in secondary prevention,1–10 among the elderly,11,12 and
in individuals with diabetes.13,14 Initially focused on
secondary prevention, statin therapy has become
more common as the limits of treatment have expanded
over time to include persons at progressively lower risk
of developing cardiovascular disease.15 As the number
of individuals eligible for statin therapy continues to
increase both in primary and secondary prevention,
two questions warrant further investigation. First,
there is no consensus around the benefit of statins in
primary prevention.16 Although previous meta-ana-
lyses have provided evidence in support of the use of
statins in individuals with no evidence of cardiovascular
disease,17 recent studies challenged these findings.18,19
Second, whether individual statins vary in terms of
their eﬀect on clinical outcomes when compared
head-to-head is unclear and has not been studied in a
comprehensive manner in previous meta-analyses.20
Information regarding the relative clinical value of dif-
ferent statins in primary and secondary prevention of
cardiovascular disease is needed to better inform
patients, clinicians, and other healthcare decision
makers.
Previous network meta-analyses that indirectly com-
pared individual statins were limited to placebo-
controlled trials and did not take into account evidence
from a large number of active-comparator trials.21–23
Equally importantly, these analyses did not diﬀerenti-
ate between primary- and secondary-prevention popu-
lations.24 Finally, previous network meta-analyses did
not assess diﬀerences in dosages of individual statins
across populations and did not compare statins at simi-
lar doses.
We report a comprehensive network meta-analysis
that combines evidence from both placebo-controlled
and active-comparator trials. We evaluate the eﬀect of
statins on major coronary events and all-cause mortal-
ity across all populations, in addition to secondary and
primary prevention of cardiovascular disease separ-
ately. We also compare the eﬀectiveness of diﬀerent
statins head-to-head in these patient populations,




We developed a protocol and subsequently made it
publicly available on the first author’s institutional
website before starting this study (PROSPERO regis-
tration: 2011:CRD42011001470).25
Search strategy and selection criteria
We searched MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews, and Cochrane
Central Register of Controlled Trials to identify studies
published between 1 January 1985 and 1 January 2011.
To identify the active-comparator trials that were not
included in previous meta-analyses, we developed a
search strategy using the search terms atorvastatin, flu-
vastatin, simvastatin, lovastatin, pravastatin, rosuvas-
tatin, cholesterol, cardiovascular disease, and
hydroxymethylglutaryl-CoA reductase inhibitors/
therapeutic use. We also performed manual searches
using the authors’ files and reference lists from original
communications and review articles to cross check ref-
erences. Two researchers (BT, HT) independently per-
formed abstract, title, and full-text screening. A third
researcher approved study selection (HN).
We included open-label and double-blind rando-
mized controlled trials comparing one statin with
another at any dose or with control (placebo, diet, or
usual care) for adults with, or at risk of developing,
cardiovascular disease. We included trials of atorvasta-
tin, fluvastatin, lovastatin, pravastatin, rosuvastatin,
and simvastatin if they had more than 50 participants
per trial arm, lasted longer than 4 weeks, and reported
major coronary events or all-cause mortality. Both
fixed-dose and titration designs were included. Per
pre-defined criteria, we excluded trials conducted in
patients with renal insuﬃciency.
Trial categorization
Whenever possible, we categorized included trials as
primary prevention, secondary prevention, or mixed
2 European Journal of Preventive Cardiology 0(00)
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patient population. Trials that included at least 80% of
participants without established cardiovascular disease
or reported data separately on a sole primary preven-
tion group were categorized as primary prevention.
Trials that included at least 80% of participants with
established cardiovascular disease or reported data sep-
arately on a sole secondary prevention group were cate-
gorized as secondary prevention. All remaining trials
were categorized as having a mixed patient population.
Whenever possible, we used data extracted in previ-
ous meta-analyses to benefit from earlier attempts at
contacting authors of trials and obtaining unpublished
information. For instance, for the analysis of the pri-
mary prevention trials, data inputs used in the recent
meta-analysis by Ray et al.18 were used to ensure that
only patients without coronary artery disease at base-
line were included.
Outcomes
Primary outcomes were major coronary events and all-
cause mortality. We defined the composite of major
coronary events as deaths from coronary heart disease
and non-fatal myocardial infarctions.
Data extraction
We used a structured form to extract data on trial and
patient population characteristics, and outcomes. Full
list of data extraction elements can be found on our
publicly available protocol. We also extracted informa-
tion on study quality using the Cochrane risk-of-bias
tool. One researcher extracted data (HN) and another
independently checked for accuracy (BT).
Statistical analysis
We first qualitatively summarized included trials,
describing the types of direct and indirect comparisons
and important clinical and methodological variables
(such as trial population, year of publication, age,
and risk of cardiovascular disease).
For each pairwise comparison between two treat-
ments, we calculated the relative eﬀect with a 95% con-
fidence interval. First, we performed classical pairwise
meta-analyses to synthesize studies that compared the
same two treatments using the Mantel–Haenszel (fixed-
eﬀect) and Der Simonian Laird (random-eﬀects)
method.26 Forest plots of the relative treatment eﬀects
from the individual trials and pairwise meta-analyses
were visually inspected to search for heterogeneity.
We also statistically inspected heterogeneity using the
I2 measure.
To determine the comparative eﬀects of statins,
we conducted network meta-analyses.27 This type of
analysis allowed for combining the direct within-trial
comparisons between two treatments (atorvastatin vs.
control) with indirect comparisons constructed from
trials that had one treatment in common (atorvastatin
vs. control and simvastatin vs. control).28 This analysis
preserved the within-trial randomized treatment com-
parison of each trial while combining all available com-
parisons between treatments. Study-level relative
treatment eﬀects were combined using random-eﬀects
models using Bayesian Markov chain Monte Carlo
methods.29 We considered the findings significant
when the 95% credible intervals (CI) for odds ratios
(OR) did not include the null value 1.00. We assessed
the probability that each statin is best by calculating its
treatment eﬀect compared with control and counting
the proportion of iterations of the Markov chain in
which each statin has the highest treatment eﬀect, the
second highest, and so on. This approach took into
account the magnitude of the estimated odds ratio as
well as the uncertainty around it. We developed ranko-
grams and cumulative probability plots to graphically
present the distribution of ranking probabilities and
estimated the surface under the cumulative ranking
(SUCRA) line for each statin.30 To estimate inconsist-
ency between direct and indirect evidence, we calcu-
lated the ratio of relative eﬀects for indirect vs. direct
evidence. We defined inconsistency as the disagreement
between direct and indirect evidence with a 95% CI
excluding 1.31
To obtain a comprehensive estimate of the eﬀect of
statins in major coronary events and all-cause mortal-
ity, our network meta-analysis pooled all primary and
secondary prevention trials in addition to trials with
mixed patient populations, including all placebo-
controlled and active-comparator trials eligible for
inclusion in this review. We also performed separate
analyses for the primary and secondary prevention
populations, as categorized by the criteria mentioned
above.
For the base-case analysis, we excluded trials with
high doses (80mg/day for atorvastatin, fluvastatin,
lovastatin, simvastatin, and !40mg/day for rosuvasta-
tin) and evaluated the benefits of statins at comparable
doses. In a sensitivity analysis, we also included trials
that evaluated statins at high doses. A dose-specific
analysis explored the eﬀects of individual statins at
low, medium, and high doses separately. We categor-
ized doses as low ("20mg/day), medium (21–40mg/
day), and high (>40mg/day) for atorvastatin, fluvasta-
tin, lovastatin, pravastatin, and simvastatin. For
rosuvastatin, doses "10mg/day was categorized as
low, 11–20mg/day as medium, and >20mg/day as
high.
We also investigated whether potential heterogeneity
and inconsistency across the evidence base in the
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network meta-analysis could be explained by diﬀer-
ences in study-level covariates. We performed meta-
regression analyses to evaluate whether diﬀerences in
trial publication year, patients’ baseline LDL concen-
tration, and age could explain potential heterogeneity.
We performed all meta-regression analyses by allowing
for a common treatment–covariate interaction for each
statin compared to control.32
All analyses were based on the total number of ran-
domly assigned participants. We conducted pairwise
meta-analyses in STATA 11.0, multiple-treatments
meta-analyses in WinBugs 1.4.3, and evaluated incon-
sistency in the trial network using R 2.11.1. Graphical
presentation of the trial network, inconsistency
plots, rankograms, and SUCRA plots were developed
in R 2.11.1.
Results
We included 92 trials (Figure 1), totalling 199,721 par-
ticipants (Supplemental Table S1). Overall, the average
trial duration was 116 weeks (2.2 years). There were 59
two-armed placebo-controlled trials and the remaining
33 were two- or multi-armed active-comparator trials.
Of the 15 possible pairwise comparisons between the six
statins, nine were available for the all-cause mortality
outcome and only six were available for the major cor-
onary events outcome. There were only a few trials that
evaluated fluvastatin. Most frequent comparisons
occurred between pravastatin and placebo, atorvastatin
and placebo, and rosuvastatin and atorvastatin. There
were 4709 participants in the placebo-controlled trials
of fluvastatin as compared to 54,617 and 28,762 in the
placebo-controlled trials of pravastatin and rosuvasta-
tin, respectively. No trial directly compared all six sta-
tins with each other (Figure 2).
The overall quality of included trials was rated as
moderate. Older trials were more prone to bias with
inadequate sequence generation and treatment alloca-
tion concealment. A large number of trials did not
report details about randomization procedures and
allocation concealment. Only a small number of trials
were at low risk of bias.
Pairwise meta-analysis findings: benefit of statin
therapy vs. control
In the pairwise meta-analysis of statin therapy vs. con-
trol, 157,217 participants contributed information on
12,398 deaths, and 153,578 participants contributed
information on 9715 major coronary events. Overall,
statin therapy was associated with a reduction in all-
cause mortality (OR 0.87, 95% CI 0.82–0.92) (Figure 3)
and major coronary events (OR 0.69, 95% CI 0.64–
0.75) when compared to control (Figure 4). Among
statins, only fluvastatin and pravastatin were associated
with a significant reduction in all-cause mortality com-
pared with the control, while atorvastatin, lovastatin,
rosuvastatin, and simvastatin were not. Atorvastatin,
fluvastatin, pravastatin, and simvastatin were asso-
ciated with significantly fewer major coronary events
than control treatment.
In the secondary prevention population, statin ther-
apy was associated with a significant reduction in all-
cause mortality (OR 0.82, 95% CI 0.75–0.90) and
major coronary events (OR 0.69, 95% CI 0.62–0.77)
when compared to control. Fluvastatin and pravastatin
resulted in significantly fewer deaths as compared to
control (Figure 3), while atorvastatin, fluvastatin, and
pravastatin led to significantly fewer major coronary
events than control treatment (Figure 4).
In the primary prevention population, statin therapy
was associated with a significant reduction in all-cause
mortality (OR 0.91, 95% CI 0.83–0.99) (Figure 3) and
major coronary events (OR 0.69, 95% CI 0.61–0.79)
(Figure 4). In this population, only rosuvastatin had
suﬃcient evidence for a significant benefit on all-cause
mortality, while atorvastatin, fluvastatin, lovastatin,
and pravastatin did not. Atorvastatin, lovastatin, pra-
vastatin, and rosuvastatin were associated with signifi-
cantly fewer major coronary events as compared to
control.
Overall, statistical heterogeneity in pairwise com-
parisons of statin therapy vs. control in all-cause mor-
tality was low to moderate in analyses of primary
prevention (I2 8.9%), secondary prevention (I2
14.8%), and all populations together (I2 22.6%). We
observed moderate heterogeneity in pairwise compari-
sons of statin therapy vs. control in major coronary
events (I2 29.4% in secondary prevention, I2 40.2% in
primary prevention, and I2 40.9% in all populations
together).
Network meta-analysis findings: comparative
benefits of statins
In addition to the trials included in the pairwise com-
parisons of statin therapy vs. control, there were
39 direct head-to-head statin comparisons, providing
information on 43,174 participants. In the base-case
network meta-analysis, 64 and 48 trials provided infor-
mation for the all-cause mortality and major coronary
events analyses, respectively. In total, 161,379 partici-
pants were included in the base-case analysis on all-
cause mortality, which provided information on
11,914 deaths. For the major coronary events outcome,
there were 9363 events among 151,520 participants.
In the sensitivity analysis inclusive of high-dose
trials, 80 and 62 trials provided information for the
all-cause mortality and major coronary events analyses,
4 European Journal of Preventive Cardiology 0(00)
 at JOHNS HOPKINS UNIV on March 1, 2013cpr.sagepub.comDownloaded from 
XML Template (2013) [25.2.2013–4:54pm] [1–17]
//blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/CPRJ/Vol00000/130176/APPFile/SG-CPRJ130176.3d (CPR) [PREPRINTER stage]
Titles identified through MEDLINE, EMBASE, and 
COCHRANE databases (n=19,837) 
Abstracts screened after duplicates removed 
(n=18,540) 
Full-text articles assessed for eligibility (n=450) 
Trials included in meta-analysis (n=92)* 
atorvastatin vs. placebo (n=14) 
fluvastatin vs. placebo (n=7) 
lovastatin vs. placebo (n=8) 
pravastatin vs. placebo (n=22) 
rosuvastatin vs. placebo (n=5) 
simvastatin vs. placebo (n=6) 
atorvastatin vs. simvastatin (n=5) 
atorvastatin vs. rosuvastaitn (n=14) 
atorvastatin vs. pravastatin (n=3) 
atorvastatin vs. lovastatin (n=1) 
atorvastatin vs. fluvastatin (n=1) 
fluvastatin vs. simvastatin (n=1) 
fluvastatin vs. lovastatin (n=1) 
lovastatin vs. simvastatin (n=1) 
pravastatin vs. simvastatin (n=1) 
rosuvastatin vs. simvastatin (n=3) 
atorvastatin vs. atorvastatin (n=4) ‡
lovastatin vs. lovastatin (n=1) ‡
pravastatin vs. pravastatin (n=1)
 ‡
simvastatin vs. simvastatin (n=2)
 ‡
Duplicates removed (n=1,297) 
Abstracts excluded (n=18,090) 
Full-text articles excluded (n=358) 
Not randomized trial (n=24) 
Not used in cardiovascular disease (n=7) 
Duration <4 weeks (n=19) 
Sample size <50 per arm (n=35) 
Combination therapy (n=46) 
Kin publications (n=73) 
Outcome not reported (n=154) 
Figure 1. Flow diagram of trial identification and selection.
*Ninety-two randomized trials correspond to 101 comparisons because some trials had more than two arms.
zEight randomized trials compared the same statin at a high dose vs. low dose.
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 = 17,134
0.81 (0.55, 1.19)
Figure 2. Network of eligible pairwise comparisons for (A) all-cause mortality and (B) major coronary events in placebo-controlled
and active-comparator trials of participants with and without prior coronary heart disease at baseline (overall population). Connecting
lines indicate the direct pairwise comparison between two treatments (k¼ number of pairwise comparisons; N¼ overall number of
participants; odds ratios and 95% confidence intervals are given). Arrows depict the direction of comparison (e.g. atorvastatin vs.
control). Supplementary Figures S1 (all-cause mortality) and S2 (major coronary events) provide separate network diagrams for
secondary and primary prevention populations. A total of 93 out of 101 comparisons are shown in these network diagrams as eight
trials compared the same statin (high vs. low dose comparisons), which are not depicted in this figure.
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Figure 3. Findings of pairwise meta-analyses: effect of statins compared to control on all-cause mortality in placebo-controlled trials
of participants (A) with and without prior coronary heart disease at baseline (overall population), (B) with coronary heart disease at
baseline (secondary prevention), (C) without coronary heart disease at baseline (primary prevention). Results shown are based on an
analysis of 157,217 participants in placebo-controlled trials. Supplementary Figures S3 (overall population), S4 (secondary prevention),
and S5 (primary prevention) provide the list of studies and their findings included in separate meta-analyses.
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Figure 4. Findings of pairwise meta-analyses: effect of statins compared to control on major coronary events in placebo-controlled
trials of participants (A) with and without prior coronary heart disease at baseline (overall population), (B) with coronary heart
disease at baseline (secondary prevention), (C) without coronary heart disease at baseline (primary prevention). Results shown are
based on an analysis of 153,578 participants. Supplementary Figures S6 (overall population), S7 (secondary prevention), and S8
(primary prevention) provide the list of studies and their findings included in separate meta-analyses.
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respectively. In total, 183,844 participants were
included in the sensitivity analysis on all-cause mortal-
ity, which provided information on a total of 13,210
deaths. For the major coronary events outcome, there
were 10,664 events among 173,062 participants.
In the dose-specific analysis that included all placebo-
controlled, active-comparator, and dose-comparison
trials, a total of 13,892 deaths among 196,765 partici-
pants in 86 trials, and 11,515 major coronary events
among 186,375 participants in 69 trials, were included.
In the base-case analysis, the average dose was
16.7mg/day for atorvastatin as compared to
40.0mg/day for fluvastatin, 39.3mg/day for lovastatin,
30.9mg/day for pravastatin, 14.8mg/day for rosuvasta-
tin, and 33.3mg/day for simvastatin. In this analysis,
there were no significant diﬀerences among statins in
terms of all-cause mortality when all trials of primary
prevention, secondary prevention, and mixed patient
populations were pooled (Figure 5). For the overall
population, rosuvastatin resulted in significantly fewer
major coronary events compared to atorvastatin and
fluvastatin. Among participants with established car-
diovascular disease, atorvastatin was associated with
significantly fewer major coronary events compared to
pravastatin and simvastatin. There were no statistical
diﬀerences among individual statins without estab-
lished cardiovascular disease.
In the sensitivity analysis, the average dose of ator-
vastatin was 39.6mg/day as compared to 72.3mg/day
for fluvastatin, 40.7mg/day for lovastatin, 31.2mg/day
for pravastatin, 17.2mg/day for rosuvastatin, and
33.3mg/day for simvastatin. There were no significant
diﬀerences in the treatment benefit among statins when
we pooled trials of primary prevention, secondary pre-
vention, and mixed patient populations for both all-
cause mortality and major coronary events (Figure 6).
However, among participants with established cardio-
vascular disease, atorvastatin was associated with sig-
nificantly fewer major coronary events compared to
pravastatin. Participants randomized to lovastatin
were estimated to experience significantly more major
coronary events than those randomized to atorvastatin,
fluvastatin, and simvastatin in trials of secondary pre-
vention. There were no detectable statistical diﬀerences
among statins for participants without established car-
diovascular disease.
When we ranked statins according to cumulative
probability of reducing all-cause mortality and major
coronary events across all populations, atorvastatin
(80%), fluvastatin (79%), and simvastatin (62%) were
among the most eﬀective treatments at comparable
doses (Figure 7). In a sensitivity analysis, fluvastatin
(89%), atorvastatin (76%), and simvastatin (60%) con-
sistently ranked as the most eﬀective treatments when
high-dose trials were included in the analysis.
In the dose-specific analysis, low-dose atorvastatin
and low-dose pravastatin resulted in significantly
fewer deaths than control treatment while other statins
did not have adequate evidence to show superiority
over placebo (Figure 8). Statins in higher doses did
not have a greater impact on all-cause mortality than
lower doses. In terms of major coronary events, all sta-
tins except for low-dose lovastatin, high-dose lovasta-
tin, low-dose rosuvastatin, high-dose rosuvastatin, and
low-dose simvastatin were associated with significantly
fewer major coronary events as compared to control
treatment. Higher doses of atorvastatin and fluvastatin
had the highest number of significant diﬀerences com-
pared with other statins (Supplementary Figure S13).
There was no evidence of inconsistency in the trial
network as the direct estimate of the summary eﬀect did
not diﬀerentiate from the indirect estimate in each loop
of the network for both outcomes (Supplementary
Figures S14 and 15). Comparative benefit estimates of
statins did not change in meta-regression analyses when
we adjusted for publication year and baseline mean age
of patients. Although we detected a modest association
between mean LDL concentrations of patients at base-
line and eﬀects of statins, comparative eﬀect estimates
did not change after adjustment (Supplementary
Exhibit S1).
Discussion
This network meta-analysis of 199,721 participants
provides evidence on the statistically and clinically
meaningful benefits of statins in both primary and sec-
ondary prevention of all-cause mortality and major
coronary events. Overall, statins were associated with
an 18% reduction in relative odds of all-cause mortality
among patients with cardiovascular disease. In primary
prevention, statin therapy resulted in a modest but sig-
nificant 9% reduction in relative odds of all-cause mor-
tality. Benefits of statins in reducing the relative odds of
major coronary events by 31% were consistent across
primary and secondary prevention populations. This
meta-analysis is the most comprehensive study to inves-
tigate the comparative eﬀect of diﬀerent statins using
both placebo-controlled and active-comparator trials
and separately for primary- and secondary-prevention
populations. Existing statin trial evidence appeared
asymmetric given the extremely small numbers of indi-
viduals included in fluvastatin trials relative to other
statins. Across all populations, our base-case analysis
provided evidence to suggest that there may be diﬀer-
ences among individual statins for preventing coronary
events. Among statins, atorvastatin, fluvastatin,
and simvastatin were likely to be ranked superior to
their alternatives at comparable doses across all
populations.
Naci et al. 9
 at JOHNS HOPKINS UNIV on March 1, 2013cpr.sagepub.comDownloaded from 
XML Template (2013) [25.2.2013–4:54pm] [1–17]


























































































































(0.15, 5.53) – 
1.05 




(0.22, 2.32) – 
0.90 
(0.54, 1.84) – 
0.86 
(0.48, 1.81) Pravastatin 
1.02 
(0.34, 2.17) – 
1.41 




(0.63, 3.24) Rosuvastatin – 
– – – – – Simvastatin 
Figure 5. Base-case analysis findings: comparative effect of individual statins on all-cause mortality (in white) and major coronary
events (in grey) according to network meta-analysis of participants (A) with and without coronary heart disease at baseline (overall
population), (B) with coronary heart disease at baseline (secondary prevention), and (C) without coronary heart disease at baseline
(primary prevention). Values are odds ratios (95% CI). Comparisons between drugs should be read from left to right and the estimate
is in the cell in common between the column-defining treatment and the row-defining treatment. For both outcomes, odds ratios less
than 1 favour the column-defining treatment. To obtain odds ratios for comparisons in the opposite direction, reciprocals should be
taken.
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(0.18, 4.34) – 
1.10 




(0.35, 1.91) – 
0.88 
(0.63, 1.43) – 
0.81 
(0.51, 1.38) Pravastatin 
1.08 
(0.51, 1.75) – 
1.44 




(0.80, 2.98) Rosuvastatin – 
– – – – – Simvastatin 
Figure 6. Sensitivity analysis findings: comparative effect of individual statins on all-cause mortality (in white) and major coronary
events (in grey) according to network meta-analysis of participants (A) with and without coronary heart disease at baseline (overall
population), (B) with coronary heart disease at baseline (secondary prevention), and (C) without coronary heart disease at baseline
(primary prevention). Values are odds ratios (95% CI). Comparisons between drugs should be read from left to right and the estimate
is in the cell in common between the column-defining treatment and the row-defining treatment. For both outcomes, odds ratios less
than 1 favour the column-defining treatment. To obtain odds ratios for comparisons in the opposite direction, reciprocals should
be taken.
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Although the benefits of statins in the secondary pre-
vention setting are well documented,9 their impact in
individuals free of cardiovascular disease has been dis-
puted.16 The present analysis suggests that all-cause
mortality benefits of statins are clinically and statistic-
ally significant. With reductions estimated at 9%, our
analysis confirms the all-cause mortality benefit of
statin therapy observed in previous meta-analyses.17
In contrast to most recent reviews,18 our analysis
achieved a higher precision around this estimate
(with statistical significance) as a result of including
trials with very few events that were not considered
previously.
Our analysis emphasizes that clinical objectives of
primary prevention of cardiovascular disease should
not be limited to reductions in all-cause mortality and
that decisions about whether to use statins for patients
without established cardiovascular disease should
include consideration of other outcomes. Our finding
that the benefits of statins in preventing major coronary
events are consistent across primary and secondary
populations provides supporting evidence for prescrib-
ing statins to high-risk individuals who stand to benefit
from this therapy. This is particularly important as the
prevention of coronary events also prevents individuals
from graduating into a considerably higher risk
category.
In addition to pairwise meta-analyses that compared
statins to control treatment, we also performed net-
work meta-analysis, which is a relatively new method
that diﬀers from pairwise meta-analysis by incorporat-
ing data from both direct (from head-to-head compari-
sons within trials) and indirect (from comparisons
between trials) sources of evidence. Using this
approach, we combined the results of placebo-
controlled and active-comparator trials, allowing for
more informed estimates of the relative eﬀect of indi-
vidual statins that have not been compared head-to-
head in clinical trials. As with traditional meta-analysis,
our network meta-analysis required an assumption of
similarity across the pooled set of trials in terms of
patient population and trial characteristics. We also
assumed consistency in the trial network when we com-
bined both active-comparator and placebo-controlled
trials.
Our analysis diﬀered from previous network meta-
analyses in three important aspects. First, our review
incorporated data from a comprehensive list of trials
irrespective of placebo or active controls. Second, we
























Control Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
Figure 7. Overall ranking of statins in placebo-controlled and active-comparator trials of participants with and without prior
coronary heart disease at baseline (overall population) by their overall probability to be the best treatment in terms of both reducing
the risk of all-cause mortality and major coronary events (black). Sensitivity of the overall ranking to inclusion of high-dose trials is also
presented (white). Each statin was scored with points up to a maximum of 50 for all-cause mortality and 50 for major coronary events
(overall maximum score 100), with data from rankograms and SUCRAs. Supplementary Figures S9–S12 present rankograms and
SUCRAs.
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Figure 8. Dose-specific analysis findings: comparative effect of individual statins compared to control for (A) all-cause mortality and
(B) major coronary events in placebo-controlled and active-comparator trials of participants with and without prior coronary heart
disease at baseline (overall population).
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and secondary prevention populations. Third, we made
an attempt to evaluate the comparative eﬃcacy of indi-
vidual statins at similar doses.
Our base-case analysis detected significant diﬀer-
ences among individual statins with potential implica-
tions for prescribing decisions in clinical practice. Doses
considered in our base-case analysis were comparable
and, as expected, resulted in approximately 30–40%
reductions from baseline serum low-density lipoprotein
cholesterol (LDL-C) levels.7 Atorvastatin and fluvasta-
tin performed significantly better than rosuvastatin in
terms of reducing major coronary events across all
populations. Atorvastatin and fluvastatin had a
strong eﬀect in reducing mortality and morbidity
among individuals with established cardiovascular dis-
ease. Among individuals with established disease, ator-
vastatin resulted in marginally fewer major coronary
events as compared with pravastatin and simvastatin.
Relative treatment eﬀects for statins were not sensitive
to the findings of the meta-regression analysis and the
sensitivity analysis that included intensive dose trials.
In the sensitivity analysis, atorvastatin was significantly
more eﬀective than lovastatin and pravastatin in redu-
cing major coronary events in the secondary prevention
setting. Also, fluvastatin was more eﬀective than lovas-
tatin in reducing major coronary events. Unfortunately,
fluvastatin and simvastatin had insuﬃcient evidence in
the primary prevention setting as there was no trial for
either statin that provided information for their eﬀect-
iveness in high-risk individuals without established
disease.
Our dose-specific analysis paralleled the findings of
previous meta-analyses in that statins at higher doses
do not reduce all-cause mortality more so than statins
at lower doses.33 Similar to previous meta-analyses,
there was a general dose-response relationship across
placebo-controlled and active-comparator trials in
terms of reducing major coronary events. However,
this relationship was not apparent for all statins. For
instance, low-dose and high-dose formulations of
lovastatin fared worse than the medium-dose formula-
tion.34–37 Similarly, currently available randomized evi-
dence is not adequate to suggest that high-dose
rosuvastatin is beneficial in reducing major coronary
events.38–40 Although high-dose formulations of ator-
vastatin and fluvastatin have not been compared dir-
ectly in trials, the findings of our network meta-analysis
provided compelling evidence that these agents are
equally eﬀective in reducing the occurrence of major
coronary events. Placebo-controlled trials of atorvasta-
tin and fluvastatin were comparable in terms of known
relative treatment eﬀect modifiers and individuals in the
placebo arms experienced major coronary events at
similar rates.41–45 Given the greatly diﬀering incremen-
tal LDL-C-lowering eﬀects of high-dose atorvastatin
and fluvastatin,7 this analysis suggests that incremental
LDL-C-reducing eﬀects alone may not be responsible
for the comparative benefits of statins. In the case of
fluvastatin, prospective studies should further evaluate
whether pleiotropic eﬀects are responsible for its
favourable benefits relative to other statins.46
Findings of this study should be interpreted in light
of its limitations. First, as a literature-based meta-
analysis, our analysis shares the limitations of the pub-
lished evidence base. The quality of included trials was
moderate with older trials being more prone to bias
than newer trials. This was particularly the case for
the trials of lovastatin and fluvastatin. However, the
implications of this in our analysis were not clear.
The quality of reporting remains well below an accept-
able level, particularly for older trials, which compli-
cates assessments of their conduct and validity.47
Second, there were only a few head-to-head trials of
statins that were prospectively designed to capture dif-
ferences in clinical outcomes as primary endpoints.
Third, there was an apparent asymmetry in the evi-
dence network where specific interventions appear to
be avoided (e.g. fluvastatin), which may be indicative
of a biased clinical research agenda. The reasons behind
this should be investigated further. Fourth, heterogen-
eity ranged from low to moderate across various pair-
wise meta-analyses of statins vs. control. Although the
estimate of between-study heterogeneity was low in net-
work meta-analyses, it remains a possibility that our
analysis did not fully account for heterogeneity due to
unobserved or unmeasured factors. However, we used a
random-eﬀects model and our analyses took into
account potential unexplained heterogeneity across
the studies. We also performed meta-regressions to fur-
ther evaluate heterogeneity and inconsistency and did
not detect a significant association between publication
year and baseline age of patients. According to meta-
regressions, findings of our analysis were consistent
with previous reviews that showed that the impact of
statins might vary modestly across diﬀering levels of
baseline LDL-C.
Heterogeneity that is unexplained or unaccounted
for may introduce bias only if it influences diﬀerent
statins to a diﬀerent extent.48 For instance, it is possible
that there is an imbalance across the included set of
trials in terms of baseline characteristics: trials of ator-
vastatin may have included patients who were on aver-
age older than those of pravastatin. Although baseline
age is not a relative eﬀect modifier, as shown in previ-
ous individual patient-level meta-analyses, there may be
imbalances across studies in terms of unmeasured or
unknown relative eﬀect modifiers. Hence, we caution,
as we would in any meta-analysis, that any compari-
son of statins should be tempered by the diﬀerences
that may result from additional (unobserved or
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unmeasured) diﬀerences in patient populations across
diﬀerent trials. An individual patient-level data meta-
analysis such as that produced by the Cholesterol
Treatment Trialists’ Collaboration9,49 may provide a
more nuanced examination of the comparative benefits
of statins in specific subgroups – such as those with or
without cardiovascular disease, by age, and diabetes
status.
In spite of these limitations, this study has important
methodological strengths. Our review is the largest
meta-analysis on statin therapy to-date. We included
39 direct head-to-head statin comparisons, providing
information on 43,174 participants that were not con-
sidered in prior meta-analyses on clinical outcomes.
Due to the comprehensive nature of our review, our
findings are generalizable to patients in clinical practice.
We included a broad range of patients and observed
that the benefits of statins are consistent in studies
with populations that varied in age, geographic
region, and severity of underlying illness, which adds
to the strength of our overall inferences – providing
conclusive evidence that statins work in both primary
and secondary prevention, and that there may be dif-
ferences between individual statins, which should be
investigated in future prospective studies.
What are the clinical implications of this network
meta-analysis when initiating statin therapy? First,
there is strong evidence that statins as a class are eﬀect-
ive in the primary and secondary prevention of major
coronary events and all-cause mortality. According to
the findings of this comprehensive analysis, there is con-
sistently strong evidence on the benefits of atorvastatin
and simvastatin, which should be favoured in clinical
practice. Although fluvastatin ranked superior to its
alternatives in our analyses, we caution against over-
interpreting this finding, particularly given the small
number of trials that evaluated this agent. Future stu-
dies on fluvastatin are needed to confirm its favourable
eﬀect on mortality and coronary disease outcomes.
Finally, we acknowledge the multifaceted nature
of making prescribing decisions and urge prescribers
to also consider other important outcomes such as
harmful side eﬀects when choosing among individual
statins.
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Summary
Statins are important in the prevention of major cere-
brovascular events. Whether, and the extent to which,
individual statins differ in terms of their effect on these
outcomes has not been studied. The aim of this review
was to evaluate the comparative effects of individual
statins on major cerebrovascular events. We system-
atically reviewed 61 trials including 187038 individ-
uals with, or at risk of developing, cardiovascular
disease. We performed pair-wise and multiple-
treatments meta-analyses for major cerebrovascular
events, in addition to fatal and non-fatal strokes sep-
arately. Across all populations, statins were signifi-
cantly more effective than control in reducing major
cerebrovascular events [odds ratio (OR): 0.82, 95%
CI: 0.77, 0.87], with no differences among individual
statins. Statins were also effective in patients with
established cardiovascular disease (OR: 0.83, 95%
CI: 0.75, 0.91) and in those without (OR: 0.80, 95%
CI: 0.71, 0.91). Considering individual statins, signifi-
cant risk reductions were achieved with atorvastatin
(OR: 0.74, 95% CI: 0.63, 0.85), pravastatin (OR: 0.86,
95% CI: 0.76, 0.97) and simvastatin (OR: 0.75, 95%
CI: 0.62, 0.88) as compared with control on major
cerebrovascular events across all populations. Statins
led to significant reductions in the risk of non-fatal
strokes (OR: 0.77, 95% CI: 0.71, 0.85) but not of
fatal strokes (OR: 0.96, 95% CI: 0.80, 1.15). Findings
were not sensitive to dose differentials of individual
statins across the trials. No significant heterogeneity
or inconsistency was detected. Statins significantly
reduce the incidence of major cerebrovascular
events as compared with control. Our analysis pro-
vided evidence to confirm the class effect of statins
in preventing major cerebrovascular events.
Introduction
Stroke is among the leading causes of death and dis-
ability worldwide. Annually, !16million incident
strokes occur globally, causing an estimated total of
5.7million deaths.1 About half of stroke survivors
experience physical or cognitive impairment, impact-
ing their physical function, social function and activ-
ities of daily living.2 In addition to its health impact,
stroke is costly to individuals, their families and the
wider society—with an economic burden amounting
to an estimated $65.5 billion in the USA alone.3,4
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Although the evidence from epidemiological
studies remains inconclusive,5,6 lipid management
is an important milestone in the prevention of
stroke.7 Hydroxymethylglutaryl-CoA (HMG-CoA) re-
ductase inhibitors, also known as statins, effectively
reduce the risk of strokes.8,9 Recent reviews and
meta-analyses of randomized controlled trials have
confirmed the considerable benefits of statins in the
prevention of strokes among individuals with a his-
tory of established cardiovascular disease.10–15
Previous meta-analyses showed that statins effect-
ively reduce the risk of stroke in the elderly,16,17
among diabetics18,19 and in individuals with no es-
tablished cardiovascular disease.20–22 According to
analyses of individual patient-level data from different
trials, there appear to be a significant trend towards
greater proportional reductions in stroke being asso-
ciated with greater mean absolute low-density lipo-
protein (LDL) cholesterol reductions.23 Indeed, in
direct comparisons of different dosing regimens,
high-dose statin therapy reduces the risk of stroke to
a greater extent compared with standard doses.24
An important question that remains unanswered
in previous meta-analyses is whether individual sta-
tins are different in terms of their effect on the risk of
stroke in individuals with or without a history of
established cardiovascular disease. Earlier meta-
analyses did not address this question in part be-
cause their focus was to establish the class effect
of statins over control treatment on the basis of pla-
cebo-controlled trials. Incidence of cerebrovascular
events was not an endpoint of interest in previous
reviews that compared statins head-to-head in net-
work meta-analyses.21,25–27 Only one review indir-
ectly compared statins (atorvastatin, pravastatin and
simvastatin) in terms of major cerebrovascular
events but this study was based on a small number
of placebo-controlled trials, without making use of
the valuable information from active-comparator
trials of statins.28
The objective of our study was to systematically
review the placebo-controlled and active-comparator
trials of statins, and perform a multiple-treatments
meta-analysis of individual statins in terms of their
effect on major cerebrovascular events across all
populations, in addition to secondary and primary
prevention of cardiovascular disease separately.
Methods
Systematic review methods
We searched MEDLINE, EMBASE, Cochrane Data-
base of Systematic Reviews and Cochrane Central
Register of Controlled Trials to identify studies
published between 1 January 1985 and 1 January
2011. To comprehensively identify the active-
comparator trials that were not included in previous
meta-analyses of placebo-controlled trials, we used
the search terms ‘atorvastatin’, ‘fluvastatin’, ‘simvas-
tatin’, ‘lovastatin’, ‘pravastatin’, ‘rosuvastatin’, ‘chol-
esterol’, ‘cardiovascular disease’ and ‘HMG-CoA
reductase inhibitors/therapeutic use’. Two re-
searchers (BT and HT) independently performed ab-
stract, title and full-text screening. A third researcher
approved study selection (HN).
We included open-label and double-blind rando-
mized controlled trials comparing one statin with
another statin at therapeutic dose or with control
(placebo, diet or usual care) for adults with, or at
risk of developing, cardiovascular disease. We
included trials of atorvastatin, fluvastatin, lovastatin,
pravastatin, rosuvastatin and simvastatin if they had
more than 50 participants per trial arm, lasted longer
than 4weeks and reported major cerebrovascular
events. Both fixed dose and titration designs were
included. Per pre-defined criteria, we excluded trials
conducted in patients with renal insufficiency.
Trials that included at least 80% of participants
without established cardiovascular disease or re-
ported data separately on a sole primary prevention
group were categorized as primary prevention.
Trials that included more than 80% of participants
with established cardiovascular disease or reported
data separately on a sole secondary prevention
group were categorized as secondary prevention.
All remaining trials were categorized as having a
mixed patient population.
The primary outcome was major cerebrovascular
events. In line with previous meta-analyses, we
defined the composite of major cerebrovascular
events as fatal- and non-fatal strokes and transient
ischaemic attacks. As secondary endpoints, we eval-
uated fatal- and non-fatal strokes separately. For the
analysis on non-fatal strokes, transient ischaemic at-
tacks were not included.
We used a structured form to extract data on trial
(reference, publication year, design features such as
blinding and dosing regimen) and patient popula-
tion characteristics (age, baseline LDL cholesterol,
cardiovascular risk factors), and outcome measures.
One researcher extracted data (HN) and another in-
dependently checked for accuracy (BT). To ensure
quality, we checked the consistency of extracted
data with previously published meta-analyses.
Statistical analysis methods
We first qualitatively summarized included trials,
describing the types of direct and indirect compari-
sons. For each pair-wise comparison between two
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statins, we calculated the odds ratio (OR) with a
95% confidence interval. First, we performed clas-
sical pair-wise meta-analyses to synthesize studies
that compared the same two statins using the
DerSimonian Laird (random-effects) method.29
The random-effects meta-analysis model assumed
the observed estimates of treatment effect could
vary across studies because of real differences in
the treatment effect in each study and sampling vari-
ability (chance).30 Forest plots of the relative treat-
ment effects from the individual trials and pair-wise
meta-analyses were visually inspected to search for
heterogeneity. We also statistically inspected het-
erogeneity using the I2 statistic, which was used to
estimate the percentage of total variation among stu-
dies that can be considered to be due to heterogen-
eity. We used rough thresholds of 25, 50 and 75% to
define low, moderate and high heterogeneity, and
investigated moderate and high heterogeneity by in-
specting trial-level variables that may explain
observed differences.
To determine the comparative effects of statins,
we conducted multiple-treatments meta-analyses.31
In these analyses, study-level relative treatment ef-
fects were combined using random-effects models
within a Bayesian framework using Markov chain
Monte Carlo methods.32,33 We used the model de-
veloped by Dias et al.34 for the National Institute of
Health Clinical Excellence Decision Support Unit in
the UK. This was based on modelling the outcomes
in every treatment group of every study, and specify-
ing the relations among the relative effects across
studies making different comparisons.
To obtain a comprehensive estimate of the effect
of statins in major cerebrovascular events, the
multiple-treatments meta-analysis pooled all pri-
mary and secondary prevention trials in addition
to trials with mixed patient populations. This ana-
lysis included all placebo-controlled and active-
comparator trials eligible for inclusion in this
review. We also performed separate analyses for
the primary and secondary prevention populations,
as categorized by the criteria mentioned earlier. For
the base case analysis, we included trials at all
doses. We separately evaluated the impact of dose
differentials across the trials by excluding high-dose
trials (80mg/day for atorvastatin, fluvastatin, lovas-
tatin, simvastatin and 540mg/day for rosuvastatin)
in a sensitivity analysis and evaluating the benefits
of statins at comparable doses.
Results
We included 61 trials (Figure 1), totalling 187 038
individuals. Overall, the average trial duration was
140weeks (2.7 years). There were 51 two-armed
placebo-controlled trials and the remaining 10
were two- or multi-armed active-comparator trials.
There were 28 secondary prevention and 12 primary
prevention trials. The remaining were in individuals
who experienced acute coronary syndromes (n=8)
and those with mixed populations (n=13). Of the 15
possible pair-wise comparisons between the six sta-
tins, only five were available for the major cerebro-
vascular events outcome. No trial directly compared
all six statins to each other (Figure 2). Characteristics
of included trials are summarized in Supplementary
Table S1.
Benefit of statin therapy vs. control:
findings of the pair-wise meta-analyses
In the pair-wise meta-analysis of statin therapy
vs. control across all populations, 171 731 individ-
uals contributed information on 4533 events.
Overall, statin therapy was associated with a
reduction in the risk of major cerebrovascular
events (OR: 0.82, 95% CI: 0.77, 0.87) when
compared with control (Figure 3). Among statins,
atorvastatin, pravastatin and simvastatin were
associated with a significant reduction in major
cerebrovascular events compared with the control,
while fluvastatin, lovastatin and rosuvastatin were
not.
In the secondary prevention population, statin
therapy was associated with a significant reduction
in major cerebrovascular events (OR: 0.83, 95% CI:
0.75, 0.91) when compared with control (Figure 3).
Only atorvastatin resulted in significantly fewer
events as compared with control in this population.
In the primary prevention population, statin ther-
apy was associated with a significant reduction in
major cerebrovascular events (OR: 0.80, 95% CI:
0.71, 0.91) (Figure 3). In this population, only ator-
vastatin and rosuvastatin had sufficient evidence for
a significant benefit on major cerebrovascular
events, while fluvastatin, lovastatin, pravastatin did
not. Simvastatin did not have any trials in primary
prevention.
Overall, statistical heterogeneity in pair-wise
comparisons of statin therapy vs. control in all-cause
mortality was low in analyses of primary prevention
(I2: 9.2%), secondary prevention (I2: 0.0%) and all
populations together (I2: 0.0%). We observed high
heterogeneity in pair-wise comparisons of rosuvas-
tatin vs. control (I2: 81.3%), mainly as a result of the
differences in patient populations between JUPITER
(primary prevention), GISSI-HF and CORONA (heart
failure).
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* 61 trials when primary and secondary prevention populations within trials are considered separately.  
Titles identified through MEDLINE, EMBASE,
and COCHRANE databases  
(n=19,837) 
Abstracts screened after duplicates removed  
(n=18,540) 
Full-text articles assessed for eligibility  
(n=450) 
Trials included in meta-analysis  
(n=59)* 
Trials in secondary prevention (n=28) 
Trials in primary prevention (n=12) 
Trials in acute coronary syndrome (n=8) 
Trials in hypercholesterolemia with or without 
established cardiovascular heart disease (n=13) 
Duplicates removed  
(n=1,297) 
Abstracts excluded  
(n=18,090) 
Full-text articles excluded  
(n = 391) 
Not randomized trial (n=24) 
Not used in cardiovascular disease (n=7) 
Duration <4 weeks (n=19) 
Sample size <50 per arm (n=35) 
Combination therapy (n=46) 
Kin publications (n=73) 
Outcome not reported (n=187) 











































































k=7, n=17, 869, l 2=19.5%
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k=12, n=31, 739, l 2=0%
OR:0.88(0.80, 0.97)


















k=5, n=14, 973, l 2=0%
Figure 2. Network diagram of available comparisons.
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Comparative benefits of statins on major
cerebrovascular events: findings of the
multiple-treatments meta-analyses
In addition to the trials included in the pair-wise com-
parisons of statin therapy vs. control, there were 11
direct head-to-head statin comparisons, providing in-
formation on 20072 participants. In the multiple-
treatments meta-analysis, 61 placebo-controlled and
active-comparator trials provided information for
major cerebrovascular events analysis. In total,
187038 individuals were included in this analysis,
which provided information on 4913 events.
In this analysis, there were no significant differen-
ces among statins in terms of major cerebrovascular
events when all trials of primary prevention,
secondary prevention and mixed patient popula-
tions were pooled (Figure 5). There were also no
statistical differences among individual statins in
terms of reducing the risk of major cerebrovascular
events in primary and secondary prevention of car-
diovascular disease.
The findings of the multiple-treatments meta-
analysis were not sensitive to dose differentials
across trials (Figure 4). When high-dose trials were
excluded from the analysis, estimated comparative
benefits of individuals were not materially different
and there were no statistically meaningful differ-
ences between statins (Figure 5).
Comparative benefits of statins on
non-fatal and fatal strokes
Across all populations, statins were effective in redu-
cing the incidence of non-fatal strokes (OR: 0.77,
95% CI: 0.71, 0.85) as compared with control treat-
ment (Figure 6). Only rosuvastatin (OR: 0.69, 95%
CI: 0.44, 0.99) and simvastatin (OR: 0.69, 95% CI:
0.45, 0.96) had sufficient statistical power to show
superiority over control treatment across all popula-
tions. Statins were not effective in reducing the risk
of fatal strokes (OR: 0.96, 95% CI: 0.80, 1.15) al-
though atorvastatin was independently superior to
control treatment in preventing fatal strokes (OR:
0.49, 95% CI: 0.30, 0.80). There were no statistical
differences between the individual statins.
Discussion
This multiple-treatments meta-analysis of 187 038
individuals provides evidence on the statistically
and clinically meaningful benefits of statins in redu-
cing the risk of major cerebrovascular events in both
Odds Ratios









































Figure 3. Multiple-treatments meta-analysis findings:
















Figure 4. Sensitivity analysis findings: comparative ef-
fects of statins compared with control on major cerebro-
vascular events.
Page 5 of 8
Comparative benefits of statins on cerebrovascular events




individuals with or without established cardiovascu-
lar disease. Overall, statins were associated with an
18% reduction in relative odds of major cerebrovas-
cular events across all populations. Benefits of statins
in reducing the relative odds of major cerebrovascu-
lar events by !18% were consistent across primary
and secondary prevention populations. Across all
populations, given the lack of statistical difference
between different statins, our analysis provided evi-
dence to confirm the class effect of statins in prevent-
ing major cerebrovascular events.
Our overall findings reinforce and extend the re-
sults of previous meta-analyses on statin therapy.
Previous reviews elucidated the importance of
lipid management with statins in the prevention of
strokes and found consistent evidence that would
warrant advocating statin use for the prevention of
incident strokes.35,36 Clinical practice guidelines
also recommend statin therapy in secondary preven-
tion of stroke for patients with non-cardioembolic
stroke.37,38 As SPARCL was the only trial that inves-
tigated the benefits of statins for the secondary pre-
vention of strokes in individuals with a history of
transient ischaemic attack or stroke, we did not ex-
plore the comparative benefits of statins in this
population separately.39 Our base-case analysis in
individuals with or without a history of established
cardiovascular disease did not detect significant dif-
ferences among individual statins. However, it re-
mains a possibility that there are actual differences
between individual statins which could not be de-
tected in our analysis.
Indeed, although there were no statistical differ-
ences, our review suggested that the randomized
trial evidence base for some statins was more robust
and consistent than it was for others. This was particu-
larly the case for atorvastatin and simvastatin. There
was essentially no detectable heterogeneity across the
trials of atorvastatin and simvastatin with consistent
evidence for their benefits in the prevention of major
cerebrovascular events. Unlike simvastatin that did
not have evidence in individuals with no history of
cardiovascular disease, atorvastatin was able to
reach statistical significance in both primary and sec-
ondary prevention populations (as well as across all
populations) as compared with control treatment.
Although atorvastatin led to a significant reduction in
the risk of fatal strokes, unexpectedly, it was not asso-
ciated with significantly fewer non-fatal strokes as
compared with control. Trial evidence for fluvastatin
and lovastatinwas inconsistent across individualswith
and without cardiovascular disease and there was
large uncertainty around the benefits of these agents
in the prevention of strokes. Finally, therewas substan-
tial heterogeneity in the evidence base for rosuvasta-
tin. Given the small number of trials, JUPITER
appeared to drive the pooled estimates for rosuvasta-
tin, specifically for individuals without a history of car-
diovascular disease.40
In addition to pair-wise meta-analyses that com-
pared statins with control treatment, we also per-
formed multiple-treatments meta-analysis, which is
a relatively new method that differs from pair-wise
meta-analysis by incorporating data from both
direct (from head-to-head comparisons within trials)
and indirect (from comparisons between trials)
sources of evidence. Using this approach, we com-
bined the results of placebo-controlled and active-
comparator trials, allowing for more informed esti-
mates of the relative effect of individual statins that
have not been compared head-to-head in clinical
trials. Our analysis differed from previous
multiple-treatments meta-analyses in two important
aspects. First, our review incorporated data from a
comprehensive list of trials irrespective of placebo
or active controls. Second, we provided comparative
estimates separately for populations in primary and
secondary prevention of cardiovascular disease.



























































Figure 5. Comparative effects of individual statins on major cerebrovascular events according to the multiple-treatments
meta-analysis of all eligible trials (bottom half of figure) and sensitivity analysis excluding trials with high-dose formulations
of statins (top half of the figure).
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Findings of this study should be interpreted in
light of its limitations. First, as a literature-based
meta-analysis, our analysis shares the limitations of
the published evidence base. There were only a few
head-to-head trials of statins that were prospectively
designed to capture differences in clinical outcomes
as primary endpoints. Second, as a multiple-
treatments meta-analysis combining direct and in-
direct sources of evidence, it remains a possibility
that potential imbalances in the occurrence of effect
modifiers across the contrasts impacted the results,
potentially confounding the comparative estimates
between statins.
In spite of these limitations, this study has import-
ant methodological strengths. Our review is the lar-
gest meta-analysis on the benefits of statin therapy
on cerebrovascular events to date. We included 11
direct head-to-head statin comparisons, providing
information on additional 20 072 individuals that
were not considered in prior meta-analyses on
strokes. Our statistical models were appropriate for
the evidence base as we did not detect any signifi-
cant heterogeneity in the trial network. Although
there was no considerable heterogeneity, we still
used a random-effects model to take into account
potential unexplained heterogeneity across the
studies.
Supplementary data
Supplementary material is available at QJMED
online.
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Statins are widely used to prolong survival and reduce the occurrence of coronary and cerebrovascular events in 
patients with and without cardiovascular disease. Prior meta-
analyses have demonstrated the effectiveness of statins for 
the primary and secondary prevention of cardiovascular dis-
ease,1–5 with consistent benefits across subgroups, including 
the elderly,6 women,7 and individuals with diabetes mellitus.2 
Initially focused on secondary prevention, statin therapy has 
become more common because the limits of treatment have 
expanded over time to include people at progressively lower 
risk of developing cardiovascular disease.8 As the number of 
individuals eligible for statin therapy continues to increase,9 
the comparative tolerability and harms of different statins war-
rant further investigation.
There is no comprehensive analysis on the comparative 
adverse event profiles of different statins, which builds on the 
totality of the existing randomized, controlled trial evidence 
base. Although large-scale meta-analyses confirmed that the 
frequency of clinically significant side effects associated with 
statin therapy is low,10 more research is needed to synthesize the 
evidence on a more diverse range of outcomes that are important 
for individuals receiving statins. These range from previously 
studied outcomes, such as cancer11–13 and diabetes mellitus,14,15 
to muscle aches and clinically meaningful elevations in liver 
enzymes, which may be among factors contributing to nonad-
herence to long-term statin therapy.16,17 Information regarding 
the relative tolerability and harms of different statins in the 
prevention of cardiovascular disease is needed to better inform 
patients, clinicians, and other healthcare decision makers.
Several reviews established the favorable safety profile of 
statins.18–22 An important limitation of previous reviews is 
their focus on placebo-controlled trials, which did not take 
into account evidence from a large number of trials with direct 
head-to-head comparisons of statins. Equally important, 
Background—Our objective was to estimate the comparative harms of individual statins using both placebo-controlled and 
active-comparator trials.
Methods and Results—We systematically reviewed randomized trials evaluating different statins in participants with and 
without cardiovascular disease. We performed random-effects pairwise and network meta-analyses to quantify the relative 
harms of individual statins. We included 55 two-armed placebo-controlled and 80 two- or multiarmed active-comparator 
trials including 246 955 individuals. According to pairwise meta-analyses, individual statins were not different than 
control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations because of adverse events. Statins 
as a class resulted in significantly higher odds of diabetes mellitus (odds ratio, 1.09; 95% confidence interval, 1.02–
1.16) and transaminase elevations (odds ratio, 1.51; 95% confidence interval, 1.24–1.84) compared with control. When 
individual statins were compared in network meta-analyses, there were numerous statistically detectable differences, 
favoring simvastatin and pravastatin. According to dose-level comparisons, individual statins resulted in higher odds of 
discontinuations with higher doses of atorvastatin and rosuvastatin. Similarly, higher doses of atorvasatin, fluvastatin, 
lovastatin, and simvastatin were associated with higher odds of transaminase elevations. Simvastatin at its highest doses 
was associated with creatine kinase elevations (odds ratio, 4.14; 95% credible interval, 1.08–16.24). Meta-regression 
analyses adjusting for study-level age at baseline, low-density lipoprotein cholesterol level, and publication year did not 
explain heterogeneity. There was no detectable inconsistency in the network.
Conclusions—As a class, adverse events associated with statin therapy are not common. Statins are not associated with 
cancer risk but do result in a higher odds of diabetes mellitus. Among individual statins, simvastatin and pravastatin seem 
safer and more tolerable than other statins.  (Circ Cardiovasc Qual Outcomes. 2013;06:390-399.)
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previous reviews did not assess differences in dosages of indi-
vidual statins across populations and did not compare statins 
at similar doses.
Our objective in this study was to systematically review 
and synthesize the totality of the randomized, controlled trial 
evidence on different statins and determine their comparative 




Our search strategy was based on a publicly available protocol pre-
viously developed by the study authors to evaluate the comparative 
clinical benefits of statins.23 We searched MEDLINE, EMBASE, 
Cochrane Database of Systematic Reviews, and Cochrane Central 
Register of Controlled Trials to identify studies published between 
January 1, 1985, and March 10, 2013. To identify the relevant lit-
erature, we developed a search strategy using the search terms ator-
vastatin, fluvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin, 
cholesterol, cardiovascular disease, and hydroxymethylglutaryl-co-
enzyme A reductase inhibitors/therapeutic use. Our updated search 
in MEDLINE adopted Cochrane Collaboration’s sensitivity and pre-
cision-maximizing strategy.24 We searched for pitavastatin trials post 
hoc separately because our protocol did not include pitavastatin (pro-
tocol finalization coincided with the Food and Drug Administration 
approval of this agent). We also performed manual searches using 
the authors’ files and reference lists from original communications 
and review articles to cross-check references. Two researchers (B.T., 
H.T.) independently performed abstract, title, and full-text screening. 
A third researcher approved study selection (H.N.).
We included open-label and double-blind randomized, controlled 
trials comparing one statin with another at any dose or with control 
(placebo, diet, or usual care) for adults with, or at risk of developing, 
cardiovascular disease. We included trials of atorvastatin, fluvastatin, 
lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin if 
they had >50 participants per trial arm and lasted >4 weeks based on 
prespecified inclusion and exclusion criteria.
Outcomes of interest were determined after protocol finalization. 
We included trials that reported tolerability (number of participants 
who discontinued the study medication because of adverse events), 
elevations in hepatic transaminases (number of participants with 
clinically meaningful elevations in either alanine aminotransferase or 
aspartate aminotransferase, 3× baseline values as commonly defined 
by trial investigators), elevations in creatine kinase (CK; number of 
participants with clinically meaningful increases in baseline CK lev-
els as defined by trial investigators, ranging from 3× to 10× higher 
than baseline concentrations), myalgia (number of individuals with 
muscle pain, as defined by trial investigators), myopathy (number 
of participants with 10× baseline CK levels associated with muscle 
symptoms), and rhabdomyolysis (number of participants with severe 
muscle damage, as diagnosed by trial investigators). In addition, we 
were interested in the incidence of cancer and diabetes mellitus (as 
defined by trial investigators), so trials reporting these outcomes were 
also eligible for inclusion. Both fixed dose and titration designs were 
included. As per our protocol, we excluded trials conducted in pa-
tients with renal insufficiency.
We used a structured form developed in MS Excel to extract data 
on trial and patient population characteristics and outcomes. We also 
extracted information on the methodological quality of included stud-
ies. In particular, information was collected on blinding, random se-
quence generation, allocation concealment, indications of incomplete 
outcome data, indications of selective reporting (possible for trials 
with published protocols), and industry sponsorship. One researcher 
extracted data (H.N.) and another independently checked for accu-
racy (B.T.).
Statistical Analysis
We qualitatively summarized included trials, describing the types of 
direct and indirect comparisons and important clinical and trial design 
characteristics. For each pairwise comparison between 2 treatments, 
we calculated the relative effect with a 95% confidence interval (CI). 
We performed classical pairwise meta-analyses to synthesize studies 
that compared the same 2 treatments using the DerSimonian–Laird 
(random-effects) method. Forest plots of the relative treatment effects 
from the individual trials and pairwise meta-analyses were visually 
inspected to search for heterogeneity. We also statistically inspected 
heterogeneity using the I2 measure.
To determine the comparative tolerability and harms of individual 
statins, we conducted network meta-analyses, which are generaliza-
tions of indirect comparisons with >2 (or multiple pairs of) treatments 
being compared indirectly and ≥1 pair of treatments compared both 
directly and indirectly.25,26 This type of analysis allowed for simul-
taneously combining the direct within-trial comparisons between 2 
treatments (eg, atorvastatin versus control) with indirect comparisons 
constructed from trials that had 1 treatment in common (eg, atorvas-
tatin versus control and simvastatin versus control).27 This analysis 
preserved the within-trial randomized treatment comparison of each 
trial while combining all available comparisons between treatments. 
We combined study-level relative treatment effects using Bayesian 
Markov chain Monte Carlo methods in WinBUGS version 1.4.3. We 
used the model developed by Dias et al28 for the UK National Institute 
of Health Clinical Excellence Decision Support Unit. This was based 
on modeling the outcomes in every treatment group of every study 
and specifying the relationships among the relative effects across 
studies making different comparisons, while taking into account the 
correlations between treatment effects within multiarm trials. Our 
models adopted random effects. The random-effects model took into 
account potential heterogeneity by assuming that each treatment was 
drawn from the same distribution, whose mean and variance were 
estimated from the data.29 Additional details of our analytic approach 
are provided in the online-only Data Supplement Appendix.
Findings were reported in terms of odds ratios (OR). The differ-
ence between treatments was assessed on the basis of 95% CI in 
pairwise meta-analyses and 95% credible intervals (CrI) in network 
meta-analyses. CrIs may be interpreted as Bayesian equivalents of 
95% CIs. The 95% CrI can be interpreted as indicating a 95% prob-
ability that the true OR falls within the reported range. If a 95% CrI 
does not include the null value 1.00, this can be interpreted as in-
dicating <5% probability that there is no difference between the 2 
comparators (referred to as significant difference between treatments 
hereafter). Given the Bayesian nature of the statistical analyses, P 
values are not estimated and reported for network meta-analyses.
WHAT IS KNOWN
? The frequency of clinically significant side effects 
associated with statin therapy is low.
? There is no comprehensive analysis on the compara-
tive adverse event profiles of different statins that 
builds on both placebo-controlled and active-com-
parator trials.
WHAT THE STUDY ADDS
? Higher doses of some statins are associated with 
larger numbers of transaminase and creatine kinase 
elevations, and discontinuations because of adverse 
events.
? There are clinically meaningful differences among 
individual statins, with simvastatin and pravastatin 
likely to be ranked superior to their alternatives in 
terms of their safety profile.
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We assessed the probability that each statin has the most favorable 
harm profile by calculating its treatment effect compared with control 
treatment and counting the proportion of iterations for which each 
statin has the highest treatment effect (ie, least harmful), the second 
highest, and so on. This approach took into account the magnitude of 
the estimated treatment effect, as well as the uncertainty around it. We 
graphically presented the distribution of ranking probabilities and es-
timated the surface under the cumulative ranking line for each statin.30 
The surface under the cumulative ranking line for each statin would 
be 1.00 when a treatment is certain to be the best (most favorable 
tolerability and harm profile) and 0.00 when a treatment is certain to 
be the worst (least favorable tolerability and harm profile). Ranking 
probabilities were estimated for the 4 outcomes with the most data 
(discontinuations because of adverse events, myalgia, elevations in 
hepatic transaminases, and elevations in CK levels) and combined in 
a composite measure with each of the 4 outcomes contributing 0.25 
to the total ranking score of 1.00.
To obtain a comprehensive estimate of the comparative tolerability 
and harms of individual statins, our network meta-analysis pooled 
all primary and secondary prevention trials in addition to trials with 
mixed patient populations, including all placebo-controlled and 
active-comparator trials eligible for inclusion in this review. In sub-
group analyses, we also investigated the comparative effects of indi-
vidual statins in primary and secondary prevention separately.
Primary analyses were at the drug level (referred to as drug-level net-
work meta-analyses hereafter), comparing individual statins to each oth-
er (eg, atorvastatin versus simvastatin). Sensitivity analyses were dose 
specific and explored the comparative harms of individual statins at dif-
ferent doses separately (referred to as dose level hereafter). Each statin–
dose combination was treated as a different treatment, and no trends 
were fitted or assumed. The following daily doses were considered for 
atorvastatin, lovastatin, pravastatin, and simvastatin: ≤10 mg, >10 and 
≤20 mg, >20 and ≤40 mg, and >40 mg. For fluvastatin, daily doses 
were ≤20 mg, >20 and ≤40 mg, and >40 mg. For rosuvastatin, the daily 
doses were ≤5 mg, >5 and ≤10 mg, >10 and ≤20 mg, and >20 mg. For 
pitavastatin, 2 and 4 mg/d formulations were considered. All analyses 
were based on the total number of randomly assigned participants.
We investigated whether potential heterogeneity and inconsistency 
across the evidence base in the network meta-analysis of discontinu-
ations, myalgia, transaminase elevations, and CK elevations could 
be explained by mean age at baseline, mean low-density lipoprotein 
cholesterol concentration at baseline, or the publication year of the 
trial using meta-regression analyses. All meta-regression analyses al-
lowed for a common treatment–covariate interaction for each statin 
compared with control.31 An additional sensitivity analysis excluded 
open-label trials and explored the comparative harms and tolerability 
of individual statins in double-blind trials.
For all outcomes, we also qualitatively evaluated the consistency of 
relative treatment effects obtained from an analysis of head-to-head 
trials with those obtained from an analysis combining both placebo-
controlled and active-comparator trials. In particular, we first per-
formed pairwise meta-analyses on all available direct comparisons 
(ie, direct evidence) and then compared the findings of these pairwise 
meta-analyses with the results of network meta-analysis (ie, mixed 
evidence). The consistency of the relative treatment effects was visu-
ally inspected for potential differences between estimates obtained 
from 2 sets of analyses (ie, direct and mixed estimates). We checked 
for discrepancy in terms of the direction of effect, as well as its 
magnitude, and confirmed that all 95% intervals greatly overlapped, 
which suggested adequate consistency. We also evaluated small-study 
effects using contour-enhanced funnel plots, which tested a compos-
ite hypothesis of publication and reporting bias, and chance.
Figure 1. Flow diagram 
of trial identification and 
selection.
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Results
Our review included 135 trials (Figure 1), totaling 246 955 
participants. Overall, the average trial follow-up was 68 weeks 
(1.3 years). There were 55 two-armed placebo-controlled 
trials, and the remaining 80 were 2-armed or multiarmed 
active-comparator trials. Of the 28 possible pairwise com-
parisons between the 8 treatments (7 statins and control), 22 
were available. Most frequent comparisons occurred between 
pravastatin and placebo, atorvastatin and placebo, and rosuv-
astatin and atorvastatin. A total of 53 325 participants received 
atorvastatin, whereas 35 404 participants received simvastatin 
and 29 557 received pravastatin. No trial directly compared 
all 7 statins with each other for the drug-level comparison 
(Figure 2). Similarly, a small number of fluvastatin, lovastatin, 
and pitavastatin trials contributed to the dose-level network 
meta-analysis. No trial directly compared all statin–dose com-
binations with each other (Figure 3). Based on analyses on 
discontinuations because of adverse events, myalgia, trans-
aminase elevations, and CK elevations, there was no evidence 
of differential effects between more precise and less precise 
trials according to contour-enhanced funnel plots (ie, no evi-
dence of small-study effects).
The overall methodological quality of included trials was 
moderate. Older trials had lower methodological quality with 
inadequate sequence generation and treatment allocation con-
cealment. A large number of trials did not report details about 
randomization procedures and allocation concealment. Only 
11 trials had high methodological quality on all 6 items.
Discontinuations Because of Adverse Events
According to the pairwise meta-analysis of placebo-con-
trolled trials including 76 462 participants, statins as a class 
were not significantly different than control (OR, 0.95; 95% 
CI, 0.83–1.08; I2, 21.9%). In the trials that directly com-
pared individual statins head-to-head, simvastatin was sig-
nificantly more tolerable than atorvastatin (OR, 0.61; 95% 
CI, 0.42–0.89; I2, 71.9%) and rosuvastatin (OR, 0.49; 95% 
CI, 0.27–0.88; I2, 0.0%).
In the drug-level network meta-analysis of individual statins, 
131 503 participants contributed information on 7811 events 
(6% of all participants). Individual statins were similar to con-
trol in terms of discontinuations because of adverse events 
(Figure 4A). When compared head-to-head, participants ran-
domized to pravastatin (OR, 1.46; 95% CrI, 1.10–1.92) and 
simvastatin (OR, 1.34; 95% CrI, 1.06–1.69) were significantly 
less likely to stop treatment because of adverse events com-
pared with those randomized to atorvastatin (Table 1).
The dose-level network meta-analysis of discontinua-
tions because of adverse events included 151 823 partici-
pants, providing information on 8719 discontinuations. 
Atorvastatin at >20 and ≤40 mg/d (OR, 2.72; 95% CrI, 
1.46–5,09) and atorvastatin at >40 mg/d (OR, 1.69; 95% 
CrI, 1.18–2.44) led to significantly more discontinuations 
compared with control. There was no strong dose–response 
relationship for most statin–dose combinations (higher 
doses did not necessarily result in higher discontinuation 
rates; Figure 5A).
Myalgia
When the placebo-controlled trials of statins were pooled 
as a class in a pairwise meta-analysis including 43 531 par-
ticipants, statins were not significantly different than con-
trol treatment (OR, 1.07; 95% CI, 0.89–1.29; I2, 22.1%) in 
terms of myalgia incidence. The pairwise meta-analysis of 
head-to-head simvastatin versus atorvastatin trials showed 
that participants randomized to simvastatin had lower odds of 
experiencing myalgia compared with those receiving atorvas-
tatin (OR, 0.56; 95% CI, 0.42–0.75; I2, 0.0%).
Although the direction and magnitude of the difference 
between simvastatin and atorvastatin were similar in the drug-
level network meta-analysis, there was greater variability 
around this estimate when all eligible direct and indirect trials 









Figure 2. Network of available comparisons for the drug-level 
analysis. Connecting lines indicate the existing direct pairwise 
comparisons between 2 treatments. The width of the lines is 
proportional to the number of pairwise comparisons between 
2 treatments, and the size of every node is proportional to the 
number of participants.
Control Atorva ≤10
Atorva >10 and ≤20
Atorva >20 and ≤40
Atorva >40
Fluva ≤20
Fluva >20 and ≤40
Fluva >40
Lova ≤10
Lova >10 and ≤20
Lova >20 and ≤40
Lova >40
Prava ≤10
Prava >10 and ≤20
Prava >20 and ≤40
Prava >40
Rosuva ≤5
Rosuva >5 and ≤10
Rosuva >10 and ≤20
Rosuva >20
Simva ≤10
Simva >10 and ≤20




Figure 3. Network of available comparisons for dose-specific 
analysis. Connecting lines indicate the existing direct pairwise 
comparisons between 2 treatments. The width of the lines is 
proportional to the number of pairwise comparisons between 
2 treatments, and the size of every node is proportional to the 
number of participants.
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reported in Table 1). According to the findings of the network 
meta-analysis including 84 391 participants with 1986 myal-
gia events (2% of all participants), there were no significant 
differences between individual statins.
In the dose-level network meta-analysis including 99 433 
participants with 2533 events, there was a lack of an apparent 
dose–response relationship for myalgia (Figure 5B) with no 
statistically detectable differences between individual statin–
dose combinations and control treatment.
Transaminase Elevations
The pairwise meta-analysis of placebo-controlled trials 
including 122 665 participants showed that participants ran-
domized to statins had significantly higher odds of experienc-
ing alanine aminotransferase and aspartate aminotransferase 
elevations compared with those randomized to control (OR, 
1.51; 95% CI, 1.24–1.84; I2, 52.3%). Among the trials that 
directly compared pravastatin and atorvastatin, participants 
randomized to pravastatin had significantly lower odds of 
transaminase elevations (OR, 0.27; 95% CI, 0.10–0.74; I2, 
61.3%).
In the drug-level network meta-analysis of individual 
statins, 165 534 participants contributed information on 2075 
clinically meaningful elevations in hepatic transaminases (1% 
of all participants). Individuals randomized to atorvastatin 
(OR, 2.55; 95% CrI, 1.71–3.74) and fluvastatin (OR, 5.18; 
95% CrI, 1.89–15.55) had higher odds of transaminase eleva-
tions (Figure 4C). When compared head-to-head, pravastatin 
(OR, 0.39; 95% CrI, 0.24–0.65), rosuvastatin (OR, 0.63; 95% 
CrI, 0.42–0.94), and simvastatin (OR, 0.45; 95% CrI, 0.28–
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Figure 4. Findings of drug-level network meta-analyses: effect of statins compared with control on (A) discontinuations because of 
adverse events, (B) occurrence of myalgia, (C) clinically meaningful elevation in hepatic transaminases, (D) clinically meaningful elevation 
in CK levels, (E) incidence of cancer, and (F) incidence of diabetes mellitus. There were no data to estimate cancer incidence with 
pitavastatin and diabetes mellitus incidence with fluvastatin and pitavastatin. CK indicates creatine kinase; OR, odds ratio.
Table 1. Findings of Drug-Level Network Meta-Analyses, Showing the OR Comparing Statins (95% Credible Interval): Comparative 
Head-to-Head Effects of Individual Statins on Myalgia (top half of the table) and Discontinuations Because of Adverse Events 
(bottom half of the table)
Atorvastatin 1.08 (0.56, 2.17) 0.87 (0.54, 1.46) 1.1 (0.77, 1.53) 0.88 (0.71, 1.08) 1.28 (0.88, 1.80) 0.49 (0.15, 1.42)
0.97 (0.64, 1.47) Fluvastatin 0.81 (0.37, 1.71) 1.02 (0.48, 2.02) 0.82 (0.40, 1.58) 1.19 (0.56, 2.37) 0.46 (0.12, 1.52)
1.30 (0.87, 1.94) 1.33 (0.83, 2.14) Lovastatin 1.26 (0.7, 2.15) 1.00 (0.58, 1.68) 1.46 (0.80, 2.54) 0.57 (0.15, 1.79)
1.46 (1.10, 1.92) 1.50 (0.97, 2.33) 1.13 (0.75, 1.7) Pravastatin 0.80 (0.55, 1.19) 1.17 (0.74, 1.82) 0.45 (0.13, 1.35)
1.04 (0.85, 1.27) 1.07 (0.69, 1.65) 0.80 (0.52, 1.22) 0.71 (0.52, 0.97) Rosuvastatin 1.46 (0.98, 2.14) 0.56 (0.17, 1.64)
1.34 (1.06, 1.69) 1.37 (0.89, 2.14) 1.03 (0.67, 1.57) 0.91 (0.67, 1.26) 1.28 (0.98, 1.69) Simvastatin 0.39 (0.12, 1.12)
1.29 (0.62, 2.66) 1.32 (0.57, 3.06) 0.99 (0.43, 2.26) 0.88 (0.41, 1.89) 1.24 (0.59, 2.58) 0.96 (0.46, 2.02) Pitavastatin
Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining 
treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. OR 
indicates odds ratio.
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with atorvastatin (reciprocals reported in Table 2). Fluvastatin 
resulted in significantly higher odds of elevations than pravas-
tatin (OR, 5.19; 95% CrI, 1.75–16.73), rosuvastatin (OR, 3.25; 
95% CrI, 1.08–10.50), and simvastatin (OR, 4.50; 95% CrI, 
1.49–14.19).
The dose-level network meta-analysis for clinically mean-
ingful elevations in hepatic transaminases included 188 503 
participants, providing information on 2298 events. There was 
a clear dose–response relationship for atorvastatin, lovastatin, 
and simvastatin, with higher doses resulting in higher odds 
of transaminase elevations (Figure 5C). Individuals receiv-
ing simvastatin at ≤10 mg/d had lower odds of experienc-
ing transaminase elevations compared with those receiving 
control (OR, 0.41; 95% CrI, 0.18–0.85). Atorvastatin at >20 
and ≤40 mg/d (OR, 2.42; 95% CrI, 1.10–5.55), atorvastatin at 
>40 mg/d (OR, 5.25; 95% CrI, 3.89–7.24), fluvastatin at >40 
mg/d (OR, 4.16; 95% CrI, 1.60–14.36), and simvastatin at >40 
mg/d (OR, 2.83; 95% CrI, 1.47–5.87) resulted in significantly 
higher odds of elevations than control.
CK Elevations
When the placebo-controlled trials of statins were pooled in a 
pairwise meta-analysis including 101 324 participants, statins 
as a class were not significantly different than control treatment 
(OR, 1.13; 95% CI, 0.85–1.51; I2, 20.4%). In the drug-level 
network meta-analysis of individual statins, 127 571 partici-
pants provided information on 721 individuals with clinically 
meaningful CK elevations (0.6% of all participants). Accord-
ing to this analysis, pitavastatin resulted in significantly more 
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Figure 5. Findings of dose-level network meta-analyses: effects of statin–dose combinations compared with control on (A) 
discontinuations because of adverse events, (B) occurrence of myalgia, (C) clinically meaningful elevation in hepatic transaminases, and 
(D) clinically meaningful elevation in CK levels. CK indicates creatine kinase; OR, odds ratio.
Table 2. Findings of Drug-Level Network Meta-Analyses: Comparative Head- to-Head Effects of Individual Statins on CK (top half 
of the table) and Transaminase Elevations (bottom half of the table).
Atorvastatin 5.59 (1.22, 25.52) 1.32 (0.54, 2.88) 1.13 (0.65, 1.78) 0.99 (0.64, 1.53) 1.13 (0.65, 1.97) 0.38 (0.10, 1.23)
0.49 (0.15, 1.42) Fluvastatin 0.24 (0.05, 1.17) 0.20 (0.04, 0.88) 0.18 (0.04, 0.81) 0.20 (0.04, 0.94) 0.07 (0.01, 0.46)
1.26 (0.57, 2.73) 2.58 (0.76, 9.03) Lovastatin 0.84 (0.39, 1.94) 0.76 (0.34, 1.85) 0.86 (0.37, 2.23) 0.29 (0.06, 1.18)
2.55 (1.54, 4.14) 5.19 (1.75, 16.73) 2.03 (0.90, 4.56) Pravastatin 0.89 (0.51, 1.63) 1.01 (0.55, 2.00) 0.34 (0.09, 1.18)
1.60 (1.06, 2.38) 3.25 (1.08, 10.5) 1.27 (0.55, 2.93) 0.63 (0.36, 1.10) Rosuvastatin 1.14 (0.62, 2.19) 0.38 (0.10, 1.23)
2.20 (1.36, 3.52) 4.50 (1.49, 14.19) 1.76 (0.75, 4.12) 0.87 (0.47, 1.57) 1.38 (0.79, 2.38) Simvastatin 0.34 (0.08, 1.13)
0.89 (0.24, 3.23) 1.82 (0.34, 10.00) 0.71 (0.16, 3.13) 0.34 (0.08, 1.35) 0.55 (0.15, 2.04) 0.40 (0.10, 1.56) Pitavastatin
CK, creatine kinase. Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment 
and the row-defining treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals 
should be taken. OR indicates odds ratio.
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1.10–14.10; Figure 4D). Individuals randomized to fluvastatin 
had significantly lower odds of experiencing CK elevations 
compared with all other statins, except for lovastatin (Table 2).
The dose-level network meta-analysis for clinically mean-
ingful elevations in baseline CK levels included 137 980 
participants, providing information on 778 individuals who 
experienced elevations. There was a small dose–response 
relationship with lovatatin and simvastatin, with higher doses 
resulting in higher odds of elevations (Figure 4D). Simvastatin 
at >40 mg/d resulted in significantly higher odds of experi-
encing elevations compared with control treatment (OR, 4.14; 
95% CrI, 1.08–16.24).
Cancer
The pairwise meta-analysis of placebo-controlled trials includ-
ing 100 523 participants showed that statins as a class were not 
significantly different than control treatment (OR, 0.96; 95% 
CrI, 0.91–1.02; I2, 0.0%). Similarly, there was no evidence 
from the drug-level network meta-analyses that individual 
statins were different than control treatment on the basis of 
5511 cancer occurrences among 105 450 participants (5.2% 
of all participants). There was also no evidence of potential 
head-to-head differences between individual statins (Table 3).
Diabetes Mellitus
On the basis of placebo-controlled trials including 113 698 
participants, the pairwise meta-analysis showed that statins 
as a class were statistically significantly different than con-
trol (OR, 1.09; 95% CrI, 1.02–1.16; I2, 2.8%). According to 
placebo-controlled trials, rosuvastatin resulted in significantly 
higher odds of diabetes mellitus compared with control (OR, 
1.16; 95% CI, 1.02–1.31; I2, 0.0%). However, the drug-level 
network meta-analysis did not achieve statistical significance 
for any of the individual statins as a result of wider 95% CrIs 
(rosuvastatin had a similar effect size estimate in both pairwise 
and network meta-analyses; Figure 4D). Also, there were no 
statistically detectable differences between individual statins 
in terms of diabetes mellitus incidence (Table 3).
Additional Outcomes
There was limited information on both myopathy and rhabdo-
myolysis outcomes. In the drug-level network meta-analysis, 
individual statins were not significantly different than control: 
atorvastatin (OR, 1.21; 95% CrI, 0.25–4.95), pravastatin (OR, 
1.06; 95% CrI, 0.18–4.81), rosuvastatin (OR, 0.91; 95% CrI, 
0.12–4.43), and simvastatin (OR, 1.23; 95% CrI, 0.29–4.21). 
There was no evidence of potential differences between indi-
vidual statins in terms of myopathy outcomes (results not 
shown). Similarly, drug-level network meta-analysis showed 
that individual statins were not different than control treat-
ment in terms of rhabdomyolysis: atorvastatin (OR, 1.33; 95% 
CrI, 0.31–6.92), pravastatin (OR, 0.20; 95% CrI, 0.00–11.15), 
rosuvastatin (OR, 0.19; 95% CrI, 0.00–9.22), and simvastatin 
(OR, 2.03; 95% CrI, 0.40–14.81). There were no statistically 
detectable differences between individual statins in terms of 
rhabdomyolysis.
When the individual statins were ranked in terms of the mag-
nitude of the estimated treatment effect, as well as the uncer-
tainty around it, pravastatin (0.71) and simvastatin (0.70) had 
the highest combined score out of a total of 1.00, suggesting that 
these statins had the most favorable tolerability and harm pro-
file on the basis of discontinuations because of adverse events, 
myalgia, transaminase elevations, and CK elevations (Figure 6). 
Baseline low-density lipoprotein cholesterol concentration, 
baseline mean age of the study population, and publication year 
did not explain the observed heterogeneity in the evidence base. 
Estimate of between-study heterogeneity in the drug-level net-
work meta-analyses did not decrease in meta-regression anal-
yses. According to the sensitivity analyses, findings from the 
base-case network meta-analyses did not change when adjusting 
for baseline low-density lipoprotein cholesterol concentration, 
mean age, and publication year in meta-regression analyses, 
with statistically nonsignificant coefficients (results provided 
in the online-only Data Supplement Appendix). Limiting the 
analysis to double-blind trials also did not change the observed 
ORs. Although small sample size was a limitation of subgroup 
analyses, we did not obtain materially different comparative 
harm and tolerability estimates for individual statins in primary 
versus secondary prevention populations (results provided in 
the online-only Data Supplement Appendix).
Discussion
This network meta-analysis of 246 955 participants provides 
evidence on the comparative tolerability and harms of indi-
vidual statins using both placebo-controlled and active-com-
parator trials. Overall, statins as a class are associated with an 
increased risk of diabetes mellitus and hepatic transaminase 
elevations, with no statistically detectable effect on myalgia, 
myopathy, rhabdomyolysis, and cancer. Across the totality of 
the evidence base, higher doses of some statins result in higher 
Table 3. Findings of Drug-Level Network Meta-Analyses: Comparative Head- to-Head Effects of Individual Statins on Diabetes (top 
half of the table) and Cancer (bottom half of the table)
Atorvastatin - 1.18 (0.71, 1.99) 1.12 (0.79, 1.62) 1.01 (0.69, 1.47) 1.06 (0.72, 1.57)
0.94 (0.59, 1.47) Fluvastatin - - - -
0.86 (0.60, 1.20) 0.91 (0.58, 1.43) Lovastatin 0.95 (0.62, 1.46) 0.85 (0.54, 1.33) 0.90 (0.56, 1.41)
0.90 (0.69, 1.20) 0.97 (0.65, 1.45) 1.06 (0.81, 1.42) Pravastatin 0.90 (0.70, 1.12) 0.94 (0.72, 1.21)
0.84 (0.62, 1.16) 0.90 (0.58, 1.39) 0.99 (0.73, 1.36) 0.94 (0.73, 1.19) Rosuvastatin 1.05 (0.80, 1.40)
0.84 (0.66, 1.08) 0.90 (0.60, 1.37) 0.98 (0.75, 1.34) 0.93 (0.77, 1.15) 0.99 (0.78, 1.30) Simvastatin
Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining 
treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. OR 
indicates odds ratio.
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odds of experiencing transaminase elevations, CK eleva-
tions, and discontinuations because of adverse events. When 
compared head-to-head in network meta-analyses, there are 
differences among individual statins, with simvastatin and 
pravastatin likely to be ranked superior to their alternatives in 
terms of their safety profile.
Although the benefits of statins for individuals with estab-
lished cardiovascular disease are well documented,9 their 
effect in individuals free of cardiovascular disease has been 
disputed.8,32–34 Recent meta-analyses based on both individual 
patient-level data4 and study-level reports5 confirm that all-
cause mortality benefits of statins in the primary prevention 
setting are clinically and statistically significant. These recent 
findings provide supporting evidence for initiating statin ther-
apy in individuals who are at an increased risk of developing 
cardiovascular disease. Nevertheless, expanding the limits of 
statin therapy to a wider population of individuals may have 
important safety implications. Although rare, adverse events 
associated with statin therapy range from mild to moderate 
and seem to increase with treatment intensity. With notable 
exceptions,35 randomized trial evidence on the long-term 
safety of individual statin treatments remains limited.
Our review confirms the findings of previous pairwise 
meta-analyses in that statins as a class are associated with 
higher odds of developing diabetes mellitus15 and experi-
encing hepatic transaminase elevations.36 There is a lack of 
evidence that statins are associated with an increased risk of 
developing cancers. Although our review did not find statisti-
cal evidence of myopathy, this may be because of an underde-
tection of muscle toxicity in clinical trials.37–39
At the population level, mortality and cardiovascular ben-
efits of statin therapy greatly overweigh its potential harms, 
even taking into account the recent finding that statin use is 
associated with a modest increase in diabetes mellitus inci-
dence.40 At the individual level, however, there may be a 
risk of exposing a large group of individuals to the (primar-
ily minor) harms of statin therapy for the benefit of a smaller 
number of individuals. This brings into sharp focus the impor-
tance of correctly identifying the set of individuals who stand 
to benefit from statin therapy. There are emerging tools that 
can be used to predict personalized long-term harms and ben-
efits associated with statin therapy.41
Available statins differ to a various extent in pharmacologi-
cal properties, and it would be expected that they differ in 
terms of their clinical efficacy.42,43 Nonetheless, their compara-
tive harms had not been evaluated in a comprehensive man-
ner in previous reviews. In addition to pairwise meta-analysis 
that compared statins with control treatment, we performed 
network meta-analysis, which is a relatively new method that 
differs from pairwise meta-analysis by incorporating data 
from both direct (from trials that include a specific pairwise 
comparison) and indirect (from a network of trials that do not 
include that comparison) sources of evidence. We previously 
used this method to compare individual statins in terms of 
their cholesterol-lowering effects, as well as their effects on 
deaths, coronary events, and cerebrovascular events.44–46
Our findings show that there are statistically detectable dif-
ferences between individual statins in terms of their tolerabil-
ity, hepatic transaminase elevations, and CK elevations. At the 
drug level, individuals receiving simvastatin and pravastatin 
seem to have the lowest odds of experiencing myalgia, trans-
aminase and CK elevations, and discontinuations because of 
adverse events.
Our dose-specific analysis parallels the findings of previous 
meta-analyses in that more intensive statin therapy is associ-
ated with greater risk of harm and less favorable tolerability 
compared with lower doses.19,47–49 Similar to previous stud-
ies, we observed a general dose–response relationship across 
placebo-controlled and active-comparator trials in terms of 
discontinuations because of adverse events, transaminase ele-
vations, and CK elevations.
As with any meta-analysis, our network meta-analysis 
required an assumption of similarity across the pooled set of 
trials in terms of patient population and trial characteristics. 
More specifically, we assumed that the distribution of rela-
tive treatment effect modifiers (eg, baseline cholesterol lev-
els) was balanced across different treatment comparisons in 
the evidence network. An imbalance in the distribution of 
these variables in a single randomized, controlled trial would 
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Figure 6. Overall ranking of individual 
statins in placebo-controlled and active-
comparator trials of participants by 
their overall probability to be the best 
treatment in terms of discontinuations 
because of adverse events, myalgia, 
hepatic transaminase elevation, and CK 
elevation. In addition to the overall score 
for each statin, the relative contribution 
of each of the 4 outcomes to the overall 
score is also shown. Each statin was 
scored with points up to a maximum of 
0.25 for each outcome (overall maximum 
score: 1.00). Higher scores indicate a 
better tolerability and safety profile. CK 
indicates creatine kinase.
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trials would result in between-study heterogeneity in pairwise 
meta-analyses; and an imbalance across different treatment 
comparisons would result in inconsistency in network meta-
analyses, potentially biasing the results. To account for such 
imbalances, we evaluated several study-level characteristics in 
the meta-regression analyses. Specifically, our analyses sug-
gested that baseline mean age, low-density lipoprotein choles-
terol concentration, and trial publication year did not have an 
impact on the observed findings.
Findings of this study should be interpreted in light of its 
limitations. First, as a literature-based meta-analysis, our anal-
ysis shares the limitations of the published evidence base. The 
quality of included trials was moderate, with older trials being 
more prone to bias than newer trials. Second, given the large 
volume of available studies in the literature, our meta-analysis 
did not use individual patient-level data, which would have 
advantages when exploring potential differences across relative 
treatment effect modifiers. Third, although there was no evi-
dence of small-study effects, there was an apparent asymme-
try in the evidence network where specific interventions seem 
to be avoided (eg, fluvastatin). For instance, the relative effect 
of fluvastatin on CK elevations was estimated on the basis 
of 8 events observed in 4 trials including 2646 participants. 
Similarly, there were only 4 trials of fluvastatin, which reported 
hepatic transaminase elevations. As expected, the evidence 
base for pitavastatin was also sparse. Although pitavastatin was 
recently approved by the Food and Drug Administration, it has 
been in use in other settings since 2003 (most notably in Japan 
and South Korea) without a corresponding evidence base in 
the English language literature. Fourth, there was considerable 
heterogeneity across various pairwise meta-analyses of statins 
versus control, particularly for hepatic transaminase elevations. 
It remains a possibility that our analysis did not fully account 
for heterogeneity as a result of unobserved or unmeasured 
factors. However, we used a random-effects model, and our 
analyses took into account potential unexplained heterogene-
ity across the studies. We also performed meta-regressions to 
further evaluate heterogeneity and inconsistency and did not 
detect a significant effect of study-level characteristics.
Despite these limitations, our study has important method-
ological strengths. First, this review is the largest meta-anal-
ysis on the harms of statin therapy to date, including almost 
a quarter million trial participants. Second, we incorporated 
data from a comprehensive list of trials, irrespective of pla-
cebo or active controls, including all clinically used statins. In 
total, we included 80 active-comparator trials with or without 
a placebo or usual care arm. Third, we evaluated the dose-
comparative harms of individual statins.
Our findings have important clinical implications. First, 
there is strong evidence that statins as a class are generally 
safe with uncommon side effects. According to the findings 
of this comprehensive analysis, there is consistently strong 
evidence on the comparatively favorable side effect profile of 
simvastatin and pravastatin, particularly at low-to-moderate 
doses, which should be favored in clinical practice. This meta-
analysis sheds new light on the discussion of the relationship 
between statins and diabetes mellitus incidence and confirms 
that statin use is not associated with cancer incidence. Finally, 
we acknowledge the complex nature of making prescribing 
decisions and urge prescribers to consider the findings of this 
analysis in light of the comparative benefit profiles of indi-
vidual statins in preventing all-cause mortality in addition to 
cardiovascular and cerebrovascular events.44–46
Acknowledgments
The authors thank Dr Rachael Fleurence from the Patient-Centered 
Outcomes Research Institute (Washington, DC) for her valuable con-
tributions to earlier parts of this systematic review and meta-analysis 
and Bernice Tsoi and Harleen Toor from the McMaster University 
(Toronto, Canada) for their assistance with study identification, selec-




 1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, 
Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment 
Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 
14 randomised trials of statins. Lancet. 2005;366:1267–1278.
 2. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage 
J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people 
with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 
2008;371:117–125.
 3. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, 
Peto R, Barnes EH, Keech A, Simes J, Collins R, Cholesterol Treatment 
Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive low-
ering of LDL cholesterol: a meta-analysis of data from 170 000 partici-
pants in 26 randomised trials. Lancet. 2010;376:1670–1681.
 4. Milaylova B, Emberson J, Blackwell J, Keech A, Simes J, Barnes EH, 
Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL 
cholesterol with statin therapy in people at low risk of vascular disease: 
meta-analysis of individual data from 27 randomised trials. Lancet. 
2012;380:581–590.
 5. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de 
Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers 
JW. The benefits of statins in people without established cardiovascular 
disease but with cardiovascular risk factors: meta-analysis of randomised 
controlled trials. BMJ. 2009;338:b2376.
 6. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. 
Statins for secondary prevention in elderly patients: a hierarchical 
Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45.
 7. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-
analysis of statin effects in women versus men. J Am Coll Cardiol. 
2012;59:572–582.
 8. Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. 
Evidence-based use of statins for primary prevention of cardiovascular 
disease. Am J Med. 2012;125:440–446.
 9. Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet. 
2012;380:545–547.
 10. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 
2006;97(8A):52C–60C.
 11. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large 
randomized clinical trials. Am J Med. 2001;110:716–723.
 12. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic 
review and meta-analysis. Eur J Cancer. 2008;44:2122–2132.
 13. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and 
cancer risk: a meta-analysis. JAMA. 2006;295:74–80.
 14. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker 
PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. 
Diabetes Care. 2009;32:1924–1929.
 15. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, 
Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, 
Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, 
Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus 
J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura 
H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident dia-
betes: a collaborative meta-analysis of randomised statin trials. Lancet. 
2010;375:735–742.
 by guest on September 13, 2013http://circoutcomes.ahajournals.org/Downloaded from 
Naci et al  Comparative Harms of Statins  399
 16. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors 
of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 
2007;21:311–316.
 17. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from 
myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18:401–408.
 18. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse 
events: a meta-analysis. Clin Ther. 2006;28:26–35.
 19. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, 
Gandhi P. Meta-analysis of drug-induced adverse events associated with 
intensive-dose statin therapy. Clin Ther. 2007;29:253–260.
 20. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin 
derived from analysis of 44 completed trials in 9,416 patients. Am J 
Cardiol. 2003;92:670–676.
 21. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks 
of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head 
randomized controlled trials. Am J Cardiol. 2008;102:1654–1662.
 22. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated 
with individual statin treatments for cardiovascular disease: an indirect 
comparison meta-analysis. QJM. 2012;105:145–157.
 23. Naci H, Brugts J, Fleurence R, Ades AE. Comparative efficacy and 
safety of statins: a systematic review and mixed treatment comparison—
final protocol. 2009; www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/
HNaciProtocol.pdf. Accessed April 5, 2013.
 24. Higgins JPT, Green S. Cochrane handbook for systematic reviews of inter-
ventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 
www.cochrane-handbook.org.2011. Accessed April 5, 2013.
 25. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of 
multiple treatments: combining direct and indirect evidence. BMJ. 
2005;331:897–900.
 26. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat 
Med. 2002;21:2313–2324.
 27. Lu G, Ades AE. Combination of direct and indirect evidence in mixed 
treatment comparisons. Stat Med. 2004;23:3105–3124.
 28. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support doc-
ument 1: introduction to evidence synthesis for decision making—report 
by the decision support unit. 2011; http://www.nicedsu.org.uk. Accessed 
April 5, 2013.
 29. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduc-
tion to fixed-effect and random-effects models for meta-analysis. Research 
Synthesis Methods 2010;1:97–111.
 30. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical sum-
maries for presenting results from multiple-treatment meta-analysis: an 
overview and tutorial. J Clin Epidemiol. 2011;64:163–171.
 31. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing be-
tween-study heterogeneity and inconsistency in mixed treatment com-
parisons: application to stroke prevention treatments in individuals with 
non-rheumatic atrial fibrillation. Stat Med. 2009;28:1861–1881.
 32. Redberg R, Katz M, Grady D. Diagnostic tests: another frontier for less 
is more: or why talking to your patient is a safe and effective method of 
reassurance. Arch Intern Med. 2011;171:619.
 33. Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 
2012;307:1491–1492.
 34. Taylor F, Ward K, Moore Theresa HM, Burke M, Davey Smith G, Casas 
J-P, Ebrahim S. Statins for the primary prevention of cardiovascular 
disease. Cochrane Database Syst Rev [serial on the Internet]. 2011;1: 
http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/
CD004816/frame.html. Accessed April 5, 2013.
 35. Heart Protection Study Collaborative G. MRC/BHF Heart Protection 
Study of cholesterol lowering with simvastatin in 20,536 high-risk in-
dividuals: a randomised placebo-controlled trial. Lancet [serial on the 
Internet]. 2002;9326: http://www.mrw.interscience.wiley.com/cochrane/
clcentral/articles/225/CN-00390225/frame.html. Accessed April 5, 2013.
 36. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, 
Krumholz HM. Risks associated with statin therapy: a systematic over-
view of randomized clinical trials. Circulation. 2006;114:2788–2797.
 37. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a 
common dilemma not reflected in clinical trials. Cleve Clin J Med. 
2011;78:393–403.
 38. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for 
myopathy? An observational study of 32 225 diabetic and nondiabetic pa-
tients. Clin Ther. 2007;29:1761–1770.
 39. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern 
Med. 2009;150:858–868.
 40. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular 
benefits and diabetes risks of statin therapy in primary prevention: an anal-
ysis from the JUPITER trial. Lancet. 2012;380:565–571.
 41. Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, 
Nijhuis RL, Hofman A, Steyerberg EW, Hunink MG. Personalized predic-
tion of lifetime benefits with statin therapy for asymptomatic individuals: 
a modeling study. PLoS Med. 2012;9:e1001361.
 42. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class inter-
changeable? Lancet. 1999;354:1202–1204.
 43. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reduc-
tase inhibitors. Ann Pharmacother. 2002;36:1907–1917.
 44. Naci H, Brugts J, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative 
benefits of statins in the primary and secondary prevention of major coro-
nary events and all-cause mortality: a network meta-analysis of placebo-
controlled and active-comparator trials. Eur J Prev Cardiol. 2013;Feb 27. 
[Epub ahead of print].
 45. Naci H, Brugts J, Fleurence R, Ades AE. Dose-comparative effects of dif-
ferent statins on serum lipid levels: a network meta-analysis of 256,827 
individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 
2013;Mar 25. [Epub ahead of print].
 46. Naci H, Brugts JJ, Fleurence R, Ades AE. Comparative effects of statins 
on major cerebrovascular events: a multiple-treatments meta-analysis of 
placebo-controlled and active-comparator trials. QJM. 2013;106:299–306.
 47. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am 
Coll Cardiol. 2007;49:1753–1762.
 48. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco 
DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de 
Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. 
Risk of incident diabetes with intensive-dose compared with moderate-
dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–2564.
 49. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the mag-
nitude of lipid lowering on risk of elevated liver enzymes, rhabdomyoly-
sis, and cancer: insights from large randomized statin trials. J Am Coll 
Cardiol. 2007;50:409–418.




































































 by guest on September 13, 2013http://circoutcomes.ahajournals.org/Downloaded from 
COMMENTARY
Assessing comparative effectiveness of new drugs before approval using
prospective network meta-analyses
Huseyin Nacia,*, Alec B. O’Connorb
aLSE Health, Department of Social Policy, London School of Economics & Political Science, 20 Houghton Street, London WC2A 2AE, UK
bUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Accepted 12 April 2013
1. Introduction
Comparative efficacy and safety data are often lacking at
the time of new drug approval for market entry. Regulatory
agencies in the United States (the Food and Drug Adminis-
tration [FDA]) and the European Union (the European
Medicines Agency [EMA]) often evaluate each new drug
on its own (often in placebo-controlled trials), and without
comparative assessments against other available drugs [1].
The existing lack of comparative evidence at the time of
new drug approval poses important challenges for patients,
prescribers, payers, and the wider health care systems. Pre-
scribers and patients do not have adequate information on
the comparative clinical efficacy and safety of various alter-
native drugs for a given condition, which can lead to wide-
spread adoption of treatments, with potentially inferior
efficacy or safety relative to existing alternatives [2e5].
Recent proposals call for requiring comparative evi-
dence at the time of marketing authorization decisions
[6e8]. In this article, we propose an approach that uses pro-
spective network meta-analysis (NMA) to expand the com-
parative clinical efficacy and safety evidence available at
the time of new drug approval. We characterize how pro-
spective NMA can facilitate the comparison of new drugs
with their alternatives in the regulatory setting.
2. Pairwise and network meta-analysis
Pairwise meta-analysis (PMA) is a statistical tool for
pooling the results of multiple comparable, randomized,
controlled trials that compare the same two interventions
directly [9]. The main consideration when performing and
interpreting PMA is similarity (also known as homogene-
ity) across the pooled set of studies in terms of trial and pa-
tient population characteristics [10].
In the regulatory setting, PMA addresses essential ques-
tions such as safety concerns. For example, a series of re-
cent PMAs was pivotal in identifying safety concerns for
rosiglitazone [11,12]. In the United States, these concerns
also contributed to the FDA’s Guidance for Industry [13],
which encourages manufacturers of new antidiabetic drugs
to perform prospective PMAs to evaluate cardiovascular
events associated with their products. In Europe, the EMA’s
Committee for Medicinal Products for Human Use fre-
quently refers to findings of PMAs to evaluate the evolving
benefiteharm balance of drug options on the market. In one
recent example, the Committee for Medicinal Products for
Human Use referred to the findings of PMAs in its assess-
ment report for nonsteroidal anti-inflammatory drugs and
cardiovascular risk [14].
In conditions with several drug options, PMA is limited
by the relatively small number (or the lack) of trials that
compare a particular pair of drugs directly. By definition,
PMA is incapable of comparing multiple active compara-
tors simultaneously. When there are multiple drugs, per-
forming separate PMAs for each comparison becomes
impractical (or impossible, if there are no trials that include
the comparison of interest) [15]. Focusing on two drugs at
a time, such an approach also does not take into account ad-
equately the correlation structure in multiarm trials [16].
NMA is a relatively new method that differs from PMA
by incorporating data from both direct (from trials that in-
clude a specific pairwise comparison) and indirect (from
a network of trials that do not include that comparison)
sources of evidence [15]. NMA is capable of evaluating
the relative efficacy and safety of two or more drugs
[17,18]. The latest statistical methods facilitate the compar-
ison of treatments in any network structure and complexity,
as long as treatments are connected in a network (i.e., all
treatments are connected to each other either directly or in-
directly) [19e21].
As with PMA, NMA requires an assumption of similar-
ity across the pooled set of trials in terms of patient popu-
lation and trial characteristics [16]. Significant deviations
in trial characteristics, such as outcome definition and
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assessment or patient population, can violate the similarity
assumptions [22]. This may result in biased estimates of
comparative efficacy and safety when the factors responsi-
ble for differences across trial or patient population charac-
teristics are relative treatment effect modifiers [23]. When
both direct and indirect evidence is available, it is essential
to check whether they are consistent [24e26]. Occasion-
ally, conflicting results are obtained from direct and indirect
comparisons, which suggests the possibility of imbalances
in the distribution of relative treatment effect modifiers
[27]. The similarity assumption in the NMA can be ex-
plored using metaregression and subgroup analyses [28].
A more detailed overview of NMA methods is provided
by Dias et al. [29].
3. Regulatory process for new drugs and the proposed
role of NMA
NMA could be used to estimate the efficacy and safety
of new drugs relative to existing alternatives at the time
of market entry. These estimates could be used during
regulatory assessment for market authorization of new
drugs.
An overview of the current regulatory process is pro-
vided in Fig. 1. There are three phases of experimentation
before the regulatory assessment of new drugs for market
entry [30,31]. During phase 1, an investigational drug is
tested in a small number of healthy volunteers to explore
its toxicity profile. During phase 2, trials are performed that
involve a larger number of individuals (100e300) with
a given condition or disease (1) to assess whether the drug
provides the intended clinical benefits and (2) to monitor
short-term side effects. During phase 3 trials, the drug is
tested in a larger group of individuals (600e3,000) with
a given condition or disease to establish its clinical efficacy
and safety. Regulatory assessment for market authorization
follows the completion of phase 3.
As shown in Fig. 1, regulators are involved in clinical
development of new therapies. In the case of the FDA, an
end-of-phase 2 meeting is arranged to determine the safety
of proceeding to phase 3, to evaluate the phase 3 trial plan,
and to identify any additional information necessary to sup-
port regulatory assessment after the completion of phase 3
[32]. After the completion of phase 3, regulators and manu-
facturers have another opportunity to discuss a number of
topics with regard to the marketing application, including
the appropriate methods to use for statistical analysis of
the data, and to discuss the best approach to the presenta-
tion of data in the marketing application. These processes
are closely paralleled by the regulatory involvement in clin-
ical development by the EMA in Europe [33].
At the time of regulatory assessment for market authori-
zation, NMA could be used to estimate the comparative
efficacy and safety of the new drug and its existing alterna-
tives. In cases when no active comparator trials exist, NMA
could generate estimates of comparative efficacy and
safety. In cases when both placebo-controlled and active
comparator trials exist, NMA could combine the findings
of the direct comparisons with those from indirect compar-
isons for support of superiority or noninferiority claims. In
cases when only active comparator trials exist, these could
be combined in NMA as long as drugs are compared with
each other in a connected network.
Active comparator trials and, in particular, noninferiority
designs, are increasingly common in regulatory settings
[34]. Noninferiority trials are designed to assess whether
a new drug is not worse than an active control by more than
a specified noninferiority margin [35]. In contrast to supe-
riority trials, which are successful in showing a difference
between drugs, noninferiority trials cannot establish that
the active control had its expected effect in the study
Fig. 1. A simplified overview of regulatory involvement during the phased experimentation of drug development, and potential outcomes of market
entry assessment.
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(i.e., that the trial had assay sensitivity) unless they also
have a placebo arm (which is often not feasible) [36]. Non-
inferiority trials without a placebo arm require an assump-
tion based on the results of preceding trials that the active
control had its expected effect in the study. NMA can be
particularly helpful in these situations.
First, in cases when the drugs are not connected in a net-
work as a result of a lack of placebo or other common com-
parator, external trial evidence could be used to compare
drugs with each other in a network. Consider a hypothetical
scenario with four drugs of interest: A, B, C, and D. If the
existing trials compare separately drug Avs. drug B and drug
C vs. drug D, NMA methods cannot be used to compare all
drugs, given the lack of a connected network. If there are
trials that compare drug B vs. drug E and drug D vs. drug
E, however, all treatments can be connected in a network
(connected through drug E), and compared in NMA.
Second, external evidence on placebo or historical con-
trols could be incorporated in NMAs to provide information
on assay sensitivity and to establish historical evidence of
sensitivity to drug effects [36]. This involves identifying
trials that used a specific active control (in general, the one
that is also used during the noninferiority trial) that showed
this treatment to be superior to placebo (or some other treat-
ment). These findings can be incorporated in an NMA to al-
low for a reliable estimate of the drug’s effect size compared
with placebo in those past studies.
4. NMA and market authorization decisions
At the time of regulatory assessments for market entry,
NMA could potentially suggest that a new drug is superior,
equivalent (or noninferior), or inferior to one or more exist-
ing alternatives. Superiority could be determined via more
beneficial (e.g., more efficacy at the primary end point)
and/or less harmful (e.g., less discontinuation resulting
from adverse events) effects. Similarly, inferiority could
be determined via less beneficial (e.g., less efficacy at the
primary end point) and/or more harmful (e.g., more discon-
tinuation problems) effects. In cases when a new drug does
not appear to offer at least a comparable balance of harms
vs. benefits relative to existing treatment alternatives, regu-
lators could consider requiring additional evidence (e.g.,
a head-to-head randomized, controlled trial) before market
approval or could deny market access. For products that of-
fer superiority over placebo but uncertain benefit relative to
existing agents on the basis of NMA, conditional approval
could be granted while further evidence is gathered from
other types of study designs, such as an active comparator
trial. This type of adaptive licensing is gaining momentum
among regulators [37].
5. Planning for future NMAs
Although the validity of the statistical methods underly-
ing NMA is widely accepted, there is concern about the
combination of direct and indirect evidence post hoc from
published data (in a so-called retrospective NMA) [38].
In particular, the potential inconsistency between direct
and indirect evidence is a commonly raised criticism
[39]. The validity of retrospectively conducted NMA is
threatened by publication and reporting biases. Prospective
NMA would offer important benefits. A prospective NMA
can be defined as a meta-analysis of trials that are identi-
fied, evaluated, and determined to be eligible for the
meta-analysis before the results of any of those studies
are known [40]. Phase 3 trials submitted to regulators for
market authorization assessment could form the basis for
performing prospective NMA.
The keys to performing prospective NMA are having tri-
als of comparable characteristics with similar patient popu-
lations. Regulators could help emphasize the use of similar
trial designs and patient populations for different drugs
seeking approval for a shared indication in anticipation of
future NMA. Whenever possible, trials for a specific indica-
tion should conform in terms of patient populations, out-
comes, outcome assessment techniques, follow-up time
points, and dosing regimens.
Regulatory agency involvement in the design of the tri-
als would help minimize design and population differences
among trials, reducing the risk for bias when comparing
across trials by ensuring that trials are comparable in terms
of relative treatment effect modifiers. Clear communication
and regulatory guidance are essential to plan successfully
for future NMAs. Similar to current collaborative efforts
in determining acceptable surrogate end points and time
points for follow-up assessments of randomized trials,
manufacturers and regulators could collaborate on predeter-
mining noninferiority and superiority margins when two or
more active comparators are evaluated [41]. Reaching con-
sensus a priori on how to evaluate the balance between ben-
efits and harms would be particularly important given the
existing challenges in quantifying side effects objectivelyd
which form the basis of regulatory decisionsdin relation to
clinical effects [42].
Having access to the individual patient-level data from
the clinical trials would strengthen considerably the useful-
ness of NMA. In the case of the FDA, regulatory agency
statisticians have access to all individual patient-level data
from clinical trials, published or not, which include a large,
computerized data set for each clinical study as well as the
trial’s protocol and clinical study report. Although not re-
quired, NMA with individual patient-level data would be
desirable when taking into account relative treatment effect
modifiers [43]. Using data sources that are, to a great ex-
tent, not available to the wider public, regulators can per-
form their own analyses, assessing the comparability of
trials, sources of potential bias, and so forth. Accordingly,
regulators could then incorporate NMA results into their
decision making and into product labeling, helping to in-
form the public more completely about new treatments be-
fore treatment patterns are established. This not only would
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allow for performing comparative assessments at the
regulatory level, but also would facilitate downstream
after-approval evaluations of drugs by health technology as-
sessment agencies and payers.
6. Challenges ahead
Planning future trials to inform future NMAs would go
against the current (perceived) practice of planning each in-
dividual trial in isolation from others [44]. Although manu-
facturers may be opposed to designing their trials to mirror
those of their competitors, regulators already provide scien-
tific guidance to ensure that separate trials submitted at
different time points by different manufacturers are suffi-
ciently comparable clinically to warrant the same indica-
tion. Given their current level of involvement, regulators
could play a greater role in guiding the design of phase 3
trials to allow future NMAs to be conducted. In an attempt
to arrive at a feasible approach, we urge regulators and
manufacturers to continue collaborating on issues related
to trial design and selection of appropriate comparators,
and to ensure that patient populations are as similar as pos-
sible across future phase 3 trials in terms of relative treat-
ment effect modifiers.
Moving forward, it may not be possible to design pro-
spectively every aspect of future NMAs. In the case of non-
inferiority trials without a placebo arm, there may be a need
to use historical evidence from older trials to assess for the
assay sensitivity of trials. Certain aspects of our proposal
may require legislative action. At the moment, regulators
are not required to consider comparative evidence in their
market authorization decisions. Although the EMA is fa-
voring increasingly the submission of comparative data
for market entry considerations [45], the FDA prefers to
consider them on a case-by-case basis [46]. Furthermore,
the EMA and the FDA may not be allowed to use proprie-
tary information from the marketing application of one
drug in the evaluation of another, which would prevent reg-
ulators from performing their own analyses with data sets
that are not available to the research community.
Manufacturers may have feasibility concerns about in-
creasing the evidence standards for market entry. As such,
it is conceivable that manufacturers may try to circumvent
the use of NMA by launching their products in areas with
fewer (or weaker) alternatives. However, this challenge
extends beyond our proposal and applies to all regulatory
evidence standards, particularly in jurisdictions in which
off-label use is permitted and commonplace.
7. Conclusions
Maximizing the availability of comparative efficacy and
safety evidence at the time of market authorization remains
critical to maximizing health care value. NMA can be a use-
ful tool to generate comparative evidence at the time of
market authorization assessments. Regulators are posi-
tioned uniquely to oversee the design of trials to allow fu-
ture NMA. During clinical development, regulators and
manufacturers should continue to collaborate to choose
comparators, determine sample sizes of future trials, and
identify relative treatment effect modifiers for future explo-
ration of heterogeneity. NMA can inform approval deci-
sions, may help decrease the likelihood that treatments
inferior to existing alternatives are approved, and would
help focus downstream comparative effectiveness research
efforts by streamlining the information needs of regulators,
payers, and health technology assessment agencies.
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